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Abstract
Summary This report describes epidemiology, burden, and
treatment of osteoporosis in each of the 27 countries of the
European Union (EU27).
Introduction In 2010, 22 million women and 5.5 million
men were estimated to have osteoporosis in the EU; and 3.5
million new fragility fractures were sustained, comprising
620,000 hip fractures, 520,000 vertebral fractures, 560,000
forearm fractures and 1,800,000 other fractures. The eco-
nomic burden of incident and prior fragility fractures was
estimated at € 37 billion. Previous and incident fractures
also accounted for 1,180,000 quality-adjusted life years lost
during 2010. The costs are expected to increase by 25 % in
2025. The majority of individuals who have sustained an
osteoporosis-related fracture or who are at high risk of
fracture are untreated and the number of patients on treat-
ment is declining. The aim of this report was to characterize
the burden of osteoporosis in each of the EU27 countries in
2010 and beyond.
Methods The data on fracture incidence and costs of frac-
tures in the EU27 were taken from a concurrent publication
in this journal (Osteoporosis in the European Union:
EU review panel of the IOF Austria: HP Dimai; Belgium:
M Hiligsmann, S Goemaere, J-Y Reginster; Bulgaria: A-M Borissova,
M Boyanov, Z Kolarov, R Kovacheva, R Rachkov, P Popivanov,
A Shinkov; Cyprus: GL Georgiades; Czech Republic: M Bayer;
Denmark: B Abrahamsen; Estonia: K Maasalu; Finland: H Kröger;
Germany: K Dreinhoefer; Greece: GP Lyritis, P Makras; Hungary:
P Lakatos, I Marton, L Szekeres, K Zalatnai; Ireland: M O’Brien; Italy:
ML Brandi, M Rossini, F Silveri; Latvia: S Berza; I Pavlina, I Rasa;
Lithuania: VAlekna, M Tamulaitiene; Luxembourg: M Hirsch; Malta:
RP Galea; Netherlands: S Papapoulos; Poland: JE Badurski,
E Czerwinski, M Jaworski, R Lorenc; Portugal: J Monteiro; Romania:
D Grigorie; Slovakia: P Jackuliak, P Masaryk, J Payer; Slovenia:
T Kocjan; Spain: A Diez-Perez; Sweden: K Åkesson
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Medical Management, Epidemiology and Economic Bur-
den) and country specific information extracted.
Results The clinical and economic burden of osteoporotic
fractures in 2010 is given for each of the 27 countries of the
EU. The costs are expected to increase on average by 25 %
in 2025. The majority of individuals who have sustained an
osteoporosis-related fracture or who are at high risk of
fracture are untreated and the number of patients on treat-
ment is declining.
Conclusions In spite of the high cost of osteoporosis, a
substantial treatment gap and projected increase of the eco-
nomic burden driven by aging populations, the use of phar-
macological prevention of osteoporosis has decreased in
recent years, suggesting that a change in healthcare policy
concerning the disease is warranted.
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List of abbreviations
DDD Defined daily dosage
DXA Dual-energy X-ray absorptiometry
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SD Standard deviation
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Introduction
Osteoporosis, literally “porous bone”, is a disease character-
ized by weak bone. It is a major public health problem,
affecting hundreds of millions of people worldwide, predom-
inantly postmenopausal women. The main clinical conse-
quence of the disease is bone fractures. It is estimated that
one in three women and one in five men over the age of fifty
worldwide will sustain an osteoporotic fracture. Hip and spine
fractures are the two most serious fracture types, associated
with substantial pain and suffering, disability, and even death.
As a result, osteoporosis imposes a significant burden on both
the individual and society. During the past two decades, a
range of medications has become available for the treatment
and prevention of osteoporosis. The primary aim of pharma-
cological therapy is to reduce the risk of osteoporotic fractures.
A recent report ‘Osteoporosis in the European Union:
Medical Management, Epidemiology and Economic Bur-
den’ published concurrently with this report described the
current burden of osteoporosis in the EU in 2010. Twenty
two million women and 5.5 million men were estimated to
have osteoporosis; and 3.5 million new fragility fractures
were sustained, comprising 620,000 hip fractures, 520,000
vertebral fractures, 560,000 forearm fractures and 1,800,000
other fractures (i.e. fractures of the pelvis, rib, humerus,
tibia, fibula, clavicle, scapula, sternum and other femoral
fractures). The economic burden of incident and prior fra-
gility fractures was estimated at € 37 billion. Incident frac-
tures represented 66 % of this cost, long-term fracture care
29 % and pharmacological prevention 5 %. Previous and
incident fractures also accounted for 1,180,000 quality-
adjusted life years lost during 2010. The costs are expected
to increase by 25 % in 2025. The majority of individuals
who have sustained an osteoporosis-related fracture or who
are at high risk of fracture are untreated and the number of
patients on treatment is declining.
The objective of this report is to review and describe
the current burden of osteoporosis in each of the EU
member states. Epidemiological and health economic
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aspects of osteoporosis and osteoporotic fractures are
summarised for 2010 with projections of the future
prevalence of osteoporosis, the number of incident frac-
tures, the direct and total cost of the disease including
the value of QALYs lost. The report may serve as a
basis for the formulation of healthcare policy concerning
osteoporosis in general and the treatment and prevention
of osteoporosis in particular. It may also provide guid-
ance regarding the overall healthcare priority of the
disease in each member state.
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Epidemiology and Economic Burden of Osteoporosis in
Austria
A report prepared in collaboration with the International
Osteoporosis Foundation (IOF) and the European
Federation of Pharmaceutical Industry Associations
(EFPIA).
A Svedbom, E Hernlund, M Ivergård, J Compston,
C Cooper, J Stenmark, EV McCloskey, B Jönsson,
HP Dimai and JA Kanis
Axel Svedbom, OptumInsight, Stockholm, Sweden
Abstract
Summary This report describes epidemiology, burden, and
treatment of osteoporosis in Austria.
Introduction Osteoporosis is characterized by reduced bone
mass and disruption of bone architecture, resulting in increased
risks of fragility fractures which represent the main clinical
consequence of the disease. Fragility fractures are associated
with substantial pain and suffering, disability and even death
for the affected patients and substantial costs to society. The aim
of this study is to describe the epidemiology and economic
burden of fragility fractures as a consequence of osteoporosis in
Austria, as a further detailed addition to the report for the entire
European Union (EU27): Osteoporosis in the European Union:
Medical Management, Epidemiology and Economic Burden.
Methods The literature on fracture incidence and costs of
fractures in Austria was reviewed and incorporated into a
model estimating the clinical and economic burden of oste-
oporotic fractures in 2010. Furthermore, data on sales of
osteoporosis treatments and the population at high risk were
used to estimate treatment uptake and treatment gap.
Results It was estimated that approximately 87,000 new fra-
gility fractures were sustained in Austria, comprising 16,000
hip fractures, 13,000 vertebral fractures, 13,000 forearm frac-
tures and 44,000 other fractures (i.e. fractures of the pelvis,
rib, humerus, tibia, fibula, clavicle, scapula, sternum and other
femoral fractures) in 2010. The economic burden of incident
and previous fragility fractures was estimated at € 799 million
for the same year. Incident fractures represented 68 % of this
cost, long-term fracture care 29 % and pharmacological pre-
vention 4 %. Previous and incident fractures also accounted
for 27,900 quality-adjusted life years (QALYs) lost during
2010. When accounting for the demographic projections for
2025, the number of incident fractures was estimated at
116,000 in 2025, representing an increase of 30,000 fractures.
Hip, clinical vertebral (spine), forearm and other fractures
were estimated to increase by 5,700, 4,400, 3,700 and
15,900, respectively. The burden of fractures in Austria in
2025 was estimated to increase by 28 % to € 1,025 million.
Though the uptake of osteoporosis treatments increased from
2001, the proportion of patients aged 50 or above who re-
ceived treatment declined in the past few years. The majority
of women at high fracture risk did not receive active treatment.
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Conclusions In spite of the high cost of osteoporosis, a
substantial treatment gap and projected increase of the eco-
nomic burden driven by aging populations, the use of phar-
macological prevention of osteoporosis is significantly less
than optimal, suggesting that a change in healthcare policy
concerning the disease is warranted.
Introduction
Osteoporosis is characterized by reduced bone mass and
disruption of bone architecture, resulting in increased
risks of fragility fractures which represent the main
clinical consequence of the disease. Fragility fractures
are associated with substantial pain and suffering, dis-
ability and even death for the affected patients and
substantial costs to society. The aim of this report was
to characterize the burden of osteoporosis in Austria in
2010 and beyond.
Methods
The literature on fracture incidence and costs of frac-
tures in Austria was reviewed and incorporated into a
model estimating the clinical and economic burden of
osteoporotic fractures in 2010. Details of the methods
used are found in Chapters 3 and 4 of the report
Osteoporosis in the European Union: Medical Manage-
ment, Epidemiology and Economic Burden, published con-
currently in Archives of Osteoporosis.
Epidemiology of osteoporosis in Austria
For the purpose of this report, the population at risk of
osteoporosis was considered to include men and women
≥50 years. The number of men and women ≥50 years of
age amounted to 1,381,000 and 1,660,000 respectively in
Austria in 2010 (Table 1).
In the population at risk, the number of individuals
with osteoporosis—as defined by the WHO diagnostic
criteria—was estimated at 460,000 (Table 2). There
were 28.7 DXA scan machines per million inhabitants
[2] and guidelines for the assessment and treatment of
osteoporosis are available [3, 4]. A country specific
FRAX model is also available for the assessment of
fracture risk (http://www.shef.ac.uk/FRAX/).
Data on hip fracture incidence are available for Aus-
tria [6]. Given that country specific incidences of verte-
bral, forearm and, “other” fractures were not found,
these were imputed using the methods described in
Chapter 3 of the main report. Fracture incidence is
presented in Table 3. Standardized to the EU27 popula-
tion, hip fracture incidence (per 100,000 person years)
in men and women ≥50 years of age was estimated at
322.9 and 757.2 respectively.
The number of incident fractures in 2010 was estimated
at 87,000 (Table 4). Incident hip, clinical spine, forearm and
“other” fractures were estimated at 16,000, 13,000, 13,000
and 44,000 respectively. 66 % of fractures occurred in
women. These estimates are in close agreement with recent-
ly published data for 2008 [7].
A prior fracture was defined as a fracture in an
individual who was alive during the index year (i.e.
2010) which had occurred after the age of 50 years
and before 2010. In the population ≥50 years of age,
the proportions of individuals who had suffered a frac-
ture prior to 2010 were estimated at 2.44 % for hip and
2.75 % for clinical vertebral fractures. The estimated
proportions of men and women with prior hip and
vertebral fractures by age are presented in Table 5.
In the population over 50 years of age, the number of in-
dividuals with hip and vertebral fractures that occurred before
2010 was estimated at 74,000 and 84,000 respectively (Table 6).
Note that fractures sustained in 2010 were not included in the
estimate.
Table 1 Population at risk: men and women over the age of 50 in
Austria, 2010 [1]
Age (years) Women Men All
50–59 556,000 545,000 1,101,000
60–69 477,000 435,000 912,000
70–79 351,000 275,000 626,000
80–89 238,000 116,000 354,000
90+ 38,000 10,000 48,000
50+ 1,660,000 1,381,000 3,041,000
Table 2 Estimated number of women and men with osteoporosis
(defined as a T-score ≤−2.5 SD) in Austria by age using female-
derived reference ranges at the femoral neck, 2010 [5]
Age (years) Women Men
50–54 19,026 7,525
55–59 24,384 8,540
60–64 34,320 12,992
65–69 47,874 15,614
70–74 54,684 12,636
75–79 58,125 11,639
80+ 130,272 20,916
50+ 368,685 89,862
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The incidence of causally related deaths (per 100,000) in
the first year after fracture by age is presented in Table 7.
The number of causally related deaths in 2010 was estimat-
ed at 1,018 (Table 8). Hip, vertebral and “other” fractures
accounted for 505, 317 and 195 deaths respectively. Overall,
approximately 55 % of deaths occurred in women.
Cost of osteoporosis in Austria including and excluding
values of QALYs lost
For the purpose of this report, the cost of osteoporosis in
2010 (excluding value of QALYs lost) was considered to
consist of three components: (i) cost of fractures that oc-
curred in 2010 (“first year costs”); (ii) cost of fractures
sustained prior to year 2010 but which still incurred costs
Table 4 Estimated number of incident fractures in Austria, 2010
Fracture at the All
Age (years) hip vertebra forearm other fractures
Women
50–74 2,159 3,328 6,166 8,204 19,857
75+ 9,675 4,952 4,883 17,824 37,335
Total 11,835 8,280 11,049 26,029 57,192
Men
50–74 1,603 2,819 1,820 10,509 16,751
75+ 2,650 2,004 554 7,385 12,593
Total 4,254 4,822 2,373 17,894 29,343
Men and Women
50–74 3,763 6,146 7,986 18,713 36,608
75+ 12,326 6,956 5,437 25,209 49,928
Total 16,088 13,102 13,422 43,923 86,536
Table 5 Proportion of men and women (in %) with a prior hip or
clinical vertebral fracture in Austria, 2010
Age (years) Hip fracture Vertebral fracture
Women
50– 2.01.045
55– 8.03.095
60– 5.16.046
65– 3.22.196
70– 7.33.247
75– 8.54.497
80– 4.84.848
4.316.71+58
Men
50– 2.01.045
55– 8.04.095
60– 4.18.046
65– 0.23.196
70– 6.20.247
75– 5.31.397
80– 5.43.548
9.74.01+58
Table 6 Number of men and women in Austria with a prior hip or
clinical vertebral fracture after the age of 50 years, 2010
Age (years) Hip fracture Vertebral fracture
Women
50– 518,81068,947
921,93857,24+57
449,75716,25latoT
Men
50– 133,41500,947
843,11846,21+57
976,52356,12latoT
Men and Women
50– 641,33568,8147
674,05504,55+57
326,38072,47latoT
Table 3 Incidence per 100,000 person years of hip, clinical vertebral,
forearm, and “other” fractures in Austria by age
Fracture at the
Age (years) hip vertebra forearm other
Women
50–54 34 88 217 224
55–59 69 191 528 605
60–64 115 203 433 442
65–69 203 296 493 694
70–74 411 579 738 1,165
75–79 845 821 824 1,777
80–84 1,773 1,114 1,109 3,014
85+ 3,132 1,473 1,337 5,262
Men
50–
55–
60–
65–
70–
75–
80–
54 57 146 52 253
59 79 138 121 741
64 109 260 205 1,069
69 162 255 243 1,044
74 262 399 168 1,345
79 470 542 133 1,255
84 924 642 179 2,457
85+ 1,652 1,110 303 4,785
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in 2010 (“long-term disability cost”); and (iii) cost of phar-
macological fracture prevention including administration
and monitoring costs (“pharmacological fracture prevention
costs”). See Chapter 4 of the main report for further details.
For Austria, only inpatient costs the first year after hip
fracture had been reported at the cut off date [8]. Total first
year costs after fracture were imputed by applying the
inpatient cost for Austria to the ratio of inpatient cost to
total first year costs observed in Sweden, resulting in an
estimated total first year hip fracture cost of € 13,527. Given
that no cost data for the other fracture sites were found, these
were imputed as described in Chapter 4 of the main report.
A recent publication provides similar estimates [7].
Long-term disability costs were estimated by multi-
plying the yearly cost of residing in nursing home
(€ 33,317 [9]) with the simulated number of individuals
with prior fractures that had been transferred to nursing
homes due to the fracture.
Cost of pharmacological fracture prevention including its
administration were based on treatment uptake reported by
IMS Health [10]. Annual drug cost for individual treatments
Table 8 The number of deaths in men and women in Austria in the
first year after fracture attributable to the fracture event (causally
related), 2010
Fracture at the
Age (years) hip vertebra “other”
Women
50–74 31 48 4
75+ 257 97 124
Total 288 145 128
Men
50–74 46 80 10
75+ 171 93 57
Total 217 172 67
Men and Women
50–74 77 128 15
75+ 428 189 181
Total 505 317 195
Table 9 One year costs
for relevant pharmaceuti-
cals in Austria, 2010 [11]
Annual drug
cost (€)
Alendronate 174
Risedronate 173
Etidronate 337
Ibandronate 266
Zoledronic acid 368
Raloxifene 463
Strontium ranelate 602
Parathyroid hormone 4,881
Teriparatide 5,033
Table 10 Cost of osteoporosis (€) in Austria by age in men and
women, 2010
Age First year
fracture
cost
(years)
Long term
disability
costs
Fracture
prevention
cost
Total cost
Women
50–74 102,053,686 20,498,662 16,211,264 138,763,611
75+ 251,821,366 139,171,528 10,238,872 401,231,767
All 353,875,052 159,670,190 26,450,136 539,995,378
Men
50–74 100,949,687 22,209,312 2,580,748 125,739,747
75+ 84,698,294 47,262,010 1,137,709 133,098,012
All 185,647,981 69,471,322 3,718,456 258,837,759
Women and Men
50–74 203,003,373 42,707,973 18,792,012 264,503,358
75+ 336,519,660 186,433,538 11,376,581 534,329,779
All 539,523,033 229,141,511 30,168,592 798,833,136
Table 7 Incidence (per 100,000) of causally related deaths in Austria
within the first year after fracture (adjusted for comorbidities), 2010
Age (years) Hip Clinical vertebral “Other” fracture
Women
50–54 573 744 15
55–59 609 749 18
60–64 990 1,150 31
65–69 1,314 1,441 49
70–74 1,510 1,558 69
75–79 2,100 2,029 132
80–84 2,513 2,224 280
85–89 3,111 2,418 545
90+ 2,936 1,655 1,021
Men
50–54 1,549 1,857 24
55–59 1,852 2,105 38
60–64 2,577 2,772 70
65–69 2,731 2,770 98
70–74 3,110 2,961 140
75–79 3,979 3,529 236
80–84 5,017 4,074 421
85–89 6,643 4,856 718
90+ 10,106 6,577 1,264
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is shown in Table 9. In addition, it was assumed that patients
on treatment made an annual physician visit costing € 30
[11] and a DXA scan costing € 30 every second year to
monitor treatment [11].
The cost of osteoporosis in 2010 was estimated at € 799
million (Table 10). These costs are close to recently pub-
lished estimates for 2008 [7]. First year costs, subsequent
year costs and pharmacological fracture prevention costs
amounted to € 540 million, € 229 million and € 30 million,
respectively. It is notable that pharmacological fracture pre-
vention costs amounted to only 3.8 % of the total cost.
When stratifying costs of osteoporosis by fracture
type, hip fractures were most costly (€ 421 million)
followed by “other” (€ 300 million), spine (€ 36
Table 11 Total cost (€) in 2010 by fracture site in men and women in Austria. Note that costs for fracture prevention therapy and monitoring are
not included
Age Hip Spine Forearm Other All
Women
50–74 48,671,702 9,608,786 5,096,281 59,175,579 122,552,347
75+ 254,284,487 13,377,107 4,036,070 119,295,231 390,992,895
All 302,956,189 22,985,893 9,132,351 178,470,809 513,545,242
Men
50–74 42,389,664 7,862,829 1,504,074 71,402,432 123,158,999
75+ 75,870,194 5,017,929 457,487 50,614,693 131,960,303
All 118,259,858 12,880,758 1,961,561 122,017,126 255,119,302
Women and Men
50–74 91,061,365 17,471,615 6,600,355 130,578,011 245,711,346
75+ 330,154,681 18,395,036 4,493,557 169,909,924 522,953,198
All 421,216,047 35,866,651 11,093,912 300,487,935 768,664,544
Hip
55%
Spine
5%
Forearm
1%
Other
39%
Fig. 1 Share (%) of fracture cost by fracture site in Austria. Note that
costs for fracture prevention therapy and monitoring are not included
Table 12 Number of QALYs lost due to fractures during 2010 in men
and women in Austria according to age
Age (years)
50–74 75+ 50+
Women
Incident hip fractures 518 2,013 2,531
Incident vertebral fractures 1,099 1,411 2,510
Incident forearm fractures 217 147 365
Incident other fractures 982 1,841 2,824
Prior hip fractures 1,545 5,741 7,286
Prior vertebral fractures 1,052 1,889 2,940
654,81340,31314,5latoT
Men
Incident hip fractures 391 633 1,025
Incident vertebral fractures 938 638 1,575
Incident forearm fractures 63 18 81
Incident other fractures 1,246 839 2,085
Prior hip fractures 1,407 1,873 3,280
Prior vertebral fractures 796 598 1,395
144,9995,4248,4latoT
Men and Women
Incident hip fractures 910 2,646 3,556
Incident vertebral fractures 2,037 2,049 4,086
Incident forearm fractures 281 165 446
Incident other fractures 2,229 2,680 4,909
Prior hip fractures 2,952 7,614 10,565
Prior vertebral fractures 1,848 2,487 4,335
798,72246,71552,01latoT
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million) and forearm fractures (€ 11 million) (Table 11
and Fig. 1). Please note that costs for pharmacological
fracture prevention were not included given that they
cannot be allocated to specific fracture sites. The re-
sults are generally consistent with a recent cost of
illness study undertaken for the year 2008 [7].
The number of quality adjusted life years (QALYs) lost
due to osteoporosis in 2010 was estimated at 27,900
(Table 12). 66 % of the total QALY loss was incurred in
women. Prior fractures accounted for 53 % of the total
QALY loss. The monetary value of a QALY was varied
between 1 to 3 times the gross domestic product (GDP)
per capita (Table 13). Assuming a QALY is valued at 2
times GDP/capita, the total cost of the QALYs lost was
estimated at € 1.90 billion.
When the cost of osteoporosis was combined with the
value for QALYs lost (valued at 2 × GDP), the cost of
osteoporosis amounted to € 2.70 billion in Austria in 2010.
Incident fracture, prior fracture, pharmacological fracture
prevention, and value of QALYs lost accounted for 20 %,
8 %, 1 %, 70 % respectively.
Burden of osteoporosis up to 2025
The population above 50 years of age is expected to
increase from 3.0 million in 2010 to 3.8 million in 2025,
corresponding to an increase of 26 % (Table 14).
The total number of fractures was estimated to rise from
87,000 in 2010 to 116,000 in 2025 (Table 15), corresponding
to an increase of 34 %. Hip, clinical spine, forearm and
other fractures increased by 5,700, 4,400, 3,700 and
15,900 respectively. The increase in the number of
fractures ranged from 28 % to 36 %, depending on
fracture site. The increase was estimated to be particu-
larly marked in men (49 %) compared to women
(27 %). Note that the calculations assume no change
in the age- and sex-specific incidence of fracture. In the
case of hip fracture, there is evidence that age specific
rates have been decreasing in recent years [13].
The cost of osteoporosis (excluding values of QALYs
lost) was estimated to rise from € 799 million in 2010 to €
1,025 million in 2025, corresponding to an increase of 28 %
(Table 16). Costs incurred in women and men increased by
21 % and 43 % respectively.
The total number of QALYs lost due to fracture was
estimated to rise from 27,900 in 2010 to 34,600 in 2025,
corresponding to an increase of 24 % (Table 17). The increase
was estimated to be particularly marked in men (38 %) com-
pared to women (17 %). Incident and prior fractures
accounted for 67 % and 33 % of the increase respectively.
The cost of osteoporosis including value of QALYs lost
was estimated to increase from approximately € 2.7 billion
in 2010 to € 3.4 billion in 2025. The increase was estimated
to be particularly marked in men (+39 %) compared to
women (+18 %) (Table 18).
Treatment uptake
To estimate uptake of individual osteoporosis treatments,
sales data from IMS Health (2001–2011) were used to
Table 13 Value of lost QALYs (€) in men and women in Austria in
2010
1 × GDP/
capita
2 × GDP/
capita
3 × GDP/
capita
Incident hip
fractures
121,258,606 242,517,213 363,775,819
Incident vertebral
fractures
139,325,710 278,651,420 417,977,130
Incident forearm
fractures
15,209,448 30,418,897 45,628,345
Incident other
fractures
167,398,442 334,796,883 502,195,325
Prior hip fractures 360,280,447 720,560,893 1,080,841,340
Prior vertebral
fractures
147,816,230 295,632,461 443,448,691
Total 951,288,883 1,902,577,766 2,853,866,649
Table 14 Population projections in Austria by age and sex [12]
Population
2010 2015 2020 2025
Women
50–59 556,000 646,000 689,000 642,000
60–69 477,000 481,000 536,000 624,000
70–79 351,000 402,000 425,000 433,000
80–89 238,000 220,000 235,000 275,000
90+ 38,000 59,000 66,000 66,000
Men
50–59 545,000 642,979 688,000 633,000
60–69 435,000 443,000 501,000 597,000
70–79 275,000 324,000 350,000 362,000
80–89 116,000 129,000 151,000 185,000
90+ 10,000 17,000 24,000 28,000
All
50–59 1,101,000 1,288,979 1,377,000 1,275,000
60–69 912,000 924,000 1,037,000 1,221,000
70–79 626,000 726,000 775,000 795,000
80–89 354,000 349,000 386,000 460,000
90+ 48,000 76,000 90,000 94,000
000,548,3000,140,3
Arch Osteoporos (2013) 8:137 Page 9 of 218, 137
derive the number of defined daily doses (DDDs) sold per
100,000 persons aged 50 years or above (Fig. 2).
Adjusting the sales data for compliance allowed for
an estimation of the proportion of population aged
50 years or above who received any osteoporosis
treatment (see Chapter 5 of the report on Osteoporosis
in the European Union: Medical Management, Epide-
miology and Economic Burden for further details).
The proportion of persons over the age of 50 years
who were treated increased from 3.06 % in 2001 to
6.1 % in 2006 but subsequently decreased to 5.17 %
in 2011.
Treatment gap
In order to assess the potential treatment gap, the numbers of
men and women eligible for treatment in Austria were defined
as individuals with a 10-year fracture probability exceeding
that of a woman with a prior fragility fracture derived from
FRAX®, equivalent to a ‘fracture threshold’ (See Chapter 5 of
the main report for further details). Subsequently, these esti-
mates were compared to the number individuals who received
osteoporosis treatment obtained from the analysis of IMS
Health data. The treatment gaps in men and women were
Table 15 Projected annual number of incident fractures in 2010 and 2025 by fracture site and age in men and women in Austria
rehtOmraeroFenipSpiH
2010 2025 2010 2025 2010 2025 2010 2025
Women
50–74 2,159 2,645 3,328 4,083 6,166 7,606 8,204 10,061
75+ 9,675 12,528 4,952 6,362 4,883 6,185 17,824 23,076
All 11,835 15,173 8,280 10,445 11,049 13,791 26,029 33,136
Men
50–74 1,603 2,041 2,819 3,608 1,820 2,382 10,509 13,631
75+ 2,650 4,616 2,004 3,492 554 961 7,385 13,031
All 4,254 6,657 4,822 7,100 2,373 3,343 17,894 26,662
Women and Men
50–74 3,763 4,686 6,146 7,692 7,986 9,989 18,713 23,691
75+ 12,326 17,144 6,956 9,853 5,437 7,145 25,209 36,107
All 16,088 21,830 13,102 17,545 13,422 17,134 43,923 59,798
Table 16 Current and future cost (€ 000,000) of osteoporosis (exclud-
ing values of QALYs lost) by age and calendar year in men and women
in Austria
2010 2015 2020 2025
Women
50–74 139 150 156 166
75+ 401 425 454 488
All 540 575 610 654
Men
50–74 126 136 146 159
75+ 133 153 181 212
All 259 290 327 370
Women and Men
50–74 265 286 302 325
75+ 534 578 635 700
All 799 864 937 1,025
Table 17 Projected QALYs lost due to incident and prior fractures for
the years 2010 and 2025 by age in men and women in Austria
Incident fractures Prior fractures All fractures
2010 2025 2010 2025 2010 2025
Women
50–74 2,817 3,457 2,596 2,800 5,413 6,257
75+ 5,413 6,952 7,630 8,386 13,043 15,338
All 8,230 10,409 10,226 11,187 18,456 21,595
Men
50–74 2,638 3,393 2,203 2,552 4,842 5,944
75+ 2,128 3,716 2,471 3,373 4,599 7,089
All 4,767 7,109 4,674 5,924 9,441 13,033
Women and Men
50–74 5,456 6,850 4,800 5,352 10,255 12,202
75+ 7,541 10,668 10,101 11,759 17,642 22,427
All 12,997 17,518 14,900 17,111 27,897 34,628
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estimated at 52 % and 51 % respectively (Table 19). Note that
the estimate of the treatment gap is conservative given that it
assumes that current use of osteoporosis treatments are only
directed to men and women at high risk.
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All 1,799 1,903 2,002 2,127
Men
50–74 456 486 520 564
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50–74 964 1,026 1,081 1,157
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Fig. 2 Treatment uptake in Austria (Defined daily doses [DDDs] per
100,000 persons aged 50 years or above)
Table 19 Number of men and women eligible for treatment, treated
and treatment gap in 2010
Number
potentially
treated
(1000 s)
Number
eligible for
treatment
(1000 s)
Difference
(1000 s)
Treatment
gap (%)
Men 21 43 22 52
Women 139 282 143 51
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Abstract
Summary This report describes epidemiology, burden, and
treatment of osteoporosis in Belgium.
Introduction Osteoporosis is characterized by reduced bone
mass and disruption of bone architecture, resulting in increased
risks of fragility fractures which represent the main clinical
consequence of the disease. Fragility fractures are associated
with substantial pain and suffering, disability and even death for
the affected patients and substantial costs to society. The aim of
this study is to describe the epidemiology and economic burden
of fragility fractures as a consequence of osteoporosis in Bel-
gium, as a further detailed addition to the report for the entire
European Union (EU27): Osteoporosis in the European Union:
Medical Management, Epidemiology and Economic Burden.
Methods The literature on fracture incidence and costs of
fractures in Belgium were reviewed and incorporated into a
model estimating the clinical and economic burden of oste-
oporotic fractures in 2010. Furthermore, data on sales of
osteoporosis treatments and the population at high risk were
used to estimate treatment uptake and treatment gap.
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Results It was estimated that approximately 80,000 new fra-
gility fractures were sustained in Belgium, comprising 15,000
hip fractures, 12,000 vertebral fractures, 12,000 forearm frac-
tures and 41,000 other fractures (i.e. fractures of the pelvis,
rib, humerus, tibia, fibula, clavicle, scapula, sternum and other
femoral fractures) in 2010. The economic burden of incident
and previous fragility fractures was estimated at € 606 million
for the same year. Incident fractures represented 69 % of this
cost, long-term fracture care 26 % and pharmacological pre-
vention 5 %. Previous and incident fractures also accounted
for 26,800 quality-adjusted life years (QALYs) lost during
2010. When accounting for the demographic projections for
2025, the number of incident fractures was estimated at
99,000 in 2025, representing an increase of 19,000 fractures.
Hip, clinical spine, forearm and other fractures was estimated
to increase by 3,900, 2,900, 2,300 and 10,300, respectively.
The burden of fractures in Belgium in 2025 was estimated to
increase by 21 % to € 733 million. Though the uptake of
osteoporosis treatments increased from 2001, the proportion
of patients aged 50 or above who received treatment declined
in the past few years. A substantial proportion of women at
high fracture risk did not receive active treatment.
Conclusions In spite of the high cost of osteoporosis, a
substantial treatment gap and projected increase of the eco-
nomic burden driven by aging populations, the use of phar-
macological prevention of osteoporosis is significantly less
than optimal, suggesting that a change in healthcare policy
concerning the disease is warranted.
Introduction
Osteoporosis is characterized by reduced bone mass and
disruption of bone architecture, resulting in increased
risks of fragility fractures which represent the main
clinical consequence of the disease. Fragility fractures
are associated with substantial pain and suffering, dis-
ability and even death for the affected patients and
substantial costs to society. The aim of this report was
to characterize the burden of osteoporosis in Belgium in
2010 and beyond.
Methods
The literature on fracture incidence and costs of frac-
tures in Belgium was reviewed and incorporated into a
model estimating the clinical and economic burden of
osteoporotic fractures in 2010. Details of the methods
used are found in Chapters 3 and 4 of the report
Osteoporosis in the European Union: Medical Manage-
ment, Epidemiology and Economic Burden, published
concurrently in Archives of Osteoporosis.
Epidemiology of osteoporosis in Belgium
For the purpose of this report, the population at risk of osteoporosis
was considered to includemen andwomen≥50years. Thenumber
of men and women ≥50 years of age amounted to 1,829,000 and
2,130,000 respectively in Belgium in 2010 (Table 1).
The number of individuals with osteoporosis—as defined by
the WHO diagnostic criteria—was estimated at 600,000
(Table 2), similar to an earlier estimate in 2008 [2]. There
are 53 DXA scan machines per million inhabitants [3], and
guidelines for the assessment and treatment of osteoporosis
are available [4–8]. A country specific FRAX model is also
available for the assessment of fracture risk (http://
www.shef.ac.uk/FRAX/).
Data on hip fracture incidence are available for Belgium and
we used a mean estimate for 2005–7 [10]. The incidence of hip
fractures was determined using the national hospital database,
which fully covers the annual hospital stays in Belgium (source:
INAMI-RIZIV [Institut National d’Assurance Maladie
Invalidité–Rijksinstituut voor Ziekte en Invaliditeitsverzekering]
and SPF Public Health). Given that country specific incidence of
vertebral, forearm and, “other” fractures were not found, these
were imputed using the methods described in Chapter 3 of the
main report. Fracture incidence is presented in Table 3. Stan-
dardized to the EU27 population, hip fracture incidence (per
100,000 person years) in men and women ≥50 years of age
was estimated at 228.5 and 538.7 respectively.
Table 1 Population at risk: men and women over the age of 50 in
Belgium, 2010 [1]
Age (years) Women Men All
50–59 727,000 728,000 1,455,000
60–69 568,000 540,000 1,108,000
70–79 480,000 379,000 859,000
80–89 308,000 168,000 476,000
90+ 47,000 14,000 61,000
50+ 2,130,000 1,829,000 3,959,000
Table 2 Estimated number of women and men with osteoporosis
(defined as a T-score ≤-2.5 SD) in Belgium by age using female-
derived reference ranges at the femoral neck, 2010 [9]
Age (years) Women Men
50–54 23,940 9,550
55–59 33,312 12,110
60–64 46,189 18,212
65–69 49,490 16,724
70–74 68,634 16,068
75–79 87,750 17,819
80+ 167,560 30,212
50+ 476,875 120,695
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The number of incident fractures in 2010 was estimated at
80,000 (Table 4). Incident hip, clinical vertebral, forearm and
“other” fractures were estimated at 15,000, 12,000, 12,000
and 41,000 respectively. 66% of fractures occurred in women.
A prior fracture was defined as a fracture in an individual
who was alive during the index year (i.e. 2010) which had
occurred after the age of 50 years and before 2010. In the
population ≥50 years of age, the proportions of individuals
who had suffered a fracture prior to 2010 were estimated at
1.88 % for hip and 2.04 % for clinical vertebral fractures.
The estimated proportions of men and women with prior hip
and vertebral fractures by age are presented in Table 5.
In the population over 50 years of age, the number of individ-
uals with hip and vertebral fractures that occurred before 2010was
Table 3 Incidence per 100,000 person years of hip, clinical vertebral,
forearm, and “other” fractures in Belgium by age
Fracture at the
Age (years) hip vertebra forearm other
Women
50–54 27 70 173 179
55–59 53 148 410 469
60–64 84 149 317 324
65–69 140 203 339 477
70–74 271 382 486 768
75–79 606 589 591 1,274
80–84 1,263 794 791 2,148
85+ 2,371 1,115 1,012 3,983
Men
50–54 34 88 32 152
55–59 49 85 74 455
60–64 73 174 137 716
65–69 104 164 157 673
70–74 159 243 102 819
75–79 313 361 89 836
80–84 669 464 130 1,778
85+ 1,371 921 251 3,971
Table 4 Estimated number of incident fractures in Belgium, 2010
Fracture at the All
Age (years) hip vertebra forearm other fractures
Women
50–74 1,829 2,890 5,562 7,230 17,511
75+ 8,932 4,676 4,701 16,579 34,888
Total 10,761 7,566 10,263 23,809 52,399
Men
50–74 1,280 2,293 1,490 8,571 13,634
75+ 2,919 2,187 605 8,148 13,860
Total 4,199 4,480 2,095 16,720 27,493
Men and Women
50–74 3,109 5,182 7,052 15,802 31,144
75+ 11,851 6,863 5,306 24,727 48,748
Total 14,960 12,046 12,358 40,529 79,892
Table 5 Proportion of men and women (in %) with a prior hip or
clinical vertebral fracture in Belgium, 2010
Age (years) Hip fracture Vertebral fracture
Women
50– 1.00.045
55– 7.02.095
60– 3.15.046
65– 7.19.096
70– 7.27.147
75– 3.44.397
80– 2.65.648
3.016.41+58
Men
50– 1.01.045
55– 4.03.095
60– 9.05.046
65– 3.18.096
70– 7.13.147
75– 4.21.297
80– 3.37.348
1.63.8+58
Table 6 Number of men and women in Belgium with a prior hip or
clinical vertebral fracture fracture after the age of 50 years, 2010
Age (years) Hip fracture Vertebral fracture
Women
50– 861,81590,947
759,83146,44+57
421,75737,35latoT
Men
50– 693,11792,747
681,21154,31+57
285,32947,02latoT
Men and Women
50– 365,92393,6147
341,15390,85+57
607,08584,47latoT
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estimated at 74,000 and 81,000 respectively (Table 6). Note that
fractures sustained in 2010 were not included in the estimate.
The incidence of causally related deaths (per 100,000) in
the first year after fracture by age is presented in Table 7.
These comprise approximately 30% of deaths associated with
fracture [11]. The number of causally related deaths in 2010
was estimated at 979 (Table 8). Hip, vertebral and “other”
fractures accounted for 492, 310 and 177 deaths respectively.
Overall, approximately 51 % of deaths occurred in women.
Cost of osteoporosis in Belgium including and excluding
values of QALYs lost
For the purpose of this report, the cost of osteoporosis in
2010 (excluding value of QALYs lost) was considered to
consist of three components: (i) cost of fractures that oc-
curred in 2010 (“first year costs”); (ii) cost of fractures
sustained prior to year 2010 but which still incurred costs
in 2010 (“long-term disability cost”); and (iii) cost of phar-
macological fracture prevention including administration
and monitoring costs (“pharmacological fracture prevention
costs”). See Chapter 4 of the main report for further details.
Table 7 Incidence (per 100,000) of causally related deaths in Belgium
within the first year after fracture (adjusted for comorbidities), 2010
Age (years) Hip Clinical vertebral “Other” fracture
Women
50–54 601 781 16
55–59 852 1,048 25
60–64 1,165 1,352 37
65–69 1,603 1,757 60
70–74 1,807 1,865 82
75–79 2,174 2,100 136
80–84 2,451 2,169 273
85–89 3,038 2,362 532
90+ 2,528 1,425 879
Men
50–54 1,906 2,286 30
55–59 2,135 2,427 44
60–64 2,502 2,691 68
65–69 2,854 2,895 102
70–74 3,378 3,216 152
75–79 4,157 3,687 247
80–84 5,017 4,074 421
85–89 7,048 5,152 761
90+ 9,359 6,090 1,171
Table 8 The number of deaths in men and women in Belgium in the
first year after fracture attributable to the fracture event (causally
related), 2010
Fracture at the
Age (years) hip vertebra “other”
Women
50–74 29 46 4
75+ 230 91 102
Total 259 137 106
Men
50–74 39 68 8
75+ 195 105 63
Total 233 173 71
Men and Women
50–74 67 114 13
75+ 425 196 165
Total 492 310 177
Table 9 One year costs
for relevant pharmaceuti-
cals in Belgium, 2010
[15]
Annual drug
cost (€)
Alendronate 123
Risedronate 19
Etidronate 93
Ibandronate 160
Zoledronic acid 324
Raloxifene 395
Strontium ranelate 464
Parathyroid hormone -
Teriparatide 3,656
Table 10 Cost of osteoporosis (€) in Belgium by age in men and
women, 2010
Age 
(years)
First year
fracture
cost
Long term
disability
costs
Fracture
prevention
cost
Total cost
Women
50–74 73,267,761 12,842,111 15,118,387 101,228,259
75+ 199,531,556 97,521,075 10,688,414 307,741,045
All 272,799,317 110,363,186 25,806,802 408,969,304
Men
50–74 67,907,494 11,998,486 2,395,596 82,301,576
75+ 78,540,769 35,072,065 1,229,492 114,842,326
All 146,448,264 47,070,551 3,625,088 197,143,903
Women and Men
50–74 141,175,255 24,840,597 17,513,983 183,529,836
75+ 278,072,325 132,593,139 11,917,906 422,583,371
All 419,247,581 157,433,737 29,431,890 606,113,207
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The cost of a hip fracture has been estimated at € 11,426
in Belgium [12] comparable to a more recent estimate [13].
Given that no cost data for the other fracture sites were
found, these were imputed as described in Chapter 4 of the
main report.
Long-term disability costs were estimated by multiplying
the yearly cost of residing in nursing home (€ 22,608 [14])
with the simulated number of individuals with prior frac-
tures that had been transferred to nursing homes due to the
fracture.
Annual drug costs (€) for individual treatments are shown
in Table 9. In addition, it was assumed that patients on treat-
ment made an annual physician visit costing € 19 and a DXA
scan at € 34 every second year to monitor treatment [15].
The cost of osteoporosis in 2010 was estimated at €
606 million (Table 10). First year costs, subsequent year
costs and pharmacological fracture prevention costs
Table 11 Total cost (€) in 2010 by fracture site in men and women in
Belgium. Note that costs for fracture prevention therapy and monitor-
ing are not included
Age Hip Vertebral Forearm Other All
Women
50–74 32,930,499 7,022,947 3,883,014 42,273,412 86,109,872
75+ 188,200,459 10,747,124 3,281,739 94,823,308 297,052,631
All 221,130,958 17,770,070 7,164,754 137,096,720 383,162,503
Men
50–74 25,561,846 5,384,963 1,039,942 47,919,230 79,905,981
75+ 61,536,698 4,607,182 422,622 47,046,332 113,612,834
All 87,098,543 9,992,145 1,462,564 94,965,562 193,518,815
Women and Men
50–74 58,492,345 12,407,909 4,922,956 90,192,643 166,015,853
75+ 249,737,157 15,354,306 3,704,361 141,869,640 410,665,465
All 308,229,502 27,762,216 8,627,318 232,062,283 576,681,318
Hip
53%
Spine
5%
Forearm
2%
Other
40%
Fig 1 Share (%) of fracture cost by fracture site in Belgium. Note that
costs for fracture prevention therapy and monitoring are not included
Table 12 Number of QALYs lost due to fractures during 2010 in men
and women in Belgium according to age
Age (years)
50–74 75+ 50+
Women
Incident hip fractures 441 1,868 2,308
Incident vertebral fractures 959 1,341 2,299
Incident forearm fractures 197 143 339
Incident other fractures 869 1,719 2,588
Prior hip fractures 1,426 6,006 7,432
Prior vertebral fractures 1,018 1,887 2,905
278,71369,21909,4latoT
Men
Incident hip fractures 313 699 1,012
Incident vertebral fractures 764 69 ,461
Incident forearm fractures 52 20 71
Incident other fractures 1,017 92
7 1
6 1,943
Prior hip fractures 1,140 1,989 3,129
Prior vertebral fractures 633 642 1,275
298,8479,4819,3latoT
Men and Women
Incident hip fractures 753 2,567 3,321
Incident vertebral fractures 1,722 2,038 3,760
Incident forearm fractures 249 162 411
Incident other fractures 1,885 2,645 4,531
Prior hip fractures 2,566 7,995 10,561
Prior vertebral fractures 1,651 2,529 4,180
367,62739,71728,8latoT
Table 13 Value of lost QALYs (€) in men and women in Belgium in
2010
1 × GDP/
capita
2 × GDP/
capita
3 × GDP/
capita
Incident hip
fractures
107,584,970 215,169,940 322,754,911
Incident vertebral
fractures
121,830,873 243,661,747 365,492,620
Incident forearm
fractures
13,312,751 26,625,503 39,938,254
Incident other
fractures
146,788,449 293,576,898 440,365,347
Prior hip fractures 342,179,611 684,359,221 1,026,538,832
Prior vertebral
fractures
135,438,142 270,876,285 406,314,427
Total 867,134,797 1,734,269,594 2,601,404,391
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amounted to € 419 million, € 157 million and € 29
million, respectively. It is notable that pharmacological
fracture prevention costs amounted to only 4.8 % of the
total cost. This cost is very likely overinflated since
reimbursement for DXA only came into effect in
August of 2010 and repeat DXA is only reimbursed at
5 years.
When stratifying costs of osteoporosis by fracture type, hip
fractures were most costly (€ 308million) followed by “other”
(€ 232 million), spine (€ 28 million) and forearm fractures (€
9 million) (Table 11 and Fig. 1). Please note that costs for
pharmacological fracture prevention were not included given
that they cannot be allocated to specific fracture sites.
The number of quality adjusted life years (QALYs)
lost due to osteoporosis in 2010 was estimated at
26,800 (Table 12). 67 % of the total QALY loss was
incurred in women. Prior fractures accounted for 55 %
Table 14 Population projections in Belgium by age and sex [16]
Population
2010 2015 2020 2025
Women
50–59 727,000 770,000 775,000 747,000
60–69 568,000 652,000 696,000 738,000
70–79 480,000 454,000 506,000 583,000
80–89 308,000 319,000 316,000 305,000
90+ 47,000 68,000 83,000 92,000
Men
50–59 728,000 769,358 778,000 747,000
60–69 540,000 622,000 664,000 707,000
70–79 379,000 372,000 430,000 499,000
80–89 168,000 187,000 194,000 195,000
90+ 14,000 23,000 29,000 36,000
All
50–59 1,455,000 1,539,358 1,553,000 1,494,000
60–69 1,108,000 1,274,000 1,360,000 1,445,000
70–79 859,000 826,000 936,000 1,082,000
80–89 476,000 506,000 510,000 500,000
90+ 61,000 91,000 112,000 128,000
000,946,4000,959,3
Table 15 Projected annual number of incident fractures in 2010 and 2025 by fracture site and age in men and women in Belgium
Table 16 Current and future cost (€ 000,000) of osteoporosis (exclud-
ing value of QALYs lost) by age and calendar year in men and women
in Belgium
2010 2015 2020 2025
Women
50–74 101 107 119 124
75+ 308 326 336 355
All 409 433 455 479
Men
50–74 82 89 98 103
75+ 115 126 136 151
All 197 215 234 254
Women and Men
50–74 184 196 217 227
75+ 423 452 472 507
All 606 648 689 733
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of the total QALY loss. The monetary value of a QALY
was varied between 1 to 3 times the gross domestic
product (GDP) per capita (Table 13). Assuming a
QALY is valued at 2 times GDP/capita, the total cost
of the QALYs lost was estimated at € 1.73 billion.
When the cost of osteoporosis was combined with
the value for QALYs lost (valued at 2 × GDP), the
cost of osteoporosis amounted to € 2.34 billion in
Belgium in 2010. Incident fracture, prior fracture,
pharmacological fracture prevention, and value of
QALYs lost accounted for 18 %, 7 %, 1 %, 74 %
respectively.
Burden of osteoporosis up to 2025
The population above 50 years of age is expected to increase
from 4.0 million in 2010 to 4.6 million in 2025, correspond-
ing to an increase of 17 % (Table 14).
The total number of fractures was estimated to rise
from 80,000 in 2010 to 99,000 in 2025 (Table 15),
corresponding to an increase of 24 %. Hip, clinical
vertebral, forearm and other fractures increased by
3,900, 2,900, 2,300 and 10,300 respectively. The increase
in the number of fractures ranged from 19 % to 26 %,
depending on fracture site. The increase was estimated to
be particularly marked in men (32 %) compared to
women (20 %). Note that no change in the age and sex
specific incidence was assumed over this period.
The cost of osteoporosis (excluding values of QALYs
lost) was estimated to rise from € 606 million in 2010 to €
733 million in 2025, corresponding to an increase of 21 %
(Table 16). Costs incurred in women and men increased by
17 % and 29 % respectively.
The total number of QALYs lost due to fracture was
estimated to rise from 26,800 in 2010 to 31,300 in 2025,
corresponding to an increase of 17 % (Table 17). The increase
was estimated to be particularly marked in men (25 %) com-
pared to women (13 %). Incident and prior fractures
accounted for 65 % and 35 % of the increase respectively.
The cost of osteoporosis including value of QALYs lost
was estimated to increase from approximately € 2.3 billion
in 2010 to € 2.8 billion in 2025. The increase was estimated
Table 18 Present and future cost (€ 000,000) of fracture (direct cost
and cost of QALYs) by age and calendar year in men and women in
Belgium assuming the uptake of treatment remains unchanged
2010 2015 2020 2025
Women
50–74 419 438 471 491
75+ 1,148 1,209 1,239 1,295
All 1,567 1,647 1,711 1,786
Men
50–74 336 354 384 407
75+ 437 469 503 569
All 773 823 888 976
Women and Men
50–74 756 792 856 898
75+ 1,585 1,678 1,743 1,864
All 2,340 2,471 2,599 2,762
Table 17 Projected QALYs lost due to incident and prior fractures for
the years 2010 and 2025 by age in men and women in Belgium
Incident fractures Prior fractures All fractures
2010 2025 2010 2025 2010 2025
Women
50–74 2,465 3,001 2,444 2,663 4,909 5,664
75+ 5,070 6,040 7,893 8,458 12,963 14,499
All 7,535 9,041 10,337 11,121 17,872 20,163
Men
50–74 2,145 2,643 1,773 2,050 3,918 4,693
75+ 2,342 3,275 2,631 3,173 4,974 6,447
All 4,487 5,918 4,405 5,222 8,892 11,140
Women and Men
50–74 4,609 5,644 4,217 4,713 8,827 10,357
75+ 7,413 9,315 10,524 11,631 17,937 20,946
All 12,022 14,959 14,741 16,344 26,763 31,303
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Fig. 2 Treatment uptake in Belgium (Defined daily doses [DDDs] per
100,000 persons aged 50 years or above)
Table 19 Number of men and women eligible for treatment, treated
and treatment gap in 2010
Number
potentially
treated
(1000 s)
Number
eligible for
treatment
(1000 s)
Difference
(1000 s)
Treatment
gap (%)
Men 32 58 26 45
Women 214 402 188 47
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to be particularly marked in men (+26 %) compared to
women (+14 %) (Table 18).
Treatment uptake
To estimate uptake of individual osteoporosis treatments,
sales data from IMS Health (2001–2011) were used to
derive the number of defined daily doses (DDDs) sold per
100,000 persons aged 50 years or above (Fig. 2).
Adjusting the sales data for compliance allowed for an
estimation of the proportion of population aged 50 years or
above who received any osteoporosis treatment (see Chapter
5 of the report on Osteoporosis in the European Union:
Medical Management, Epidemiology and Economic Burden
for further details). The proportion of persons over the age
of 50 years who were treated increased from 2 % in 2001 to
6.3 % in 2011 and thereafter decreased.
Treatment gap
In order to assess the potential treatment gap, the numbers of
men and women eligible for treatment in Belgium were
defined as individuals with a 10-year fracture probability
exceeding that of a woman with a prior fragility fracture
derived from FRAX®, equivalent to a ‘fracture threshold’
(See Chapter 5 of the main report for further details). Sub-
sequently, these estimates were compared to the number
individuals who received osteoporosis treatment obtained
from the analysis of IMS Health data. The treatment gaps
in men and women were estimated at 45 % and 47 %
respectively (Table 19). Note that the estimate of the treat-
ment gap is conservative given that it assumes that current
use of osteoporosis treatments are only directed to men and
women at high risk. Not all individuals at high risk as
assessed by FRAX are eligible for reimbursement with the
present reimbursement criteria.
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Epidemiology and Economic Burden of Osteoporosis in
Bulgaria
A report prepared in collaboration with the Internation-
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Abstract
Summary This report describes epidemiology, burden, and
treatment of osteoporosis in Bulgaria.
Introduction Osteoporosis is characterized by reduced
bone mass and disruption of bone architecture, resulting
in increased risks of fragility fractures which represent
the main clinical consequence of the disease. Fragility
fractures are associated with substantial pain and suffer-
ing, disability and even death for the affected patients
and substantial costs to society. The aim of this study is
to describe the epidemiology and economic burden of
fragility fractures as a consequence of osteoporosis in
Bulgaria, as a further detailed addition to the report for
the entire European Union (EU27): Osteoporosis in the
European Union: Medical Management, Epidemiology
and Economic Burden.
Methods The literature on fracture incidence and costs of
fractures in Bulgaria was reviewed and incorporated into a
model estimating the clinical and economic burden of oste-
oporotic fractures in 2010. Furthermore, data on sales of
osteoporosis treatments and the population at high risk were
used to estimate treatment uptake and treatment gap.
Results It was estimated that approximately 38,000 new
fragility fractures were sustained in Bulgaria, comprising
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5,900 hip fractures, 6,400 vertebral fractures, 6,500
forearm fractures and 19,400 other fractures (i.e. frac-
tures of the pelvis, rib, humerus, tibia, fibula, clavicle,
scapula, sternum and other femoral fractures) in 2010.
The economic burden of incident and previous fragility
fractures was estimated at € 42 million for the same
year. Incident fractures represented 71 % of this cost,
long-term fracture care 25 % and pharmacological pre-
vention 3 %. Previous and incident fractures also
accounted for 12,300 quality-adjusted life years
(QALYs) lost during 2010. When accounting for the
demographic projections for 2025, the number of inci-
dent fractures was estimated at 40,000 in 2025,
representing an increase of 1,400 fractures. Hip, clinical
vertebral (spine), forearm and other fractures were esti-
mated to increase by 400, 200, 100 and 600, respec-
tively. The burden of fractures in Bulgaria in 2025 was
estimated to increase by 5 % to € 45 million. Though
the uptake of osteoporosis treatments increased from
2001, the proportion of patients aged 50 or above who
received treatment remained at very low levels in the
past few years. The majority of women at high fracture
risk did not receive active treatment.
Conclusions In spite of the high cost of osteoporosis, a
substantial treatment gap and projected increase of the eco-
nomic burden driven by aging populations, the use of phar-
macological prevention of osteoporosis is significantly less
than optimal, suggesting that a change in healthcare policy
concerning the disease is warranted.
Introduction
Osteoporosis is characterized by reduced bone mass and
disruption of bone architecture, resulting in increased
risks of fragility fractures which represent the main
clinical consequence of the disease. Fragility fractures
are associated with substantial pain and suffering, dis-
ability and even death for the affected patients and
substantial costs to society. The aim of this report was
to characterize the burden of osteoporosis in Bulgaria in
2010 and beyond.
Methods
The literature on fracture incidence and costs of fractures in
Bulgaria was reviewed and incorporated into a model estimat-
ing the clinical and economic burden of osteoporotic fractures
in 2010. Details of the methods used are found in Chapters 3
and 4 of the report Osteoporosis in the European Union:
Medical Management, Epidemiology and Economic Burden,
published concurrently in Archives of Osteoporosis.
Epidemiology of osteoporosis in Bulgaria
For the purpose of this report, the population at risk of
osteoporosis was considered to include men and women
≥50 years. The number of men and women ≥50 years of
age amounted to 1,270,000 and 1,606,000 respectively in
Bulgaria in 2010 (Table 1). A more recent census in 2011
indicates a small decrease in the population aged 50 years or
more from 2.88 million to 2.84 million [2].
In the population at risk, the number of individuals
with osteoporosis—as defined by the WHO diagnostic
criteria—was estimated at 420,000 (Table 2). Allowing
for differences in the calculation of T-scores the esti-
mate for women is similar to previously published data
[3]. There are 1.2 DXA scan machines per million in-
habitants [4], and guidelines for the assessment and
treatment of osteoporosis are available [5]. A country
specific FRAX model for the assessment of fracture risk
is not available for Bulgaria.
Incidence data were not available for Bulgaria; therefore
data for hip fractures was imputed from Romanian age-
standardized incidence rates [7]. Fracture incidence is
presented in Table 3. Standardized to the EU27 population,
this hip fracture incidence (per 100,000 person years) in
men and women ≥50 years of age was estimated at 170.3
and 282.3 respectively.
Table 1 Population at risk: men and women over the age of 50 in
Bulgaria, 2010 [2]
Age (years) Women Men All
50–59 545,000 503,000 1,048,000
60–69 503,000 407,000 910,000
70–79 376,000 257,000 633,000
80–89 170,000 97,000 267,000
90+ 12,000 6,000 18,000
50+ 1,606,000 1,270,000 2,876,000
Table 2 Estimated number of women and men with osteoporosis
(defined as a T-score ≤−2.5 SD) in Bulgaria by age using female-
derived reference ranges at the femoral neck, 2010 [6]
Age (years) Women Men
50–54 16,947 6,375
55–59 26,496 8,680
60–64 40,040 13,630
65–69 45,046 12,728
70–74 55,242 10,920
75–79 66,750 12,051
80+ 85,904 17,098
50+ 336,425 81,482
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The number of incident fractures in 2010 was esti-
mated at 38,000 (Table 4). Incident hip, clinical spine,
forearm and “other” fractures were estimated at 6,000,
6,000, 6,000 and 19,000 respectively. 56 % of fractures
occurred in women. The number of hip fractures is
consistent with Government sources when accounting
for multiple admissions [8].
A prior fracture was defined as a fracture in an individual
who was alive during the index year (i.e. 2010) which had
occurred after the age of 50 years and before 2010. In the
population ≥50 years of age, the proportions of individuals
who had suffered a fracture prior to 2010 were estimated at
1.09 % for hip and 1.14 % for clinical vertebral fractures.
The estimated proportions of men and women with prior hip
and vertebral fractures by age, presented in Table 5, are
consistent with an earlier report of a survey in Bulgarian
women [9].
In the population over 50 years of age, the number of
individuals with hip and clinical vertebral fractures that
occurred before 2010 was estimated at 31,000 and 33,000
respectively (Table 6). Note that fractures sustained in 2010
were not included in the estimate.
The incidence of causally related deaths (per 100,000) in
the first year after fracture by age is presented in Table 7.
The number of causally related deaths in 2010 was estimat-
ed at 647 (Table 8). Hip, vertebral and “other” fractures
accounted for 294, 283 and 71 deaths respectively. Overall,
approximately 47 % of deaths occurred in women.
Cost of osteoporosis in Bulgaria including and excluding
values of QALYs lost
For the purpose of this report, the cost of osteoporosis in
2010 (excluding value of QALYs lost) was considered to
Table 4 Estimated number of incident fractures in Bulgaria, 2010
Fracture at the All
Age (years) hip vertebra forearm other fractures
Women
50–74 1,298 1,997 3,423 4,594 11,312
75+ 2,559 1,562 1,491 4,553 10,164
Total 3,857 3,558 4,914 9,147 21,476
Men
50–74 1,139 2,075 1,380 7,822 12,416
75+ 922 730 198 2,454 4,304
Total 2,061 2,805 1,579 10,277 16,721
Men and Women
50–74 2,437 4,072 4,803 12,416 23,729
75+ 3,481 2,291 1,689 7,007 14,468
Total 5,918 6,363 6,493 19,424 38,197
Table 5 Proportion of men and women (in %) with a prior hip or
clinical vertebral fracture in Bulgaria, 2010
Age (years) Hip fracture Vertebral fracture
Women
50– 1.00.045
55– 5.01.095
60– 8.04.046
65– 2.17.096
70– 8.14.147
75– 5.24.297
80– 2.31.448
5.46.7+58
Men
50– 2.01.045
55– 6.03.095
60– 9.05.046
65– 1.19.096
70– 3.13.147
75– 5.19.197
80– 9.16.248
0.30.5+58
Table 3 Incidence per 100,000 person years of hip, clinical vertebral,
forearm, and “other” fractures in Bulgaria by age
Fracture at the
Age (years) hip vertebra forearm other
Women
50–54 17 44 108 112
55–59 34 94 260 298
60–64 60 105 225 230
65–69 115 168 280 394
70–74 228 321 409 646
75–79 407 396 397 856
80–84 667 419 417 1,133
85+ 1,048 493 447 1,761
Men
50–54 50 129 46 223
55–59 70 121 106 648
60–64 94 225 177 924
65–69 124 194 186 797
70–74 186 283 119 954
75–79 274 316 78 732
80–84 410 285 80 1,091
85+ 587 394 108 1,701
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consist of three components: (i) cost of fractures that oc-
curred in 2010 (“first year costs”); (ii) cost of fractures
sustained prior to year 2010 but which still incurred
costs in 2010 (“long-term disability cost”); and (iii) cost
of pharmacological fracture prevention including admin-
istration and monitoring costs (“pharmacological fracture
prevention costs”). See Chapter 4 of the main report for
further details.
The cost of a hip fracture has been estimated at € 1,826 in
Bulgaria based on hip fracture costs in Slovenia [10]. The
costs are consistent with the information available from the
Romanian National Health Insurance Fund [11]. No other
fracture costs were available. Given that no cost data for the
other fracture sites were found, these were imputed as de-
scribed in Chapter 4 of the main report.
Long-term disability costs were estimated by multiplying
the yearly cost of residing in nursing home (€ 4,044 [12]) with
the simulated number of individuals with prior fractures that
had been transferred to nursing homes due to the fracture.
Annual drug costs (€) for individual treatments are shown in
Table 9. In addition, it was assumed that patients on treatment
made an annual physician visit costing € 2 [13] and a DXA
scan costing € 59 [14] every second year to monitor treatment.
Table 8 The number of deaths in men and women in Bulgaria in the
first year after fracture attributable to the fracture event (causally
related), 2010
Fracture at the
Age (years) hip vertebra “other”
Women
50–74 36 55 5
75+ 115 60 31
Total 151 114 36
Men
50–74 66 121 14
75+ 77 47 20
Total 143 168 34
Men and Women
50–74 102 176 19
75+ 192 107 51
Total 294 283 71
Table 6 Number of men and women in Bulgaria with a prior hip or
clinical vertebral fracture after the age of 50 years, 2010
Age (years) Hip fracture Vertebral fracture
Women
50– 638,9649,547
780,11570,41+57
429,02120,02latoT
Men
50– 227,7095,547
531,4957,5+57
658,11943,11latoT
Men and Women
50– 855,71535,1147
222,51538,91+57
087,23073,13latoT
Table 7 Incidence (per 100,000) of causally related deaths in Bulgaria
within the first year after fracture (adjusted for comorbidities), 2010
Age (years) Hip Clinical vertebral “Other” fracture
Women
50–54 941 1,222 24
55–59 1,314 1,616 39
60–64 1,709 1,984 54
65–69 2,127 2,332 80
70–74 3,224 3,327 147
75–79 4,257 4,113 267
80–84 4,372 3,868 487
85–89 5,207 4,047 912
90+ 3,560 2,007 1,238
Men
50–54 3,892 4,669 61
55–59 4,446 5,055 91
60–64 5,306 5,706 144
65–69 5,591 5,671 201
70–74 6,207 5,910 280
75–79 7,407 6,569 439
80–84 7,920 6,432 665
85–89 9,521 6,959 1,029
90+ 11,042 7,185 1,381
Table 9 One year costs for relevant pharmaceuticals in Bulgaria, 2010
[15]
Annual drug cost (€)
Alendronate 80
Risedronate 147
Etidronate -
Ibandronate 142
Zoledronic acid 309
Raloxifene 279
Strontium ranelate 389
Parathyroid hormone -
Teriparatide 3,198
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The cost of osteoporosis in 2010 was estimated at € 42
million (Table 10). First year costs, subsequent year costs
and pharmacological fracture prevention costs amounted to
€ 30 million, € 11 million and € 1 million, respectively. It is
notable that pharmacological fracture prevention costs
amounted to only 3.1 % of the total cost.
When stratifying costs of osteoporosis by fracture type, hip
fractures were most costly (€ 20 million) followed by “other”
(€ 18 million), spine (€ 2 million) and forearm fractures (€ 1
million) (Table 11 and Fig. 1). Please note that costs for
pharmacological fracture prevention were not included given
that they cannot be allocated to specific fracture sites.
Table 10 Cost of osteoporosis (€) in Bulgaria by age in men and
women, 2010
Age 
(years)
First year
fracture
cost
Long term
disability
costs
Fracture
prevention
cost
Total cost
Women
50–74 7,842,874 1,504,059 731,354 10,078,286
75+ 9,024,313 5,039,264 405,975 14,469,553
Men
50–
Women and Men
50–
All 16,867,187 6,543,323 1,137,328 24,547,839
74 9,471,297 1,653,408 110,324 11,235,029
75+ 3,891,789 2,577,775 49,708 6,519,272
All 13,363,086 4,231,183 160,032 17,754,301
74 17,314,171 3,157,466 841,678 21,313,315
75+ 12,916,102 7,617,040 455,683 20,988,825
All 30,230,273 10,774,506 1,297,361 42,302,140
Table 11 Total cost (€) in 2010 by fracture site in men and women in
Bulgaria. Note that costs for fracture prevention therapy and monitor-
ing are not included
Age Hip Spine Forearm Other All
Women
50–74 3,709,882 751,964 381,844 4,503,243 9,346,933
75+ 8,971,729 545,012 166,283 4,380,554 14,063,578
All 12,681,611 1,296,976 548,128 8,883,796 23,410,510
Men
50–74 3,446,288 722,591 153,970 6,801,854 11,124,704
75+ 3,846,808 234,747 22,141 2,365,868 6,469,564
All 7,293,096 957,338 176,112 9,167,723 17,594,269
Women and Men
50–74 7,156,170 1,474,556 535,815 11,305,097 20,471,637
75+ 12,818,537 779,759 188,425 6,746,422 20,533,142
All 19,974,707 2,254,314 724,239 18,051,519 41,004,779
Hip
49%
Spine
5%
Forearm
2%
Other
44%
Fig. 1 Share (%) of fracture cost by fracture site in Bulgaria. Note that
costs for fracture prevention therapy and monitoring are not included
Table 12 Number of QALYs lost due to fractures during 2010 in men
and women in Bulgaria according to age
Age (years)
50–74 75+ 50+
Women
Incident hip fractures 316 563 879
Incident vertebral fractures 667 469 1,136
Incident forearm fractures 121 46 167
Incident other fractures 550 487 1,037
Prior hip fractures 930 1,946 2,876
Prior vertebral fractures 551 550 1,101
791,7260,4531,3latoT
Men
Incident hip fractures 288 227 515
Incident vertebral fractures 712 239 951
Incident forearm fractures 48 7 54
Incident other fractures 932 282 1,214
Prior hip fractures 874 857 1,732
Prior vertebral fractures 430 219 649
511,5138,1482,3latoT
Men and Women
Incident hip fractures 604 790 1,394
Incident vertebral fractures 1,379 708 2,087
Incident forearm fractures 168 53 221
Incident other fractures 1,482 769 2,251
Prior hip fractures 1,805 2,803 4,608
Prior vertebral fractures 981 769 1,751
213,21398,5914,6latoT
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The number of quality adjusted life years (QALYs)
lost due to osteoporosis in 2010 was estimated at
12,300 (Table 12). 58 % of the total QALY loss was
incurred in women. Prior fractures accounted for 52 %
of the total QALY loss. The monetary value of a QALY
was varied between 1 to 3 times the gross domestic
product (GDP) per capita (Table 13). Assuming a
QALY is valued at 2 times GDP/capita, the total cost
of the QALYs lost was estimated at € 118 million.
When the cost of osteoporosis was combined with the
value for QALYs lost (valued at 2 × GDP), the cost of
osteoporosis amounted to € 160 million in Bulgaria in
2010. Incident fracture, prior fracture, pharmacological
fracture prevention, and value of QALYs lost accounted
for 19 %, 7 %, 1 %, and 74 %, respectively.
Burden of osteoporosis up to 2025
The population above 50 years of age is expected to be
approximately constant at 2.9 million between 2010 and
2025 (Table 14).
The total number of fractures was estimated to rise from
38,000 in 2010 to 40,000 in 2025 (Table 15), corresponding
to an increase of 4 %. Hip, clinical spine, forearm and other
fractures increased by 400, 200, 100 and 600 respectively.
The increase in the number of fractures ranged from 2 % to
8 %, depending on fracture site. The increase in women was
estimated at 7 % while a decrease is expected in men.
The cost of osteoporosis (excluding values of QALYs
lost) was estimated to rise from € 42 million in 2010 to €
45 million in 2025, corresponding to an increase of 5 %
Table 13 Value of lost QALYs
(€) in men and women in
Bulgaria in 2010
1 × GDP/
capita
2 × GDP/
capita
3 × GDP/
capita
Incident hip fractures 6,692,022 13,384,044 20,076,066
Incident vertebral fractures 10,017,949 20,035,897 30,053,846
Incident forearm fractures 1,062,140 2,124,279 3,186,419
Incident other fractures 10,804,803 21,609,606 32,414,408
Prior hip fractures 22,118,181 44,236,361 66,354,542
Prior vertebral fractures 8,402,614 16,805,229 25,207,843
Total 59,097,708 118,195,416 177,293,124
Table 14 Population projections in Bulgaria by age and sex [16]
Population
2010 2015 2020 2025
Women
50–59 545,000 516,000 496,000 504,000
60–69 503,000 528,000 502,000 477,000
70–79 376,000 359,000 399,000 422,000
80–89 170,000 179,000 174,000 175,000
90+ 12,000 20,000 25,000 29,000
Men
50–59 503,000 480,155 472,000 487,000
60–69 407,000 425,000 408,000 396,000
70–79 257,000 238,000 264,000 278,000
80–89 97,000 99,000 90,000 88,000
90+ 6,000 9,000 10,000 10,000
All
50–59 1,048,000 996,155 968,000 991,000
60–69 910,000 953,000 910,000 873,000
70–79 633,000 597,000 663,000 700,000
80–89 267,000 278,000 264,000 263,000
90+ 18,000 29,000 35,000 39,000
000,668,2000,678,2
Table 15 Projected annual number of incident fractures in 2010 and
2025 by fracture site and age in men and women in Bulgaria
Hip Spine Forearm Other
2010 2025 2010 2025 2010 2025 2010 2025
Women
50–74 1,298 1,355 1,997 2,043 3,423 3,392 4,594 4,651
75+ 2,559 2,933 1,562 1,753 1,491 1,652 4,553 5,230
All 3,857 4,288 3,558 3,795 4,914 5,044 9,147 9,881
Men
50–74 1,139 1,159 2,075 2,072 1,380 1,348 7,822 7,743
75+ 922 918 730 733 198 199 2,454 2,445
All 2,061 2,078 2,805 2,806 1,579 1,548 10,277 10,187
Women and Men
50–74 2,437 2,514 4,072 4,115 4,803 4,740 12,416 12,393
75+ 3,481 3,852 2,291 2,486 1,689 1,852 7,007 7,675
All 5,918 6,365 6,363 6,601 6,493 6,592 19,424 20,069
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(Table 16). Costs incurred in women and men increased by
9 % and 1 % respectively.
The total number of QALYs lost due to fracture was
estimated to rise only from 12,300 in 2010 to 12,800 in
2025, corresponding to an increase of 4 % (Table 17).
The increase in men was estimated to be 1 % and the
increase in women was estimated at 6 %. Incident and
prior fractures accounted for 46 % and 54 % of the
increase respectively.
The cost of osteoporosis including value of QALYs
lost was estimated to increase from approximately € 160
million in 2010 to € 168 million in 2025. The increase
was estimated to be 1 % in men and 7 % in women
(Table 18).
Treatment uptake
To estimate uptake of individual osteoporosis treatments,
sales data from IMS Health (2001–2011) were used to
derive the number of defined daily doses (DDDs) sold per
100,000 persons aged 50 years or above (Fig. 2).
Adjusting the sales data for compliance allowed for an
estimation of the proportion of population aged 50 years or
above who received any osteoporosis treatment (see Chapter 5
of the report on Osteoporosis in the European Union: Medical
Management, Epidemiology and Economic Burden for fur-
ther details). The proportion of persons over the age of
50 years who were treated increased from 0.01 % in 2001 to
0.53 % in 2011.
Table 16 Current and future cost (€ 000, 000) of osteoporosis (ex-
cluding values of QALYs lost) by age and calendar year in men and
women in Bulgaria
2010 2015 2020 2025
Women
50–74 10 10 11 10
75+ 14 15 15 16
All 25 25 26 27
Men
50–74 11 11 12 11
75+ 7 6 6 7
All 18 18 18 18
Women and Men
50–74 21 22 22 22
75+ 21 21 21 23
All 42 43 44 45
Table 17 Projected QALYs lost due to incident and prior fractures for
the years 2010 and 2025 by age in men and women in Bulgaria
Incident fractures Prior fractures All fractures
2010 2025 2010 2025 2010 2025
Women
50–74 1,654 1,684 1,481 1,528 3,135 3,213
75+ 1,566 1,771 2,496 2,674 4,062 4,445
All 3,219 3,456 3,978 4,202 7,197 7,658
Men
50–74 1,980 1,973 1,304 1,330 3,284 3,303
75+ 755 753 1,076 1,094 1,831 1,848
All 2,734 2,726 2,381 2,424 5,115 5,151
Women and Men
50–74 3,633 3,657 2,786 2,858 6,419 6,515
75+ 2,320 2,525 3,573 3,768 5,893 6,293
All 5,954 6,182 6,358 6,626 12,312 12,808
Table 18 Present and future cost (€ 000,000) of fracture (direct cost
and cost of QALYs) by age and calendar year in men and women from
Bulgaria assuming the uptake of treatment remains unchanged
2010 2015 2020 2025
Women
50–74 40 41 42 41
75+ 53 55 56 59
All 94 95 98 100
Men
50–74 43 42 42 43
75+ 24 24 23 24
All 67 66 66 67
Women and Men
50–74 83 83 84 84
75+ 78 78 79 83
All 160 161 164 168
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Fig. 2 Treatment uptake in Bulgaria (Defined daily doses [DDDs] per
100,000 persons aged 50 years or above)
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Treatment gap
In order to assess the potential treatment gap, the numbers of
men and women eligible for treatment in Bulgaria were de-
fined as individuals with a 10-year fracture probability ex-
ceeding that of a woman with a prior fragility fracture derived
from FRAX®, equivalent to a ‘fracture threshold’ (See Chap-
ter 5 of the main report for further details). Subsequently, these
estimates were compared to the number individuals who
received osteoporosis treatment obtained from the analysis
of IMS Health data. The treatment gaps in men and women
were estimated at 98 % and 95 % respectively (Table 19).
Note that the estimate of the treatment gap is conservative
given that it assumes that current use of osteoporosis treat-
ments are only directed to men and women at high risk.
Acknowledgements This report has been sponsored by an unrestricted
educational grant from the European Federation of Pharmaceutical
Industry Associations (EFPIA) and the International Osteoporosis
Foundation (IOF). The data in this report have been used to populate
a more detailed report on Osteoporosis in the European Union: Medical
Management, Epidemiology and Economic Burden. We acknowledge
the help of Helena Johansson and Prof Anders Odén for their help in
the calculations of fracture probability. We thank Oskar Ström and
Fredrik Borgström who were prominent authors of an earlier report
covering a similar topic in a sample of EU countries and provided the
template for the present report. We also thank Dr Dominique Pierroz,
Carey Kyer and Ageeth Van Leersum of the IOF for their help in
editing the report. The report has been reviewed by the members of
the IOF EU Osteoporosis Consultation Panel and the IOF European
Parliament Osteoporosis Interest Group, and we are grateful for their
local insights on the management of osteoporosis in each country.
References
1. National Statistical Institute (NSI) (2011) 2011 census final results.
Accessed January 2013. http://censusresults.nsi.bg/Census/Reports/
2/2/R1.aspx
2. Eurostat (2011) Statistics database. Data retrieved in November,
2011: http://epp.eurostat.ec.europa.eu
3. Borissova A-M, Rashkov R, Boyanov M, Shinkov A, Popivanov P,
Temelkova N, Vlahov J, Gavrailova M (2011) Femoral neck bone
mineral density and 10-year absolute fracture risk in a national
representative sample of Bulgarian women aged 50 years and
older. Arch Osteoporosis 6:189–195
4. Kanis J (2011) personal communication, data on file.
5. The International Osteoporosis Foundation (IOF) (2011) Eastern
European & Central Asian Regional Audit—Individual Country
Reports. www.iofbonehealth.org/publications/eastern-european-
central-asian-audit-2010.html;
6. Looker AC, Wahner HW, Dunn WL, Calvo MS, Harris TB,
Heyse SP, Johnston CC, Jr., Lindsay R (1998) Updated data
on proximal femur bone mineral levels of US adults.
Osteoporos Int 8: 468–89
7. Grigorie D, Sucaliuc A, Johansson H, Kanis JA,McCloskey E (2012)
Incidence of hip fracture in Romania and the development of a
Romanian FRAX model. Calcif Tiss Intl 92: 429–36
8. BoyanovMA (2006) Prevalence of LowCentral BoneMineralDensity in
a Bulgarian Female Referral Population: a Pilot Study. Rheumatol Int
26:523–9
9. LesnyakO,Nauroy L (2010) The Eastern European and central Asian
regional audit. Epidemiology, cost and burden of osteoporosis in
2010. International Osteoporosis Foundation, Nyon. Available at
http://www.iofbonehealth.org/eastern-european-central-asian-audit
10. Dzajkovska B, Wertheimer AI, Mrhar A (2007) The burden-of-
illness study on osteoporosis in the Slovenian female population.
Pharm World Sci 29: 404–11
11. Borissova A-M, personal communication, December 2012.
12. Nursing homes (2011) Personal communication—average of three
Bulgarian nursing homes (750, 650, and 550 lev/month).
13. Vatkova J (2011) National Health Insurance Fund in Bulgaria.
Personal communication.
14. International Osteoporosis Foundation (2011) Osteoporosis in the
European Union in 2008: Ten years of progress and ongoing
challenges. IOF, Nyon
15. Ministry of Health Bulgaria (2011). Accessed December 2011.
www.mh.government.bg/Articles.aspx?lang=bg-BG&pageid=
383&categoryid=3999.
16. United Nations Department of Economic and Social
Affairs—Population Division (2011) World Population Prospects
test. Data retrieved in November, 2011: http://esa.un.org/unpd/
wpp/unpp/p2k0data.asp
Table 19 Number of men and women eligible for treatment, treated
and treatment gap in 2010
Number
potentially
treated
(1000 s)
Number
eligible for
treatment
(1000 s)
Difference
(1000 s)
Treatment
gap (%)
Men 2 92 90 98
Women 13 240 227 95
Arch Osteoporos (2013) 8:137 Page 27 of 218, 137
Epidemiology and Economic Burden of Osteoporosis in
Cyprus
A report prepared in collaboration with the Internation-
al Osteoporosis Foundation (IOF) and the European
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Abstract
Summary This report describes epidemiology, burden, and
treatment of osteoporosis in Cyprus.
Introduction Osteoporosis is characterized by reduced bone
mass and disruption of bone architecture, resulting in increased
risks of fragility fractures which represent the main clinical
consequence of the disease. Fragility fractures are associated
with substantial pain and suffering, disability and even death
for the affected patients and substantial costs to society. The aim
of this study is to describe the epidemiology and economic
burden of fragility fractures as a consequence of osteoporosis in
Cyprus, as a further detailed addition to the report for the entire
European Union (EU27): Osteoporosis in the European Union:
Medical Management, Epidemiology and Economic Burden.
Methods The literature on fracture incidence and costs of
fractures in Cyprus was reviewed and incorporated into a
model estimating the clinical and economic burden of oste-
oporotic fractures in 2010. Furthermore, data on sales of
osteoporosis treatments and the population at high risk were
used to estimate treatment uptake and treatment gap.
Results It was estimated that approximately 5,000 new fragil-
ity fractures were sustained in Cyprus, comprising 800 hip
fractures, 800 vertebral fractures, 1,000 forearm fractures and
2,600 other fractures (i.e. fractures of the pelvis, rib, humerus,
tibia, fibula, clavicle, scapula, sternum and other femoral
fractures) in 2010. The economic burden of incident and
previous fragility fractures was estimated at € 52 million for
the same year. Incident fractures represented 65% of this cost,
long-term fracture care 13 % and pharmacological prevention
22%. Previous and incident fractures also accounted for 1,800
quality-adjusted life years (QALYs) lost during 2010. When
accounting for the demographic projections for 2025, the
number of incident fractures was estimated at 7,700 in 2025,
representing an increase of 2,600 fractures. Hip, clinical ver-
tebral (spine), forearm and other fractures were estimated to
increase by 440, 390, 420 and 1,300, respectively. The burden
of fractures in Cyprus in 2025 was estimated to increase with
47 % to € 76 million.
Conclusions There is a high cost of osteoporosis with a
substantial projected increase of the economic burden driven
by an aging population, suggesting that a change in
healthcare policy concerning the disease is warranted.
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Introduction
Osteoporosis is characterized by reduced bone mass and
disruption of bone architecture, resulting in increased risks
of fragility fractures which represent the main clinical con-
sequence of the disease. Fragility fractures are associated
with substantial pain and suffering, disability and even death
for the affected patients and substantial costs to society. The
aim of this report was to characterize the burden of osteo-
porosis in Cyprus in 2010 and beyond.
Methods
The literature on fracture incidence and costs of fractures in
Cyprus was reviewed and incorporated into a model esti-
mating the clinical and economic burden of osteoporotic
fractures in 2010. Details of the methods used are found in
Chapters 3 and 4 of the report Osteoporosis in the European
Union: Medical Management, Epidemiology and Economic
Burden, published concurrently in Archives of Osteoporosis.
Epidemiology of osteoporosis in Cyprus
For the purpose of this report, the population at risk of osteo-
porosis was considered to include men and women ≥50 years.
The number of men and women ≥50 years of age amounted to
150,000 and 161,000 respectively in Cyprus in 2010 (Table 1).
In the population at risk, the number of individuals with
osteoporosis—as defined by the WHO diagnostic criteria—was
estimated at 40,000 (Table 2). There are 23.9 DXA scan ma-
chines per million (m) inhabitants [2], and there are no guide-
lines for osteoporosis treatment [3]. A country specific FRAX
model for the assessment of fracture risk is not available for
Cyprus.
Incidence data was not available for Cyprus, therefore data
for hip fractures was imputed from Greek age-standardized
incidence rates [5]. Fracture incidence is presented in Table 3.
Standardized to the EU27 population, this hip fracture incidence
(per 100,000 person years) in men and women ≥50 years of age
was estimated at 212.7 and 494.0 respectively. The incidence of
vertebral, forearm and “other” fractures was imputed using the
methods described in Chapter 3 of the main report.
The number of incident fractures in 2010 was estimated at
approximately 5,000 (Table 4). Incident hip, clinical spine,
forearm fractures were estimated at approximately 1,000 each
and “other” fractures were estimated at 3,000. 61 % of frac-
tures occurred in women.
A prior fracture was defined as a fracture in an individual
who was alive during the index year (i.e. 2010) which had
occurred after the age of 50 years and before 2010. In the
population ≥50 years of age, the proportions of individuals
Table 1 Population at risk: men and women over the age of 50 in
Cyprus, 2010 [1]
Age (years) Women Men All
50–59 65,000 66,000 131,000
60–69 49,000 45,000 94,000
70–79 30,000 27,000 57,000
80–89 15,000 11,000 26,000
90+ 2,000 1,000 3,000
50+ 161,000 150,000 311,000
Table 2 Estimated number of women and men with osteoporosis
(defined as a T-score ≤−2.5 SD) in Cyprus by age using female-
derived reference ranges at the femoral neck, 2010 [4]
Age (years) Women Men
50–54 2,205 875
55–59 2,880 1,085
60–64 3,861 1,450
65–69 4,444 1,480
70–74 4,743 1,248
75–79 4,875 1,133
80+ 8,024 1,992
50+ 31,032 9,263
Table 3 Incidence per 100,000 person years of hip, clinical vertebral,
forearm, and “other” fractures in Cyprus by age
Fracture at the
Age (years) hip vertebra forearm other
Women
50–54 2 5 12 12
55–59 61 170 469 537
60–64 120 213 455 464
65–69 198 288 480 675
70–74 436 614 783 1,235
75–79 707 688 690 1,488
80–84 1,281 805 802 2,178
85+ 1,855 872 792 3,116
Men
50–54 21 55 20 94
55–59 45 79 69 420
60–64 69 165 130 678
65–69 102 161 154 660
70–74 220 336 141 1,132
75–79 363 418 103 968
80–84 725 503 141 1,927
85+ 1,087 730 199 3,148
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who had suffered a fracture prior to 2010 were estimated at
1.58 % for hip and 1.98 % for vertebral fractures. The
estimated proportions of men and women with prior hip
and vertebral fractures by age are presented in Table 5.
In the population over 50 years of age, the number of
individuals with hip and vertebral fractures that occurred
before 2010 was estimated at 5,000 and 6,000 respectively
(Table 6). Note that fractures sustained in 2010 were not
included in the estimate.
The incidence of causally related deaths (per
100,000) in the first year after fracture by age is
presented in Table 7. The number of causally related
deaths in 2010 was estimated at 53 (Table 8). Hip,
vertebral and “other” fractures accounted for 27, 19
and 8 deaths respectively. Overall, approximately 46 %
of deaths occurred in women.
Table 5 Proportion of men and women (in %) with a prior hip or
clinical vertebral fracture in Cyprus, 2010
Age (years) Hip fracture Vertebral fracture
Women
50– 0.00.045
55– 6.02.095
60– 5.17.046
65– 4.24.196
70– 3.47.247
75– 3.68.497
80– 9.78.748
2.017.31+58
Men
50– 1.00.045
55– 5.02.095
60– 9.05.046
65– 4.18.096
70– 1.24.147
75– 0.35.297
80– 0.44.448
0.60.8+58
Table 7 Incidence (per 100,000) of causally related deaths in Cyprus
within the first year after fracture (adjusted for comorbidities), 2010
Age (years) Hip Clinical vertebral “Other” fracture
Women
50–54 641 833 17
55–59 463 569 14
60–64 683 793 22
65–69 1,007 1,104 38
70–74 1,698 1,753 77
75–79 2,642 2,552 166
80–84 3,468 3,069 386
85–89 3,096 2,407 542
90+ 4,436 2,501 1,542
Men
50–54 1,496 1,794 23
55–59 1,999 2,273 41
60–64 1,768 1,901 48
65–69 2,904 2,945 104
70–74 3,040 2,895 137
75–79 4,005 3,552 238
80–84 5,830 4,734 490
85–89 8,267 6,042 893
90+ 13,245 8,619 1,657
Table 4 Estimated number of incident fractures in Cyprus, 2010
Fracture at the All
Age (years) hip vertebra forearm other fractures
Women
50–74 178 275 579 753 1,786
75+ 316 171 208 654 1,349
Total 494 446 786 1,408 3,135
Men
50–74 115 199 129 759 1,202
75+ 167 127 36 463 793
Total 282 326 165 1,222 1,995
Men and Women
50–74 294 474 708 1,513 2,988
75+ 483 298 243 1,117 2,142
Total 777 772 951 2,630 5,130
Table 6 Number of men and women in Cyprus with a prior hip or
clinical vertebral fracture after the age of 50 years, 2010
Age (years) Hip fracture Vertebral fracture
Women
50– 888,1720,147
133,2063,2+57
912,4783,3latoT
Men
50– 930,198547
298649+57
139,1535,1latoT
Men and Women
50– 729,2616,147
322,3503,3+57
051,6129,4latoT
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Cost of osteoporosis in Cyprus including and excluding
value of QALYs lost
For the purpose of this report, the cost of osteoporosis in
2010 (excluding value of QALYs lost) was considered to
consist of three components: (i) cost of fractures that oc-
curred in 2010 (“first year costs”); (ii) cost of fractures
sustained prior to 2010 but which still incurred costs in
2010 (“long-term disability cost”); and (iii) cost of pharma-
cological fracture prevention including administration and
monitoring costs (“pharmacological fracture prevention
costs”). See Chapter 4 of the main report for further details.
The cost of a hip fracture has been estimated at
€ 14,821 in Cyprus based on cost estimates in Italy
[6]. Given that no cost data for the other fracture sites
were found, these were imputed as described in Chapter
4 of the main report.
Long-term disability costs were estimated by multiplying
the yearly cost of residing in nursing home (€ 15,261 [7,8],
approximated by adjusting the Bulgarian cost for health
adjusted price levels) with the simulated number of individ-
uals with prior fractures that had been transferred to nursing
home due to the fracture.
Annual drug costs (€) for individual treatments are
shown in Table 9. In addition, it was assumed that
patients on treatment made an annual physician visit
costing € 14 [9] and a DXA scan costing € 75 [10]
every second year to monitor treatment.
The cost of osteoporosis in 2010 was estimated at €
52 million (Table 10). First year costs, subsequent year
costs and pharmacological fracture prevention costs
amounted to € 34 million, € 7 million and € 12 million,
respectively. It is notable that pharmacological fracture pre-
vention costs accounted for only 22.4 % of the total cost.
When stratifying costs of osteoporosis by fracture type,
“other” fractures were most costly (€ 20 million) followed
by hip (€ 17million), spine (€ 2 million) and forearm fractures
(€ 1 million) (Table 11 and Fig. 1). Please note that costs for
pharmacological fracture prevention were not included given
that they cannot be allocated to specific fracture sites.
The number of QALYs lost due to osteoporosis in 2010
was estimated at 1,800 (Table 12). Prior fractures accounted
for 58 % of the total loss and 63 % of the loss occurred in
women. The monetary value of a QALY was varied between
1 to 3 times the gross domestic product (GDP) per capita
(Table 13). Assuming a QALY is valued at 2 times
GDP/capita, the total cost of the QALYs lost was estimated
at € 78 million.
Table 8 The number of deaths in men and women in Cyprus in the
first year after fracture attributable to the fracture event (causally
related), 2010
Fracture at the
Age (years) hip vertebra “other”
Women
50–74 2 3 0
75+ 11 4 4
Total 13 8 4
Men
50–74 3 5 1
75+ 11 6 3
Total 14 11 4
Men and Women
50–74 5 8 1
75+ 22 10 7
Total 27 19 8
Table 10 Cost of osteoporosis (€) in Cyprus by age in men and
women, 2010
Age
(years)
First year
fracture
cost
Long term
disability
costs
Fracture
prevention
cost
Total cost
Women
50–74 9,814,331 974,826 7,000,496 17,789,653
75+ 9,775,132 3,225,383 3,174,204 16,174,719
All 19,589,463 4,200,209 10,174,700 33,964,372
Men
50–74 8,073,051 670,806 1,025,858 9,769,715
75+ 5,946,705 1,636,933 405,798 7,989,436
All 14,019,756 2,307,739 1,431,655 17,759,151
Women and Men
50–74 17,887,382 1,645,632 8,026,353 27,559,367
75+ 15,721,837 4,862,316 3,580,002 24,164,155
All 33,609,219 6,507,948 11,606,355 51,723,522
Table 9 One year costs
for relevant pharmaceu-
ticals in Cyprus, 2010
[9]
Annual drug
cost (€)
Alendronate 327
Risedronate 508
Etidronate -
Ibandronate 489
Zoledronic acid 481
Raloxifene 1,037
Strontium ranelate 655
Parathyroid hormone -
Teriparatide 7,179
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When the cost of osteoporosis was combined with the
value for QALYs lost (valued at 2 × GDP), the cost of
osteoporosis amounted to € 130 million in Cyprus in
2010. Incident fracture, prior fracture, pharmacological frac-
ture prevention, and value of QALYs lost accounted for
26 %, 5 %, 9 % and 60 %, respectively.
Burden of osteoporosis up to 2025
The population above 50 years of age is expected to increase
from 311,000 in 2010 to 430,000 in 2025, corresponding to
an increase of 38 % (Table 14).
The total number of fractures was estimated to rise
from 5,000 in 2010 to 8,000 in 2025 (Table 15),
corresponding to an increase of 50 %. Hip, clinical
spine, forearm and other fractures increased by 400,
400, 400 and 1,300 respectively. The increase in theHip
42%
Spine
6%Forearm2%
Other
50%
Fig. 1 Share (%) of fracture cost by fracture site in Cyprus. Note that
costs for fracture prevention therapy and monitoring are not included
Table 12 Number of QALYs lost due to fractures during 2010 in men
and women in Cyprus according to age
Age (years)
50–74 75+ 50+
Women
Incident hip fractures 43 68 111
Incident vertebral fractures 91 50 141
Incident forearm fractures 20 6 27
Incident other fractures 90 69 159
Prior hip fractures 161 324 485
Prior vertebral fractures 105 115 220
341,1236115latoT
Men
Incident hip fractures 28 40 68
Incident vertebral fractures 66 41 106
Incident forearm fractures 4 1 6
Incident other fractures 90 53 143
Prior hip fractures 92 140 232
Prior vertebral fractures 58 47 105
066223833latoT
Men and Women
Incident hip fractures 71 108 179
Incident vertebral fractures 157 91 247
Incident forearm fractures 25 8 32
Incident other fractures 180 122 302
Prior hip fractures 253 464 717
Prior vertebral fractures 163 162 325
308,1559848latoT
Table 13 Value of lost QALYs (€) in men and women in Cyprus in
2010
1 × GDP/
capita
2 × GDP/
capita
3 × GDP/
capita
Incident hip fractures 3,878,655 7,757,311 11,635,966
Incident vertebral
fractures
5,369,465 10,738,931 16,108,396
Incident forearm
fractures
704,293 1,408,586 2,112,879
Incident other fractures 6,555,346 13,110,692 19,666,038
Prior hip fractures 15,557,915 31,115,830 46,673,745
Prior vertebral fractures 7,059,402 14,118,803 21,178,205
Total 39,125,076 78,250,153 117,375,229
Table 11 Total cost (€) in 2010 by fracture site in men and women in
Cyprus. Note that costs for fracture prevention therapy and monitoring
are not included
Age Hip Spine Forearm Other All
Women
50–74 3,540,884 878,017 524,142 5,846,114 10,789,157
75+ 7,293,878 501,030 187,921 5,017,685 13,000,515
All 10,834,762 1,379,048 712,063 10,863,799 23,789,672
Men
50–74 2,272,964 611,810 116,786 5,742,298 8,743,857
75+ 3,627,001 350,429 32,421 3,573,787 7,583,638
All 5,899,965 962,239 149,206 9,316,085 16,327,495
Women and Men
50–74 5,813,848 1,489,828 640,927 11,588,411 19,533,014
75+ 10,920,880 851,460 220,342 8,591,472 20,584,153
All 16,734,727 2,341,287 861,269 20,179,883 40,117,167
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number of fractures ranged from 44 % to 57 %,
depending on fracture site. The increase was estimated
to be particularly marked in men (49 %) compared to
women (51 %).
The cost of osteoporosis (excluding value of QALYs lost)
was estimated to rise from € 52 million in 2010 to € 76
million in 2025, corresponding to an increase of 47 % (Table
16). Costs incurred in women and men increased by 47 %
and 48 % respectively.
The total number of QALYs lost due to fracture was
estimated to rise from 1,800 in 2010 to 2,300 in 2025, corre-
sponding to an increase of 29 % (Table 17). The increase was
estimated to be particularly marked in men (38 %) compared
to women (24 %). Incident and prior fractures accounted for
73 % and 27 % of the increase respectively.
Table 14 Population projections in Cyprus by age and sex [11]
Population
2010 2015 2020 2025
Women
50–59 65,000 71,000 73,000 77,000
60–69 49,000 56,000 63,000 68,000
70–79 30,000 36,000 42,000 49,000
80–89 15,000 17,000 20,000 23,000
90+ 2,000 2,000 4,000 4,000
Men
50–59 66,000 72,000 75,000 80,000
60–69 45,000 54,000 62,000 68,000
70–79 27,000 31,000 36,000 43,000
80–89 11,000 12,000 14,000 16,000
90+ 1,000 1,000 1,000 2,000
All
50–59 131,000 143,000 148,000 157,000
60–69 94,000 110,000 125,000 136,000
70–79 57,000 67,000 78,000 92,000
80–89 26,000 29,000 34,000 39,000
90+ 3,000 3,000 5,000 6,000
000,034000,113
Table 15 Projected annual number of incident fractures in 2010 and
2025 by fracture site and age in men and women in Cyprus
Hip Spine Forearm Other
2010 2025 2010 2025 2010 2025 2010 2025
Women
50–74 178 257 275 386 579 791 753 1,051
75+ 316 527 171 283 208 339 654 1,090
All 494 784 446 669 786 1,130 1,408 2,141
Men
50–74 115 170 199 288 129 184 759 1,088
75+ 167 263 127 202 36 57 463 729
All 282 433 326 490 165 241 1,222 1,817
Women and Men
50–74 294 426 474 674 708 975 1,513 2,139
75+ 483 790 298 485 243 396 1,117 1,819
All 777 1,217 772 1,159 951 1,371 2,630 3,958
Table 16 Current and future cost (€ 000,000) of osteoporosis (exclud-
ing value of QALYs lost) by age and calendar year in men and women
in Cyprus
2010 2015 2020 2025
Women
50–74 18 21 23 25
75+ 16 18 22 25
All 34 39 45 50
Men
50–74 10 11 13 14
75+ 8 9 10 12
All 18 20 23 26
Women and Men
50–74 28 32 35 39
75+ 24 27 32 37
All 52 59 67 76
Table 17 Projected QALYs lost due to incident and prior fractures for
the years 2010 and 2025 by age in men and women in Cyprus
Incident fractures Prior fractures All fractures
2010 2025 2010 2025 2010 2025
Women
50–74 244 342 266 288 511 630
75+ 193 320 439 472 632 792
All 438 662 705 760 1,143 1,422
Men
50–74 188 271 150 186 338 458
75+ 135 213 187 242 322 454
All 323 484 337 428 660 912
Women and Men
50–74 433 613 416 474 848 1,087
75+ 328 533 626 714 955 1,247
All 761 1,146 1,042 1,188 1,803 2,334
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The cost of osteoporosis including value of QALYs lost
was estimated to increase from approximately € 130 million
in 2010 to € 177 million in 2025. The increase was estimat-
ed to be particularly marked in men (+42 %) compared to
women (+33 %) (Table 18).
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Abstract
Summary This report describes epidemiology, burden, and
treatment of osteoporosis in the Czech Republic.
Introduction Osteoporosis is characterized by reduced
bone mass and disruption of bone architecture, resulting
in increased risks of fragility fractures which represent
the main clinical consequence of the disease. Fragility
fractures are associated with substantial pain and suffer-
ing, disability and even death for the affected patients
and substantial costs to society. The aim of this study is
to describe the epidemiology and economic burden of
fragility fractures as a consequence of osteoporosis in
the Czech Republic, as a further detailed addition to
the report for the entire European Union (EU27): Oste-
oporosis in the European Union: Medical Management,
Epidemiology and Economic Burden.
Methods The literature on fracture incidence and costs of
fractures in the Czech Republic was reviewed and in-
corporated into a model estimating the clinical and
economic burden of osteoporotic fractures in 2010. Fur-
thermore, data on sales of osteoporosis treatments and
the population at high risk were used to estimate treat-
ment uptake and treatment gap.
Results It was estimated that approximately 72,000 new
fragility fractures were sustained in the Czech Republic,
comprising 12,000 hip fractures, 11,000 vertebral frac-
tures, 12,000 forearm fractures and 37,000 other frac-
tures (i.e. fractures of the pelvis, rib, humerus, tibia,
fibula, clavicle, scapula, sternum and other femoral frac-
tures) in 2010. The economic burden of incident and
previous fragility fractures was estimated at € 273 mil-
lion for the same year. Incident fractures represented
60 % of this cost, long-term fracture care 20 % and
pharmacological prevention 19 %. Previous and incident
fractures also accounted for 22,800 quality-adjusted life
years (QALYs) lost during 2010. When accounting for
the demographic projections for 2025, the number of
incident fractures was estimated at 94,000 in 2025,
representing an increase of 21,000 fractures. Hip, clini-
cal vertebral (spine), forearm and other fractures were
estimated to increase by 4,700, 3,400, 2,400 and
11,000, respectively. The burden of fractures in the
Czech Republic in 2025 was estimated to increase by
29 % to € 352 million. Though the uptake of osteopo-
rosis treatments increased from 2001, the proportion of
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patients aged 50 or above who received treatment
remained at very low levels in the past few years. The
majority of women at high fracture risk did not receive
active treatment.
Conclusions In spite of the high cost of osteoporosis, a
substantial treatment gap and projected increase of the eco-
nomic burden driven by an aging population, the use of
pharmacological prevention of osteoporosis is significantly
less than optimal, suggesting that a change in healthcare
policy concerning the disease is warranted.
Introduction
Osteoporosis is characterized by reduced bone mass and
disruption of bone architecture, resulting in increased risks
of fragility fractures which represent the main clinical con-
sequence of the disease. Fragility fractures are associated
with substantial pain and suffering, disability and even death
for the affected patients and substantial costs to society. The
aim of this report was to characterize the burden of osteo-
porosis in the Czech Republic in 2010 and beyond.
Methods
The literature on fracture incidence and costs of fractures in
the Czech Republic was reviewed and incorporated into a
model estimating the clinical and economic burden of oste-
oporotic fractures in 2010. Details of the methods used are
found in Chapters 3 and 4 of the report Osteoporosis in the
European Union: Medical Management, Epidemiology and
Economic Burden, published concurrently in Archives of
Osteoporosis.
Epidemiology of osteoporosis in the Czech Republic
For the purpose of this report, the population at risk of
osteoporosis was considered to include men and women
≥50 years. The number of men and women ≥50 years of
age amounted to 1,710,000 and 2,092,000 respectively in
the Czech Republic in 2010 (Table 1).
In the population at risk, the number of individuals
with osteoporosis—as defined by the WHO diagnostic
criteria—was estimated at 530,000 (Table 2). There are
5.2 DXA scan machines per million inhabitants [2], and
guidelines for the assessment and treatment of osteopo-
rosis are available [3]. A country specific FRAX model
is also available for the assessment of fracture risk
(http://www.shef.ac.uk/FRAX/).
Data on hip fracture incidence are available for the
Czech Republic [5]. Given that country specific
incidence of vertebral, forearm and, “other” fractures
were not found, these were imputed using the methods
described in Chapter 3 of the main report. Fracture
incidence is presented in Table 3. Standardized to the
EU27 population, hip fracture incidence (per 100,000
person years) in men and women ≥50 years of age
was estimated at 277.1 and 566.6 respectively.
The number of incident fractures in 2010 was estimated at
72,000 (Table 4). Incident hip, clinical spine, forearm and
“other” fractures were estimated at 12,000, 11,000, 12,000
and 37,000 respectively. 61% of fractures occurred in women.
A prior fracture was defined as a fracture in an individual
who was alive during the index year (i.e. 2010) which had
occurred after the age of 50 years and before 2010. In the
population ≥50 years of age, the proportions of individuals
who had suffered a fracture prior to 2010 were estimated at
1.55 % for hip and 1.69 % for clinical vertebral fractures.
The estimated proportions of men and women with prior hip
and vertebral fractures by age are presented in Table 5.
In the population over 50 years of age, the number of
individuals with hip and vertebral fractures that occurred
before 2010 was estimated at 59,000 and 64,000 respectively
(Table 6). Note that fractures sustained in 2010 were not
included in the estimate.
Table 1 Population at risk: men and women over the age of 50 in the
Czech Republic, 2010 [1]
Age (years) Women Men All
50–59 768,000 746,000 1,514,000
60–69 662,000 573,000 1,235,000
70–79 406,000 276,000 682,000
80–89 235,000 109,000 344,000
90+ 21,000 6,000 27,000
50+ 2,092,000 1,710,000 3,802,000
Table 2 Estimated number of women and men with osteoporosis
(defined as a T-score ≤−2.5 SD) in the Czech Republic by age using
female-derived reference ranges at the femoral neck, 2010 [4]
Age (years) Women Men
50–54 23,310 9,200
55–59 38,208 13,230
60–64 55,484 20,068
65–69 55,348 16,798
70–74 56,637 11,544
75–79 76,125 13,184
80+ 120,832 19,090
50+ 425,944 103,114
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The incidence of causally related deaths (per 100,000) in
the first year after fracture by age is presented in Table 7. The
number of causally related deaths in 2010 was estimated at
1,034 (Table 8). Hip, vertebral and “other” fractures accounted
for 501, 380 and 154 deaths respectively. Overall, approxi-
mately 50 % of deaths occurred in women.
Cost of osteoporosis in the Czech Republic including
and excluding values of QALYs lost
For the purpose of this report, the cost of osteoporosis
in 2010 (excluding value of QALYs lost) was consid-
ered to consist of three components: (i) cost of fractures
that occurred in 2010 (“first year costs”); (ii) cost of
fractures sustained prior to year 2010 but which still
Table 4 Estimated number of incident fractures in the Czech Repub-
lic, 2010
Fracture at the All
Age (years) hip vertebra forearm other fractures
Women
50–74 1,826 2,860 5,590 7,252 17,529
75+ 6,504 3,546 3,774 12,390 26,213
Total 8,330 6,406 9,364 19,642 43,741
Men
50–74 1,649 3,017 2,102 11,698 18,466
75+ 2,111 1,606 448 5,821 9,987
Total 3,761 4,623 2,550 17,519 28,453
Men and Women
50–74 3,476 5,877 7,692 18,950 35,995
75+ 8,615 5,151 4,222 18,211 36,199
Total 12,091 11,029 11,914 37,161 72,194
Table 5 Proportion of men and women (in %) with a prior hip or
clinical vertebral fracture in the Czech Republic, 2010
Age (years) Hip fracture Vertebral fracture
Women
50– 1.01.045
55– 6.02.095
60– 0.15.046
65– 5.19.096
70– 6.28.147
75– 1.45.397
80– 9.57.648
3.99.31+58
Men
50– 2.01.045
55– 6.04.095
60– 1.17.046
65– 5.10.196
70– 9.15.147
75– 5.23.297
80– 3.30.448
7.54.8+58
Table 6 Number of men and women in the Czech Republic with a
prior hip or clinical vertebral fracture after the age of 50 years, 2010
Age (years) Hip fracture Vertebral fracture
Women
50– 090,61681,947
739,62738,13+57
720,34320,14latoT
Men
50– 723,31076,847
689,7682,9+57
313,12659,71latoT
Men and Women
50– 714,92658,7147
329,43321,14+57
043,46979,85latoT
Table 3 Incidence per 100,000 person years of hip, clinical vertebral,
forearm, and “other” fractures in the Czech Republic by age
Fracture at the
Age (years) hip vertebra forearm other
Women
50–54 23 58 143 148
55–59 45 124 344 394
60–64 80 141 302 308
65–69 144 210 350 493
70–74 301 424 541 853
75–79 679 660 662 1,429
80–84 1,380 867 864 2,347
85+ 2,462 1,158 1,051 4,135
Men
50–54 46 118 42 204
55–59 69 120 105 640
60–64 100 239 188 982
65–69 143 225 215 923
70–74 221 338 142 1,138
75–79 409 471 116 1,091
80–84 810 562 157 2,154
85+ 1,457 979 267 4,221
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incurred costs in 2010 (“long-term disability cost”);
and (iii) cost of pharmacological fracture prevention
including administration and monitoring costs (“pharma-
cological fracture prevention costs”). See Chapter 4 of
the main report for further details.
The cost of a hip fracture has been estimated at € 5,169 in
the Czech Republic [6]. Given that no cost data for the other
fracture sites were found, these were imputed as described in
Chapter 4 of the main report.
Long-term disability costs were estimated by multiplying
the yearly cost of residing in nursing home (€ 10,614 [6])
with the simulated number of individuals with prior
fractures that had been transferred to nursing home due
to the fracture.
Annual drug costs (€) for individual treatments are shown
in Table 9. In addition, it was assumed that patients on
treatment made an annual physician visit costing € 18 (ap-
proximated by adjusting Polish cost for health adjusted price
levels [7]) and a DXA scan costing € 32 [8] every
second year to monitor treatment.
Table 8 The number of deaths in men and women in the Czech
Republic in the first year after fracture attributable to the fracture event
(causally related), 2010
Fracture at the
Age (years) hip vertebra “other”
Women
50–74 37 58 5
75+ 231 101 85
Total 268 159 90
Men
50–74 70 129 16
75+ 163 92 48
Total 233 221 63
Men and Women
50–74 107 186 21
75+ 394 193 132
Total 501 380 154
Table 9 One year costs
for relevant pharmaceu-
ticals in the Czech Re-
public, 2010 [9]
Annual drug
cost (€)
Alendronate 187
Risedronate 231
Etidronate -
Ibandronate 328
Zoledronic acid 355
Raloxifene 454
Strontium ranelate 478
Parathyroid hormone 4,485
Teriparatide 4,753
Table 7 Incidence (per 100,000) of causally related deaths in the
Czech Republic within the first year after fracture (adjusted for
comorbidities), 2010
Age (years) Hip Clinical vertebral “Other” fracture
Women
50–54 637 827 16
55–59 841 1,034 25
60–64 1,283 1,490 41
65–69 1,941 2,127 73
70–74 2,411 2,488 110
75–79 3,240 3,130 203
80–84 3,382 2,992 377
85–89 4,112 3,196 720
90+ 3,254 1,835 1,131
Men
50–54 2,197 2,635 34
55–59 3,144 3,575 65
60–64 3,643 3,918 99
65–69 4,501 4,566 161
70–74 4,815 4,584 217
75–79 5,758 5,106 341
80–84 6,681 5,425 561
85–89 8,607 6,291 930
90+ 10,459 6,806 1,308
Table 10 Cost of osteoporosis (€) in the Czech Republic by age in
men and women, 2010
Age
(years)
First year
fracture
cost
Long term
disability
costs
Fracture
prevention
cost
Total cost
Women
50–74 33,155,972 6,053,193 29,527,124 68,736,288
75+ 66,493,086 31,809,286 16,565,776 114,868,147
All 99,649,058 37,862,478 46,092,899 183,604,435
Men
50–74 39,982,017 6,564,719 4,719,626 51,266,361
75+ 25,536,336 11,208,040 1,772,569 38,516,945
All 65,518,352 17,772,759 6,492,194 89,783,306
Women and Men
50–74 73,137,988 12,617,912 34,246,749 120,002,649
75+ 92,029,422 43,017,326 18,338,344 153,385,092
All 165,167,410 55,635,237 52,585,094 273,387,741
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The cost of osteoporosis in 2010 was estimated at €
273 million (Table 10). First year costs, subsequent year
costs and pharmacological fracture prevention costs
amounted to € 165 million, € 56 million and € 53
million, respectively. It is notable that pharmacological
fracture prevention costs amounted to only 19.2 % of
the total cost.
When stratifying costs of osteoporosis by fracture
type, hip fractures were most costly (€ 110 million)
followed by “other” (€ 96 million), spine (€ 11 million)
and forearm fractures (€ 4 million) (Table 11 and Fig.
1). Please note that costs for pharmacological fracture
prevention were not included given that they cannot be
allocated to specific fracture sites. The number of quality adjusted life years (QALYs) lost
due to osteoporosis in 2010 was estimated at 22,800 (Table
12). Prior fractures accounted for 52 % of the total loss and
63 % of the loss occurred in women. The monetary value of
Table 11 Total cost (€) in 2010 by fracture site in men and women in
the Czech Republic. Note that costs for fracture prevention therapy and
monitoring are not included
Age Hip Spine Forearm Other All
Women
50–74 15,018,232 3,110,191 1,765,305 19,315,436 39,209,164
75+ 60,773,117 3,584,788 1,191,836 32,752,631 98,302,372
All 75,791,350 6,694,979 2,957,141 52,068,066 137,511,536
Men
50–74 14,221,056 3,101,243 663,766 28,560,671 46,546,736
75+ 19,582,345 1,487,887 141,547 15,532,597 36,744,376
All 33,803,401 4,589,130 805,313 44,093,268 83,291,111
Women and Men
50–74 29,239,289 6,211,434 2,429,071 47,876,106 85,755,900
75+ 80,355,462 5,072,675 1,333,383 48,285,228 135,046,748
All 109,594,750 11,284,109 3,762,454 96,161,334 220,802,648
Hip
50%
Spine
5%
Forearm
2%
Other
43%
Fig. 1 Share (%) of fracture cost by fracture site in the Czech Repub-
lic. Note that costs for fracture prevention therapy and monitoring are
not included
Table 12 Number of QALYs lost due to fractures during 2010 in men
and women in the Czech Republic according to age
Age (years)
50–74 75+ 50+
Women
Incident hip fractures 443 1,393 1,836
Incident vertebral fractures 953 1,038 1,991
Incident forearm fractures 198 116 313
Incident other fractures 871 1,305 2,176
Prior hip fractures 1,444 4,341 5,784
Prior vertebral fractures 903 1,320 2,223
423,41315,9218,4latoT
Men
Incident hip fractures 410 514 924
Incident vertebral fractures 1,019 519 1,538
Incident forearm fractures 73 15 88
Incident other fractures 1,390 666 2,056
Prior hip fractures 1,357 1,378 2,735
Prior vertebral fractures 742 422 1,164
505,8415,3199,4latoT
Men and Women
Incident hip fractures 853 1,907 2,760
Incident vertebral fractures 1,972 1,557 3,529
Incident forearm fractures 271 130 401
Incident other fractures 2,262 1,971 4,232
Prior hip fractures 2,801 5,719 8,520
Prior vertebral fractures 1,645 1,742 3,387
928,22620,31308,9latoT
Table 13 Value of lost QALYs (€) in men and women in the Czech
Republic in 2010
1 × GDP/
capita
2 × GDP/
capita
3 × GDP/
capita
Incident hip fractures 38,084,562 76,169,123 114,253,685
Incident vertebral
fractures
48,705,018 97,410,035 146,115,053
Incident forearm
fractures
5,531,867 11,063,733 16,595,600
Incident other
fractures
58,403,810 116,807,619 175,211,429
Prior hip fractures 117,570,796 235,141,592 352,712,388
Prior vertebral
fractures
46,747,054 93,494,108 140,241,161
Total 315,043,105 630,086,211 945,129,316
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a QALY was varied between 1 to 3 times the gross domestic
product (GDP) per capita (Table 13). Assuming a QALY is
valued at 2 times GDP/capita, the total cost of the QALYs
lost was estimated at € 630 million.
When the cost of osteoporosis was combined with the
value for QALYs lost (valued at 2 × GDP), the cost of
osteoporosis amounted to € 900 million in Czech Republic
in 2010. Incident fracture, prior fracture, pharmacological
fracture prevention, and value of QALYs lost accounted for
18 %, 6 %, 6 %, and 70 %, respectively.
Burden of osteoporosis up to 2025
The population above 50 years of age is expected to increase
from 3.8 million in 2010 to 4.3 million in 2025, correspond-
ing to an increase of 13 % (Table 14).
Table 15 Projected annual number of incident fractures in 2010 and 2025 by fracture site and age in men and women in the Czech Republic
Table 16 Current and future cost (€ 000, 000) of osteoporosis (ex-
cluding value of QALYs lost) by age and calendar year in men and
women in the Czech Republic
2010 2015 2020 2025
Women
50–74 69 77 84 82
75+ 115 121 130 151
All 184 197 214 233
Men
50–74 51 57 62 62
75+ 39 42 47 57
All 90 99 108 119
Women and Men
50–74 120 134 146 144
75+ 153 162 176 208
All 273 297 322 352
Table 14 Population projections in the Czech Republic by age and sex
[10]
Population
2010 2015 2020 2025
Women
50–59 768,000 665,000 650,000 721,000
60–69 662,000 757,000 726,000 632,000
70–79 406,000 430,000 568,000 653,000
80–89 235,000 246,000 234,000 265,000
90+ 21,000 40,000 51,000 58,000
Men
50–59 746,000 659,000 663,000 742,000
60–69 573,000 664,000 652,000 583,000
70–79 276,000 310,000 422,000 494,000
80–89 109,000 123,000 122,000 148,000
90+ 6,000 12,000 15,000 19,000
All
50–59 1,514,000 1,324,000 1,313,000 1,463,000
60–69 1,235,000 1,421,000 1,378,000 1,215,000
70–79 682,000 740,000 990,000 1,147,000
80–89 344,000 369,000 356,000 413,000
90+ 27,000 52,000 66,000 77,000
000,513,4000,208,3
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The total number of fractures was estimated to rise from
72,000 in 2010 to 94,000 in 2025 (Table 15), corresponding
to an increase of 31 %. Hip, clinical spine, forearm and other
fractures increased by 4,700, 3,400, 2,400 and 11,000 re-
spectively. The increase in the number of fractures ranged
from 20 % to 39 %, depending on fracture site. The increase
was estimated to be similar in men (29 %) and women
(30 %).
The cost of osteoporosis (excluding value of QALYs lost)
was estimated to rise from € 273 million in 2010 to € 352
million in 2025, corresponding to an increase of 29 % (Table
16). Costs incurred in women and men increased by 27 %
and 33 % respectively.
The total number of QALYs lost due to fracture was
estimated to rise from 22,800 in 2010 to 27,900 in
2025, corresponding to an increase of 22 % (Table
17). The increase was estimated to be particularly
marked in men (27 %) compared to women (19 %).
Incident and prior fractures accounted for 67 % and
33 % of the increase respectively.
The cost of osteoporosis including value of QALYs lost
was estimated to increase from approximately € 900 million
in 2010 to € 1.1 billion in 2025. The increase was estimated
to be particularly marked in men (+28 %) compared to
women (+22 %) (Table 18).
Treatment uptake
To estimate uptake of individual osteoporosis treatments,
sales data from IMS Health (2001–2011) were used to
derive the number of defined daily doses (DDDs) sold per
100,000 persons aged 50 years or above (Fig. 2).
Adjusting the sales data for compliance allowed for an
estimation of the proportion of population aged 50 years or
above who received any osteoporosis treatment (see Chapter
5 of the report on Osteoporosis in the European Union:
Medical Management, Epidemiology and Economic Burden
for further details). The proportion of persons over the age
of 50 years who were treated increased from 0.64 % in 2001
to 2.29 % in 2011.
Table 18 Present and future cost (€ 000,000) of fracture (direct cost
and cost of QALYs) by age and calendar year in men and women in the
Czech Republic assuming the uptake of treatment remains unchanged
2010 2015 2020 2025
Women
50–74 202 218 232 231
75+ 377 396 421 473
All 579 614 653 705
Men
50–74 189 201 213 219
75+ 135 144 161 198
All 325 346 374 417
Women and Men
50–74 391 419 445 450
75+ 513 541 582 671
All 903 960 1,027 1,121
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Fig. 2 Treatment uptake in the Czech Republic (Defined daily doses
[DDDs] per 100,000 persons aged 50 years or above)
Table 17 Projected QALYs lost due to incident and prior fractures for
the years 2010 and 2025 by age in men and women in the Czech
Republic
Incident fractures Prior fractures All fractures
2010 2025 2010 2025 2010 2025
Women
50–74 2,465 2,917 2,347 2,485 4,812 5,402
75+ 3,852 5,325 5,661 6,359 9,513 11,684
All 6,317 8,242 8,008 8,844 14,324 17,086
Men
50–74 2,892 3,332 2,099 2,353 4,991 5,686
75+ 1,714 2,722 1,800 2,370 3,514 5,091
All 4,605 6,054 3,900 4,723 8,505 10,777
Women and Men
50–74 5,357 6,249 4,446 4,838 9,803 11,087
75+ 5,565 8,047 7,461 8,729 13,026 16,775
All 10,922 14,296 11,907 13,567 22,829 27,863
Table 19 Number of men and women eligible for treatment, treated
and treatment gap in 2010
Number
potentially
treated
(1000 s)
Number
eligible for
treatment
(1000 s)
Difference
(1000 s)
Treatment
gap (%)
Men 12 102 90 88
Women 79 330 251 76
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Treatment gap
In order to assess the potential treatment gap, the num-
bers of men and women eligible for treatment in the
Czech Republic were defined as individuals with a 10-
year fracture probability exceeding that of a woman
with a prior fragility fracture derived from FRAX®,
equivalent to a ‘fracture threshold’ (See Chapter 5 of
the main report for further details). Subsequently, these
estimates were compared to the number of individuals
who received osteoporosis treatment obtained from the
analysis of IMS Health data. The treatment gaps in men
and women were estimated at 88 % and 76 % respec-
tively (Table 19). Note that the estimate of the treatment
gap is conservative given that it assumes that current
use of osteoporosis treatments are only directed to men
and women at high risk.
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Epidemiology and Economic Burden of Osteoporosis in
Denmark
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(EFPIA).
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Abstract
Summary This report describes epidemiology, burden, and
treatment of osteoporosis in Denmark.
Introduction Osteoporosis is characterized by reduced
bone mass and disruption of bone architecture, resulting
in increased risks of fragility fractures which represent
the main clinical consequence of the disease. Fragility
fractures are associated with substantial pain and suffer-
ing, disability and even death for the affected patients
and substantial costs to society. The aim of this study is
to describe the epidemiology and economic burden of
fragility fractures as a consequence of osteoporosis in
Denmark, as a further detailed addition to the report for
the entire European Union (EU27): Osteoporosis in the
European Union: Medical Management, Epidemiology
and Economic Burden.
Methods The literature on fracture incidence and costs of
fractures in Denmark was reviewed and incorporated into a
model estimating the clinical and economic burden of oste-
oporotic fractures in 2010. Furthermore, data on sales of
osteoporosis treatments and the population at high risk were
used to estimate treatment uptake and treatment gap.
Results It was estimated that approximately 66,000 new
fragility fractures were sustained in Denmark, compris-
ing 12,000 hip fractures, 10,000 vertebral fractures,
10,000 forearm fractures and 34,000 other fractures
(i.e. fractures of the pelvis, rib, humerus, tibia, fibula,
clavicle, scapula, sternum and other femoral fractures)
in 2010. The economic burden of incident and previous
fragility fractures was estimated at € 1,055 million for
the same year. Incident fractures represented 68% of this cost,
long-term fracture care 28 % and pharmacological prevention
4%. Previous and incident fractures also accounted for 20,200
quality-adjusted life years (QALYs) lost during 2010. When
accounting for the demographic projections for 2025, the
number of incident fractures was estimated at 86,000 in
2025, representing an increase of 20,000 fractures. Hip, clin-
ical vertebral (spine), forearm and other fractures were esti-
mated to increase by 4,300, 3,200, 2,400 and 10,300,
respectively. The burden of fractures in Denmark in
2025 was estimated to increase by 27 % to € 1,344
million. Though the uptake of osteoporosis treatments
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increased from 2001, the proportion of patients aged 50
or above who received treatment remained at very low
levels in the past few years. The majority of women at
high fracture risk did not receive active treatment.
Conclusions In spite of the high cost of osteoporosis, a
substantial treatment gap and projected increase of the eco-
nomic burden driven by aging populations, the use of phar-
macological prevention of osteoporosis is significantly less
than optimal, suggesting that a change in healthcare policy
concerning the disease is warranted.
Introduction
Osteoporosis is characterized by reduced bone mass and
disruption of bone architecture, resulting in increased risks
of fragility fractures which represent the main clinical con-
sequence of the disease. Fragility fractures are associated
with substantial pain and suffering, disability and even death
for the affected patients and substantial costs to society. The
aim of this report was to characterize the burden of osteo-
porosis in Denmark in 2010 and beyond.
Methods
The literature on fracture incidence and costs of fractures in
Denmark was reviewed and incorporated into a model estimat-
ing the clinical and economic burden of osteoporotic fractures
in 2010. Details of the methods used are found in Chapters 3
and 4 of the report Osteoporosis in the European Union:
Medical Management, Epidemiology and Economic Burden,
published concurrently in Archives of Osteoporosis. Where
possible, country-specific data were used (see below).
Epidemiology of osteoporosis in Denmark
For the purpose of this report, the population at risk of
osteoporosis was considered to include men and women
≥50 years. The number of men and women ≥50 years of
age amounted to 950,000 and 1,053,000 respectively in
Denmark in 2010 (Table 1).
In the population at risk, the number of individuals with
osteoporosis—as defined by the WHO diagnostic
criteria—was estimated at 280,000 (Table 2). Note that the
numbers do not include patients with vertebral osteoporosis
(spine T-score <−2.5) in whom femoral neck BMD lies in
the normal or osteopenic range. There are 14.6 DXA scan
machines per million inhabitants [2], and guidelines for the
assessment and treatment of osteoporosis are available [3].
A country specific FRAX model is also available for the
assessment of fracture risk (http://www.shef.ac.uk/FRAX/).
Epidemiology of fracture in Denmark
Data on hip fracture incidence are available for Denmark
[5], based on admission statistics from the Danish Na-
tional Board of Health. These rates also included repeat
admissions which overestimate somewhat the hip fracture
incidence. Given that country specific incidence of the
vertebral, forearm and, “other” fractures were not avail-
able, these were imputed using the methods described in
Chapter 3 of the main report. Briefly, it was assumed for
each age and sex that the ratio of the incidence of non-
hip fracture to hip fractures in Sweden would be com-
parable to the ratio of vertebral fracture incidence to hip
fracture incidence in Denmark. Fracture incidence is
presented in Table 3. Standardized to the EU27 popula-
tion, hip fracture incidence (per 100,000 person years) in
men and women ≥50 years of age was estimated at
386.0 and 853.0 respectively.
The number of incident fractures in 2010 was estimated
at 66,000 (Table 4). Incident hip, clinical spine, forearm and
“other” fractures were estimated at 12,000, 10,000, 10,000
and 34,000 respectively. 63 % of fractures occurred in
women.
A prior fracture was defined as a fracture in an
individual who was alive during the index year (i.e.
Table 1 Population at risk: men and women over the age of 50 in
Denmark, 2010 [1]
Age (years) Women Men All
50–59 355,000 357,000 712,000
60–69 346,000 337,000 683,000
70–79 205,000 175,000 380,000
80–89 119,000 72,000 191,000
90+ 28,000 9,000 37,000
50+ 1,053,000 950,000 2,003,000
Table 2 Estimated number of women and men with osteoporosis
(defined as a T-score ≤−2.5 SD) in Denmark by age using female-
derived reference ranges at the femoral neck, 2010 [4]
Age (years) Women Men
50–54 11,403 4,600
55–59 16,704 6,055
60–64 27,170 10,904
65–69 31,512 11,026
70–74 32,364 8,112
75–79 33,375 7,313
80+ 69,384 13,446
50+ 221,912 61,456
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2010) which had occurred after the age of 50 years and
before 2010. In the population ≥50 years of age, the
proportion of individuals who had suffered a fracture
prior to 2010 was estimated at 2.48 % for hip and
2.92 % for clinical vertebral fractures. The estimated
proportions of men and women with prior hip and
vertebral fractures by age are presented in Table 5.
In the population over 50 years of age, the number of in-
dividuals with hip and vertebral fractures that occurred before
2010 was estimated at 50,000 and 59,000 respectively (Table 6).
Note that fractures sustained in 2010 were not included in the
estimate.
The incidence of causally related deaths (per 100,000) in
the first year after fracture by age is presented in Table 7.
The number of causally related deaths in 2010 was
Table 6 Number of men and women in Denmark with a prior hip or
clinical vertebral fracture after the age of 50 years, 2010
Age (years) Hip fracture Vertebral fracture
Women
50– 761,41395,747
457,42073,62+57
129,83369,33latoT
Men
50– 820,11984,647
426,8492,9+57
256,91387,51latoT
Men and Women
50– 591,52280,4147
873,33466,53+57
375,85647,94latoT
Table 4 Estimated number of incident fractures in Denmark, 2010
Fracture at the All
Age (years) hip vertebra forearm other fractures
Women
50–74 1,859 2,831 5,080 6,793 16,563
75+ 6,629 3,390 3,219 12,093 25,331
Total 8,488 6,221 8,299 18,886 41,894
Men
50–74 1,318 2,329 1,541 8,660 13,848
75+ 2,236 1,689 464 6,229 10,617
Total 3,553 4,018 2,004 14,889 24,464
Men and Women
50–74 3,177 5,161 6,620 15,453 30,411
75+ 8,864 5,078 3,683 18,322 35,948
Total 12,041 10,239 10,303 33,775 66,359
Table 5 Proportion of men and women (in %) with a prior hip or
clinical vertebral fracture in Denmark, 2010
Age (years) Hip fracture Vertebral fracture
Women
50– 2.01.045
55– 8.03.095
60– 6.18.046
65– 6.25.196
70– 5.48.247
75– 8.61.597
80– 2.92.948
0.610.02+58
Men
50– 3.01.045
55– 8.04.095
60– 5.18.046
65– 3.23.196
70– 9.20.247
75– 9.33.397
80– 1.58.548
4.016.21+58
Table 3 Incidence per 100,000 person years of hip, clinical vertebral,
forearm, and “other” fractures in Denmark by age
Fracture at the
Age (years) hip vertebral forearm other
Women
50–54 27 70 172 178
55–59 74 206 569 652
60–64 142 251 535 546
65–69 274 398 665 935
70–74 561 792 1,009 1,592
75–79 1,087 1,057 1,060 2,287
80–84 1,983 1,247 1,242 3,373
85+ 3,701 1,741 1,580 6,217
Men
50–54 58 148 53 257
55–59 81 141 123 753
60–64 125 298 235 1,227
65–69 201 316 302 1,296
70–74 315 480 201 1,617
75–79 592 682 168 1,581
80–84 1,189 826 230 3,161
85+ 2,242 1,505 411 6,492
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estimated at 879 (Table 8). Hip, vertebral and “other” frac-
tures accounted for 427, 293 and 158 deaths respectively.
Overall, approximately 52 % of deaths occurred in women.
Cost of osteoporosis in Denmark including and exclud-
ing values of QALYs lost
For the purpose of this report, the cost of osteoporosis
in 2010 (excluding value of QALYs lost) was consid-
ered to consist of three components: (i) cost of fractures
that occurred in 2010 (“first year costs”); (ii) cost of
fractures sustained prior to year 2010 but which still
incurred costs in 2010 (“long-term disability cost”);
and (iii) cost of pharmacological fracture prevention
including administration and monitoring costs (“pharma-
cological fracture prevention costs”). See Chapter 4 of
the main report for further details.
The cost of a hip fracture has been estimated at € 25,117
in Denmark [7, 8]. No other fracture costs were available.
Given that no cost data for the other fracture sites were
found, these were imputed as described in Chapter 4 of the
main report.
Table 8 The number of deaths in men and women in Denmark in the
first year after fracture attributable to the fracture event (causally
related), 2010
Fracture at the
Age (years) hip vertebra “other”
Women
50–74 39 59 5
75+ 185 73 92
Total 224 133 97
Men
50–74 43 74 9
75+ 160 87 52
Total 203 161 61
Men and Women
50–74 82 133 15
75+ 345 160 144
Total 427 293 158
Table 9 One year costs
for relevant pharmaceu-
ticals in Denmark, 2010
[11]
Annual drug
cost (€)
Alendronate 126
Risedronate 50
Etidrontate 103
Ibandronate 400
Zoledronic acid 468
Raloxifene 430
Strontium ranelate 721
Parathyroid hormone 6,874
Teriparatide 6,902
Table 10 Cost of osteoporosis (€) in Denmark by age in men and
women, 2010
Age
(years)
First year
fracture
cost
Long term
disability
costs
Fracture
prevention
cost
Total cost
Women
50–74 145,724,301 30,667,586 21,325,556 197,717,442
75+ 302,207,187 168,994,988 10,992,998 482,195,174
All 447,931,489 199,662,573 32,318,554 679,912,616
Men
50–74 145,200,658 31,166,101 3,257,310 179,624,069
75+ 124,862,866 69,543,398 1,290,043 195,696,307
All 270,063,525 100,709,498 4,547,353 375,320,376
Women and Men
50–74 290,924,960 61,833,686 24,582,865 377,341,511
75+ 427,070,054 238,538,386 12,283,041 677,891,481
All 717,995,013 300,372,072 36,865,907 1,055,232,992
Table 7 Estimated incidence (per 100,000) of causally related deaths
[6] in Denmark within the first year after fracture (adjusted for
comorbidities), 2010
Age (years) Hip Clinical vertebral “Other” fracture
Women
50–54 596 774 15
55–59 1,251 1,539 37
60–64 1,285 1,492 41
65–69 1,953 2,141 73
70–74 2,368 2,444 108
75–79 3,092 2,987 194
80–84 3,064 2,711 341
85–89 3,189 2,479 559
90+ 2,868 1,617 997
Men
50–54 1,704 2,044 27
55–59 2,559 2,909 53
60–64 2,658 2,858 72
65–69 3,009 3,052 108
70–74 3,821 3,638 172
75–79 4,982 4,418 295
80–84 5,634 4,575 473
85–89 7,051 5,153 762
90+ 10,259 6,676 1,283
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Long-term disability costs were estimated by multiplying
the yearly cost of residing in nursing home (€ 64,831 [9]) with
the simulated number of individuals with prior fractures that
had been transferred to nursing homes due to the fracture.
Annual drug costs (€) for individual treatments are shown
in Table 9. In addition, it was assumed that patients on
treatment made an annual physician visit costing € 160
[10] and a DXA scan costing € 187 [10] every
second year to monitor treatment.
The cost of osteoporosis in 2010 was estimated at € 1,055
million (Table 10). First year costs, subsequent year costs
and pharmacological fracture prevention costs amounted to
€ 718 million, € 300 million and € 37 million, respectively.
It is notable that pharmacological fracture prevention costs
amounted to only 3.5 % of the total cost.
When stratifying costs of osteoporosis by fracture type, hip
fractures were most costly (€ 564million) followed by “other”
(€ 431 million), spine (€ 12 million) and forearm fractures (€
12 million) (Table 11 and Fig. 1). Please note that costs for
pharmacological fracture prevention were not included given
that they cannot be allocated to specific fracture sites.
The number of quality adjusted life years (QALYs) lost
due to osteoporosis in 2010 was estimated at 20,200 (Table
12). Prior fractures accounted for 50 % of the total loss and
63 % of the loss occurred in women. The monetary value of
a QALY was varied between 1 to 3 times the gross domestic
product (GDP) per capita (Table 13). Assuming a QALY is
valued at 2 times GDP/capita, the total cost of the QALYs
lost was estimated at € 1.7 billion.
When the cost of osteoporosis was combined with the
value for QALYs lost (valued at 2 × GDP), the cost of
osteoporosis amounted to € 2.76 billion in Denmark in
2010. Incident fracture, prior fracture, pharmacological
fracture prevention, and value of QALYs lost accounted
for 26 %, 11 %, 1 %, 62 % respectively.
Burden of osteoporosis up to 2025
The population above 50 years of age is expected to increase
from 2.0 million in 2010 to 2.4 million in 2025, correspond-
ing to an increase of 18 % (Table 14).
The total number of fractures was estimated to rise from
66,000 in 2010 to 86,000 in 2025 (Table 15), corresponding
to an increase of 30 %, assuming that age-specific fracture
rates remain unchanged over time. At present, hip fracture
rates are falling in Denmark [13], so that if this trend
Table 11 Total cost (€) in 2010 by fracture site inmen and women in Denmark. Note that costs for fracture prevention therapy andmonitoring are not included
Hip
56%
Spine
1%
Forearm
1%
Other
42%
Fig. 1 Share (%) of fracture cost by fracture site in Denmark. Note that
costs for fracture prevention therapy and monitoring are not included
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continues, the present analysis may be an overestimate. Hip,
spine, forearm and other fractures increased by 4,300, 3,200,
2,400 and 10,300, respectively. The increase in the number
of fractures ranged from 23 % to 35 %, depending on
fracture site. The increase was estimated to be particularly
marked in men (35 %) compared to women (28 %).
The cost of osteoporosis (excluding value of QALYs lost)
was estimated to rise from € 1055 million in 2010 to € 1344
million in 2025, corresponding to an increase of 27 % (Table
16). Costs incurred in women and men increased by 23 %
and 34 % respectively.
The total number of QALYs lost due to fracture was
estimated to rise from 20,200 in 2010 to 24,900 in 2025,
corresponding to an increase of 23 % (Table 17). The increase
was estimated to be particularly marked in men (30 %) com-
pared to women (19 %). Incident and prior fractures
accounted for 67 % and 33 % of the increase respectively.
The cost of osteoporosis including value of QALYs lost
was estimated to increase from approximately € 2.8 billion
in 2010 to € 3.4 billion in 2025. The increase was estimated
to be particularly marked in men (+32 %) compared to
women (+21 %) (Table 18).
Treatment uptake
To estimate uptake of individual osteoporosis treatments,
sales data from IMS Health (2001–2011) were used to
derive the number of defined daily doses (DDDs) sold per
100,000 persons aged 50 years or above (Fig. 2).
Table 14 Population projections in Denmark by age and sex [12]
Population
2010 2015 2020 2025
Women
50–59 355,000 375,000 395,000 389,000
60–69 346,000 350,000 336,000 356,000
70–79 205,000 245,000 294,000 300,000
80–89 119,000 117,000 129,000 159,000
90+ 28,000 31,000 33,000 35,000
Men
50–59 357,000 377,837 399,000 389,000
60–69 337,000 341,000 325,000 347,000
70–79 175,000 216,000 263,000 268,000
80–89 72,000 76,000 89,000 115,000
90+ 9,000 11,000 13,000 15,000
All
50–59 712,000 752,837 794,000 778,000
60–69 683,000 691,000 661,000 703,000
70–79 380,000 461,000 557,000 568,000
80–89 191,000 193,000 218,000 274,000
90+ 37,000 42,000 46,000 50,000
000,373,2000,300,2
Table 13 Value of lost QALYs (€) in men andwomen in Denmark in 2010
1 × GDP/
capita
2 × GDP/
capita
3 × GDP/
capita
Incident hip
fractures
113,232,433 226,464,867 339,697,300
Incident vertebral
fractures
135,875,793 271,751,585 407,627,378
Incident forearm
fractures
14,518,357 29,036,714 43,555,071
Incident other
fractures
159,969,903 319,939,806 479,909,708
Prior hip fractures 299,757,795 599,515,589 899,273,384
Prior vertebral
fractures
128,584,668 257,169,335 385,754,003
Total 851,938,948 1,703,877,896 2,555,816,844
Table 12 Number of QALYs lost due to fractures during 2010 in men
and women in Denmark according to age
Age (years)
50–74 75+ 50+
Women
Incident hip fractures 450 1,373 1,823
Incident vertebral fractures 940 965 1,905
Incident forearm fractures 179 97 276
Incident other fractures 813 1,244 2,057
Prior hip fractures 1,191 3,527 4,717
Prior vertebral fractures 792 1,189 1,981
857,21593,8463,4latoT
Men
Incident hip fractures 322 538 860
Incident vertebral fractures 776 540 1,315
Incident forearm fractures 53 15 68
Incident other fractures 1,025 709 1,734
Prior hip fractures 1,014 1,372 2,386
Prior vertebral fractures 612 453 1,066
034,7726,3308,3latoT
Men and Women
Incident hip fractures 772 1,911 2,683
Incident vertebral fractures 1,716 1,504 3,220
Incident forearm fractures 232 112 344
Incident other fractures 1,838 1,953 3,791
Prior hip fractures 2,204 4,899 7,103
Prior vertebral fractures 1,405 1,643 3,047
881,02220,21661,8latoT
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Adjusting the sales data for compliance allowed for an esti-
mation of the proportion of population aged 50 years or above
who received any osteoporosis treatment (see Chapter 5 of the
report on Osteoporosis in the European Union: Medical Manage-
ment, Epidemiology and Economic Burden for further details).
The proportion of persons over the age of 50 years who were
treated increased from 0.79 % in 2001 to 5.71 % in 2011. This is
near the European average but high byNorth European standards.
Treatment gap
In order to assess the potential treatment gap, the numbers of
men and women eligible for treatment in each country were
defined as individuals with a 10-year fracture probability
exceeding that of a woman with a prior fragility fracture
derived from FRAX®, equivalent to a ‘fracture threshold’
(See Chapter 5 of the main report for further details). Sub-
sequently, these estimates were compared to the number
individuals who received osteoporosis treatment obtained
from the analysis of IMS Health data. The treatment gaps
in men and women were estimated at 50 % and 54 %
respectively (Table 19). Note that the estimate of the treat-
ment gap is conservative given that it assumes that current
use of osteoporosis treatments are only directed to men and
women at high risk.
Table 15 Projected annual number of incident fractures in 2010 and 2025 by fracture site and age in men and women in Denmark
Table 16 Current and future cost of osteoporosis (excluding value of
QALYs lost) by age and calendar year in men and women in Denmark
2010 2015 2020 2025
Women
50–74 198 219 229 224
75+ 482 499 541 615
All 680 718 770 839
Men
50–74 180 196 203 202
75+ 196 213 249 302
All 375 410 452 504
Women and Men
50–74 377 415 431 426
75+ 678 712 790 917
All 1,055 1,127 1,222 1,344
Table 17 Projected QALYs lost due to incident and prior fractures for
the years 2010 and 2025 by age in men and women in Denmark
Incident fractures Prior fractures All fractures
2010 2025 2010 2025 2010 2025
Women
50–74 2,381 2,715 1,983 2,079 4,364 4,793
75+ 3,679 5,052 4,716 5,386 8,395 10,438
All 6,060 7,767 6,699 7,465 12,758 15,232
Men
50–74 2,177 2,439 1,626 1,751 3,803 4,190
75+ 1,801 2,988 1,826 2,495 3,627 5,483
All 3,978 5,427 3,452 4,246 7,430 9,673
Women and Men
50–74 4,558 5,154 3,609 3,830 8,166 8,984
75+ 5,480 8,040 6,542 7,882 12,022 15,921
All 10,038 13,194 10,150 11,711 20,188 24,905
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Women
50–74 566 610 620 629
75+ 1,191 1,237 1,457 1,496
All 1,757 1,846 2,078 2,125
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50–74 501 531 504 556
75+ 502 539 532 765
All 1,002 1,070 1,036 1,321
Women and Men
50–74 1,067 1,141 1,124 1,184
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Fig. 2 Treatment uptake in Denmark (Defined daily doses [DDDs] per
100,000 persons aged 50 years or above)
Table 19 Number of men and women eligible for treatment, treated
and treatment gap in 2010
Number
potentially
treated
(1000 s)
Number
eligible for
treatment
(1000 s)
Difference
(1000 s)
Treatment
gap (%)
Men 13 26 13 50
Women 87 190 103 54
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Epidemiology and Economic Burden of Osteoporosis in
Estonia
A report prepared in collaboration with the Internation-
al Osteoporosis Foundation (IOF) and the European
Federation of Pharmaceutical Industry Associations
(EFPIA).
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Abstract
Summary This report describes epidemiology, burden, and
treatment of osteoporosis in Estonia.
Introduction Osteoporosis is characterized by reduced
bone mass and disruption of bone architecture, resulting
in increased risks of fragility fractures which represent
the main clinical consequence of the disease. Fragility
fractures are associated with substantial pain and suffer-
ing, disability and even death for the affected patients
and substantial costs to society. The aim of this study is
to describe the epidemiology and economic burden of
fragility fractures as a consequence of osteoporosis in
Estonia, as a further detailed addition to the report for
the entire European Union (EU27): Osteoporosis in the
European Union: Medical Management, Epidemiology
and Economic Burden.
Methods The literature on fracture incidence and costs of
fractures in Estonia was reviewed and incorporated into
a model estimating the clinical and economic burden of
osteoporotic fractures in 2010. Furthermore, data on
sales of osteoporosis treatments and the population at
high risk were used to estimate treatment uptake and
treatment gap.
Results It was estimated that approximately 9,000 new
fragility fractures were sustained in Estonia, comprising
1,600 hip fractures, 1,400 vertebral fractures, 1,400
forearm fractures and 4,300 other fractures (i.e. fractures
of the pelvis, rib, humerus, tibia, fibula, clavicle, scap-
ula, sternum and other femoral fractures) in 2010. The
economic burden of incident and previous fragility frac-
tures was estimated at € 30 million for the same year.
Incident fractures represented 73 % of this cost, long-
term fracture care 23 % and pharmacological prevention
3 %. Previous and incident fractures also accounted for 2,800
quality-adjusted life years (QALYs) lost during 2010. When
accounting for the demographic projections for 2025, the
number of incident fractures was estimated at 10,000 in
2025, representing an increase of 1,500 fractures. Hip, clinical
spine (vertebral), forearm and other fractures were estimated
to increase by 400, 200, 100 and 800, respectively. The burden
of fractures in Estonia in 2025 was estimated to increase by
18 % to € 35 million. Though the uptake of osteoporosis
treatments increased from 2001, the proportion of patients
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aged 50 or above whom received treatment remained at very
low levels in the past few years. The majority of women at
high fracture risk did not receive active treatment.
Conclusions In spite of the high cost of osteoporosis, a
substantial treatment gap and projected increase of the eco-
nomic burden driven by aging populations, the use of phar-
macological prevention of osteoporosis is significantly less
than optimal, suggesting that a change in healthcare policy
concerning the disease is warranted.
Introduction
Osteoporosis is characterized by reduced bone mass and
disruption of bone architecture, resulting in increased risks
of fragility fractures which represent the main clinical con-
sequence of the disease. Fragility fractures are associated
with substantial pain and suffering, disability and even death
for the affected patients and substantial costs to society. The
aim of this report was to characterize the burden of osteo-
porosis in Estonia in 2010 and beyond.
Methods
The literature on fracture incidence and costs of fractures in
Estonia was reviewed and incorporated into a model estimat-
ing the clinical and economic burden of osteoporotic fractures
in 2010. Details of the methods used are found in Chapters 3
and 4 of the report Osteoporosis in the European Union:
Medical Management, Epidemiology and Economic Burden,
published concurrently in Archives of Osteoporosis.
Epidemiology of osteoporosis in Estonia
For the purpose of this report, the population at risk of
osteoporosis was considered to include men and women
≥50 years. The number of men and women ≥50 years of
age amounted to 188,000 and 297,000 respectively in Esto-
nia in 2010 (Table 1).
In the population at risk, the number of individuals with
osteoporosis—as defined by theWHOdiagnostic criteria—was
estimated at 80,000 (Table 2). There are 8.9 DXA scan ma-
chines per million (m) inhabitants, and guidelines for the as-
sessment and treatment of osteoporosis are available [2]. A
country specific FRAX model for the assessment of fracture
risk is not available for Estonia. Based on the likelihood that the
fracture rate andmortality in Lithuania was equal to Estonia, the
FRAX model for Lithuania was used as a surrogate,
There are limited data on fracture rates in Estonia and no
specific information on hip fracture incidence [4] Data for hip
fractures were imputed from Finnish age-standardized inci-
dence rates [5]. Fracture incidence is presented in Table 3.
Standardized to the EU27 population, this hip fracture inci-
dence (per 100,000 person years) in men and women
≥50 years of age was estimated at 238 and 440 respectively.
The number of incident fractures in 2010 was estimated
at 8,700 (Table 4). Incident hip, clinical spine, forearm and
“other” fractures were estimated at 1,600, 1,400, 1,400 and
4,300 respectively. 69 % of fractures occurred in women.
A prior fracture was defined as a fracture in an individual
who was alive during the index year (i.e. 2010) which had
occurred after the age of 50 years and before 2010. In the
population ≥50 years of age, the proportion of individuals
who had suffered a fracture prior to 2010 was estimated at
1.52 % for hip and 1.54 % for clinical vertebral fractures.
The estimated proportions of men and women with prior hip
and vertebral fractures by age are presented in Table 5.
In the population over 50 years of age, the number of both
men and women with hip or vertebral fractures that occurred
before 2010 was estimated at 7,000 (Table 6). Note that
fractures sustained in 2010 were not included in the estimate.
The incidence of causally related deaths (per 100,000) in the
first year after fracture by age is presented in Table 7. The
number of causally related deaths in 2010 was estimated at
134 (Table 8). Hip, vertebral and “other” fractures
accounted for 65, 50 and 19 deaths respectively. Overall,
approximately 54 % of deaths occurred in women.
Table 1 Population at risk: men and women over the age of 50 in
Estonia, 2010 [1]
Age (years) Women Men All
50–59 99,000 81,000 180,000
60–69 81,000 55,000 136,000
70–79 74,000 38,000 112,000
80–89 38,000 13,000 51,000
90+ 5,000 1,000 6,000
50+ 297,000 188,000 485,000
Table 2 Estimated number of women and men with osteoporosis
(defined as a T-score ≤−2.5 SD) in Estonia by age using female-
derived reference ranges at the femoral neck, 2010 [3]
Age (years) Women Men
50–54 3,150 1,075
55–59 4,704 1,330
60–64 6,149 1,798
65–69 7,676 1,776
70–74 11,439 1,794
75–79 12,375 1,545
80+ 20,296 2,324
50+ 65,789 11,642
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Cost of osteoporosis in Estonia including and excluding
value of QALYs Lost
For the purpose of this report, the cost of osteoporosis
in 2010 (excluding value of QALYs lost) was consid-
ered to consist of three components: (i) cost of fractures
that occurred in 2010 (“first year costs”); (ii) cost of
fractures sustained prior to year 2010 but which still
incurred costs in 2010 (“long-term disability cost”);
and (iii) cost of pharmacological fracture prevention
including administration and monitoring costs (“pharma-
cological fracture prevention costs”). See Chapter 4 of
the main report for further details.
In Estonia, the cost of a hip fracture has been esti-
mated at € 5,580 using the fracture cost in Finland [6].
Table 4 Estimated number of incident fractures in Estonia, 2010
llAehttaerutcarF
Age (years) hip vertebra forearm other fractures
Women
50–74 263 401 676 920 2,260
75+ 966 542 510 1,707 3,725
Total 1,229 942 1,186 2,628 5,986
Men
50–74 160 279 175 1,040 1,654
75+ 224 172 47 606 1,049
Total 384 451 222 1,646 2,703
Men and Women
50–74 423 680 851 1,960 3,915
75+ 1,190 713 557 2,314 4,774
Total 1,613 1,393 1,409 4,274 8,689
Table 5 Proportion of men and women (in %) with a prior hip or
clinical vertebral fracture in Estonia, 2010
Age (years) Hip fracture Vertebral fracture
Women
50– 1.00.045
55– 5.02.095
60– 9.04.046
65– 4.18.096
70– 2.24.147
75– 4.39.297
80– 7.47.548
7.71.21+58
Men
50– 1.01.045
55– 4.02.095
60– 7.05.046
65– 0.18.096
70– 2.11.147
75– 0.20.297
80– 7.23.348
2.54.7+58
Table 6 Number of men and women in Estonia with a prior hip or
clinical vertebral fracture after the age of 50 years, 2010
Age (years) Hip fracture Vertebral fracture
Women
50– 101,2561,147
776,3955,4+57
977,5527,5latoT
Men
50– 03930747
777229+57
707,1526,1latoT
Men and Women
50– 230,3968,147
454,4184,5+57
684,7053,7latoT
Table 3 Incidence per 100,000 person years of hip, clinical vertebral,
forearm, and “other” fractures in Estonia by age
Fracture at the
Age (years) hip vertebra forearm other
Women
50–54 21 53 132 136
55–59 38 105 292 334
60–64 63 111 237 242
65–69 116 169 282 396
70–74 248 350 446 704
75–79 541 526 527 1,137
80–84 1,068 671 669 1,816
85+ 1,825 858 779 3,066
Men
50–54 35 89 32 154
55–59 54 94 82 503
60–64 77 183 144 753
65–69 116 183 175 750
70–74 197 301 126 1,012
75–79 377 435 107 1,008
80–84 708 492 137 1,882
85+ 1,254 842 230 3,632
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Given that no cost data for the other fracture sites were
found, these were imputed as described in Chapter 4 of
the main report.
Long-term disability costs were estimated by multiplying
the yearly cost of residing in nursing home (€ 10,483 [7,8],
based on Finnish cost of nursing home that was PPP adjust-
ed) with the simulated number of individuals with prior
fractures that had been transferred to nursing homes due to
the fracture.
Annual drug costs (€) for individual treatments are
shown in Table 9. In addition, it was assumed that
patients on treatment made an annual physician visit
costing € 12 [9] and a DXA scan costing € 187 [9]
every second year to monitor treatment. The cost is
conservative in that monitoring is usually conducted
annually.
The cost of osteoporosis in 2010 was estimated at €
30 million (Table 10). First year costs, subsequent year
costs and pharmacological fracture prevention costs
amounted to € 22 million, € 7 million and € 1 million
Table 8 The number of deaths in men and women in Estonia in the
first year after fracture attributable to the fracture event (causally
related), 2010
Fracture at the
Age (years) hip vertebra “other”
Women
50–74 6 9 1
75+ 31 14 11
Total 37 23 12
Men
50–74 10 17 2
75+ 18 10 5
Total 27 27 7
Men and Women
50–74 15 26 3
75+ 49 25 16
Total 65 50 19
Table 9 One year costs
for relevant pharmaceu-
ticals in Estonia, 2010
[10]
Annual drug
cost (€)
Alendronate 171
Risedronate 143
Etidronate -
Ibandronate 283
Zoledronic acid 202
Raloxifene -
Strontium ranelate 446
Parathyroid hormone -
Teriparatide -
Table 10 Cost of osteoporosis (€) in Estonia by age inmen andwomen, 2010
Age
(years)
First year
fracture
cost
Long term
disability
costs
Fracture
prevention
cost
Total cost
Women
50–
Men
50–
Women and Men
50–
74 4,887,070 765,480 465,897 6,118,447
75+ 10,337,649 4,543,605 289,565 15,170,818
All 15,224,719 5,309,085 755,461 21,289,265
74 4,015,343 554,793 76,494 4,646,630
75+ 2,906,657 1,106,876 29,882 4,043,415
All 6,922,000 1,661,670 106,376 8,690,045
74 8,902,413 1,320,273 542,391 10,765,077
75+ 13,244,306 5,650,481 319,446 19,214,234
All 22,146,719 6,970,754 861,837 29,979,310
Table 7 Incidence (per 100,000) of causally related deaths in Estonia
within the first year after fracture (adjusted for comorbidities), 2010
Age (years) Hip Clinical vertebral “Other” fracture
Women
50–54 831 1,080 21
55–59 1,008 1,240 30
60–64 1,327 1,541 42
65–69 1,971 2,160 74
70–74 2,456 2,535 112
75–79 3,052 2,948 191
80–84 3,247 2,873 362
85–89 3,717 2,889 651
90+ 3,187 1,797 1,108
Men
50–54 4,696 5,633 74
55–59 5,076 5,771 104
60–64 6,210 6,679 168
65–69 5,997 6,084 215
70–74 7,114 6,774 321
75–79 6,591 5,845 391
80–84 7,241 5,880 608
85–89 8,501 6,213 918
90+ 10,571 6,879 1,322
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respectively. It is notable that pharmacological fracture
prevention costs amounted to only 3.3 % of the total
cost.
When stratifying costs of osteoporosis by fracture type, hip
fractures were most costly (€ 15 million) followed by “other”
(€ 12 million), spine (€ 1.5 million) and forearm fractures (€
0.5 million) (Table 11 and Fig. 1). Please note that costs for
pharmacological fracture prevention were not included given
that they cannot be allocated to specific fracture sites.
The number of quality adjusted life years (QALYs)
lost due to osteoporosis in 2010 was estimated at 2,800
(Table 12). 72 % of the total QALY loss was incurred
in women. Prior fractures accounted for 52 % of the
total QALY loss. The monetary value of a QALY was
varied between 1 to 3 times the gross domestic product
(GDP) per capita (Table 13). Assuming a QALY is
valued at 2 times GDP/capita, the total cost of the
QALYs lost was estimated at € 60 million.
When the cost of osteoporosis was combined with the
value for QALYs lost (valued at 2 × GDP), the cost of
osteoporosis amounted to € 90 million in Estonia in 2010.
Incident fracture, prior fracture, pharmacological fracture
prevention, and value of QALYs lost accounted for 25 %,
8 %, 1 %, 66 % respectively.
Burden of osteoporosis up to 2025
The population above 50 years of age is expected to increase
from 485,000 in 2010 to 511,000 in 2025, corresponding to
an increase of 5 % (Table 14).
Table 11 Total cost (€) in 2010 by fracture site in men and women
from Estonia. Note that costs for fracture prevention therapy and
monitoring are not included
Age Hip Spine Forearm Other All
Women
50–74 2,154,893 468,140 230,565 2,798,952 5,652,550
75+ 9,241,445 597,087 173,937 4,868,785 14,881,254
All 11,396,338 1,065,227 404,502 7,667,737 20,533,804
Men
50–74 1,314,861 295,118 59,693 2,900,464 4,570,136
75+ 2,062,812 170,580 16,014 1,764,128 4,013,533
All 3,377,673 465,698 75,707 4,664,592 8,583,669
Women and Men
50–74 3,469,754 763,257 290,258 5,699,416 10,222,686
75+ 11,304,256 767,667 189,950 6,632,913 18,894,787
All 14,774,011 1,530,925 480,209 12,332,329 29,117,473
Hip
51%
Spine
5%
Forearm
2%
Other
42%
Fig. 1 Share (%) of fracture cost by fracture site in Estonia. Note that
costs for fracture prevention therapy and monitoring are not included
Table 12 Number of QALYs lost due to fractures during 2010 in men
and women in Estonia according to age
Age (years)
50–74 75+ 50+
Women
Incident hip fractures 64 206 269
Incident vertebral fractures 133 158 291
Incident forearm fractures 24 16 39
Incident other fractures 110 179 289
Prior hip fractures 182 619 801
Prior vertebral fractures 117 180 297
789,1753,1036latoT
Men
Incident hip fractures 40 55 95
Incident vertebral fractures 96 56 152
Incident forearm fractures 6 2 8
Incident other fractures 124 69 193
Prior hip fractures 110 137 247
Prior vertebral fractures 52 41 93
787953824latoT
Men and Women
Incident hip fractures 104 261 364
Incident vertebral fractures 229 214 443
Incident forearm fractures 30 17 47
Incident other fractures 234 249 482
Prior hip fractures 292 756 1,048
Prior vertebral fractures 169 221 390
477,2717,1850,1latoT
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The total number of fractures was estimated to rise from
9,000 in 2010 to 10,000 in 2025 (Table 15), corresponding
to an increase of 11 %. Hip, clinical spine, forearm and other
fractures increased by 400, 200, 100 and 800 respectively.
The increase in the number of fractures ranged from 9 % to
23 %, depending on fracture site. The increase was estimat-
ed to be 19 % in men and 17 % in women.
The cost of osteoporosis (excluding value of QALYs lost)
was estimated to rise from € 30million in 2010 to € 35million
in 2025, corresponding to an increase of 18 % (Table 16).
Costs incurred in both women and men increased by 18 %.
The total number of QALYs lost due to fracture was
estimated to rise from 2,800 in 2010 to 3,200 in 2025, corre-
sponding to an increase of 15 % (Table 17). The increase was
estimated to be particularly marked in men (17 %) compared
to women (15 %). Incident and prior fractures accounted for
53 % and 47 % of the increase respectively.
The cost of osteoporosis including value of QALYs
lost was estimated to increase from approximately € 89
Table 14 Population projections in Estonia by age and sex [11]
Population
2010 2015 2020 2025
Women
50–59 99,000 97,000 91,000 88,000
60–69 81,000 88,000 93,000 90,000
70–79 74,000 71,000 68,000 76,000
80–89 38,000 41,000 44,000 42,000
90+ 5,000 7,000 10,000 11,000
Men
50–59 81,000 80,769 77,000 79,000
60–69 55,000 61,000 66,000 66,000
70–79 38,000 37,000 37,000 41,000
80–89 13,000 15,000 16,000 16,000
90+ 1,000 1,000 2,000 2,000
All
50–59 180,000 177,769 168,000 167,000
60–69 136,000 149,000 159,000 156,000
70–79 112,000 108,000 105,000 117,000
80–89 51,000 56,000 60,000 58,000
90+ 6,000 8,000 12,000 13,000
000,115000,584
Table 15 Projected annual number of incident fractures in 2010 and
2025 by fracture site and age in men and women from Estonia
Hip Spine Forearm Other
2010 2025 2010 2025 2010 2025 2010 2025
Women
50–74 263 275 401 412 676 682 920 939
75+ 966 1,241 542 658 510 600 1,707 2,196
All 1,229 1,516 942 1,070 1,186 1,282 2,628 3,135
Men
50–74 160 174 279 304 175 193 1,040 1,130
75+ 224 300 172 229 47 62 606 825
All 384 474 451 532 222 255 1,646 1,955
Women and Men
50–74 423 450 680 716 851 875 1,960 2,069
75+ 1,190 1,541 713 886 557 663 2,314 3,021
All 1,613 1,991 1,393 1,602 1,409 1,537 4,274 5,090
Table 16 Current and future cost (€ 000,000) of osteoporosis (exclud-
ing value of QALYs lost) by age and calendar year in men and women
in Estonia
2010 2015 2020 2025
Women
50–74 6 6 6 6
75+ 15 17 18 19
All 21 23 24 25
Men
50–74 5 5 5 5
75+ 4 5 5 5
All 9 9 10 10
Women and Men
50–74 11 11 11 11
75+ 19 21 23 24
All 30 32 34 35
Table 13 Value of lost QALYs (€) in men and women in Estonia in
2010
1 × GDP/
capita
2 × GDP/
capita
3 × GDP/
capita
Incident hip fractures 3,899,777 7,799,554 11,699,331
Incident vertebral
fractures
4,735,018 9,470,037 14,205,055
Incident forearm
fractures
503,032 1,006,063 1,509,095
Incident other
fractures
5,159,726 10,319,452 15,479,178
Prior hip fractures 11,216,129 22,432,259 33,648,388
Prior vertebral
fractures
4,170,935 8,341,869 12,512,804
Total 29,684,617 59,369,234 89,053,851
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million in 2010 to € 104 million in 2025. The increase
was estimated to be 17 % in men and 16 % in women
(Table 18).
Treatment uptake
To estimate uptake of individual osteoporosis treat-
ments, sales data from IMS Health (2001–2011) were
used to derive the number of defined daily doses
(DDDs) sold per 100,000 persons aged 50 years or
above (Fig. 2).
Adjusting the sales data for compliance allowed for an
estimation of the proportion of population aged 50 years or
above who received any osteoporosis treatment (see Chapter
5 of the report Osteoporosis in the European Union: Medical
Management, Epidemiology and Economic Burden for fur-
ther details). The proportion of persons over the age of
50 years who were treated increased from 0.13 % in 2001
to 1.66 % in 2011.
Treatment gap
In order to assess the potential treatment gap, the
numbers of men and women eligible for treatment in
Estonia were defined as individuals with a 10-year
fracture probability exceeding that of a woman with a
prior fragility fracture derived from FRAX®, equivalent
to a ‘fracture threshold’ (See Chapter 5 of the main
report for further details). Subsequently, these estimates
were compared to the number of individuals who re-
ceived osteoporosis treatment obtained from the analy-
sis of IMS Health data. The treatment gaps in men and
women were estimated at 93 % and 86 % respectively
(Table 19). Note that the estimate of the treatment gap
is conservative given that it assumes that current use of
osteoporosis treatments are only directed to men and
women at high risk.
Table 18 Present and future cost (€ 000,000) of fracture (direct cost
and cost of QALYs) by age and calendar year in men and women in
Estonia assuming the uptake of treatment remains unchanged
2010 2015 2020 2025
Women
50–74 20 19 20 20
75+ 44 48 51 54
All 64 67 70 74
Men
50–74 14 14 14 15
75+ 12 13 14 15
All 26 27 28 30
Women and Men
50–74 33 33 34 35
75+ 56 61 64 69
All 89 94 99 104
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Fig. 2 Treatment uptake in Estonia (Defined daily doses [DDDs] per
100,000 persons aged 50 years or above)
Table 19 Number of men and women eligible for treatment, treated
and treatment gap in 2010
Number
potentially
treated
(1000 s)
Number
eligible for
treatment
(1000 s)
Difference
(1000 s)
Treatment
gap (%)
Men 1 14 13 93
Women 7 48 41 86
Table 17 Projected QALYs lost due to incident and prior fractures for
the years 2010 and 2025 by age in men and women in Estonia
Incident fractures Prior fractures All fractures
2010 2025 2010 2025 2010 2025
Women
50–74 330 339 300 310 630 648
75+ 559 695 798 943 1,357 1,638
All 889 1,033 1,098 1,253 1,987 2,286
Men
50–74 266 289 162 172 428 462
75+ 181 243 178 213 359 456
All 447 532 340 385 787 917
Women and Men
50–74 596 628 462 482 1,058 1,110
75+ 740 938 976 1,156 1,717 2,094
All 1,336 1,566 1,438 1,638 2,774 3,204
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ORIGINAL ARTICLE
Abstract
Summary This report describes epidemiology, burden, and
treatment of osteoporosis in Finland.
Introduction Osteoporosis is characterized by reduced
bone mass and disruption of bone architecture, resulting
in increased risks of fragility fractures which represent
the main clinical consequence of the disease. Fragility
fractures are associated with substantial pain and suffer-
ing, disability and even death for the affected patients
and substantial costs to society. The aim of this study is
to describe the epidemiology and economic burden of
fragility fractures as a consequence of osteoporosis in
Finland, as a further detailed addition to the report for
the entire European Union (EU27): Osteoporosis in the
European Union: Medical Management, Epidemiology
and Economic Burden.
Methods The literature on fracture incidence and costs of
fractures in Finland was reviewed and incorporated into
a model estimating the clinical and economic burden of
osteoporotic fractures in 2010. Furthermore, data on
sales of osteoporosis treatments and the population at
high risk were used to estimate treatment uptake and
treatment gap.
Results It was estimated that approximately 36,000 new
fragility fractures were sustained in Finland, comprising
7,000 hip fractures, 6,000 vertebral fractures, 6,000 forearm
fractures and 19,000 other fractures (i.e. fractures of the
pelvis, rib, humerus, tibia, fibula, clavicle, scapula, sternum
and other femoral fractures) in 2010. The economic burden
of incident and previous fragility fractures was estimated at
€ 383 million for the same year. Incident fractures repre-
sented 70 % of this cost, long-term fracture care 27 % and
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pharmacological prevention 3 %. Previous and incident
fractures also accounted for 12,300 quality-adjusted life
years (QALYs) lost during 2010. When accounting for the
demographic projections for 2025, the number of incident
fractures was estimated at 49,000 in 2025, representing an
increase of 13,000 fractures. Hip, clinical vertebral (spine),
forearm and other fractures were estimated to increase by
2,900, 2,000, 1,200 and 6,600, respectively. The burden of
fractures in Finland in 2025 was estimated to increase by
34 % to € 514 million. Though the uptake of osteoporosis
treatments increased from 2001, the proportion of patients
aged 50 or above who received treatment declined in the
past few years. The majority of women at high fracture risk
did not receive active treatment.
Conclusions In spite of the high cost of osteoporosis, a
substantial treatment gap and projected increase of the eco-
nomic burden driven by aging populations, the use of phar-
macological prevention of osteoporosis is significantly less
than optimal, suggesting that a change in healthcare policy
concerning the disease is warranted.
Introduction
Osteoporosis is characterized by reduced bone mass and
disruption of bone architecture, resulting in increased
risks of fragility fractures which represent the main
clinical consequence of the disease. Fragility fractures
are associated with substantial pain and suffering, dis-
ability and even death for the affected patients and
substantial costs to society. The aim of this report was
to characterize the burden of osteoporosis in Finland in
2010 and beyond.
Methods
The literature on fracture incidence and costs of fractures in
Finland was reviewed and incorporated into a model estimat-
ing the clinical and economic burden of osteoporotic fractures
in 2010. Details of the methods used are found in Chapters 3
and 4 of the report Osteoporosis in the European Union:
Medical Management, Epidemiology and Economic Burden,
published concurrently in Archives of Osteoporosis.
Epidemiology of osteoporosis in Finland
For the purpose of this report, the population at risk of
osteoporosis was considered to include men and women
≥50 years. The number of men and women ≥50 years of
age amounted to 960,000 and 1,130,000 respectively in
Finland in 2010 (Table 1).
In the population at risk, the number of individuals with
osteoporosis—as defined by the WHO diagnostic
criteria—was estimated at 300,000 (Table 2). There are
16.8 DXA scan machines per million (m) inhabitants [2],
and guidelines for the assessment and treatment of osteopo-
rosis are available [3]. A country specific FRAX model is
also available for the assessment of fracture risk ( http://
www.shef.ac.uk/FRAX/).
Data on the incidence of hip fractures are available for
Finland [5–7] and that used to build the FRAX model was
chosen for this study [7]. Given that country specific incidence
of the vertebral, forearm and, “other” fractures were not found,
these were imputed using the methods described in Chapter 3
of the main report. Empirical data are expected in the near
future [8]. Fracture incidence is presented in Table 3. Standard-
ized to the EU27 population for 2010, hip fracture incidence
(per 100,000 person years) in men and women ≥50 years of age
was estimated at 238.0 and 440.0 respectively.
The number of incident fractures in 2010 was estimated
at 36,000 (Table 4). Incident hip, clinical spine, forearm and
“other” fractures were estimated at 7,000, 6,000, 6,000 and
19,000 respectively. 60 % of fractures occurred in women.
A prior fracture was defined as a fracture in an individual
who was alive during the index year (i.e. 2010) which had
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Table 1 Population at risk: men and women over the age of 50 in
Finland, 2010 [1]
Age (years) Women Men All
50–59 383,000 379,000 762,000
60–69 348,000 327,000 675,000
70–79 227,000 175,000 402,000
80–89 147,000 72,000 219,000
90+ 25,000 7,000 32,000
50+ 1,130,000 960,000 2,090,000
Table 2 Estimated number of women and men with osteoporosis
(defined as a T-score ≤−2.5 SD) in Finland by age using female-
derived reference ranges at the femoral neck, 2010 [4]
Age (years) Women Men
50–54 11,844 4,700
55–59 18,720 6,685
60–64 29,458 11,484
65–69 28,684 9,546
70–74 33,759 7,800
75–79 39,750 7,725
80+ 81,184 13,114
50+ 243,399 61,054
occurred after the age of 50 years and before 2010. In the
population ≥50 years of age, the proportion of individuals
who had suffered a fracture prior to 2010 was estimated at
1.64 % for hip and 1.78 % for clinical vertebral fractures.
The estimated proportions of men and women with prior hip
and vertebral fractures by age are presented in Table 5.
In the population over 50 years of age, the number of in-
dividuals with hip and vertebral fractures that occurred before
2010 was estimated at 34,000 and 37,000 respectively (Table 6).
Note that fractures sustained in 2010 were not included in the
estimate.
The incidence of causally related deaths (per 100,000) in
the first year after fracture by age is presented in Table 7.
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Table 4 Estimated number of incident fractures in Finland, 2010
Table 5 Estimated proportion of men and women (in %) with a prior
hip or clinical fracture in Finland, 2010
Table 3 Incidence per 100,000 person years of hip, clinical vertebral,
forearm, and “other” fractures in Finland by age
Table 6 Estimated number of men and women in Finland with a prior
hip or clinical fracture after the age of 50 years, 2010
The number of causally related deaths in 2010 was estimat-
ed at 425 (Table 8). Hip, vertebral and “other” fractures
accounted for 209, 144 and 72 deaths respectively. Overall,
approximately 47 % of deaths occurred in women.
Cost of osteoporosis in Finland including and excluding
value of QALYs lost
For the purpose of this report, the cost of osteoporosis in
2010 (excluding value of QALYs lost) was considered to
consist of three components: (i) cost of fractures that oc-
curred in 2010 (“first year costs”); (ii) cost of fractures
sustained prior to year 2010 but which still incurred costs
in 2010 (“long-term disability cost”); and (iii) cost of phar-
macological fracture prevention including administration
and monitoring costs (“pharmacological fracture prevention
costs”). See Chapter 4 of the main report for further details.
In Finland, the cost of a hip fracture has been esti-
mated at € 16,066 [10] No other fracture costs were
available. Given that no cost data for the other fracture
sites were found, these were imputed as described in
Chapter 4 of the main report.
Long-term disability costs were estimated by multiplying
the yearly cost of residing in nursing home (€ 32,930 [11])
with the simulated number of individuals with prior fractures
that had been transferred to nursing home due to the fracture.
Annual drug costs (€) for individual treatments are shown
in Table 9. In addition, it was assumed that patients on
treatment made an annual physician visit costing € 17 [12]
and a DXA scan costing € 146 [12] every second year to
monitor treatment.
The cost of osteoporosis in 2010 was estimated at € 383
million (Table 10). First year costs, subsequent year costs
and pharmacological fracture prevention costs amounted to
€ 269 million, € 104 million and € 10 million, respectively.
It is notable that pharmacological fracture prevention costs
amounted to only 2.6 % of the total cost.
When stratifying costs of osteoporosis by fracture
type, hip fractures were most costly (€ 198 million)
followed by “other” (€ 151 million), spine (€ 18 mil-
lion) and forearm fractures (€ 5 million) (Table 11 and
Fig. 1). Please note that costs for pharmacological frac-
ture prevention were not included given that they cannot
be allocated to specific fracture sites.
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Table 7 Incidence (per 100,000) of causally related deaths [9] in Finland
within the first year after fracture (adjusted for comorbidities), 2010
Table 8 The number of deaths in men and women in Finland in the
first year after fracture attributable to the fracture event (causally
related), 2010
Table 9 One year costs
for relevant pharmaceuti-
cals in Finland, 2010 [12]
Annual drug
cost (€)
Alendronate 40
Risedronate 40
Etidronate 1,072
Ibandronate 456
Zoledronic acid 394
Raloxifene 488
Strontium ranelate 527
Parathyroid hormone 5,593
Teriparatide 5,933
The number of quality adjusted life years (QALYs) lost due
to osteoporosis in 2010 was estimated at 12,300 (Table 12).
62 % of the total QALY loss was incurred in women. Prior
fractures accounted for 55 % of the total QALY loss. The
monetary value of a QALY was varied between 1 to 3 times
the gross domestic product (GDP) per capita (Table 13).
Assuming a QALY is valued at 2 times GDP/capita, the total
cost of the QALYs lost was estimated at € 830 million.
When the cost of osteoporosis was combined with the
value for QALYs lost (valued at 2 × GDP), the cost of
osteoporosis amounted to € 1.21 billion in Finland in 2010.
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Table 10 Cost of osteoporosis (€) in Finland by age in men and
women, 2010
Table 11 Total cost (€) in 2010 by fracture site in men and women in
Finland. Note that costs for fracture prevention therapy and monitoring
are not included
Hip
53%
Spine
5%
Forearm
1%
Other
41%
Fig. 1 Share (%) of fracture cost by fracture site in Finland. Note that
costs for fracture prevention therapy and monitoring are not included
Table 12 Number of QALYs lost due to fractures during 2010 in men
and women in Finland according to age
Incident fracture, prior fracture, pharmacological fracture pre-
vention, and value of QALYs lost accounted for 22 %, 9 %,
1 %, 68 % respectively.
Burden of osteoporosis up to 2025
The population above 50 years of age is expected to increase
from 2.1 million in 2010 to 2.3 million in 2025, correspond-
ing to an increase of 12 % (Table 14).
The total number of fractures was estimated to rise from
36,000 in 2010 to 49,000 in 2025 (Table 15), corresponding
to an increase of 36 %. Hip, clinical spine, forearm and other
fractures increased by 2,900, 2,000, 1,200 and 6,600 respec-
tively. The increase in the number of fractures ranged from
21 % to 44 %, depending on fracture site. The increase was
estimated to be particularly marked in men (42 %) compared
to women (30 %).
The cost of osteoporosis (excluding value of QALYs lost)
was estimated to rise from € 383 million in 2010 to € 514
million in 2025, corresponding to an increase of 34 % (Table
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Table 13 Value of lost QALYs (€) inmen andwomen in Finland in 2010
1 × GDP/
capita
2 × GDP/
capita
3 × GDP/
capita
Incident hip fractures 49,153,821 98,307,641 147,461,462
Incident vertebral
fractures
59,720,352 119,440,704 179,161,056
Incident forearm
fractures
6,212,943 12,425,886 18,638,829
Incident other
fractures
70,640,403 141,280,807 211,921,210
Prior hip fractures 163,554,941 327,109,882 490,664,823
Prior vertebral
fractures
65,017,379 130,034,757 195,052,136
Total 414,299,839 828,599,677 1,242,899,516
Table 14 Population projections in Finland by age and sex [13]
Table 15 Projected annual number of incident fractures in 2010 and
2025 by fracture site and age in men and women from Finland
Table 16 Current and future cost (€ 000, 000) of osteoporosis (ex-
cluding value of QALYs lost) by age and calendar year in men and
women in Finland
16). Costs incurred in women and men increased by 28 %
and 44 % respectively.
The total number of QALYs lost due to fracture was esti-
mated to rise from 12,300 in 2010 to 15,800 in 2025,
corresponding to an increase of 28 % (Table 17). The
increase was estimated to be particularly marked in men
(38 %) compared to women (22 %). Incident and prior
fractures accounted for 59 % and 41 % of the increase
respectively.
The cost of osteoporosis including value of QALYs lost was
estimated to increase from approximately € 1.2 billion in
2010 to € 1.6 billion in 2025. The increase was estimated to
be particularly marked in men (+40 %) compared to women
(+24 %) (Table 18).
Treatment uptake
To estimate uptake of individual osteoporosis treatments,
sales data from IMS Health (2001–2011) were used to
derive the number of defined daily doses (DDDs) sold per
100,000 persons aged 50 years or above (Fig. 2).
Adjusting the sales data for compliance allowed for an estima-
tion of the proportion of population aged 50 years or abovewho
received any osteoporosis treatment (see Chapter 5 of the report
Osteoporosis in the European Union: Medical Management,
Epidemiology and Economic Burden for further details). The
proportion of persons over the age of 50 years whowere treated
increased from 1.38 % in 2001 to 4.22 % in 2011.
Treatment gap
In order to assess the potential treatment gap, the numbers of
men and women eligible for treatment in Finland were defined
as individuals with a 10-year fracture probability exceeding that
of a woman with a prior fragility fracture derived from
FRAX®, equivalent to a ‘fracture threshold’ (See Chapter 5
of the main report for further details). Subsequently, these
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Table 17 Projected QALYs lost due to incident and prior fractures for
the years 2010 and 2025 by age in men and women in Finland
Table 18 Present and future cost (€ 000,000) of fracture (direct
cost and cost of QALYs) by age and calendar year in men and
women in Finland assuming the uptake of treatment remains
unchanged
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Fig. 2 Treatment uptake in Finland (Defined daily doses [DDDs] per
100,000 persons aged 50 years or above)
Table 19 Number of men and women eligible for treatment, treated
and treatment gap in 2010
Number
potentially
treated
(1000 s)
Number eligible
for treatment
(1000 s)
Difference
(1000 s)
Treatment
gap (%)
Men 8 51 43 84
Women 53 172 119 69
estimates were compared to the numberof individuals who
received osteoporosis treatment obtained from the analysis of
IMS Health data. The treatment gaps in men and women were
estimated at 84 % and 69 % respectively (Table 19). Note that
the estimate of the treatment gap is conservative given that it
assumes that current use of osteoporosis treatments are only
directed to men and women at high risk.
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Abstract
Summary This report describes epidemiology, burden, and
treatment of osteoporosis in France.
Introduction Osteoporosis is characterized by reduced
bone mass and disruption of bone architecture, resulting
in increased risks of fragility fractures which represent
the main clinical consequence of the disease. Fragility
fractures are associated with substantial pain and suffer-
ing, disability and even death for the affected patients
and substantial costs to society. The aim of this study is
to describe the epidemiology and economic burden of
fragility fractures as a consequence of osteoporosis in
France, as a further detailed addition to the report for
the entire European Union (EU27): Osteoporosis in the
European Union: Medical Management, Epidemiology
and Economic Burden.
Methods The literature on fracture incidence and costs of
fractures in France was reviewed and incorporated into
a model estimating the clinical and economic burden of
osteoporotic fractures in 2010. Furthermore, data on
sales of osteoporosis treatments and the population at
high risk were used to estimate treatment uptake and
treatment gap.
Results It was estimated that approximately 377,000 new
fragility fractures were sustained in France, comprising
74,000 hip fractures, 56,000 vertebral fractures, 56,000
forearm fractures and 191,000 other fractures (i.e. fractures
of the pelvis, rib, humerus, tibia, fibula, clavicle, scapula,
sternum and other femoral fractures) in 2010. The economic
burden of incident and previous fragility fractures was esti-
mated at € 4,853 million for the same year. Incident frac-
tures represented 66 % of this cost, long-term fracture care
27 % and pharmacological prevention 7 %. Previous and
incident fractures also accounted for 139,400 quality-
adjusted life years (QALYs) lost during 2010. When ac-
counting for the demographic projections for 2025, the
number of incident fractures was estimated at 491,000 in
2025, representing an increase of 115,000 fractures. Hip,
clinical vertebral (spine), forearm and other fractures were
estimated to increase by 24,500, 17,200, 12,900 and 60,000,
respectively. The burden of fractures in France in 2025 was
estimated to increase by 26 % to € 6,111 million. Though
the uptake of osteoporosis treatments increased from 2001,
the proportion of patients aged 50 or above who received
treatment declined in the past few years. A substantial
minority of women at high fracture risk did not receive
active treatment.
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Conclusions In spite of the high cost of osteoporosis, a
substantial treatment gap and projected increase of the eco-
nomic burden driven by aging populations, the use of phar-
macological prevention of osteoporosis is significantly less
than optimal, suggesting that a change in healthcare policy
concerning the disease is warranted.
Introduction
Osteoporosis is characterized by reduced bone mass and
disruption of bone architecture, resulting in increased
risks of fragility fractures which represent the main
clinical consequence of the disease. Fragility fractures
are associated with substantial pain and suffering, dis-
ability and even death for the affected patients and
substantial costs to society. The aim of this report was
to characterize the burden of osteoporosis in France in
2010 and beyond.
Methods
The literature on fracture incidence and costs of frac-
tures in France was reviewed and incorporated into a
model estimating the clinical and economic burden of
osteoporotic fractures in 2010. Details of the methods
used are found in Chapters 3 and 4 of the report
Osteoporosis in the European Union: Medical Manage-
ment, Epidemiology and Economic Burden, published
concurrently in Archives of Osteoporosis.
Epidemiology of osteoporosis in France
For the purpose of this report, the population at risk of
osteoporosis was considered to include men and women
≥50 years. The number of men and women ≥50 years of
age amounted to 10,287,000 and 12,358,000 respectively in
France in 2010 (Table 1).
In the population at risk, the number of individuals with
osteoporosis—as defined by the WHO diagnostic
criteria—was estimated at 3,480,000 (Table 2). There are
29.1 DXA scan machines per million (m) inhabitants [2],
and guidelines for the assessment and treatment of osteopo-
rosis are available [3]. A country specific FRAX model is
also available for the assessment of fracture risk (http://
www.shef.ac.uk/FRAX/).
Data on hip fracture incidence are available for
France [5]. Given that country specific incidence of
vertebral, forearm and, “other” fractures were not found,
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Table 1 Population at risk: men and women over the age of 50 in
France, 2010 [1]
Age (years) Women Men All
50–59 4,222,000 4,006,000 8,228,000
60–69 3,330,000 3,122,000 6,452,000
70–79 2,578,000 2,015,000 4,593,000
80–89 1,877,000 1,034,000 2,911,000
90+ 351,000 110,000 461,000
50+ 12,358,000 10,287,000 22,645,000
Table 2 Estimated number of women and men with osteoporosis
(defined as a T-score ≤−2.5 SD) in France by age using female-
derived reference ranges at the femoral neck, 2010 [4]
Age (years) Women Men
50–54 134,757 50,850
55–59 199,968 69,020
60–64 284,141 109,330
65–69 271,286 91,538
70–74 361,305 84,474
75–79 481,125 95,996
80+ 1,051,616 189,904
50+ 2,784,198 691,112
Table 3 Incidence per 100,000 person years of hip, clinical vertebral,
forearm, and “other” fractures in France by age
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these were imputed using the methods described in
Chapter 3 of the main report. Fracture incidence is
presented in Table 3. Standardized to the EU27 popula-
tion, hip fracture incidence (per 100,000 person years)
in men and women ≥50 years of age was estimated at
168 and 443 respectively.
The number of incident fractures in 2010 was estimated at
377,000 (Table 4). Incident hip, clinical spine, forearm and
“other” fractures were estimated at 74,000, 56,000, 56,000
and 191,000 respectively. 68 % of fractures occurred in
women.
A prior fracture was defined as a fracture in an
individual who was alive during the index year (i.e.
2010) which had occurred after the age of 50 years
and before 2010. In the population ≥50 years of age,
the proportion of individuals who had suffered a frac-
ture prior to 2010 was estimated at 1.92 % for hip and
1.92 % for clinical vertebral fractures. The estimated
proportions of men and women with prior hip and
vertebral fractures by age are presented in Table 5.
In the population over 50 years of age, the number of
individuals with hip and vertebral fractures that occurred
before 2010 was estimated at 435,000 and 436,000 respec-
tively (Table 6). Note that fractures sustained in 2010 were
not included in the estimate.
The incidence of causally related deaths (per 100,000)
in the first year after fracture by age is presented in
Table 7. The number of causally related deaths in 2010
was estimated at 4,233 (Table 8). Hip, vertebral and
“other” fractures accounted for 2,098, 1,256 and 880
deaths respectively. Overall, approximately 51 % of
deaths occurred in women.
Cost of osteoporosis in France including and excluding
value of QALYs lost
For the purpose of this report, the cost of osteoporosis in
2010 (excluding value of QALYs lost) was considered to
consist of three components: (i) cost of fractures that oc-
curred in 2010 (“first year costs”); (ii) cost of fractures
sustained prior to year 2010 but which still incurred costs
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Table 6 Number of men and women in France with a prior hip or
clinical vertebral fracture after the age of 50 years, 2010
Table 5 Proportion of men and women (in %) with a prior hip or
clinical vertebral fracture in France, 2010
Table 4 Estimated number of incident fractures in France, 2010
in 2010 (“long-term disability cost”); and (iii) cost of phar-
macological fracture prevention including administration
and monitoring costs (“pharmacological fracture prevention
costs”). See Chapter 4 of the main report for further details.
The cost of a hip fracture in France was not available.
Therefore, it was imputed from the UK cost of a hip fracture
by adjusting for differences in health care price levels and
estimated at € 12,030 [6,7]. Given that no cost data for the
other fracture sites were found, these were imputed as de-
scribed in Chapter 4 of the main report.
Long-term disability costs were estimated by multiplying
the yearly cost of residing in nursing home (€ 31,512 [6],
imputed from the UK long term care cost adjusting for
differences in the health care price levels) with the simulated
number of individuals with prior fractures that had been
transferred to nursing home due to the fracture.
Annual drug cost (€) for individual treatments is shown
in Table 9. In addition, it was assumed that patients on
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Table 9 One year costs
for relevant pharmaceuti-
cals in France, 2010 [10]
Annual drug
cost (€)
Alendronate 209
Risedronate 380
Etidrontate 99
Ibandronate 327
Zoledronic acid 410
Raloxifene 365
Strontium ranelate 579
Parathyroid hormone -
Teriparatide 4,829
Table 10 Cost of osteoporosis (€) in France by age in men and
women, 2010
Table 8 The number of deaths in men and women in France in the first
year after fracture attributable to the fracture event (causally related),
2010
Table 7 Incidence (per 100,000) of causally related deaths in
France within the first year after fracture (adjusted for
comorbidities), 2010
137, Page 70 of 218
treatment made an annual physician visit costing € 50 [8]
and a DXA scan costing € 41 [9] every second year to
monitor treatment.
The cost of osteoporosis in 2010 was estimated at € 4,853
million (Table 10). First year costs, subsequent year costs
and pharmacological fracture prevention costs amounted to
€ 3,179 million, € 1,329 million and € 346 million, respec-
tively. It is notable that pharmacological fracture prevention
costs amounted to only 7.1 % of the total cost.
When stratifying costs of osteoporosis by fracture type, hip
fractures were most costly (€ 2,588 million) followed by
“other” (€ 1,689 million), spine (€ 153 million) and forearm
fractures (€ 77 million) (Table 11 and Fig. 1). Please note that
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Table 11 Total cost (€) in 2010 by fracture site inmen andwomen in France. Note that costs for fracture prevention therapy andmonitoring are not included
Hip
57%
Spine
3%
Forearm
2%
Other
38%
Fig. 1 Share (%) of fracture cost by fracture site in France. Note that
costs for fracture prevention therapy and monitoring are not included
Table 12 Number of QALYs lost due to fractures during 2010 in men
and women in France according to age
costs for pharmacological fracture prevention were not includ-
ed given that they cannot be allocated to specific fracture sites.
The number of quality adjusted life years (QALYs) lost
due to osteoporosis in 2010 was estimated at 139,400 (Table
12). 70 % of the total QALY loss was incurred in women.
Prior fractures accounted for 60 % of the total QALY loss.
The monetary value of a QALY was varied between 1 to 3
times the gross domestic product (GDP) per capita (Table
13). Assuming a QALY is valued at 2 times GDP/capita, the
total cost of the QALYs lost was estimated at € 8.31 billion.
When the cost of osteoporosis was combined with the
value for QALYs lost (valued at 2 × GDP), the cost of
osteoporosis amounted to € 13.16 billion in France in 2010.
Incident fracture, prior fracture, pharmacological fracture pre-
vention, and value of QALYs lost accounted for 24 %, 10 %,
3 %, and 63 % respectively.
Burden of osteoporosis up to 2025
The population above 50 years of age is expected to increase
from 22.6 million in 2010 to 27.1 million in 2025, corre-
sponding to an increase of 20 % (Table 14).
The total number of fractures was estimated to rise from
377,000 in 2010 to 491,000 in 2025 (Table 15), corresponding
to an increase of 30 %. Hip, clinical spine, forearm and other
fractures increased by 24,500, 17,200, 12,900 and 60,000
respectively. The increase in the number of fractures ranged
from 23 % to 33 %, depending on fracture site. The increase
was estimated to be particularly marked in men (36 %) com-
pared to women (28 %).
The cost of osteoporosis (excluding value of QALYs lost)
was estimated to rise from € 4.9 billion in 2010 to € 6.1
billion in 2025, corresponding to an increase of 26 % (Table
16). Costs incurred in women and men increased by 23 %
and 35 % respectively.
The total number of QALYs lost due to fracture was
estimated to rise from 139,400 in 2010 to 167,900 in 2025,
corresponding to an increase of 20 % (Table 17). The increase
was estimated to be particularly marked in men (29 %) com-
pared to women (17 %). Incident and prior fractures
accounted for 61 % and 39 % of the increase respectively.
The cost of osteoporosis including value of QALYs lost
was estimated to increase from approximately € 13.2 billion
in 2010 to € 16.1 billion in 2025. The increase was estimat-
ed to be particularly marked in men (+31 %) compared to
women (+19 %) (Table 18).
Treatment uptake
To estimate uptake of individual osteoporosis treatments,
sales data from IMS Health (2001–2011) were used to
derive the number of defined daily doses (DDDs) sold per
100,000 persons aged 50 years or above (Fig. 2).
Adjusting the sales data for compliance allowed for an
estimation of the proportion of population aged 50 years
or above who received any osteoporosis treatment (see
Chapter 5 of the report Osteoporosis in the European Union:
Medical Management, Epidemiology and Economic Burden
for further details). The proportion of persons over the age
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Table 13 Value of lost QALYs (€) in men and women in France in 2010
1 × GDP/
capita
2 × GDP/
capita
3 × GDP/
capita
Incident hip
fractures
478,803,425 957,606,851 1,436,410,276
Incident vertebral
fractures
510,715,979 1,021,431,958 1,532,147,937
Incident forearm
fractures
55,054,072 110,108,144 165,162,216
Incident other
fractures
630,485,223 1,260,970,447 1,891,455,670
Prior hip fractures 1,814,820,821 3,629,641,642 5,444,462,463
Prior vertebral
fractures
664,773,990 1,329,547,980 1,994,321,969
Total 4,154,653,510 8,309,307,021 12,463,960,531
Table 14 Population projections in France by age and sex [11]
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of 50 years who were treated increased from 1.21 % in 2001
to 7.18 % in 2008, but fell back to 6.30 % in 2011.
Treatment gap
In order to assess the potential treatment gap, the num-
bers of men and women eligible for treatment in France
were defined as individuals with a 10-year fracture
probability exceeding that of a woman with a prior
fragility fracture derived from FRAX®, equivalent to a
‘fracture threshold’ (See Chapter 5 of the main report
for further details). Subsequently, these estimates were
compared to the number of individuals who received
osteoporosis treatment obtained from the analysis of
IMS Health data. The treatment gaps in men and wom-
en were estimated at 26 % and 43 % respectively (Table
19). Note that the estimate of the treatment gap is
conservative given that it assumes that current use of
osteoporosis treatments are only directed to men and
women at high risk.
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Table 15 Projected annual number of incident fractures in 2010 and 2025 by fracture site and age in men and women in France
Table 16 Current and future cost (€ 000, 000) of osteoporosis (ex-
cluding value of QALYs lost) by age and calendar year in men and
women in France
Table 17 Projected QALYs lost due to incident and prior fractures for
the years 2010 and 2025 by age in men and women in France
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Table 18 Present and future cost (€ 000,000) of fracture (direct cost
and cost of QALYs) by age and calendar year in men and women in
France assuming the uptake of treatment remains unchanged
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Fig. 2 Treatment uptake in France (Defined daily doses [DDDs] per
100,000 persons aged 50 years or above)
Table 19 Number of men and women eligible for treatment, treated
and treatment gap in 2010
Number
potentially
treated
(1000 s)
Number eligible
for treatment
(1000 s)
Difference
(1000 s)
Treatment
gap (%)
Men 208 282 74 26
Women 1,390 2,437 1,047 43
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Abstract
Summary This report describes epidemiology, burden, and
treatment of osteoporosis in Germany.
Introduction Osteoporosis is characterized by reduced
bone mass and disruption of bone architecture, resulting
in increased risks of fragility fractures which represent
the main clinical consequence of the disease. Fragility
fractures are associated with substantial pain and suffer-
ing, disability and even death for the affected patients
and substantial costs to society. The aim of this study is
to describe the epidemiology and economic burden of
fragility fractures as a consequence of osteoporosis in
Germany, as a further detailed addition to the report for
the entire European Union (EU27): Osteoporosis in the
European Union: Medical Management, Epidemiology
and Economic Burden.
Methods The literature on fracture incidence and costs of
fractures in Germany was reviewed and incorporated into a
model estimating the clinical and economic burden of oste-
oporotic fractures in 2010. Furthermore, data on sales of
osteoporosis treatments and the population at high risk were
used to estimate treatment uptake and treatment gap.
Results It was estimated that approximately 725,000 new
fragility fractures were sustained in Germany, comprising
130,000 hip fractures, 114,000 vertebral fractures, 118,000
forearm fractures and 363,000 other fractures (i.e. fractures
of the pelvis, rib, humerus, tibia, fibula, clavicle, scapula,
sternum and other femoral fractures) in 2010. The economic
burden of incident and previous fragility fractures was esti-
mated at € 9,008 million for the same year. Incident fractures
represented 73 % of this cost, long-term fracture care 23 %
and pharmacological prevention 4 %. Previous and incident
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fractures also accounted for 246,300 quality-adjusted life
years (QALYs) lost during 2010. When accounting for the
demographic projections for 2025, the number of incident
fractures was estimated at 928,000 in 2025, representing an
increase of 203,000 fractures. Hip, clinical vertebral (spine),
forearm and other fractures were estimated to increase by
42,900, 28,000, 23,200 and 108,800, respectively. The burden
of fractures in Germany in 2025 was estimated to increase by
25 % to € 11,261 million. Though the uptake of osteoporosis
treatments increased from 2001, the proportion of patients
aged 50 or above who received treatment remained at very
low levels in the past few years. The majority of women at
high fracture risk did not receive active treatment.
Conclusions In spite of the high cost of osteoporosis, a
substantial treatment gap and projected increase of the eco-
nomic burden driven by aging populations, the use of phar-
macological prevention of osteoporosis is significantly less
than optimal, suggesting that a change in healthcare policy
concerning the disease is warranted.
Introduction
Osteoporosis is characterized by reduced bone mass and
disruption of bone architecture, resulting in increased
risks of fragility fractures which represent the main
clinical consequence of the disease. Fragility fractures
are associated with substantial pain and suffering, dis-
ability and even death for the affected patients and
substantial costs to society. The aim of this report was
to characterize the burden of osteoporosis in Germany
in 2010 and beyond.
Methods
The literature on fracture incidence and costs of frac-
tures in Germany was reviewed and incorporated into a
model estimating the clinical and economic burden of
osteoporotic fractures in 2010. Details of the methods
used are found in Chapters 3 and 4 of the report
Osteoporosis in the European Union: Medical Manage-
ment, Epidemiology and Economic Burden, published
concurrently in Archives of Osteoporosis.
Epidemiology of osteoporosis in Germany
For the purpose of this report, the population at risk of
osteoporosis was considered to include men and women
≥50 years. The number of men and women ≥50 years of
age amounted to 15,246,000 and 17,764,000 respectively in
Germany in 2010 (Table 1).
In the population at risk, the number of individuals with
osteoporosis—as defined by the WHO diagnostic
criteria—was estimated at 5,020,000 (Table 2). There are
29.1 DXA scan machines per million (m) inhabitants [2],
and guidelines for the assessment and treatment of osteopo-
rosis are available. A country specific FRAX model is also
available for the assessment of fracture risk (http://
www.shef.ac.uk/FRAX/).
Data on hip fracture incidence are available for Ger-
many [4] and are in the process of being updated [5].
Given that country specific incidence of vertebral, fore-
arm and, “other” fractures were not found, these were
imputed using the methods described in Chapter 3 of
the main report. Fracture incidence is presented in Table
3. Standardized to the EU27 population, hip fracture
incidence (per 100,000 person years) in men and wom-
en ≥50 years of age was estimated at 218 and 522
respectively.
The number of incident fractures in 2010 was estimated
at 725,000 (Table 4). Incident hip, clinical spine, forearm
and “other” fractures were estimated at 130,000, 114,000,
118,000 and 363,000 respectively. 67 % of fractures oc-
curred in women.
A prior fracture was defined as a fracture in an
individual who was alive during the index year (i.e.
2010) which had occurred after the age of 50 years
and before 2010. In the population ≥50 years of age,
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Table 1 Population at risk: men and women over the age of 50 in
Germany, 2010 [1]
Age (years) Women Men All
50–59 5,799,000 5,813,000 11,612,000
60–69 4,641,000 4,405,000 9,046,000
70–79 4,485,000 3,677,000 8,162,000
80–89 2,455,000 1,247,000 3,702,000
90+ 384,000 104,000 488,000
50+ 17,764,000 15,246,000 33,010,000
Table 2 Estimated number of women and men with osteoporosis
(defined as a T-score ≤−2.5 SD) in Germany by age using female-
derived reference ranges at the femoral neck, 2010 [3]
Age (years) Women Men
50–54 192,528 78,050
55–59 263,328 94,185
60–64 335,621 131,950
65–69 463,388 157,620
70–74 754,137 181,428
75–79 668,250 139,153
80+ 1,340,008 224,266
50+ 4,017,260 1,006,652
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the proportion of individuals who had suffered a frac-
ture prior to 2010 was estimated at 2.03 % for hip and
2.35 % for clinical vertebral fractures. The estimated
proportions of men and women with prior hip and
vertebral fractures by age are presented in Table 5.
In the population over 50 years of age, the number of
individuals with hip and vertebral fractures that occurred
before 2010 was estimated at 670,000 and 776,000 respec-
tively (Table 6). Note that fractures sustained in 2010 were
not included in the estimate.
The incidence of causally related deaths (per
100,000) in the first year after fracture by age is
presented in Table 7. The number of causally related
deaths in 2010 was estimated at 8,777 (Table 8). Hip,
vertebral and “other” fractures accounted for 4,285,
Table 6 Number of men and women in Germany with a prior hip or
clinical vertebral fracture after the age of 50 years, 2010
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Table 3 Incidence per 100,000 person years of hip, clinical vertebral,
forearm, and “other” fractures in Germany by age
Table 5 Proportion of men and women (in %) with a prior hip or
clinical vertebral fracture in Germany, 2010
Table 4 Estimated number of incident fractures in Germany, 2010
2,965 and 1,527 deaths respectively. Overall, approxi-
mately 57 % of deaths occurred in women.
Cost of osteoporosis in Germany including and excluding
value of QALYs lost
For the purpose of this report, the cost of osteoporosis in
2010 (excluding value of QALYs lost) was considered to
consist of three components: (i) cost of fractures that oc-
curred in 2010 (“first year costs”); (ii) cost of fractures
sustained prior to year 2010 but which still incurred costs
in 2010 (“long–term disability cost”); and (iii) cost of phar-
macological fracture prevention including administration
and monitoring costs (“pharmacological fracture prevention
costs”). See Chapter 4 of the main report for further details.
In Germany, the cost of a hip fracture and the cost of a
vertebral fracture has been estimated at € 19,218 [6] and
€5,585 [7], respectively. Given that no cost data for the other
fracture sites were found, these were imputed as described in
Chapter 4 of the main report.
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Table 7 Incidence (per 100,000) of causally related deaths in Germa-
ny within the first year after fracture (adjusted for comorbidities), 2010
Table 8 The number of deaths in men and women in Germany in the
first year after fracture attributable to the fracture event (causally
related), 2010
Table 9 One year costs
for relevant pharmaceuti-
cals in Germany, 2010
[11]
Annual drug
cost (€)
Alendronate 245
Risedronate 509
Etidronate 475
Ibandronate 576
Zoledronic acid 562
Raloxifene 540
Strontium ranelate 611
Parathyroid hormone 7,853
Teriparatide 7,700
Table 10 Cost of osteoporosis (€) in Germany by age in men and
women, 2010
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Long-term disability costs were estimated by multiplying
the yearly cost of residing in nursing home (€ 34,534 [8], an
average of 4 long term care facilities) with the simulated
number of individuals with prior fractures that had been
transferred to nursing home due to the fracture.
Annual drug cost (€) for individual treatments is shown in
Table 9. In addition, it was assumed that patients on treatment
made an annual physician visit costing € 38 [9] and a DXA
scan costing € 36 [10] every second year to monitor treatment.
The cost of osteoporosis in 2010 was estimated at € 9,008
million (Table 10). First year costs, subsequent year costs
and pharmacological fracture prevention costs amounted to
€ 6,617 million, € 2,055 million and € 336 million
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Table 11 Total cost (€) in 2010 by fracture site in men and women in Germany. Note that costs for fracture prevention therapy and monitoring are
not included
Hip
49%
Spine
7%
Forearm
2%
Other
42%
Fig. 1 Share (%) of fracture cost by fracture site in Germany. Note that
costs for fracture prevention therapy and monitoring are not included
Table 12 Number of QALYs lost due to fractures during 2010 in men
and women in Germany according to age
respectively. It is notable that pharmacological fracture pre-
vention costs amounted to only 3.7 % of the total cost.
When stratifying costs of osteoporosis by fracture type, hip
fractures were most costly (€ 4,251 million) followed by
“other” (€ 3,625 million), spine (€ 657 million) and forearm
fractures (€ 139million) (Table 11 and Fig. 1). Please note that
costs for pharmacological fracture prevention were not includ-
ed given that they cannot be allocated to specific fracture sites.
The number of quality adjusted life years (QALYs) lost due
to osteoporosis in 2010 was estimated at 246,300 (Table 12).
68 % of the total QALY loss was incurred in women. Prior
fractures accounted for 55 % of the total QALY loss. The
monetary value of a QALY was varied between 1 to 3 times
the gross domestic product (GDP) per capita (Table 13).
Assuming a QALY is valued at 2 times GDP/capita, the total
cost of the QALYs lost was estimated at € 14.93 billion.
When the cost of osteoporosis was combined with the
value for QALYs lost (valued at 2 × GDP), the cost of
osteoporosis amounted to € 23.94 billion in Germany in
2010. Incident fracture, prior fracture, pharmacological frac-
ture prevention, and value of QALYs lost accounted for
28 %, 9 %, 1 % and 62 % respectively.
Burden of osteoporosis up to 2025
The population above 50 years of age is expected to increase
from 33 million in 2010 to 38.5 million in 2025, corre-
sponding to an increase of 17 % (Table 14).
The total number of fractures was estimated to rise from
725,000 in 2010 to 928,000 in 2025 (Table 15), correspond-
ing to an increase of 28 %. Hip, clinical spine, forearm and
other fractures increased by 42,900, 28,000, 23,200 and
108,800 respectively. The increase in the number of frac-
tures ranged from 20 % to 33 %, depending on fracture site.
The increase was estimated to be particularly marked in men
(37 %) compared to women (24 %).
The cost of osteoporosis (excluding value of QALYs lost) was
estimated to rise from € 9 billion in 2010 to € 11 billion in 2025,
corresponding to an increase of 25 % (Table 16). Costs incurred
in women and men increased by 21 % and 34 % respectively.
The total number of QALYs lost due to fracture was
estimated to rise from 246,300 in 2010 to 296,800 in 2025,
corresponding to an increase of 20 % (Table 17). The increase
was estimated to be particularly marked in men (31 %) com-
pared to women (16 %). Incident and prior fractures
accounted for 60 % and 40 % of the increase respectively.
The cost of osteoporosis including value of QALYs lost
was estimated to increase from approximately € 23.9 billion
in 2010 to € 29.2 billion in 2025. The increase was estimat-
ed to be particularly marked in men (+32 %) compared to
women (+17 %) (Table 18).
Treatment uptake
To estimate uptake of individual osteoporosis treatments,
sales data from IMS Health (2001–2011) were used to
derive the number of defined daily doses (DDDs) sold per
100,000 persons aged 50 years or above (Fig. 2).
Adjusting the sales data for compliance allowed for an
estimation of the proportion of population aged 50 years or
above who received any osteoporosis treatment (see Chapter 5
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Table 13 Value of lost QALYs (€) in men and women in Germany in 2010
1 × GDP/
capita
2 × GDP/
capita
3 × GDP/
capita
Incident hip
fractures
881,109,143 1,762,218,285 2,643,327,428
Incident vertebral
fractures
1,085,336,609 2,170,673,218 3,256,009,827
Incident forearm
fractures
120,265,846 240,531,692 360,797,537
Incident other
fractures
1,240,870,037 2,481,740,073 3,722,610,110
Prior hip fractures 2,909,128,253 5,818,256,507 8,727,384,760
Prior vertebral
fractures
1,227,012,854 2,454,025,708 3,681,038,562
Total 7,463,722,741 14,927,445,482 22,391,168,223
Table 14 Population projections in Germany by age and sex [12]
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of the report Osteoporosis in the European Union: Medical
Management, Epidemiology and Economic Burden for further
details). The proportion of persons over the age of 50 years who
were treated increased from 1.59 % in 2001 to 2.67 % in 2011.
Treatment gap
In order to assess the potential treatment gap, the num-
bers of men and women eligible for treatment in Ger-
many were defined as individuals with a 10-year
fracture probability exceeding that of a woman with a
prior fragility fracture derived from FRAX®, equivalent
to a ‘fracture threshold’ (See Chapter 5 of the main
report for further details). Subsequently, these estimates
were compared to the number of individuals who re-
ceived osteoporosis treatment obtained from the analysis
of IMS Health data. The treatment gaps in men and
women were estimated at 80 % and 77 % respectively
(Table 19). Note that the estimate of the treatment gap
is conservative given that it assumes that current use of
osteoporosis treatments are only directed to men and
women at high risk.
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Table 15 Projected annual number of incident fractures in 2010 and 2025 by fracture site and age in men and women in Germany
Table 16 Current and future cost (€ 000,000) of osteoporosis (exclud-
ing value of QALYs lost) by age and calendar year in men and women
in Germany
Table 17 Projected QALYs lost due to incident and prior fractures for
the years 2010 and 2025 by age in men and women in Germany
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Table 19 Number of men and women eligible for treatment, treated
and treatment gap in 2010
Number
potentially
treated
(1000 s)
Number eligible
for treatment
(1000 s)
Difference
(1000 s)
Treatment
gap (%)
Men 109 540 431 80
Women 730 3,231 2,501 77
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Abstract
Summary This report describes epidemiology, burden, and
treatment of osteoporosis in Greece.
Introduction Osteoporosis is characterized by reduced bone
mass and disruption of bone architecture, resulting in increased
risks of fragility fractures which represent the main clinical
consequence of the disease. Fragility fractures are associated
with substantial pain and suffering, disability and even death
for the affected patients and substantial costs to society. The aim
of this study is to describe the epidemiology and economic
burden of fragility fractures as a consequence of osteoporosis in
Greece, as a further detailed addition to the report for the entire
European Union (EU27): Osteoporosis in the European Union:
Medical Management, Epidemiology and Economic Burden.
Methods The literature on fracture incidence and costs of
fractures in Greece was reviewed and incorporated into a
model estimating the clinical and economic burden of
osteoporotic fractures in 2010. Furthermore, data on sales
of osteoporosis treatments and the population at high risk
were used to estimate treatment uptake and treatment gap.
Results It was estimated that approximately 86,000 new fra-
gility fractures were sustained in Greece, comprising 15,000
hip fractures, 13,000 vertebral fractures, 15,000 forearm frac-
tures and 43,000 other fractures (i.e. fractures of the pelvis,
rib, humerus, tibia, fibula, clavicle, scapula, sternum and other
femoral fractures) in 2010. The economic burden of incident
and previous fragility fractures was estimated at € 680 million
for the same year. Incident fractures represented 72 % of this
cost, long-term fracture care 15 % and pharmacological pre-
vention 13 %. Previous and incident fractures also accounted
for 31,000 quality-adjusted life years (QALYs) lost during
2010. When accounting for the demographic projections for
2025, the number of incident fractures was estimated at
107,000 in 2025, representing an increase of 21,000 fractures.
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Hip, clinical spine, forearm and other fractures were estimated
to increase by 4,100, 3,000, 2,800 and 11,300, respectively.
The burden of fractures in Greece in 2025 was estimated to
increase by 20 % to € 814 million. Though the uptake of
osteoporosis treatments increased from 2001, the proportion
of patients aged 50 or above who received treatment declined
in the past few years. A substantial minority of women at high
fracture risk did not receive active treatment.
Conclusions In spite of the high cost of osteoporosis, a
substantial treatment gap in women and projected increase
of the economic burden driven by aging populations, the use
of pharmacological prevention of osteoporosis is signifi-
cantly less than optimal, suggesting that a change in
healthcare policy concerning the disease is warranted.
Introduction
Osteoporosis is characterized by reduced bone mass and
disruption of bone architecture, resulting in increased risks
of fragility fractures which represent the main clinical con-
sequence of the disease. Fragility fractures are associated
with substantial pain and suffering, disability and even death
for the affected patients and substantial costs to society. The
aim of this report was to characterize the burden of osteo-
porosis in Greece in 2010 and beyond.
Methods
The literature on fracture incidence and costs of fractures
in Greece was reviewed and incorporated into a model
estimating the clinical and economic burden of osteopo-
rotic fractures in 2010. Details of the methods used are
found in Chapters 3 and 4 of the report Osteoporosis in
the European Union: Medical Management, Epidemiology
and Economic Burden, published concurrently in Archives
of Osteoporosis.
Epidemiology of osteoporosis in Greece
For the purpose of this report, the population at risk of osteo-
porosis was considered to include men and women ≥50 years.
The number of men and women ≥50 years of age amounted to
1,959,000 and 2,277,000 respectively inGreece in 2010 (Table 1).
In the population at risk, the number of individuals with
osteoporosis—as defined by the WHO diagnostic
criteria—was estimated at c. 640,000 (Table 2). There are
37.5 DXA scan machines per million (m) inhabitants [2],
and guidelines for the assessment and treatment of osteopo-
rosis are available [3] and have been recently updated [4]. A
country specific FRAX model is also available for the
assessment of fracture risk (http://www.shef.ac.uk/FRAX/).
Data on hip fracture incidence are available for Greece
[6] which has very recently been updated [7]. We used the
earlier report which was available at the time of writing [6].
Given that country specific incidence of the vertebral, fore-
arm and, “other” fractures were not found, these were im-
puted using the methods described in Chapter 3 of the main
report. Fracture incidence is presented in Table 3. Standard-
ized to the EU27 population, hip fracture incidence (per
100,000 person years) in men and women ≥50 years of
age was estimated at 213 and 494 respectively.
The number of incident fractures in 2010 was estimated at
86,000 (Table 4). Incident hip, clinical vertebral, forearm and
“other” fractures were estimated at 15,000, 13,000, 15,000
and 43,000 respectively. 64% of fractures occurred in women.
In the population aged 50 years or more, the proportion of
individuals who had suffered a fracture prior to 2010 was
estimated at 2.06 % for hip and 2.40 % for vertebral fractures.
The estimated proportions of men and women with prior hip
and clinical vertebral fractures by age are presented in Table 5.
In the population over 50 years of age, the number of
individuals with hip and vertebral fractures that occurred
before 2010 was estimated at 87,000 and 102,000 respectively
(Table 6). Note that fractures sustained in 2010 were not
included in the estimate.
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Table 1 Population at risk: men and women over the age of 50 in
Greece, 2010 [1]
Age (years) Women Men All
50–59 749,000 725,000 1,474,000
60–69 615,000 555,000 1,170,000
70–79 583,000 459,000 1,042,000
80–89 288,000 199,000 487,000
90+ 42,000 21,000 63,000
50+ 2,277,000 1,959,000 4,236,000
Table 2 Estimated number of women and men with osteoporosis
(defined as a T-score ≤−2.5 SD) in Greece by age using female-
derived reference ranges at the femoral neck, 2010 [5]
Age (years) Women Men
50–54 24,822 9,500
55–59 34,080 12,075
60–64 48,620 18,270
65–69 55,550 17,760
70–74 87,048 19,344
75–79 101,625 21,733
80+ 155,760 36,520
50+ 507,505 135,202
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The incidence of causally related deaths (per 100,000) in
the first year after fracture by age is presented in Table 7.
The number of causally related deaths in 2010 was estimat-
ed at 1,128 (Table 8). Hip, vertebral and “other” fractures
accounted for 566, 352 and 210 deaths respectively. Overall,
approximately 54 % of deaths occurred in women.
Cost of osteoporosis in Greece including and excluding
value of QALYs lost
For the purpose of this report, the cost of osteoporosis
in 2010 (excluding value of QALYs lost) was consid-
ered to consist of three components: (i) cost of fractures
that occurred in 2010 (“first year costs”); (ii) cost of
fractures sustained prior to year 2010 but which still
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Table 3 Incidence per 100,000 person years of hip, clinical vertebral,
forearm, and “other” fractures in Greece by age
Table 4 Estimated number of incident fractures in Greece, 2010
Table 5 Proportion of men and women (%) with a prior hip or clinical
vertebral fracture in Greece, 2010
Table 6 Number of men and women in Greece with a prior hip or
clinical vertebral fracture after the age of 50 years, 2010
incurred costs in 2010 (“long-term disability cost”); and
(iii) cost of pharmacological fracture prevention includ-
ing administration and monitoring costs (“pharmacolog-
ical fracture prevention costs”). See Chapter 4 of the
main report for further details.
As from March 2012 the Greek National Health System
reimburses € 470 (2 days admission) for a hip fracture treated
with osteosynthesis and € 1,463 (7 days admission) for a hip
fracture treated by hemiarthroplasty. More than 90% of all hip
fractures are treated surgically, usually by hemiarthroplasty.
Specific data for the cost of a hip fracture was not available for
Greece before 2012, and the cost of hip fracture was estimated
at € 12,550 using information from Italy [8]. Given that no
cost data for the other fracture sites were found, these were
imputed as described in Chapter 4 of the main report.
Long-term disability costs were estimated by multiplying the
yearly cost of residing in nursing home (€ 13,271 [9, 10], based on
Bulgarian cost of nursing home, purchasing power parity adjust-
ed) with the simulated number of individuals with prior fractures
that had been transferred to nursing home due to the fracture.
Annual drug costs (€) for individual treatments are shown
in Table 9. In addition, since patients can be followed either
in a private or in a public setting, it was assumed that
Arch Osteoporos (2013) 8:137
Table 7 Incidence (per 100,000) of causally related deaths in Greece
within the first year after fracture (adjusted for comorbidities), 2010
Table 8 The number of deaths in men and women in Greece in the first
year after fracture attributable to the fracture event (causally related), 2010
Table 9 One year costs
for relevant
pharamceuticals in
Greece, 2010 [13]
Annual drug
cost (€)
Alendronate 239
Risedronate 286
Etidrontae 79
Ibandronate 235
Zoledronic acid 357
Raloxifene 332
Strontium ranelate 494
Parathyroid hormone 3,630
Teriparatide 5,289
Table 10 Cost of osteoporosis (€) in Greece by age in men and
women, 2010
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patients on treatment made an annual physician visit costing
€ 8 [11] and a DXA scan at two sites costing € 115 [12]
every second year to monitor treatment.
The cost of osteoporosis in 2010 was estimated at € 680
million (Table 10). First year costs, subsequent year costs
and pharmacological fracture prevention costs amounted to
€ 488 million, € 102 million and € 91 million, respectively.
It is notable that pharmacological fracture prevention costs
amounted to only 13.4 % of the total cost.
When stratifying costs of osteoporosis by fracture type, hip
fractures were most costly (€ 260million) followed by “other”
(€ 284 million), spine (€ 34 million) and forearm fractures (€
11 million) (Table 11 and Fig. 1). Please note that costs for
pharmacological fracture prevention were not included given
that they cannot be allocated to specific fracture sites.
The number of quality adjusted life years (QALYs)
lost due to osteoporosis in 2010 was estimated at
31,000 (Table 12). 66 % of the total QALY loss was
incurred in women. Prior fractures accounted for 58 %
of the total QALY loss. The monetary value of a QALY
was varied between 1 to 3 times the gross domestic
product (GDP) per capita (Table 13). Assuming a
QALY is valued at 2 times GDP/capita, the total cost
of the QALYs lost was estimated at € 1.26 billion.
When the cost of osteoporosis was combined with the
value for QALYs lost (valued at 2 × GDP), the cost of
osteoporosis amounted to € 1.94 billion in Greece in 2010.
Incident fracture, prior fracture, pharmacological fracture
prevention, and value of QALYs lost accounted for 25 %,
5 %, 5 % and 65 % respectively.
Burden of osteoporosis up to 2025
The population above 50 years of age is expected to increase
from 4.2 million in 2010 to 5.1 million in 2025, correspond-
ing to an increase of 20 % (Table 14).
The total number of fractures was estimated to rise
from 86,000 in 2010 to 107,000 in 2025 (Table 15),
corresponding to an increase of 24 %. Hip, clinical
spine, forearm and other fractures increased by 4,100,
3,000, 2,800 and 11,300 respectively. The increase in
the number of fractures ranged from 19 % to 28 %,
depending on fracture site. The increase was estimated
to be particularly marked in men (28 %) compared to
women (23 %).
The cost of osteoporosis (excluding value of QALYs lost)
was estimated to rise from € 680 million in 2010 to € 814
million in 2025, corresponding to an increase of 20 % (Table
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Table 11 Total cost (€) in 2010 by fracture site in men and women in Greece. Note that costs for fracture prevention therapy and monitoring are not included
Hip
44%
Spine
6%
Forearm
2%
Other
48%
Fig. 1 Share (%) of fracture cost by fracture site in Greece. Note that
costs for fracture prevention therapy and monitoring are not included
16). Costs incurred in women and men increased by 18 %
and 24 % respectively.
The total number of QALYs lost due to fracture was esti-
mated to rise from 31,000 in 2010 to 35,200 in 2025,
corresponding to an increase of 14 % (Table 17). The increase
was estimated to be particularly marked in men (21 %) com-
pared to women (10 %). Incident and prior fractures accounted
for about 67 % and 33 % of the increase respectively.
The cost of osteoporosis including value of QALYs lost
was estimated to increase from approximately € 1.9 billion
in 2010 to € 2.2 billion in 2025. The increase was estimated
to be particularly marked in men (+22 %) compared to
women (+13 %) (Table 18).
Treatment uptake
To estimate uptake of individual osteoporosis treatments,
sales data from IMS Health (2001–2011) were used to
derive the number of defined daily doses (DDDs) sold per
100,000 persons aged 50 years or above (Fig. 2).
Adjusting the sales data for compliance allowed for an
estimation of the proportion of population aged 50 years or
above who received any osteoporosis treatment (see Chapter 5
of the report Osteoporosis in the European Union: Medical
Management, Epidemiology and Economic Burden for fur-
ther details). The proportion of persons over the age of
50 years who were treated increased from 1.67 % in 2001 to
9.1 % in 2009 but subsequently decreased to 8.2 % in 2011.
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Table 13 Value of lost QALYs (€) in men and women in Greece in 2010
1 × GDP/
capita
2 × GDP/
capita
3 × GDP/
capita
Incident hip fractures 68,416,328 136,832,656 205,248,984
Incident vertebral
fractures
86,072,643 172,145,287 258,217,930
Incident forearm
fractures
10,008,139 20,016,278 30,024,417
Incident other
fractures
99,760,468 199,520,936 299,281,404
Prior hip fractures 258,272,433 516,544,867 774,817,300
Prior vertebral
fractures
108,891,599 217,783,198 326,674,797
Total 631,421,611 1,262,843,222 1,894,264,833
Table 14 Population projections in Greece by age and sex [14]Table 12 Number of QALYs lost due to fractures during 2010 in men
and women in Greece according to age
137, Page 88 of 218
Treatment gap
In order to assess the potential treatment gap, the num-
bers of men and women eligible for treatment in Greece
were defined as individuals with a 10-year fracture
probability exceeding that of a woman with a prior
fragility fracture derived from FRAX®, equivalent to a
‘fracture threshold’ (See Chapter 5 of the main report
for further details). Subsequently, these estimates were
compared to the number of individuals who received
osteoporosis treatment obtained from the analysis of
IMS Health data. For men, the data indicate that the
volume of sold osteoporosis drugs would be sufficient
to cover treatment for more patients than the number
that fall above the fracture threshold. It should be noted,
however, that the results from this analysis should be
interpreted with some caution since it has been assumed
that the distribution of drug use between genders ob-
served in Sweden is valid for all countries. The treat-
ment gap in men and women were estimated at −25 %
and 31 % respectively (Table 19). Also note that the
estimate of the treatment gap is conservative given that
it assumes that current use of osteoporosis treatments
are only directed to men and women at high risk.
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Table 15 Projected annual number of incident fractures in 2010 and 2025 by fracture site and age in men and women in Greece
Table 16 Current and future cost (€ 000, 000) of osteoporosis (ex-
cluding value of QALYs lost) by age and calendar year in men and
women in Greece
Table 17 Projected QALYs lost due to incident and prior fractures for
the years 2010 and 2025 by age in men and women in Greece
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Table 18 Present and future cost (€ 000,000) of fracture (direct cost
and cost of QALYs) by age and calendar year in men and women in
Greece assuming the uptake of treatment remains unchanged
Table 19 Number of men and women eligible for treatment, treated
and treatment gap in 2010
Number
potentially
treated
(1000 s)
Number eligible
for treatment
(1000 s)
Difference
(1000 s)
Treatment
gap (%)
Men 50 40 −10 −25
Women 333 482 149 31
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Fig. 2 Treatment uptake in Greece (defined daily doses [DDDs] per
100,000 persons aged 50 years or above)
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Abstract
Summary This report describes epidemiology, burden, and
treatment of osteoporosis in Hungary.
Introduction Osteoporosis is characterized by reduced bone
mass and disruption of bone architecture, resulting in increased
risks of fragility fractures which represent the main clinical
consequence of the disease. Fragility fractures are associated
with substantial pain and suffering, disability and even death for
the affected patients and substantial costs to society. The aim of
this study is to describe the epidemiology and economic burden
of fragility fractures as a consequence of osteoporosis in Hun-
gary, as a further detailed addition to the report for the entire
European Union (EU27): Osteoporosis in the European Union:
Medical Management, Epidemiology and Economic Burden.
Methods The literature on fracture incidence and costs of
fractures in Hungary was reviewed and incorporated into a
model estimating the clinical and economic burden of oste-
oporotic fractures in 2010. Furthermore, data on sales of
osteoporosis treatments and the population at high risk were
used to estimate treatment uptake and treatment gap.
Results It was estimated that approximately 102,000 new
fragility fractures were sustained in Hungary, comprising
13,000 hip fractures, 11,000 vertebral fractures, 39,000 fore-
arm fractures and 38,000 other fractures (i.e. fractures of the
pelvis, rib, humerus, tibia, fibula, clavicle, scapula, sternum
and other femoral fractures) in 2010. The economic burden of
incident and previous fragility fractures was estimated at € 197
million for the same year. Incident fractures represented 64 %
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of this cost, long-term fracture care 15 % and pharmacological
prevention 20 %. Previous and incident fractures also
accounted for 23,700 quality-adjusted life years (QALYs) lost
during 2010. When accounting for the demographic projec-
tions for 2025, the number of incident fractures was estimated
at 116,000 in 2025, representing an increase of 13,000 frac-
tures. Hip, clinical vertebral (spine), forearm and other frac-
tures were estimated to increase by 2,900, 1,700, 2,700 and
6,000, respectively. The burden of fractures in Hungary in
2025 was estimated to increase by 15 % to € 226 million.
Though the uptake of osteoporosis treatments increased from
2001, the proportion of patients aged 50 or above who received
treatment declined in the past few years. A substantial minority
of women at high fracture risk did not receive active treatment.
Conclusions In spite of the high cost of osteoporosis, a
substantial treatment gap and projected increase of the eco-
nomic burden driven by aging populations, the use of phar-
macological prevention of osteoporosis is significantly less
than optimal, suggesting that a change in healthcare policy
concerning the disease is warranted.
Introduction
Osteoporosis is characterized by reduced bone mass and
disruption of bone architecture, resulting in increased
risks of fragility fractures which represent the main
clinical consequence of the disease. Fragility fractures
are associated with substantial pain and suffering, dis-
ability and even death for the affected patients and
substantial costs to society. The aim of this report was
to characterize the burden of osteoporosis in Hungary in
2010 and beyond.
Methods
The literature on fracture incidence and costs of fractures in
Hungary was reviewed and incorporated into a model esti-
mating the clinical and economic burden of osteoporotic
fractures in 2010. Details of the methods used are found in
Chapters 3 and 4 of the report Osteoporosis in the European
Union: Medical Management, Epidemiology and Economic
Burden, published concurrently in Archives of Osteoporosis.
Epidemiology of osteoporosis in Hungary
For the purpose of this report, the population at risk of
osteoporosis was considered to include men and women
≥50 years. The number of men and women ≥50 years of
age amounted to 1,540,000 and 2,143,000 respectively in
Hungary in 2010 (Table 1).
In the population at risk, the number of individuals with
osteoporosis—as defined by the WHO diagnostic
criteria—was estimated at 550,000 (Table 2). There are 6
DXA scan machines per million inhabitants [2], and guide-
lines for the assessment and treatment of osteoporosis are
available [3]. A country specific FRAX model is also avail-
able for the assessment of fracture risk (http://www.
shef.ac.uk/FRAX/).
Data on hip fracture incidence and forearm incidence are
available for Hungary [5]. Given that country specific inci-
dence of the vertebral and “other” fractures were not found,
these were imputed using the methods described in Chapter
3 of the main report. Fracture incidence is presented in Table
3. Standardized to the EU27 population, hip fracture inci-
dence (per 100,000 person years) in men and women
≥50 years of age was estimated at 274.1 and 560.6
respectively.
The number of incident fractures in 2010 was estimated
at 102,000 (Table 4). Incident hip, clinical spine, forearm
and “other” fractures were estimated at 13,000, 11,000,
39,000 and 38,000 respectively. 67 % of fractures occurred
in women.
A prior fracture was defined as a fracture in an
individual who was alive during the index year (i.e.
2010) which had occurred after the age of 50 years
and before 2010. In the population ≥50 years of age,
the proportions of individuals who had suffered a
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Table 1 Population at risk: men and women over the age of 50 in
Hungary, 2010 [1]
Age (years) Women Men All
50–59 762,000 671,000 1,433,000
60–69 633,000 481,000 1,114,000
70–79 472,000 272,000 744,000
80–89 246,000 106,000 352,000
90+ 30,000 10,000 40,000
50+ 2,143,000 1,540,000 3,683,000
Table 2 Estimated number of women and men with osteoporosis
(defined as a T-score ≤−2.5 SD) in Hungary by age using female-
derived reference ranges at the femoral neck, 2010 [4]
Age (years) Women Men
50–54 22,806 8,200
55–59 38,400 12,005
60–64 47,762 15,486
65–69 60,398 15,836
70–74 71,145 12,012
75–79 81,375 12,154
80+ 130,272 19,256
50+ 452,158 94,949
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fracture prior to 2010 were estimated at 1.55 % for hip
and 1.65 % for vertebral fractures. The estimated pro-
portions of men and women with prior hip and vertebral
fractures by age are presented in Table 5.
In the population over 50 years of age, the number of
individuals with hip and vertebral fractures that occurred
before 2010 was estimated at 57,000 and 61,000
respectively (Table 6). Note that fractures sustained in
2010 were not included in the estimate.
The incidence of causally related deaths (per 100,000) in
the first year after fracture by age is presented in Table 7.
The number of causally related deaths in 2010 was estimat-
ed at 1,241 (Table 8). Hip, vertebral and “other” fractures
accounted for 592, 460 and 189 deaths respectively. Overall,
approximately 51 % of deaths occurred in women.
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Table 3 Incidence per 100,000 person years of hip, clinical vertebral,
forearm, and “other” fractures in Hungary by age
Table 4 Estimated number of incident fractures in Hungary, 2010
Table 5 Proportion of men and women (in %) with a prior hip or
clinical vertebral fracture in Hungary, 2010
Table 6 Number of men and women in Hungary with a prior hip or
clinical vertebral fracture after the age of 50 years, 2010
Cost of osteoporosis in Hungary including and excluding
value of QALYs lost
For the purpose of this report, the cost of osteoporosis in
2010 (excluding value of QALYs lost) was considered to
consist of three components: (i) cost of fractures that oc-
curred in 2010 (“first year costs”); (ii) cost of fractures
sustained prior to year 2010 but which still incurred costs
in 2010 (“long-term disability cost”); and (iii) cost of phar-
macological fracture prevention including administration
and monitoring costs (“pharmacological fracture prevention
costs”). See Chapter 4 of the main report for further details.
The cost of a hip fracture was not available specifically
for Hungary, therefore the hip fracture cost was estimated at
€ 3,594 based on the cost in Slovenia [6]. Given that no cost
data for the other fracture sites were found, these were
imputed as described in Chapter 4 of the main report.
Long-term disability costs were estimated by multiplying
the yearly cost of residing in nursing home (€ 5,789 [7]) with
the simulated number of individuals with prior fractures that
had been transferred to nursing home due to the fracture.
Annual drug costs for individual treatments are shown in
Table 9. In addition, it was assumed that patients on
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Table 7 Incidence (per 100,000) of causally related deaths in Hungary
within the first year after fracture (adjusted for comorbidities), 2010
Table 8 The number of deaths in men and women in Hungary in the first
year after fracture attributable to the fracture event (causally related), 2010
Table 9 One year costs
for relevant pharmaceu-
ticals in Hungary, 2010
[9]
Annual drug
cost (€)
Alendronate 115
Risedronate 247
Etidronate -
Ibandronate 329
Zoledronic acid 254
Raloxifene 383
Strontium ranelate 449
Parathyroid hormone -
Teriparatide 4,663
Table 10 Cost of osteoporosis (€) in Hungary by age in men and
women, 2010
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treatment made an annual physician visit costing € 43 (ap-
proximated by adjusting Romanian cost for health adjusted
price levels [8]) and a DXA scan costing € 7 [7] every
second year to monitor treatment.
The cost of osteoporosis in 2010 was estimated at € 197
million (Table 10). First year costs, subsequent year costs
and pharmacological fracture prevention costs amounted to
€ 127 million, € 30 million and € 40 million respectively. It
is notable that pharmacological fracture prevention costs
amounted to only 20.3 % of the total cost.
When stratifying costs of osteoporosis by fracture type, hip
fractures were most costly (€ 71 million) followed by “other”
(€ 69 million), forearm (€ 9 million) and spine fractures
(€ 8 million) (Table 11 and Fig. 1). Please note that costs for
pharmacological fracture prevention were not included given
that they cannot be allocated to specific fracture sites.
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Table 11 Total cost (€) in 2010 by fracture site in men and women in
Hungary. Note that costs for fracture prevention therapy and monitor-
ing are not included
Hip
45%
Spine
5%
Forearm
6%
Other
44%
Fig. 1 Share (%) of fracture cost (%) by fracture site in Hungary. Note
that costs for fracture prevention therapy and monitoring are not
included
Table 12 Number of QALYs lost due to fractures during 2010 in men
and women in Hungary according to age
Table 13 Value of lost QALYs (€) in men and women in Hungary in
2010
1 × GDP/
capita
2 × GDP/
capita
3 × GDP/
capita
Incident hip fractures 29,729,410 59,458,819 89,188,229
Incident vertebral
fractures
35,535,859 71,071,717 106,607,576
Incident forearm
fractures
12,972,073 25,944,146 38,916,219
Incident other fractures 42,596,507 85,193,013 127,789,520
Prior hip fractures 80,158,522 160,317,044 240,475,567
Prior vertebral
fractures
30,940,008 61,880,016 92,820,023
Total 231,932,378 463,864,756 695,797,134
The number of quality adjusted life years (QALYs)
lost due to osteoporosis in 2010 was estimated at
23,700 (Table 12). 68 % of the total QALY loss was
incurred in women. Prior fractures accounted for 48 %
of the total QALY loss. The monetary value of a QALY
was varied between 1 to 3 times the gross domestic
product (GDP) per capita (Table 13). Assuming a
QALY is valued at 2 times GDP/capita, the total cost
of the QALYs lost was estimated at € 460 million.
When the cost of osteoporosis was combined with
the value for QALYs lost (valued at 2 × GDP), the
cost of osteoporosis amounted to € 660 million in
Hungary in 2010. Incident fracture, prior fracture,
pharmacological fracture prevention, and value of
QALYs lost accounted for 19 %, 5 %, 6 % and
70 % respectively.
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Table 14 Population projections in Hungary by age and sex [10]
Table 15 Projected annual number of incident fractures in 2010 and 2025 by fracture site and age in men and women in Hungary
Table 16 Current and future cost (€ 000, 000) of osteoporosis (ex-
cluding value of QALYs lost) by age and calendar year in men and
women in Hungary
2010 2015 2020 2025
Women
50–74 54 55 56 57
75+ 86 91 96 103
All 140 146 153 160
Men
50–74 31 32 33 34
75+ 27 28 30 32
All 58 60 62 66
Women and Men
50–74 84 87 89 91
75+ 113 119 126 135
All 197 206 215 226
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Burden of osteoporosis up to 2025
The population above 50 years of age is expected to increase
from 3.7 million in 2010 to 3.9 million in 2025, correspond-
ing to an increase of 5 % (Table 14).
The total number of fractures was estimated to rise from
102,000 in 2010 to 116,000 in 2025 (Table 15), correspond-
ing to an increase of 13 %. Hip, clinical spine, forearm and
other fractures increased by 2,900, 1,700, 2,700 and 6,000
respectively. The increase in the number of fractures ranged
from 7 % to 22 %, depending on fracture site. The increase
was estimated to be 11 % in men and 14 % in women.
The cost of osteoporosis (excluding value of QALYs lost)
was estimated to rise from € 197 million in 2010 to € 226
million in 2025, corresponding to an increase of 15 % (Table
16). Costs incurred in women and men increased by 15 %
and 14 % respectively.
The total number of QALYs lost due to fracture was estimated
to rise from 23,700 in 2010 to 26,200 in 2025, corresponding
to an increase of 11 % (Table 17). The increase was estimated
to be 12 % in men and 11 % in women. Incident and prior
fractures accounted for 71 % and 29 % of the increase
respectively.
The cost of osteoporosis including value of QALYs lost
was estimated to increase from approximately € 660
million in 2010 to € 740 million in 2025. The increase
was estimated to be 12 % in both men and women
(Table 18).
Treatment uptake
To estimate uptake of individual osteoporosis treatments,
sales data from IMS Health (2001–2011) were used to
derive the number of defined daily doses (DDDs) sold per
100,000 persons aged 50 years or above (Fig. 2).
Adjusting the sales data for compliance allowed for an
estimation of the proportion of population aged 50 years or
above who received any osteoporosis treatment (see Chapter
5 of the report Osteoporosis in the European Union: Medical
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Table 17 Projected QALYs lost due to incident and prior fractures for
the years 2010 and 2025 by age in men and women in Hungary
Incident fractures Prior fractures All fractures
2010 2025 2010 2025 2010 2025
Women
50–74 3,124 3,250 2,465 2,460 5,590 5,710
75+ 4,633 5,769 5,785 6,220 10,418 11,989
All 7,758 9,019 8,250 8,680 16,008 17,699
Men
50–74 2,641 2,807 1,411 1,503 4,052 4,310
75+ 1,931 2,341 1,675 1,889 3,606 4,230
All 4,572 5,149 3,087 3,392 7,659 8,541
Women and Men
50–74 5,765 6,057 3,876 3,963 9,642 10,020
75+ 6,565 8,110 7,460 8,109 14,025 16,219
All 12,330 14,167 11,337 12,072 23,667 26,239
Table 18 Present and future cost (€ 000,000) of fracture (direct cost
and cost of QALYs) by age and calendar year in men and women in
Hungary assuming the uptake of treatment remains unchanged
2010 2015 2020 2025
Women
50–74 163 165 167 169
75+ 290 305 320 338
All 453 470 486 507
Men
50–74 110 112 113 118
75+ 98 100 104 115
All 208 212 218 233
Women and Men
50–74 273 277 280 287
75+ 388 405 424 453
All 661 683 704 740
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Fig. 2 Treatment uptake in Hungary (Defined daily doses [DDDs] per
100,000 persons aged 50 years or above)
Table 19 Number of men and women eligible for treatment, treated
and treatment gap in 2010
Number
potentially
treated
(1000 s)
Number eligible
for treatment
(1000 s)
Difference
(1000 s)
Treatment
gap (%)
Men 36 60 24 41
Women 238 332 94 28
Management, Epidemiology and Economic Burden for fur-
ther details). The proportion of persons over the age of
50 years who were treated increased from 0.97 % in 2001
to 7.6 % in 2011.
Treatment gap
In order to assess the potential treatment gap, the numbers of
men and women eligible for treatment in Hungary were
defined as individuals with a 10-year fracture probability
exceeding that of a woman with a prior fragility fracture
derived from FRAX®, equivalent to a ‘fracture threshold’
(See Chapter 5 of the main report for further details). Sub-
sequently, these estimates were compared to the number of
individuals who received osteoporosis treatment obtained
from the analysis of IMS Health data. The treatment gaps
in men and women were estimated at 41 % and 28 %
respectively (Table 19). Note that the estimate of the treat-
ment gap is conservative given that it assumes that current
use of osteoporosis treatments are only directed to men and
women at high risk. Notwithstanding, there is some evi-
dence that hip fracture rates are declining in Hungary, a
phenomenon attributed to pharmaceutical treatment [11].
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Abstract
Summary This report describes epidemiology, burden, and
treatment of osteoporosis in Ireland.
Introduction Osteoporosis is characterized by reduced bone
mass and disruption of bone architecture, resulting in in-
creased risks of fragility fractures which represent the main
clinical consequence of the disease. Fragility fractures are
associated with substantial pain and suffering, disability and
even death for the affected patients and substantial costs to
society. The aim of this study is to describe the epidemiol-
ogy and economic burden of fragility fractures as a conse-
quence of osteoporosis in Ireland, as a further detailed
addition to the report for the entire European Union
(EU27): Osteoporosis in the European Union: Medical
Management, Epidemiology and Economic Burden.
Methods The literature on fracture incidence and costs of
fractures in Ireland was reviewed and incorporated into a
model estimating the clinical and economic burden of oste-
oporotic fractures in 2010. Furthermore, data on sales of
osteoporosis treatments and the population at high risk were
used to estimate treatment uptake and treatment gap.
Results It was estimated that approximately 18,000 new
fragility fractures were sustained in Ireland, comprising
3,200 hip fractures, 2,700 vertebral fractures, 3,000 forearm
fractures and 9,200 other fractures (i.e. fractures of the
pelvis, rib, humerus, tibia, fibula, clavicle, scapula, sternum
and other femoral fractures) in 2010. The economic burden
of incident and previous fragility fractures was estimated at
€ 223 million for the same year. Incident fractures repre-
sented 56 % of this cost, long-term fracture care 28 % and
pharmacological prevention 16 %. Previous and incident
fractures also accounted for 6,100 quality-adjusted life years
(QALYs) lost during 2010. When accounting for the demo-
graphic projections for 2025, the number of incident frac-
tures was estimated at 28,000 in 2025, representing an
increase of 9,000 fractures. Hip, clinical vertebral (spine),
forearm and other fractures were estimated to increase by
1,800, 1,400, 1,400 and 4,900, respectively. The burden of
fractures in Ireland in 2025 was estimated to increase by
44 % to € 320 million. Though the uptake of osteoporosis
treatments increased from 2001, the proportion of patients
aged 50 or above who received treatment declined in the
past few years. A substantial minority of women at high
fracture risk did not receive active treatment.
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Conclusions In spite of the high cost of osteoporosis, a
substantial treatment gap and projected increase of the eco-
nomic burden driven by aging populations, the use of phar-
macological prevention of osteoporosis is significantly less
than optimal, suggesting that a change in healthcare policy
concerning the disease is warranted.
Introduction
Osteoporosis is characterized by reduced bone mass and
disruption of bone architecture, resulting in increased risks
of fragility fractures which represent the main clinical con-
sequence of the disease. Fragility fractures are associated
with substantial pain and suffering, disability and even death
for the affected patients and substantial costs to society. The
aim of this report was to characterize the burden of osteo-
porosis in Ireland in 2010 and beyond.
Methods
The literature on fracture incidence and costs of frac-
tures in Ireland was reviewed and incorporated into a
model estimating the clinical and economic burden of
osteoporotic fractures in 2010. Details of the methods
used are found in Chapters 3 and 4 of the report
Osteoporosis in the European Union: Medical Manage-
ment, Epidemiology and Economic Burden, published
concurrently in Archives of Osteoporosis.
Epidemiology of osteoporosis in Ireland
For the purpose of this report, the population at risk of
osteoporosis was considered to include men and women
≥50 years. The number of men and women ≥50 years of
age amounted to 599,000 and 647,000 respectively in Ire-
land in 2010 (Table 1).
In the population at risk, the number of individuals
with osteoporosis—as defined by the WHO diagnostic
criteria—was estimated at 170,000 (Table 2). There are
10 DXA scan machines per million inhabitants [2], and
guidelines for the assessment and treatment of osteopo-
rosis are available [3]. A country specific FRAX model
is also available for the assessment of fracture risk
(http://www.shef.ac.uk/FRAX/).
Data on hip fracture incidence are available for Ire-
land [5]. Given that country specific incidence of verte-
bral, forearm and, “other” fractures were not found,
these were imputed using the methods described in
Chapter 3 of the main report. Fracture incidence is
presented in Table 3. Standardized to the EU27 popula-
tion, hip fracture incidence (per 100,000 person years)
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Table 1 Population at risk: men and women over the age of 50 in
Ireland, 2010 [1]
Age (years) Women Men All
50–59 254,000 255,000 509,000
60–69 191,000 190,000 381,000
70–79 122,000 108,000 230,000
80–89 67,000 41,000 108,000
90+ 13,000 5,000 18,000
50+ 647,000 599,000 1,246,000
Table 2 Estimated number of women and men with osteoporosis
(defined as a T-score ≤−2.5 SD) in Ireland by age using female-
derived reference ranges at the femoral neck, 2010 [4]
Age (years) Women Men
50–54 8,442 3,350
55–59 11,520 4,235
60–64 15,301 6,264
65–69 16,968 6,068
70–74 18,693 4,836
75–79 20,625 4,738
80+ 37,760 7,636
50+ 129,309 37,127
Table 3 Incidence per 100,000 person years of hip, clinical vertebral,
forearm, and “other” fractures in Ireland by age
Fracture at the
Age (years) hip vertebra forearm other
Women
50–54 13 33 81 83
55–59 35 97 270 309
60–64 71 125 267 272
65–69 147 214 358 503
70–74 302 426 543 856
75–79 614 597 599 1,292
80–84 1,231 774 771 2,094
85+ 2,143 1,008 915 3,600
Men
50–54 22 56 20 97
55–59 30 52 45 276
60–64 47 114 89 467
65–69 76 119 114 490
70–74 143 219 92 737
75–79 264 304 75 704
80–84 519 361 101 1,381
85+ 1,014 681 186 2,935
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in men and women ≥50 years of age was estimated at
167 and 488 respectively.
The number of incident fractures in 2010 was estimated at
18,000 (Table 4). Incident hip, clinical spine and forearm
fractures were each estimated at 3 000, and “other” fractures
were estimated at 9,000. 66% of fractures occurred in women.
A prior fracture was defined as a fracture in an individual
who was alive during the index year (i.e. 2010) which had
occurred after the age of 50 years and before 2010. In the
population ≥50 years of age, the proportion of individuals
who had suffered a fracture prior to 2010 was estimated at
1.38 % for hip and 1.50 % for clinical vertebral fractures.
The estimated proportions of men and women with prior hip
and vertebral fractures by age are presented in Table 5.
In the population over 50 years of age, the number of in-
dividuals with hip and vertebral fractures that occurred before
2010 was estimated at 17,000 and 19,000 respectively (Table 6).
Note that fractures sustained in 2010 were not included in the
estimate.
The incidence of causally related deaths (per 100,000) in
the first year after fracture by age is presented in Table 7.
The number of causally related deaths in 2010 was estimat-
ed at 209 (Table 8). Hip, vertebral and “other” fractures
accounted for 104, 68 and 38 deaths respectively. Overall,
approximately 53 % of deaths occurred in women.
Cost of osteoporosis in Ireland including and excluding
value of QALYs lost
For the purpose of this report, the cost of osteoporosis in
2010 (excluding value of QALYs lost) was considered to
consist of three components: (i) cost of fractures that
occurred in 2010 (“first year costs”); (ii) cost of fractures
sustained prior to year 2010 but which still incurred costs in
2010 (“long-term disability cost”); and (iii) cost of pharma-
cological fracture prevention including administration and
monitoring costs (“pharmacological fracture prevention
costs”). See Chapter 4 of the main report for further details.
The cost of a hip fracture has been estimated at €
15,230 in Ireland based on first year hospital costs [6].
Given that no cost data for the other fracture sites were
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Table 4 Estimated number of incident fractures in Ireland, 2010
Fracture at the All
Age (years) hip vertebra forearm other fractures
Women
50–74 504 766 1,526 2,014 4,811
75+ 1,790 911 993 3,515 7,209
Total 2,294 1,677 2,519 5,530 12,020
Men
50–74 320 562 361 2,091 3,334
75+ 571 434 121 1,604 2,731
Total 892 996 482 3,695 6,065
Men and Women
50–74 824 1,328 1,887 4,105 8,144
75+ 2,361 1,345 1,114 5,120 9,940
Total 3,186 2,673 3,000 9,225 18,084
Table 5 Proportion of men and women (in %) with a prior hip or
clinical vertebral fracture in Ireland, 2010
Age (years) Hip fracture Vertebral fracture
Women
1–05 .00.045
4–55 .01.095
9–06 .04.046
5–56 .18.096
7–07 .28.147
2–57 .44.397
1–08 .65.648
5.019.41+58
Men
1–05 .00.045
3–55 .02.095
6–06 .03.046
9–56 .05.096
3–07 .19.047
0–57 .26.197
5–08 .28.248
7.57.6+58
Table 6 Number of men and women in Ireland with a prior hip or
clinical vertebral fracture after the age of 50 years, 2010
Age (years) Hip fracture Vertebral fracture
Women
50– 675,4825,247
188,8943,01+57
854,31778,21latoT
Men
50– 736,2536,147
846,2437,2+57
482,5073,4latoT
Men and Women
50– 312,7461,447
925,11380,31+57
247,81742,71latoT
found, these were imputed as described in Chapter 4 of
the main report.
Long-term disability costs were estimated by multiplying the
yearly cost of residing in nursing home (€ 39,073 [7,8], based on
purchasing power parity adjusted UK cost of public nursing
home) with the simulated number of individuals with prior frac-
tures that had been transferred to nursing home due to the fracture.
Annual drug costs for individual treatments are shown in
Table 9. In addition, it was assumed that patients on treatment
made an annual physician visit costing € 46 [9] and a DXA
scan costing € 99 [10] every second year to monitor treatment.
The cost of osteoporosis in 2010 was estimated at € 223
million (Table 10). First year costs, subsequent year costs
and pharmacological fracture prevention costs amounted to
€ 125 million, € 62 million and € 35 million, respectively. It
is notable that pharmacological fracture prevention costs
amounted to only 15.8 % of the total cost.
When stratifying costs of osteoporosis by fracture type, hip
fractures were most costly (€ 105million) followed by “other”
(€ 72 million), spine (€ 8 million) and forearm fractures (€ 3
million) (Table 11 and Fig. 1). Please note that costs for
pharmacological fracture prevention were not included given
that they cannot be allocated to specific fracture sites.
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Table 8 The number of deaths in men and women in Ireland in the first
year after fracture attributable to the fracture event (causally related),
2010
Fracture at the
Age (years) hip vertebra “other”
Women
50–74 8 13 1
75+ 48 19 22
Total 56 31 24
Men
50–74 9 16 2
75+ 38 21 12
Total 47 36 15
Men and Women
50–74 18 28 3
75+ 86 40 35
Total 104 68 38
Table 9 One year costs
for relevant pharmaceuti-
cals in Ireland, 2010 [11]
Annual drug
cost (€)
Alendronate 240
Risedronate 514
Etidronate 138
Ibandronate 432
Zoledronic acid 433
Raloxifene 420
Strontium ranelate 631
Parathyroid hormone 6,519
Teriparatide 7,111
Table 10 Cost of osteoporosis (€) in Ireland by age in men and
women, 2010
Age
(years)
First year
fracture
cost
Long term
disability
costs
Fracture
prevention
cost
Total cost
Women
50–74 27,594,675 6,177,242 20,557,255 54,329,172
75+ 54,529,973 39,173,573 10,418,501 104,122,047
All 82,124,649 45,350,815 30,975,756 158,451,220
Men
50–74 22,749,134 4,711,662 3,133,310 30,594,106
75+ 20,592,990 12,199,108 1,227,946 34,020,044
All 43,342,124 16,910,770 4,361,256 64,614,150
Women and Men
50–74 50,343,809 10,888,904 23,690,565 84,923,278
75+ 75,122,964 51,372,681 11,646,447 138,142,091
All 125,466,773 62,261,585 35,337,012 223,065,369
Table 7 Incidence (per 100,000) of causally related deaths in Ireland
within the first year after fracture (adjusted for comorbidities), 2010
Age (years) Hip Clinical vertebral “Other” fracture
Women
50–54 458 595 12
55–59 607 746 18
60–64 1,034 1,201 33
65–69 1,318 1,445 49
70–74 2,119 2,186 96
75–79 2,494 2,409 156
80–84 2,727 2,413 304
85–89 3,249 2,526 569
90+ 2,640 1,489 918
Men
50–54 1,452 1,741 23
55–59 1,775 2,018 36
60–64 2,319 2,494 63
65–69 2,720 2,759 98
70–74 3,346 3,186 151
75–79 4,444 3,941 264
80–84 6,088 4,944 511
85–89 7,252 5,301 783
90+ 8,382 5,455 1,049
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The number of quality adjusted life years (QALYs) lost
due to osteoporosis in 2010 was estimated at 6,100 (Table
12). 68 % of the total QALY loss was incurred in women.
Prior fractures accounted for 56 % of the total QALY loss.
The monetary value of a QALY was varied between 1 to 3
times the gross domestic product (GDP) per capita (Table
13). Assuming a QALY is valued at 2 times GDP/capita, the
total cost of the QALYs lost was estimated at € 430 million.
When the cost of osteoporosis was combined with the
value for QALYs lost (valued at 2 × GDP), the cost of
osteoporosis amounted to € 650 million in Ireland in 2010.
Incident fracture, prior fracture, pharmacological fracture
prevention, and value of QALYs lost accounted for 19 %,
10 %, 5 % and 66 % respectively.
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Table 11 Total cost (€) in 2010 by fracture site in men and women in Ireland. Note that costs for fracture prevention therapy and monitoring are not included
Hip
56%
Spine
4%
Forearm
2%
Other
38%
Fig. 1 Share (%) of fracture cost by fracture site in Ireland. Note that
costs for fracture prevention therapy and monitoring are not included
Table 12 Number of QALYs lost due to fractures during 2010 in men
and women in Ireland according to age
Age (years)
50–74 75+ 50+
Women
Incident hip fractures 122 373 494
Incident vertebral fractures 254 261 514
Incident forearm fractures 54 30 84
Incident other fractures 241 364 605
Prior hip fractures 396 1,389 1,785
Prior vertebral fractures 256 429 685
761,4548,2223,1latoT
Men
Incident hip fractures 78 137 215
Incident vertebral fractures 186 138 325
Incident forearm fractures 12 4 16
Incident other fractures 248 182 430
Prior hip fractures 255 404 659
Prior vertebral fractures 146 139 286
139,1400,1729latoT
Men and Women
Incident hip fractures 200 510 709
Incident vertebral fractures 440 399 839
Incident forearm fractures 66 34 100
Incident other fractures 489 546 1,035
Prior hip fractures 651 1,793 2,444
Prior vertebral fractures 402 568 970
790,6948,3842,2latoT
Burden of osteoporosis up to 2025
The population above 50 years of age is expected to increase
from 1.2 million in 2010 to 1.8 million in 2025, correspond-
ing to an increase of 42 % (Table 14).
The total number of fractures was estimated to rise from
18,000 in 2010 to 28,000 in 2025 (Table 15), corre-
sponding to an increase of 53 %. Hip, clinical spine,
forearm and other fractures increased by 1,800, 1,400,
1,400 and 4,900 respectively. The increase in the
number of fractures ranged from 47 % to 56 %,
depending on fracture site. The increase was estimated
to be 57 % in men and 50 % in women.
The cost of osteoporosis (excluding value of QALYs lost)
was estimated to rise from € 223 million in 2010 to € 320
million in 2025, corresponding to an increase of 44 % (Table
16). Costs incurred in women and men increased by 40 %
and 52 % respectively.
The total number of QALYs lost due to fracture was
estimated to rise from 6,100 in 2010 to 8,200 in 2025,
corresponding to an increase of 34 % (Table 17). The
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Table 13 Value of lost QALYs (€) in men and women in Ireland in
2010
1 × GDP/
capita
2 × GDP/
capita
3 × GDP/
capita
Incident hip fractures 24,752,860 49,505,719 74,258,579
Incident vertebral
fractures
29,289,392 58,578,785 87,868,177
Incident forearm
fractures
3,500,853 7,001,707 10,502,560
Incident other fractures 36,108,044 72,216,088 108,324,133
Prior hip fractures 85,284,615 170,569,230 255,853,844
Prior vertebral
fractures
33,866,552 67,733,103 101,599,655
Total 212,802,316 425,604,632 638,406,948
Table 14 Population projections in Ireland by age and sex [12]
Population
2010 2015 2020 2025
Women
50–59 254,000 279,000 302,000 330,000
60–69 191,000 221,000 244,000 269,000
70–79 122,000 140,000 170,000 198,000
80–89 67,000 73,000 81,000 94,000
90+ 13,000 16,000 21,000 23,000
Men
50–59 255,000 276,963 303,000 332,000
60–69 190,000 219,000 238,000 261,000
70–79 108,000 126,000 155,000 180,000
80–89 41,000 49,000 58,000 70,000
90+ 5,000 6,000 8,000 10,000
All
50–59 509,000 555,963 605,000 662,000
60–69 381,000 440,000 482,000 530,000
70–79 230,000 266,000 325,000 378,000
80–89 108,000 122,000 139,000 164,000
90+ 18,000 22,000 29,000 33,000
000,767,1000,642,1
Table 15 Projected annual number of incident fractures in 2010 and
2025 by fracture site and age in men and women in Ireland
Hip Spine Forearm Other
2010 2025 2010 2025 2010 2025 2010 2025
Women
50–74 504 748 766 1,113 1,526 2,169 2,014 2,911
75+ 1,790 2,756 911 1,404 993 1,516 3,515 5,415
All 2,294 3,504 1,677 2,518 2,519 3,686 5,530 8,326
Men
50–74 320 465 562 802 361 499 2,091 2,951
75+ 571 1,009 434 768 121 214 1,604 2,840
All 892 1,474 996 1,569 482 713 3,695 5,791
Women and Men
50–74 824 1,213 1,328 1,915 1,887 2,668 4,105 5,862
75+ 2,361 3,765 1,345 2,172 1,114 1,730 5,120 8,255
All 3,186 4,978 2,673 4,087 3,000 4,398 9,225 14,116
Table 16 Current and future cost (€ 000, 000) of osteoporosis (ex-
cluding value of QALYs lost) by age and calendar year in men and
women in Ireland
2010 2015 2020 2025
Women
50–74 54 62 71 77
75+ 104 113 127 145
All 158 175 198 222
Men
50–74 31 35 39 43
75+ 34 39 46 55
All 65 73 85 98
Women and Men
50–74 85 97 110 120
75+ 138 151 173 200
All 223 248 283 320
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increase was estimated to be particularly marked in men
(46 %) compared to women (29 %). Incident and prior
fractures accounted for 68 % and 32 % of the increase
respectively.
The cost of osteoporosis including value of QALYs lost
was estimated to increase from approximately € 650 million
in 2010 to € 890 million in 2025. The increase was estimat-
ed to be particularly marked in men (+48 %) compared to
women (+33 %) (Table 18).
Treatment uptake
To estimate uptake of individual osteoporosis treatments,
sales data from IMS Health (2001–2011) were used to
derive the number of defined daily doses (DDDs) sold per
100,000 persons aged 50 years or above (Fig. 2).
Adjusting the sales data for compliance allowed for an
estimation of the proportion of population aged 50 years or
above who received any osteoporosis treatment (see Chapter
5 of the report Osteoporosis in the European Union: Medical
Management, Epidemiology and Economic Burden for fur-
ther details). The proportion of persons over the age of
50 years who were treated increased from 1.57 % in 2001
to 8.56 % in 2011.
Treatment gap
In order to assess the potential treatment gap, the numbers of
men and women eligible for treatment in Ireland were defined
as individuals with a 10-year fracture probability exceeding
that of a woman with a prior fragility fracture derived from
FRAX®, equivalent to a ‘fracture threshold’ (See Chapter 5 of
the main report for further details). Subsequently, these esti-
mates were compared to the number individuals who received
osteoporosis treatment obtained from the analysis of IMS
Health data. The treatment gaps in men and women were
estimated at 20 % and 26 % respectively (Table 19). Note that
the estimate of the treatment gap is conservative given that it
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Table 17 Projected QALYs lost due to incident and prior fractures for
the years 2010 and 2025 by age in men and women in Ireland
Incident fractures Prior fractures All fractures
2010 2025 2010 2025 2010 2025
Women
50–74 670 972 651 732 1,322 1,704
75+ 1,027 1,577 1,818 2,088 2,845 3,665
All 1,697 2,549 2,469 2,820 4,167 5,369
Men
50–74 525 746 402 495 927 1,241
75+ 461 815 543 762 1,004 1,577
All 986 1,561 945 1,257 1,931 2,818
Women and Men
50–74 1,195 1,718 1,053 1,227 2,248 2,945
75+ 1,488 2,392 2,361 2,850 3,849 5,242
All 2,683 4,109 3,414 4,077 6,097 8,187
Table 18 Present and future cost (€ 000,000) of fracture (direct cost
and cost of QALYs) by age and calendar year in men and women in
Ireland assuming the uptake of treatment remains unchanged
2010 2015 2020 2025
Women
50–74 147 163 181 196
75+ 303 326 360 400
All 449 489 541 597
Men
50–74 95 105 117 130
75+ 104 115 135 165
All 199 220 252 295
Women and Men
50–74 242 268 298 326
75+ 407 441 495 566
All 649 709 793 892
Table 19 Number of men and women eligible for treatment, treated
and treatment gap in 2010
Number
potentially
treated
(1000 s)
Number eligible
for treatment
(1000 s)
Difference
(1000 s)
Treatment
gap (%)
Men 14 17 3 20
Women 91 124 33 26
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Fig. 2 Treatment uptake in Ireland (Defined daily doses [DDDs] per
100,000 persons aged 50 years or above)
assumes that current use of osteoporosis treatments are only
directed to men and women at high risk.
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Abstract
Summary This report describes epidemiology, burden, and
treatment of osteoporosis in Italy.
Introduction Osteoporosis is characterized by reduced
bone mass and disruption of bone architecture, resulting
in increased risks of fragility fractures which represent
the main clinical consequence of the disease. Fragility
fractures are associated with substantial pain and suffer-
ing, disability and even death for the affected patients
and substantial costs to society. The aim of this study is
to describe the epidemiology and economic burden of
fragility fractures as a consequence of osteoporosis in
Italy, as a further detailed addition to the report for the
entire European Union (EU27): Osteoporosis in the Eu-
ropean Union: Medical Management, Epidemiology and
Economic Burden.
Methods The literature on fracture incidence and costs of
fractures in Italy was reviewed and incorporated into a
model estimating the clinical and economic burden of
osteoporotic fractures in 2010. Furthermore, data on
sales of osteoporosis treatments and the population at
high risk were used to estimate treatment uptake and
treatment gap.
Results It was estimated that approximately 465,000 new
fragility fractures were sustained in Italy, comprising 91,000
hip fractures, 71,000 clinical vertebral fractures, 72,000
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forearm fractures and 232,000 other fractures (i.e. fractures
of the pelvis, rib, humerus, tibia, fibula, clavicle, scapula,
sternum and other femoral fractures) in 2010. The eco-
nomic burden of incident and previous fragility fractures
was estimated at € 7,032 million for the same year.
Incident fractures represented 61 % of this cost, long-
term fracture care 34 % and pharmacological prevention
5 %. Previous and incident fractures also accounted for
171,300 quality-adjusted life years (QALYs) lost during
2010. When accounting for the demographic projections
for 2025, the number of incident fractures was estimated
at 598,000 in 2025, representing an increase of 132,000
fractures. Hip, clinical vertebral (spine), forearm and
other fractures were estimated to increase by 27,900,
18,800, 15,400 and 70,300, respectively. The burden
of fractures in Italy in 2025 was estimated to increase
by 23 % to € 8,644 million. Though the uptake of
osteoporosis treatments increased from 2001, the pro-
portion of patients aged 50 or above who received
treatment remained at very low levels in the past few
years. The majority of women at high fracture risk did
not receive active treatment.
Conclusions In spite of the high cost of osteoporosis, a
substantial treatment gap and projected increase of the eco-
nomic burden driven by aging populations, the use of phar-
macological prevention of osteoporosis is significantly less
than optimal, suggesting that a change in healthcare policy
concerning the disease is warranted.
Introduction
Osteoporosis is characterized by reduced bone mass and
disruption of bone architecture, resulting in increased
risks of fragility fractures which represent the main
clinical consequence of the disease. Fragility fractures
are associated with substantial pain and suffering, dis-
ability and even death for the affected patients and
substantial costs to society. The aim of this report was
to characterize the burden of osteoporosis in Italy in
2010 and beyond.
Methods
The literature on fracture incidence and costs of frac-
tures in Italy was reviewed and incorporated into a
model estimating the clinical and economic burden of
osteoporotic fractures in 2010. Details of the methods
used are found in Chapters 3 and 4 of the report
Osteoporosis in the European Union: Medical Manage-
ment, Epidemiology and Economic Burden, published
concurrently in Archives of Osteoporosis.
Epidemiology of osteoporosis in Italy
For the purpose of this report, the population at risk of
osteoporosis was considered to include men and women
≥50 years. The number of men and women ≥50 years of
age amounted to 10,791,000 and 12,997,000 respectively in
Italy in 2010 (Table 1).
In the population at risk, the number of individuals with
osteoporosis—as defined by the WHO diagnostic
criteria—was estimated at 3,790,000 (Table 2). There are
18.6 DXA scan machines per million (m) inhabitants [2],
and guidelines for the assessment and treatment of osteopo-
rosis are available [3]. A country specific FRAX model is
also available for the assessment of fracture risk (http://
www.shef.ac.uk/FRAX/).
Data on hip fracture incidence are available for Italy [5].
Given that country specific incidence of the vertebral,
forearm and, “other” fractures were not found, these
were imputed using the methods described in Chapter
3 of the main report. Fracture incidence is presented in
Table 3. Standardized to the EU27 population, hip frac-
ture incidence (per 100,000 person years) in men and
women ≥50 years of age was estimated at 189.5 and
498.4 respectively.
The number of incident fractures in 2010 was estimated
at 465,000 (Table 4). Incident hip, clinical spine, forearm
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Table 1 Population at risk: men and women over the age of 50 in Italy,
2010 [1]
Age (years) Women Men All
50–59 3,928,000 3,799,000 7,727,000
60–69 3,595,000 3,307,000 6,902,000
70–79 3,134,000 2,478,000 5,612,000
80–89 1,997,000 1,092,000 3,089,000
90+ 343,000 115,000 458,000
50+ 12,997,000 10,791,000 23,788,000
Table 2 Estimated number of women and men with osteoporosis
(defined as a T-score ≤−2.5 SD) in Italy by age using female-derived
reference ranges at the femoral neck, 2010 [4]
Age (years) Women Men
50–54 128,709 49,800
55–59 180,960 63,245
60–64 274,703 105,386
65–69 338,148 110,260
70–74 463,419 109,356
75–79 552,375 110,828
80+ 1,104,480 200,362
50+ 3,042,794 749,237
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and “other” fractures were estimated at 91,000, 71,000,
72,000 and 232,000 respectively. 69 % of fractures occurred
in women.
A prior fracture was defined as a fracture in an
individual who was alive during the index year (i.e.
2010) which had occurred after the age of 50 years
and before 2010. In the population ≥50 years of age,
the proportion of individuals who had suffered a
fracture prior to 2010 was estimated at 2.17 % for hip
and 2.27 % for vertebral fractures. The estimated pro-
portions of men and women with prior hip and vertebral
fractures by age are presented in Table 5.
In the population over 50 years of age, the number of
individuals with hip and vertebral fractures that occurred
before 2010 was estimated at 517,000 and 539,000 respec-
tively (Table 6). Note that fractures sustained in 2010 were
not included in the estimate.
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Table 4 Estimated number of incident fractures in Italy, 2010
Fracture at the All
Age (years) hip vertebra forearm other fractures
Women
50–74 12,298 18,582 32,856 44,355 108,091
75+ 55,297 29,339 28,667 100,888 214,191
Total 67,595 47,921 61,523 145,243 322,282
Men
50–74 6,345 11,053 6,721 40,133 64,252
75+ 16,598 12,488 3,435 46,345 78,866
Total 22,944 23,540 10,156 86,478 143,118
Men and Women
50–74 18,644 29,635 39,577 84,487 172,343
75+ 71,895 41,827 32,102 147,234 293,057
Total 90,539 71,461 71,679 231,721 465,400
Table 5 Proportion of men and women (in %) with a prior hip or
clinical vertebral fracture in Italy, 2010
Age (years) Hip fracture Vertebral fracture
Women
50– 1.00.045
55– 7.02.095
60– 3.15.046
65– 0.21.196
70– 1.31.247
75– 7.49.397
80– 4.61.748
1.011.51+58
Men
50– 2.01.045
55– 5.03.095
60– 8.04.046
65– 2.17.096
70– 8.12.147
75– 6.22.297
80– 2.37.348
4.63.8+58
Table 6 Number of men and women in Italy with a prior hip or
clinical vertebral fracture after the age of 50 years, 2010
Age (years) Hip fracture Vertebral fracture
Women
50– 404,521914,9647
491,262111,513+57
795,783035,483latoT
Men
50– 087,96970,2447
956,18715,09+57
834,151695,231latoT
Men and Women
50–74 111,498 195,183
258,343826,504+57
630,935621,715latoT
Table 3 Incidence per 100,000 person years of hip, clinical vertebral,
forearm, and “other” fractures in Italy by age
Fracture at the
Age (years) hip vertebra forearm other
Women
50–54 24 62 153 158
55–59 45 125 346 396
60–64 78 139 296 302
65–69 144 209 349 491
70–74 293 414 527 832
75–79 613 596 598 1,289
80–84 1,214 763 760 2,064
85+ 2,105 990 899 3,537
Men
50–54 34 86 31 149
55–59 40 69 61 372
60–64 51 122 96 503
65–69 75 118 113 484
70–74 135 206 86 693
75–79 277 320 79 740
80–84 579 402 112 1,540
85+ 1,145 769 210 3,317
The incidence of causally related deaths (per
100,000) in the first year after fracture by age is
presented in Table 7. The number of causally related
deaths in 2010 was estimated at 5,476 (Table 8). Hip,
vertebral and “other” fractures accounted for 2,778,
1,659 and 1,039 deaths respectively. Overall, approxi-
mately 53 % of deaths occurred in women.
Cost of osteoporosis in Italy including and excluding
value of QALYs lost
For the purpose of this report, the cost of osteoporosis in
2010 (excluding value of QALYs lost) was considered to
consist of three components: (i) cost of fractures that oc-
curred in 2010 (“first year costs”); (ii) cost of fractures
sustained prior to year 2010 but which still incurred costs
in 2010 (“long-term disability cost”), and (iii) cost of phar-
macological fracture prevention including administration
and monitoring costs (“pharmacological fracture prevention
costs”). See Chapter 4 of the main report for further details.
Total first year costs after fracture were imputed by apply-
ing the inpatient cost for Italy to the ratio of inpatient cost to
total first year costs observed in Sweden, resulting in an
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Table 8 The number of deaths in men and women in Italy in the first
year after fracture attributable to the fracture event (causally related),
2010
Fracture at the
Age (years) hip vertebra “other”
Women
50–74 165 247 24
75+ 1,342 536 605
Total 1,507 784 628
Men
50–74 173 286 37
75+ 1,098 589 373
Total 1,271 875 411
Men and Women
50–74 339 534 61
75+ 2,440 1,125 978
Total 2,778 1,659 1,039
Table 9 One year costs
for relevant
pharamceuticals in Italy,
2010 [9]
Annual drug
cost (€)
Alendronate 294
Risedronate 474
Etidrontae 97
Ibandronate 524
Zoledronic acid 529
Raloxifene 452
Strontium ranelate 665
Parathyroid hormone 6,528
Teriparatide 7,445
Table 10 Cost of osteoporosis (€) in Italy by age in men and women, 2010
Age
(years)
First year
fracture
cost
Long term
disability
costs
Fracture
prevention
cost
Total cost
Women
50–74 823,498,045 216,991,128 183,526,818 1,224,015,991
75+ 2,110,554,205 1,508,825,198 132,865,817 3,752,245,221
All 2,934,052,250 1,725,816,327 316,392,635 4,976,261,212
Men
50–74 570,667,695 156,286,640 28,831,907 755,786,242
75+ 763,862,895 520,311,116 15,585,496 1,299,759,507
All 1,334,530,589 676,597,756 44,417,403 2,055,545,748
Women and Men
50–74 1,394,165,739 373,277,768 212,358,725 1,979,802,233
75+ 2,874,417,100 2,029,136,314 148,451,313 5,052,004,727
All 4,268,582,839 2,402,414,082 360,810,039 7,031,806,960
Table 7 Incidence (per 100,000) of causally related deaths in Italy
within the first year after fracture (adjusted for comorbidities), 2010
Age (years) Hip Clinical vertebral “Other” fracture
Women
50–54 426 554 11
55–59 595 732 18
60–64 893 1,037 28
65–69 1,135 1,244 43
70–74 1,533 1,583 70
75–79 2,024 1,955 127
80–84 2,250 1,991 251
85–89 2,757 2,143 483
90+ 2,705 1,525 941
Men
50–54 1,233 1,479 19
55–59 1,633 1,856 34
60–64 2,032 2,185 55
65–69 2,441 2,476 88
70–74 3,110 2,961 140
75–79 4,176 3,703 248
80–84 5,154 4,186 433
85–89 6,708 4,903 725
90+ 9,981 6,495 1,249
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estimated total first year hip fracture cost of € 19,602. Given
that no cost data for the other fracture sites were found, these
were imputed as described in Chapter 4 of the main report.
Long-term disability costs were estimated by multiplying
the yearly cost of residing in nursing home (€ 50,202 [6]) with
the simulated number of individuals with prior fractures that
had been transferred to nursing home due to the fracture.
Annual drug costs (€) for individual treatments are shown
in Table 9. In addition, it was assumed that patients on
treatment made an annual physician visit costing € 50 [7]
and a DXA scan costing € 81 [8] every second year to
monitor treatment.
The cost of osteoporosis in 2010 was estimated at € 7,032
million (Table 10). First year costs, subsequent year costs and
pharmacological fracture prevention costs amounted to €
4,269 million, € 2,402 million and € 361 million respectively.
It is notable that pharmacological fracture prevention costs
amounted to only 5.1 % of the total cost.
When stratifying costs of osteoporosis by fracture type, hip
fractures were most costly (€ 3,977 million) followed by
“other” (€ 2,324 million), spine (€ 284 million) and forearm
fractures (€ 86 million) (Table 11 and Fig. 1). Please note that
costs for pharmacological fracture prevention were not includ-
ed given that they cannot be allocated to specific fracture sites.
The number of quality adjusted life years (QALYs) lost
due to osteoporosis in 2010 was estimated at 171,300 (Table
12). 70 % of the total QALY loss was incurred in women.
Prior fractures accounted for 59 % of the total QALY loss.
The monetary value of a QALY was varied between 1 to 3
times the gross domestic product (GDP) per capita (Table
13). Assuming a QALY is valued at 2 times GDP/capita, the
total cost of the QALYs lost was estimated at € 8.77 billion.
When the cost of osteoporosis was combined with the
value for QALYs lost (valued at 2 × GDP), the cost of
osteoporosis amounted to € 15.8 billion in Italy in 2010.
Incident fracture, prior fracture, pharmacological fracture
prevention, and value of QALYs lost accounted for 27 %,
15 %, 2 % and 56 % respectively.
Burden of osteoporosis up to 2025
The population above 50 years of age is expected to increase
from 23.8 million in 2010 to 29.2 million in 2025, corre-
sponding to an increase of 23 % (Table 14).
The total number of fractures was estimated to rise from
465,000 in 2010 to 598,000 in 2025 (Table 15), correspond-
ing to an increase of 28 %. Hip, clinical spine, forearm and
other fractures increased by 27,900, 18,800, 15,400 and
70,300 respectively. The increase in the number of fractures
ranged from 21 % to 31 %, depending on fracture site. The
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Table 11 Total cost (€) in 2010 by fracture site in men and women in Italy. Note that costs for fracture prevention therapy and monitoring are not included
Hip
60%
Spine
4%
Forearm
1%
Other
35%
Fig. 1 Share of fracture cost by fracture site in Italy. Note that costs for
fracture prevention therapy and monitoring are not included
increase was estimated to be particularly marked in men
(37 %) compared to women (24 %).
The cost of osteoporosis (excluding value of QALYs lost) was
estimated to rise from € 7 billion in 2010 to € 8.6 billion in 2025,
corresponding to an increase of 23 % (Table 16). Costs incurred
in women and men increased by 20 % and 31 % respectively.
The total number of QALYs lost due to fracture was
estimated to rise from 171,300 in 2010 to 205,100 in 2025,
corresponding to an increase of 20 % (Table 17). The increase
was estimated to be particularly marked in men (28 %) com-
pared to women (16 %). Incident and prior fractures
accounted for 59 % and 41 % of the increase respectively.
The cost of osteoporosis including value of QALYs lost
was estimated to increase from approximately € 15.8 billion
in 2010 to € 19.1 billion in 2025. The increase was estimat-
ed to be particularly marked in men (+29 %) compared to
women (+18 %) (Table 18).
Treatment uptake
To estimate uptake of individual osteoporosis treatments,
sales data from IMS Health (2001–2011) were used to
derive the number of defined daily doses (DDDs) sold per
100,000 persons aged 50 years or above (Fig. 2).
Adjusting the sales data for compliance allowed for an
estimation of the proportion of population aged 50 years or
above who received any osteoporosis treatment (see Chapter 5
of the report Osteoporosis in the European Union: Medical
Management, Epidemiology and Economic Burden for
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Table 13 Value of lost QALYs (€) in men and women in Italy in 2010
1 × GDP/
capita
2 × GDP/
capita
3 × GDP/
capita
Incident hip
fractures
512,093,317 1,024,186,634 1,536,279,952
Incident vertebral
fractures
567,207,399 1,134,414,797 1,701,622,196
Incident forearm
fractures
60,693,357 121,386,713 182,080,070
Incident other
fractures
659,775,142 1,319,550,284 1,979,325,426
Prior hip fractures 1,872,214,580 3,744,429,160 5,616,643,740
Prior vertebral
fractures
713,370,642 1,426,741,285 2,140,111,927
Total 4,385,354,437 8,770,708,874 13,156,063,310
Table 14 Population projections in Italy by age and sex [10]
Population
2010 2015 2020 2025
Women
50–59 3,928,000 4,357,000 4,768,000 4,853,000
60–69 3,595,000 3,733,000 3,825,000 4,241,000
70–79 3,134,000 3,137,000 3,284,000 3,422,000
80–89 1,997,000 2,092,000 2,213,000 2,246,000
90+ 343,000 509,000 625,000 705,000
Men
50–59 3,799,000 4,302,238 4,832,000 5,033,000
60–69 3,307,000 3,476,000 3,578,000 4,063,000
70–79 2,478,000 2,553,000 2,749,000 2,902,000
80–89 1,092,000 1,228,000 1,388,000 1,454,000
90+ 115,000 178,000 226,000 272,000
All
50–59 7,727,000 8,659,238 9,600,000 9,886,000
60–69 6,902,000 7,209,000 7,403,000 8,304,000
70–79 5,612,000 5,690,000 6,033,000 6,324,000
80–89 3,089,000 3,320,000 3,601,000 3,700,000
90+ 458,000 687,000 851,000 977,000
000,191,92000,887,32
Table 12 Number of QALYs lost due to fractures during 2010 in men
and women in Italy according to age
Age (years)
50–74 75+ 50+
Women
Incident hip fractures 2,942 11,550 14,491
Incident vertebral fractures 6,110 8,412 14,522
Incident forearm fractures 1,155 871 2,026
Incident other fractures 5,293 10,460 15,753
Prior hip fractures 10,851 42,351 53,202
Prior vertebral fractures 7,002 12,696 19,698
296,911833,68453,33latoT
Men
Incident hip fractures 1,544 3,969 5,512
Incident vertebral fractures 3,663 3,972 7,635
Incident forearm fractures 233 112 345
Incident other fractures 4,754 5,265 10,020
Prior hip fractures 6,570 13,362 19,931
Prior vertebral fractures 3,874 4,294 8,168
116,15379,03736,02latoT
Men and Women
Incident hip fractures 4,485 15,518 20,004
Incident vertebral fractures 9,773 12,383 22,157
Incident forearm fractures 1,388 983 2,371
Incident other fractures 10,048 15,725 25,772
Prior hip fractures 17,421 55,712 73,133
Prior vertebral fractures 10,876 16,990 27,866
303,171213,711199,35latoT
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further details). The proportion of persons over the age of
50 years who were treated increased from 1.03 % in 2001 to
5.2 % in 2010 but subsequently decreased to 5.14 % in 2011.
Treatment gap
In order to assess the potential treatment gap, the numbers of
men and women eligible for treatment in Italy were defined
as individuals with a 10-year fracture probability exceeding
that of a woman with a prior fragility fracture derived from
FRAX®, equivalent to a ‘fracture threshold’ (See Chap-
ter 5 of the main report for further details). Subsequent-
ly, these estimates were compared to the number of
individuals who received osteoporosis treatment
obtained from the analysis of IMS Health data. The
treatment gaps in men and women were estimated at
30 % and 59 % respectively (Table 19). Note that the
estimate of the treatment gap is conservative given that
it assumes that current use of osteoporosis treatments
are only directed to men and women at high risk.
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Table 16 Current and future cost (€ 000,000) of osteoporosis (exclud-
ing value of QALYs lost) by age and calendar year in men and women
in Italy
2010 2015 2020 2025
Women
50–74 1,224 1,256 1,329 1,368
75+ 3,752 4,027 4,277 4,587
All 4,976 5,282 5,606 5,955
Men
50–74 756 787 849 893
75+ 1,300 1,451 1,606 1,796
All 2,056 2,238 2,454 2,689
Women and Men
50–74 1,980 2,043 2,178 2,261
75+ 5,052 5,478 5,882 6,383
All 7,032 7,521 8,060 8,644
Table 15 Projected annual number of incident fractures in 2010 and 2025 by fracture site and age in men and women in Italy
Table 17 Projected QALYs lost due to incident and prior fractures for
the years 2010 and 2025 by age in men and women in Italy
Incident fractures Prior fractures All fractures
2010 2025 2010 2025 2010 2025
Women
50–74 15,500 17,829 17,853 18,579 33,354 36,408
75+ 31,292 39,992 55,047 62,511 86,338 102,503
All 46,792 57,821 72,900 81,090 119,692 138,911
Men
50–74 10,194 12,438 10,443 11,541 20,637 23,979
75+ 13,317 19,856 17,656 22,313 30,973 42,169
All 23,512 32,294 28,099 33,854 51,611 66,148
Women and Men
50–74 25,695 30,267 28,297 30,120 53,991 60,387
75+ 44,609 59,848 72,703 84,824 117,312 144,672
All 70,303 90,115 100,999 114,944 171,303 205,059
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Table 18 Present and future cost (€ 000,000) of fracture (direct cost
and cost of QALYs) by age and calendar year in men and women in
Italy assuming the uptake of treatment remains unchanged
2010 2015 2020 2025
Women
50–74 2,932 3,003 3,142 3,232
75+ 8,173 8,751 9,235 9,835
All 11,104 11,753 12,377 13,067
Men
50–74 1,812 1,873 2,003 2,121
75+ 2,886 3,164 3,488 3,955
All 4,698 5,036 5,492 6,076
Women and Men
50–74 4,744 4,875 5,146 5,353
75+ 11,058 11,915 12,723 13,790
All 15,803 16,790 17,869 19,143
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Fig. 2 Treatment uptake in Italy (Defined daily doses [DDDs] per
100,000 persons aged 50 years or above)
Table 19 Number of men and women eligible for treatment, treated
and treatment gap in 2010
Number
potentially
treated
(1000 s)
Number eligible
for treatment
(1000 s)
Difference
(1000 s)
Treatment
gap (%)
Men 160 228 68 30
Women 1,069 2,635 1,566 59
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Epidemiology and Economic Burden of Osteo-
porosis in Latvia
A report prepared in collaboration with the Internation-
al Osteoporosis Foundation (IOF) and the European
Federation of Pharmaceutical Industry Associations
(EFPIA).
M Ivergård, A Svedbom, E Hernlund, J Compston, C
Cooper, J Stenmark, EVMcCloskey, B Jönsson I Rasa, I
Pavlina, S Berza and JA Kanis
Abstract
Summary This report describes epidemiology, burden, and
treatment of osteoporosis in Latvia.
Introduction Osteoporosis is characterized by reduced bone
mass and disruption of bone architecture, resulting in in-
creased risks of fragility fractures which represent the main
clinical consequence of the disease. Fragility fractures are
associated with substantial pain and suffering, disability and
even death for the affected patients and substantial costs to
society. The aim of this study is to describe the epidemiol-
ogy and economic burden of fragility fractures as a conse-
quence of osteoporosis in Latvia, as a further detailed
addition to the report for the entire European Union
(EU27): Osteoporosis in the European Union: Medical
Management, Epidemiology and Economic Burden.
Methods The literature on fracture incidence and costs of
fractures in Latvia was reviewed and incorporated into a
model estimating the clinical and economic burden of oste-
oporotic fractures in 2010. Furthermore, data on sales of
osteoporosis treatments and the population at high risk were
used to estimate treatment uptake and treatment gap.
Results It was estimated that approximately 14,000 new fragil-
ity fractures were sustained in Latvia, comprising 3,000 hip
fractures, 2,000 vertebral fractures, 2,000 forearm fractures and
7,000 other fractures (i.e. fractures of the pelvis, rib, humerus,
tibia, fibula, clavicle, scapula, sternum and other femoral
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fractures) in 2010. The economic burden of incident and previ-
ous fragility fractures was estimated at € 38 million for the same
year. Incident fractures represented 78 % of this cost, long-term
fracture care 17 % and pharmacological prevention 5 %. Previ-
ous and incident fractures also accounted for 4,500 quality-
adjusted life years (QALYs) lost during 2010.When accounting
for the demographic projections for 2025, the number of inci-
dent fractures was estimated at 16,000 in 2025, representing an
increase of 2,000 fractures. Hip, clinical vertebral (spine), fore-
arm and other fractures were estimated to increase by 500, 300,
100 and 1,100, respectively. The burden of fractures in Latvia in
2025 was estimated to increase by 13% to € 43million. Though
the uptake of osteoporosis treatments increased from 2001, the
proportion of patients aged 50 or above who received treatment
declined in the past few years. The majority of women at high
fracture risk did not receive active treatment.
Conclusions In spite of the high cost of osteoporosis, a
substantial treatment gap and projected increase of the eco-
nomic burden driven by aging populations, the use of phar-
macological prevention of osteoporosis is significantly less
than optimal, suggesting that a change in healthcare policy
concerning the disease is warranted.
Introduction
Osteoporosis is characterized by reduced bone mass and
disruption of bone architecture, resulting in increased risks
of fragility fractures which represent the main clinical con-
sequence of the disease. Fragility fractures are associated
with substantial pain and suffering, disability and even death
for the affected patients and substantial costs to society. The
aim of this report was to characterize the burden of osteo-
porosis in Latvia in 2010 and beyond.
Methods
The literature on fracture incidence and costs of frac-
tures in Latvia was reviewed and incorporated into a
model estimating the clinical and economic burden of
osteoporotic fractures in 2010. Details of the methods
used are found in Chapters 3 and 4 of the report
Osteoporosis in the European Union: Medical Manage-
ment, Epidemiology and Economic Burden, published
concurrently in Archives of Osteoporosis.
Epidemiology of osteoporosis in Latvia
For the purpose of this report, the population at risk of
osteoporosis was considered to include men and women
≥50 years. The number of men and women ≥50 years of
age amounted to 313,000 and 499,000 respectively in Latvia
in 2010 (Table 1).
In the population at risk, the number of individuals with
osteoporosis—as defined by the WHO diagnostic
criteria—was estimated at 130,000 (Table 2). There are 4.9
DXA scan machines per million inhabitants [2], and guide-
lines for the assessment and treatment of osteoporosis are
available [3]. A country specific FRAX model for the as-
sessment of fracture risk is not available for Latvia.
Incidence data was not available for Latvia, therefore
data for hip fractures was imputed from Finnish age-
standardized incidence rates [5]. Fracture incidence is
presented in Table 3. Standardized to the EU27 population,
this hip fracture incidence (per 100,000 person years) in
men and women ≥50 years of age was estimated at 238.0
and 440.0 respectively.
The number of incident fractures in 2010 was estimated at
14,300 (Table 4). Incident hip, clinical spine, forearm and
other fractures were estimated at 2,600, 2,300, 2,400 and
7,000 respectively. 69 % of fractures occurred in women.
The number of hip fractures is close to recent but unpublished
estimates [6].
A prior fracture was defined as a fracture in an
individual who was alive during the index year (i.e.
2010) which had occurred after the age of 50 years
and before 2010. In the population ≥50 years of age,
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Table 1 Population at risk: men and women over the age of 50 in
Latvia, 2010 [1]
Age (years) Women Men All
50–59 163,000 136,000 299,000
60–69 139,000 93,000 232,000
70–79 125,000 63,000 188,000
80–89 64,000 20,000 84,000
90+ 8,000 1,000 9,000
50+ 499,000 313,000 812,000
Table 2 Estimated number of women and men with osteoporosis
(defined as a T-score ≤−2.5 SD) in Latvia by age using female-
derived reference ranges at the femoral neck, 2010 [4]
Age (years) Women Men All
50–54 5,292 1,825 7,117
55–59 7,584 2,205 9,789
60–64 9,581 2,726 12,307
65–69 14,544 3,404 17,948
70–74 19,251 2,886 22,137
75–79 21,000 2,678 23,678
80+ 33,984 3,486 37,470
50+ 111,236 19,210 130,446
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the proportions of individuals who had suffered a frac-
ture prior to 2010 were estimated at 1.46 % for hip and
1.43 % for clinical vertebral fractures. The estimated
proportions of men and women with prior hip and
vertebral fractures by age are presented in Table 5.
In the population over 50 years of age, the number of
individuals with hip and vertebral fractures that occurred
before 2010 was estimated at 12,000 and 12,000 respective-
ly (Table 6). Note that fractures sustained in 2010 were not
included in the estimate.
The incidence of causally related deaths (per
100,000) in the first year after fracture by age is
presented in Table 7. The number of causally related
deaths in 2010 was estimated at 241 (Table 8). Hip,
vertebral and other fractures accounted for 116, 92 and
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Table 3 Incidence per 100,000 person years of hip, clinical vertebral,
forearm, and other fractures in Latvia by age
Fracture at the
Age (years) Hip Vertebra Forearm Other
Women
50–54 21 53 132 136
55–59 38 105 292 334
60–64 63 111 237 242
65–69 116 169 282 396
70–74 248 350 446 704
75–79 541 526 527 1,137
80–84 1,068 671 669 1,816
85+ 1,825 858 779 3,066
Men
50–54 35 89 32 154
55–59 54 94 82 503
60–64 77 183 144 753
65–69 116 183 175 750
70–74 197 301 126 1,012
75–79 377 435 107 1,008
80–84 708 492 137 1,882
85+ 1,254 842 230 3,632
Table 4 Estimated number of incident fractures in Latvia, 2010
Fracture at the All
Age (years) hip vertebra forearm other fractures
Women
50–74 442 669 1,134 1,553 3,798
75+ 1,580 889 851 2,815 6,135
Total 2,022 1,558 1,985 4,368 9,933
Men
50–74 266 460 293 1,731 2,751
75+ 347 268 74 933 1,622
Total 613 728 367 2,664 4,372
Men and Women
50–74 708 1,130 1,428 3,284 6,549
75+ 1,927 1,157 924 3,748 7,756
Total 2,634 2,286 2,352 7,032 14,305
Table 5 Proportion of men and women (in %) with a prior hip or
clinical vertebral fracture in Latvia, 2010
Age (years) Hip fracture Vertebral fracture
Women
1–05 .00.045
5–55 .02.095
8–06 .04.046
2–56 .18.096
0–07 .25.147
2–57 .39.297
6–08 .45.548
7.79.11+58
Men
1–05 .00.045
3–55 .02.095
6–06 .04.046
8–56 .07.096
0–07 .11.147
8–57 .18.197
5–08 .21.348
1.58.6+58
Table 6 Number of men and women in Latvia with a prior hip or
clinical vertebral fracture after the age of 50 years, 2010
Age (years) Hip fracture Vertebral fracture
Women
4–05 91,3070,247
659,5263,7+57
051,9334,9latoT
Men
1–05 92,1480,147
431,1643,1+57
524,2034,2latoT
Men and Women
5–05 84,4451,347
190,7807,8+57
575,11268,11latoT
33 deaths respectively. Overall, approximately 56 % of
deaths occurred in women.
Cost of osteoporosis in Latvia including and excluding
values of QALYs lost
For the purpose of this report, the cost of osteoporosis in
2010 (excluding value of QALYs lost) was considered to
consist of three components: (i) cost of fractures that oc-
curred in 2010 (“first year costs”); (ii) cost of fractures
sustained prior to year 2010 but which still incurred costs
in 2010 (“long-term disability cost”); and (iii) cost of phar-
macological fracture prevention including administration
and monitoring costs (“pharmacological fracture prevention
costs”). See Chapter 4 of the main report for further details.
As the cost of a hip fracture was not available in Latvia, the
cost of a hip fracture has been estimated at € 4,522 in Latvia
based on the cost in Finland [7]. Given that no cost data for
the other fracture sites were found, these were imputed as
described in Chapter 4 of the main report.
Long-term disability costs were estimated by multiplying
the yearly cost of residing in nursing home (€ 6,169 [8],
average for all municipalities and other organizations ad-
ministering adult social care centers) with the simulated
number of individuals with prior fractures that had been
transferred to nursing homes due to the fracture.
Annual drug cost for individual treatments is shown in
Table 9. In addition, it was assumed that patients on treatment
made an annual physician visit costing at € 9 [9] and a DXA
scan at € 18 [9] every second year to monitor treatment.
The cost of osteoporosis in 2010 was estimated at € 38
million (Table 10). First year costs, subsequent year costs
and pharmacological fracture prevention costs amounted to
€ 29 million, € 7 million and € 2 million respectively. It is
notable that pharmacological fracture prevention costs
amounted to only 5.0 % of the total cost.
When stratifying costs of osteoporosis by fracture type, hip
fractures were most costly (€ 17 million) followed by other (€
17 million), spine (€ 2 million) and forearm fractures (€ 1
million) (Table 11 and Fig. 1). Please note that costs for
pharmacological fracture prevention were not included given
that they cannot be allocated to specific fracture sites.
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Table 7 Incidence (per 100,000) of causally related deaths in Latvia
within the first year after fracture (adjusted for comorbidities), 2010
Age (years) Hip Clinical vertebral “Other” fracture
Women
50–54 884 1,149 23
55–59 1,430 1,759 42
60–64 1,879 2,182 60
65–69 1,955 2,143 73
70–74 2,778 2,867 127
75–79 3,297 3,185 207
80–84 3,557 3,147 396
85–89 4,086 3,176 716
90+ 3,503 1,975 1,218
Men
50–54 5,146 6,173 81
55–59 5,051 5,742 104
60–64 6,549 7,044 177
65–69 6,406 6,498 230
70–74 6,851 6,523 309
75–79 7,168 6,357 425
80–84 7,937 6,445 667
85–89 8,290 6,059 896
90+ 10,964 7,135 1,372
Table 8 The number of deaths in men and women in Latvia in the first
year after fracture attributable to the fracture event (causally related),
2010
Fracture at the
Age (years) hip vertebra “other”
Women
2–05 711147
026275+57
224496latoT
Men
4–05 138147
87192+57
118474latoT
Men and Women
5–05 849247
824468+57
3329611latoT
Table 9 One year costs
for relevant pharmaceu-
ticals in Latvia, 2010
[10]
Annual drug
cost (€)
Alendronate 85
Risedronate 186
Etidronate -
Ibandronate 315
Zoledronic acid 420
Raloxifene -
Strontium ranelate 431
Parathyroid hormone -
Teriparatide 5,101
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The number of quality adjusted life years (QALYs) lost
due to osteoporosis in 2010 was estimated at 4,500 (Table
12). 73 % of the total QALY loss was incurred in women.
Prior fractures accounted for 51 % of the total QALY loss.
The monetary value of a QALY was varied between 1
to 3 times the gross domestic product (GDP) per capita
(Table 13). Assuming a QALY is valued at 2 times
GDP/capita, the total cost of the QALYs lost was esti-
mated at € 72 million.
When the cost of osteoporosis was combined with the
value for QALYs lost (valued at 2 × GDP), the cost of
osteoporosis amounted to € 110 million in Latvia in 2010.
Incident fracture, prior fracture, pharmacological fracture
prevention, and value of QALYs lost accounted for 27 %,
6 %, 2 % and 66 % respectively.
Burden of osteoporosis up to 2025
The population above 50 years of age is expected to increase
modestly from 0.81 million in 2010 to 0.84 million in 2025,
corresponding to an increase of 4 % (Table 14).
The total number of fractures was estimated to rise from
14,000 in 2010 to 16,000 in 2025 (Table 15), corresponding
to an increase of 13 %. Hip, clinical spine, forearm and other
fractures increased by 500, 300, 100 and 1,100 respectively.
The increase in the number of fractures ranged from 5 % to
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Table 11 Total cost (€) in 2010 by fracture site inmen andwomen in Latvia. Note that costs for fracture prevention therapy andmonitoring are not included
Hip
46%
Spine
6%
Forearm
2%
Other
46%
Fig. 1 Share (%) of fracture cost by fracture site in Latvia. Note that
costs for fracture prevention therapy and monitoring are not included
Table 10 Cost of osteoporosis (€) in Latvia by age in men and
women, 2010
Age
(years)
First year
fracture
cost
Long term
disability
costs
Fracture
prevention
cost
Total cost
Women
50–74 6,677,139 799,118 1,026,945 8,503,201
75+ 13,685,894 4,295,540 639,010 18,620,444
All 20,363,032 5,094,658 1,665,955 27,123,645
Men
50–74 5,426,800 506,078 169,512 6,102,390
75+ 3,627,557 955,584 65,211 4,648,351
All 9,054,356 1,461,662 234,722 10,750,741
Women and Men
50–74 12,103,938 1,305,196 1,196,456 14,605,591
75+ 17,313,450 5,251,124 704,221 23,268,795
All 29,417,388 6,556,320 1,900,677 37,874,386
18 %, depending on fracture site. The increase was estimat-
ed to be particularly marked in men (20 %) compared to
women (10 %).
The cost of osteoporosis (excluding values of QALYs
lost) was estimated to rise from € 38 million in 2010 to €
43 million in 2025, corresponding to an increase of 13 %
(Table 16). Costs incurred in women and men increased by
10 % and 18 % respectively.
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Table 13 Value of lost QALYs (€) in men and women in Latvia in
2010
1 × GDP/
capita
2 × GDP/
capita
3 × GDP/
capita
Incident hip fractures 4,790,861 9,581,722 14,372,583
Incident vertebral
fractures
5,840,330 11,680,661 17,520,991
Incident forearm
fractures
628,292 1,256,584 1,884,876
Incident other
fractures
6,360,827 12,721,653 19,082,480
Prior hip fractures 13,553,267 27,106,534 40,659,801
Prior vertebral
fractures
4,809,703 9,619,406 14,429,109
Total 35,983,280 71,966,559 107,949,839
Table 14 Population projections in Latvia by age and sex [11]
Population
2010 2015 2020 2025
Women
50–59 163,000 166,000 155,000 146,000
60–69 139,000 139,000 150,000 153,000
70–79 125,000 125,000 114,000 116,000
80–89 64,000 68,000 70,000 72,000
90+ 8,000 10,000 13,000 15,000
Men
50–59 136,000 140,583 136,000 134,000
60–69 93,000 96,000 108,000 114,000
70–79 63,000 64,000 59,000 63,000
80–89 20,000 23,000 25,000 25,000
90+ 1,000 2,000 3,000 4,000
All
50–59 299,000 306,583 291,000 280,000
60–69 232,000 235,000 258,000 267,000
70–79 188,000 189,000 173,000 179,000
80–89 84,000 91,000 95,000 97,000
90+ 9,000 12,000 16,000 19,000
000,248000,218
Table 15 Projected annual number of incident fractures in 2010 and
2025 by fracture site, age and sex in men and women in Latvia
Hip Spine Forearm Other
2010 2025 2010 2025 2010 2025 2010 2025
Women
50–74 442 439 669 660 1,134 1,113 1,553 1,522
75+ 1,580 1,902 889 1,009 851 942 2,815 3,374
All 2,022 2,340 1,558 1,669 1,985 2,054 4,368 4,896
Men
50–74 266 291 460 511 293 329 1,731 1,908
75+ 347 469 268 358 74 98 933 1,303
All 613 761 728 868 367 426 2,664 3,211
Women and Men
50–74 708 730 1,130 1,171 1,428 1,441 3,284 3,430
75+ 1,927 2,371 1,157 1,366 924 1,039 3,748 4,677
All 2,634 3,101 2,286 2,537 2,352 2,481 7,032 8,107
Table 12 Number of QALYs lost due to fractures during 2010 in men
and women in Latvia according to age
Age (years)
50–74 75+ 50+
Women
Incident hip fractures 107 339 446
Incident vertebral fractures 223 261 483
Incident forearm fractures 40 26 66
Incident other fractures 185 296 482
Prior hip fractures 324 1,001 1,325
Prior vertebral fractures 178 291 469
172,3412,2750,1latoT
Men
Incident hip fractures 68 85 153
Incident vertebral fractures 159 88 247
Incident forearm fractures 10 2 13
Incident other fractures 206 107 313
Prior hip fractures 169 200 370
Prior vertebral fractures 72 60 132
722,1345486latoT
Men and Women
Incident hip fractures 175 424 599
Incident vertebral fractures 382 348 730
Incident forearm fractures 50 29 79
Incident other fractures 392 403 795
Prior hip fractures 493 1,201 1,694
Prior vertebral fractures 250 351 601
894,4657,2147,1latoT
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The total number of QALYs lost due to fracture was
estimated to rise from 4,500 in 2010 to 5,000 in 2025, corre-
sponding to an increase of 11 % (Table 17). The increase was
estimated to be particularly marked in men (17 %) compared
to women (9 %). Incident and prior fractures accounted for
58 % and 42 % of the increase respectively.
The cost of osteoporosis including value of QALYs lost
was estimated to increase from approximately € 110 million
in 2010 to € 123 million in 2025. The increase was estimat-
ed to be particularly marked in men (+17 %) compared to
women (+9 %) (Table 18).
Treatment uptake
To estimate uptake of individual osteoporosis treatments,
sales data from IMS Health (2001–2011) were used to
derive the number of defined daily doses (DDDs) sold per
100,000 persons aged 50 years or above (Fig. 2).
Adjusting the sales data for compliance allowed for an
estimation of the proportion of population aged 50 years or
above who received any osteoporosis treatment (see Chapter 5
of the report on Osteoporosis in the European Union: Medical
Management, Epidemiology and Economic Burden for fur-
ther details). The proportion of persons over the age of
50 years who were treated increased from 0.06 % in 2001 to
2.12 % in 2008 but subsequently decreased to 1.5 % in 2011.
Treatment gap
In order to assess the potential treatment gap, the num-
bers of men and women eligible for treatment in Latvia
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Table 18 Present and future cost (€ 000,000) of fracture (direct cost
and cost of QALYs) by age and calendar year in men and women in
Latvia assuming the uptake of treatment remains unchanged
2010 2015 2020 2025
Women
50–74 25 25 24 25
75+ 54 58 60 62
All 79 82 84 87
Men
50–74 17 17 17 19
75+ 13 15 16 17
All 30 32 33 36
Women and Men
50–74 42 42 42 44
75+ 67 72 76 79
All 110 114 117 123
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Fig. 2 Treatment uptake in Latvia (Defined daily doses [DDDs] per
100,000 persons aged 50 years or above)
Table 17 Projected QALYs lost due to incident and prior fractures for
the years 2010 and 2025 by age in men and women in Latvia
Incident fractures Prior fractures All fractures
2010 2025 2010 2025 2010 2025
Women
50–74 555 547 502 502 1,057 1,049
75+ 922 1,074 1,292 1,439 2,214 2,513
All 1,477 1,621 1,794 1,941 3,271 3,562
Men
50–74 443 489 241 257 684 746
75+ 282 382 260 304 543 686
All 726 871 501 561 1,227 1,432
Women and Men
50–74 998 1,035 743 759 1,741 1,795
75+ 1,204 1,456 1,552 1,743 2,756 3,199
All 2,203 2,492 2,295 2,502 4,498 4,993
Table 16 Current and future cost (€ 000,000) of osteoporosis (excluding
value of QALYs lost) by age and calendar year in men and women in Latvia
2010 2015 2020 2025
Women
50–74 9 8 8 8
75+ 19 20 21 22
All 27 28 29 30
Men
50–74 6 6 6 7
75+ 5 5 6 6
All 11 11 12 13
Women and Men
50–74 15 14 14 15
75+ 23 25 27 28
All 38 40 41 43
were defined as individuals with a 10-year fracture
probability exceeding that of a woman with a prior
fragility fracture derived from FRAX®, equivalent to a
‘fracture threshold’ (See Chapter 5 of the main report
for further details). Subsequently, these estimates were
compared to the number individuals who received oste-
oporosis treatment obtained from the analysis of IMS
Health data. The treatment gaps in men and women
were estimated at 93 % and 85 % respectively (Table
19). Note that the estimate of the treatment gap is
conservative given that it assumes that current use of
osteoporosis treatments are only directed to men and
women at high risk.
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Table 19 Number of men and women eligible for treatment, treated
and treatment gap in 2010
Number
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Difference
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Treatment
gap (%)
Men 2 24 22 93
Women 12 80 68 85
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Epidemiology and Economic Burden of Osteo-
porosis in Lithuania
A report prepared in collaboration with the Internation-
al Osteoporosis Foundation (IOF) and the European
Federation of Pharmaceutical Industry Associations
(EFPIA).
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Alekna, M Tamulaitiene, and JA Kanis
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Abstract
Summary This report describes epidemiology, burden, and
treatment of osteoporosis in Lithuania.
Introduction Osteoporosis is characterized by reduced bone
mass and disruption of bone architecture, resulting in in-
creased risks of fragility fractures which represent the main
clinical consequence of the disease. Fragility fractures are
associated with substantial pain and suffering, disability and
even death for the affected patients and substantial costs to
society. The aim of this study is to describe the epidemiology
and economic burden of fragility fractures as a consequence of
osteoporosis in Lithuania, as a further detailed addition to the
report for the entire European Union (EU27): Osteoporosis in
the European Union: Medical Management, Epidemiology
and Economic Burden.
Methods The literature on fracture incidence and costs of
fractures in Lithuania was reviewed and incorporated into a
model estimating the clinical and economic burden of oste-
oporotic fractures in 2010. Furthermore, data on sales of
osteoporosis treatments and the population at high risk were
used to estimate treatment uptake and treatment gap.
Results It was estimated that approximately 15,000 new
fragility fractures were sustained in Lithuania, compris-
ing 3,000 hip fractures, 2,000 vertebral fractures, 3,000
forearm fractures and 7,000 other fractures (i.e. fractures
of the pelvis, rib, humerus, tibia, fibula, clavicle, scap-
ula, sternum and other femoral fractures) in 2010. The
economic burden of incident and previous fragility frac-
tures was estimated at € 47 million for the same year.
Incident fractures represented 68 % of this cost, long-
term fracture care 26 % and pharmacological prevention
6 %. Previous and incident fractures also accounted for
4,900 quality-adjusted life years (QALYs) lost during
2010. When accounting for the demographic projections
for 2025, the number of incident fractures was estimated
at 17,000 in 2025, representing an increase of 2,000
fractures. Hip, clinical vertebral (spine), forearm and
other fractures were estimated to increase by 500, 300,
300 and 1,300, respectively. The burden of fractures in
Lithuania in 2025 was estimated to increase by 14 % to
€ 54 million. Though the uptake of osteoporosis treat-
ments increased from 2001, the proportion of patients
aged 50 or above who received treatment declined in
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the past few years. The majority of women at high
fracture risk did not receive active treatment.
Conclusions In spite of the high cost of osteoporosis, a
substantial treatment gap and projected increase of the eco-
nomic burden driven by aging populations, the use of phar-
macological prevention of osteoporosis is significantly less
than optimal, suggesting that a change in healthcare policy
concerning the disease is warranted.
Introduction
Osteoporosis is characterized by reduced bone mass and
disruption of bone architecture, resulting in increased
risks of fragility fractures which represent the main
clinical consequence of the disease. Fragility fractures
are associated with substantial pain and suffering, dis-
ability and even death for the affected patients and
substantial costs to society. The aim of this report was
to characterize the burden of osteoporosis in Lithuania
in 2010 and beyond.
Methods
The literature on fracture incidence and costs of fractures in
Lithuania was reviewed and incorporated into a model esti-
mating the clinical and economic burden of osteoporotic
fractures in 2010. Details of the methods used are found in
Chapters 3 and 4 of the report Osteoporosis in the European
Union: Medical Management, Epidemiology and Economic
Burden, published concurrently in Archives of Osteoporosis.
Epidemiology of osteoporosis in Lithuania
For the purpose of this report, the population at risk of
osteoporosis was considered to include men and women
≥50 years. The number of men and women ≥50 years of
age amounted to 442,000 and 685,000 respectively in Lith-
uania in 2010 (Table 1).
In the population at risk, the number of individuals with
osteoporosis—as defined by the WHO diagnostic criteria—was
estimated at 180,000 (Table 2). There are 2.4 DXA scan ma-
chines per million (m) inhabitants [2], and guidelines for the
assessment and treatment of osteoporosis are available [3]. A
country specific FRAX model is also available for the assess-
ment of fracture risk (http://www.shef.ac.uk/FRAX/).
At the time of writing the report, national data on the
incidence of fracture was not available for Lithuania, therefore
data for hip fractures was imputed from Polish age–standard-
ized incidence rates [5]. Since then, data have become available
from Vilnius [6]. Fracture incidence is presented in Table 3.
Standardized to the EU27 population, this hip fracture inci-
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Table 1 Population at risk: men and women over the age of 50 in
Lithuania, 2010 [1]
Age (years) Women Men All
50–59 236,000 195,000 431,000
60–69 189,000 127,000 316,000
70–79 169,000 88,000 257,000
80–89 83,000 30,000 113,000
90+ 8,000 2,000 10,000
50+ 685,000 442,000 1,127,000
Table 2 Estimated number of women and men with osteoporosis
(defined as a T-score ≤−2.5 SD) in the UK by age using female-
derived reference ranges at the femoral neck, 2010 [4]
Age (years) Women Men
50–54 8,190 2,750
55–59 10,176 2,975
60–64 13,728 3,944
65–69 18,786 4,366
70–74 25,668 3,978
75–79 28,875 3,811
80+ 42,952 5,312
50+ 148,375 27,136
Table 3 Incidence per 100,000 person years of hip, clinical vertebral,
forearm, and “other” fractures in Lithuania by age
Fracture at the
Age (years) hip vertebra forearm other
Women
50–54 19 49 121 124
55–59 34 93 258 296
60–64 57 101 217 221
65–69 95 139 232 326
70–74 176 248 316 499
75–79 377 366 368 793
80–84 794 499 497 1,351
85+ 1,356 638 579 2,278
Men
50–54 40 102 37 177
55–59 59 102 90 548
60–64 75 179 141 735
65–69 109 171 164 702
70–74 163 249 105 840
75–79 234 270 66 626
80–84 422 293 82 1,122
85+ 713 479 131 2,066
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dence (per 100,000 person years) in men and women ≥50 years
of age was estimated at 166.5 and 333.2 respectively.
The number of incident fractures in 2010 was estimated
at 15,000 (Table 4). Incident hip, clinical spine, forearm and
“other” fractures were estimated at 2,600, 2,400, 2,500 and
7,500 respectively. 67 % of fractures occurred in women.
A prior fracture was defined as a fracture in an individual
who was alive during the index year (i.e. 2010) which had
occurred after the age of 50 years and before 2010. In the
population ≥50 years of age, the proportions of individuals
who had suffered a fracture prior to 2010 were estimated at
1.16 % for hip and 1.13 % for clinical vertebral fractures. The
estimated proportions of men and women with prior hip and
clinical vertebral fractures by age are presented in Table 5.
In the population over 50 years of age, the number of
individuals with hip and vertebral fractures that occurred
before 2010 was estimated at 13,000 and 13,000 respective-
ly (Table 6). Note that fractures sustained in 2010 were not
included in the estimate.
The incidence of causally related deaths (per 100,000) in
the first year after fracture by age is presented in Table 7.
The number of causally related deaths in 2010 was estimat-
ed at 244 (Table 8). Hip, vertebral and “other” fractures
accounted for 114, 98 and 32 deaths respectively. Overall,
approximately 52 % of deaths occurred in women.
Cost of osteoporosis in Lithuania including and excluding
values of QALYs lost
For the purpose of this report, the cost of osteoporosis in
2010 (excluding value of QALYs lost) was considered to
consist of three components: (i) cost of fractures that oc-
curred in 2010 (“first year costs”); (ii) cost of fractures
sustained prior to year 2010 but which still incurred costs
in 2010 (“long-term disability cost”); and (iii) cost of phar-
macological fracture prevention including administration
and monitoring costs (“pharmacological fracture prevention
costs”). See Chapter 4 of the main report for further details.
The cost of a hip fracture has been estimated at € 4,810
based on Finnish costs [7]. Given that no cost data for the
other fracture sites were found, these were imputed as de-
scribed in Chapter 4 of the main report.
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Table 4 Estimated number of incident fractures in Lithuania, 2010
Fracture at the All
Age (years) hip vertebra forearm other fractures
Women
50–74 462 719 1,264 1,685 4,130
75+ 1,524 865 823 2,700 5,912
Total 1,986 1,584 2,087 4,385 10,042
Men
50–74 334 595 390 2,251 3,570
75+ 312 241 66 844 1,463
Total 646 835 456 3,095 5,033
Men and Women
50–74 797 1,314 1,654 3,936 7,700
75+ 1,836 1,106 889 3,544 7,375
Total 2,632 2,419 2,543 7,480 15,075
Table 5 Proportion of men and women (in %) with a prior hip or
clinical vertebral fracture in Lithuania, 2010
Age (years) Hip fracture Vertebral fracture
Women
50– 1.00.045
55– 5.02.095
60– 8.04.046
65– 1.17.096
70– 7.13.147
75– 5.24.297
80– 4.33.448
5.52.9+58
Men
50– 1.01.045
55– 4.03.095
60– 6.05.046
65– 8.07.096
70– 0.10.147
75– 3.14.197
80– 8.13.248
0.30.5+58
Table 6 Number of men and women in Lithuania with a prior hip or
clinical vertebral fracture after the age of 50 years, 2010
Age (years) Hip fracture Vertebral fracture
Women
50– 629,3155,247
957,5024,7+57
686,9179,9latoT
Men
50– 009,1925,147
691,1645,1+57
690,3570,3latoT
Men and Women
50– 628,5180,447
559,6569,8+57
287,21640,31latoT
Long-term disability costs were estimated by multiplying
the yearly cost of residing in nursing home (€ 10,691 [8]) with
the simulated number of individuals with prior fractures that
had been transferred to nursing homes due to the fracture.
Annual drug costs (€) for individual treatments are shown
in Table 9. In addition, it was assumed that patients on
treatment made an annual physician visit costing € 3 [9] and
a DXA scan costing € 28 [9] every second year to monitor
treatment.
The cost of osteoporosis in 2010 was estimated at €
47 million (Table 10). First year costs, subsequent year
costs and pharmacological fracture prevention costs
amounted to € 32 million, € 12 million and € 3 million
respectively. It is notable that pharmacological fracture
prevention costs amounted to only 5.5 % of the total
cost.
When stratifying costs of osteoporosis by fracture
type, hip fractures were most costly (€ 23 million)
followed by “other” (€ 18 million), spine (€ 2 million)
and forearm fractures (€ 1 million) (Table 11 and Fig.
1). Please note that costs for pharmacological fracture
prevention were not included given that they cannot be
allocated to specific fracture sites.
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Table 7 Incidence (per 100,000) of causally related deaths in Lithua-
nia within the first year after fracture (adjusted for comorbidities), 2010
Age (years) Hip Clinical vertebral “Other” fracture
Women
50–54 1,097 1,425 28
55–59 1,207 1,484 36
60–64 2,066 2,399 66
65–69 1,971 2,160 74
70–74 2,455 2,533 112
75–79 3,259 3,149 204
80–84 3,435 3,039 383
85–89 4,427 3,441 776
90+ 3,238 1,825 1,126
Men
50–54 4,747 5,693 74
55–59 6,298 7,160 129
60–64 6,425 6,910 174
65–69 7,370 7,476 264
70–74 6,712 6,391 303
75–79 7,140 6,332 423
80–84 6,901 5,604 580
85–89 9,950 7,273 1,075
90+ 12,236 7,963 1,531
Table 8 The number of deaths in men and women in Lithuania in the first
year after fracture attributable to the fracture event (causally related), 2010
Fracture at the
Age (years) hip vertebra “other”
Women
50–74 11 17 2
75+ 55 25 19
Total 66 42 20
Men
50–74 22 40 5
75+ 27 16 7
Total 49 56 12
Men and Women
50–74 33 57 6
75+ 81 41 26
Total 114 98 32
Table 9 One year costs
for relevant pharmaceu-
ticals in Lithuania, 2010
[10]
Annual drug
cost (€)
Alendronate 146
Risedronate 321
Etidronate -
Ibandronate 402
Zoledronic acid -
Raloxifene 516
Strontium ranelate 512
Parathyroid hormone 5,428
Teriparatide 5,758
Table 10 Cost of osteoporosis (€) in Lithuania by age in men and
women, 2010
Age
(years)
First year
fracture
cost
Long term
disability
costs
Fracture
prevention
cost
Total cost
Women
50–74 7,465,118 1,695,643 1,401,163 10,561,924
75+ 14,054,267 7,327,891 849,683 22,231,842
All 21,519,385 9,023,534 2,250,846 32,793,765
Men
50–74 7,229,340 1,200,128 225,794 8,655,261
75+ 3,455,749 1,877,945 91,174 5,424,868
All 10,685,088 3,078,073 316,968 14,080,129
Women and Men
50–74 14,694,458 2,895,771 1,626,957 19,217,185
75+ 17,510,016 9,205,836 940,857 27,656,709
All 32,204,473 12,101,607 2,567,814 46,873,894
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The number of quality adjusted life years (QALYs) lost
due to osteoporosis in 2010 was estimated at 4,900 (Table
12). 70 % of the total QALY loss was incurred in women.
Prior fractures accounted for 52 % of the total QALY loss.
The monetary value of a QALY was varied between 1 to 3
times the gross domestic product (GDP) per capita (Table
13). Assuming a QALY is valued at 2 times GDP/capita, the
total cost of the QALYs lost was estimated at € 80 m.
When the cost of osteoporosis was combined with the
value for QALYs lost (valued at 2 × GDP), the cost of
osteoporosis amounted to € 130 million in Lithuania in
2010. Incident fracture, prior fracture, pharmacological frac-
ture prevention, and value of QALYs lost accounted for
25 %, 9 %, 2 % and 63 % respectively. Burden of osteoporosis up to 2025
The population above 50 years of age is expected to increase
from 1.1 million in 2010 to 1.2 million in 2025, correspond-
ing to an increase of 8 % (Table 14).
Arch Osteoporos (2013) 8:137 Page 127 of 218, 137
Table 11 Total cost (€) in 2010 by fracture site in men and women in
Lithuania. Note that costs for fracture prevention therapy and monitor-
ing are not included
Age Hip Vertebral Forearm Other All
Women
50–74 3,787,138 720,220 371,450 4,281,953 9,160,761
75+ 13,637,941 813,728 241,936 6,688,554 21,382,158
All 17,425,079 1,533,948 613,385 10,970,507 30,542,919
Men
50–74 2,557,315 532,132 114,770 5,225,251 8,429,467
75+ 2,998,047 202,736 19,342 2,113,569 5,333,694
All 5,555,362 734,868 134,112 7,338,819 13,763,161
Women and Men
50–74 6,344,453 1,252,352 486,220 9,507,204 17,590,228
75+ 16,635,988 1,016,464 261,277 8,802,122 26,715,852
All 22,980,441 2,268,816 747,497 18,309,326 44,306,080
Hip
52%
Spine
5%
Forearm
2%
Other
41%
Fig. 1 Share (%) of fracture cost by fracture site in Lithuania. Note
that costs for fracture prevention therapy and monitoring are not
included
Table 12 Number of QALYs lost due to fractures during 2010 in men
and women in Lithuania according to age
Age (years)
50–74 75+ 50+
Women
Incident hip fractures 112 327 439
Incident vertebral fractures 240 254 494
Incident forearm fractures 45 25 70
Incident other fractures 202 285 487
Prior hip fractures 399 1,014 1,413
Prior vertebral fractures 220 283 502
504,3881,2712,1latoT
Men
Incident hip fractures 85 77 162
Incident vertebral fractures 206 78 285
Incident forearm fractures 14 2 16
Incident other fractures 269 97 365
Prior hip fractures 239 230 469
Prior vertebral fractures 106 63 169
664,1745919latoT
Men and Women
Incident hip fractures 197 404 601
Incident vertebral fractures 446 333 779
Incident forearm fractures 58 27 86
Incident other fractures 471 382 852
Prior hip fractures 639 1,244 1,882
Prior vertebral fractures 325 346 672
278,4537,2731,2latoT
Table 13 Value of lost QALYs (€) in men andwomen in Lithuania in 2010
1 × GDP/
capita
2 × GDP/
capita
3 × GDP/
capita
Incident hip fractures 4,991,011 9,982,021 14,973,032
Incident vertebral
fractures
6,463,375 12,926,749 19,390,124
Incident forearm
fractures
710,674 1,421,348 2,132,022
Incident other
fractures
7,073,665 14,147,329 21,220,994
Prior hip fractures 15,623,405 31,246,811 46,870,216
Prior vertebral
fractures
5,574,601 11,149,202 16,723,803
Total 40,436,730 80,873,461 121,310,191
The total number of fractures was estimated to rise from
15,000 in 2010 to 17,000 in 2025 (Table 15), corresponding
to an increase of 16 %. Hip, clinical spine, forearm and other
fractures increased by 500, 300, 300 and 1,300 respectively.
The increase in the number of fractures ranged from 11 % to
19 %, depending on fracture site. The increase was estimat-
ed to be 16 % in both men and women.
The cost of osteoporosis (excluding values of QALYs
lost) was estimated to rise from € 47 million in 2010 to €
54 million in 2025, corresponding to an increase of 15 %
(Table 16). Costs incurred in women and men increased by
15 % and 13 % respectively.
The total number of QALYs lost due to fracture was
estimated to rise from 4,900 in 2010 to 5,500 in 2025,
corresponding to an increase of 13 % (Table 17). The
increase was estimated to be 12 % in men and 13 % in
women. Incident and prior fractures accounted for 57 % and
43 % of the increase respectively.
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Table 14 Population projections in Lithuania by age and sex [11]
Population
2010 2015 2020 2025
Women
50–59 236,000 257,000 245,000 224,000
60–69 189,000 192,000 216,000 238,000
70–79 169,000 163,000 156,000 160,000
80–89 83,000 91,000 93,000 92,000
90+ 8,000 12,000 17,000 19,000
Men
50–59 195,000 215,509 211,000 195,000
60–69 127,000 131,000 152,000 170,000
70–79 88,000 84,000 80,000 85,000
80–89 30,000 33,000 34,000 33,000
90+ 2,000 2,000 3,000 4,000
All
50–59 431,000 472,509 456,000 419,000
60–69 316,000 323,000 368,000 408,000
70–79 257,000 247,000 236,000 245,000
80–89 113,000 124,000 127,000 125,000
90+ 10,000 14,000 20,000 23,000
000,022,1000,721,1
Table 15 Projected annual number of incident fractures in 2010 and
2025 by fracture site and age in men and women in Lithuania
Hip Vertebal Forearm Other
2010 2025 2010 2025 2010 2025 2010 2025
Women
50–74 462 496 719 769 1,264 1,352 1,685 1,799
75+ 1,524 1,911 865 1,016 823 938 2,700 3,379
All 1,986 2,407 1,584 1,786 2,087 2,290 4,385 5,178
Men
50–74 334 380 595 679 390 464 2,251 2,605
75+ 312 356 241 272 66 74 844 982
All 646 737 835 952 456 538 3,095 3,587
Women and Men
50–74 797 876 1,314 1,448 1,654 1,816 3,936 4,405
75+ 1,836 2,267 1,106 1,289 889 1,012 3,544 4,360
All 2,632 3,143 2,419 2,737 2,543 2,828 7,480 8,765
Table 16 Current and future cost (€ 000, 000) of osteoporosis (excluding
value ofQALYs lost) by age and calendar year inmen andwomen inLithuania
2010 2015 2020 2025
Women
50–74 11 11 11 11
75+ 22 24 26 27
All 33 35 36 38
Men
50–74 9 9 9 10
75+ 5 6 6 6
All 14 15 15 16
Women and Men
50–74 19 19 20 21
75+ 28 30 31 33
All 47 49 52 54
Table 17 Projected QALYs lost due to incident and prior fractures for
the years 2010 and 2025 by age in men and women in Lithuania
Incident fractures Prior fractures All fractures
2010 2025 2010 2025 2010 2025
Women
50–74 598 640 619 652 1,217 1,292
75+ 891 1,077 1,297 1,473 2,188 2,550
All 1,490 1,717 1,916 2,125 3,405 3,843
Men
50–74 574 659 345 379 919 1,038
75+ 254 290 293 311 547 601
All 828 949 638 689 1,466 1,639
Women and Men
50–74 1,173 1,299 964 1,031 2,137 2,330
75+ 1,145 1,367 1,590 1,784 2,735 3,151
All 2,318 2,667 2,554 2,814 4,872 5,481
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The cost of osteoporosis including value of QALYs lost
was estimated to increase from approximately € 128 million
in 2010 to € 145 million in 2025. The increase was estimat-
ed to be 12 % in men and 14 % in women (Table 18).
Treatment uptake
To estimate uptake of individual osteoporosis treatments,
sales data from IMS Health (2001–2011) were used to
derive the number of defined daily doses (DDDs) sold per
100,000 persons aged 50 years or above (Fig. 2).
Adjusting the sales data for compliance allowed for an
estimation of the proportion of population aged 50 years or
above who received any osteoporosis treatment (see Chapter 5
of the report on Osteoporosis in the European Union: Medical
Management, Epidemiology and Economic Burden for fur-
ther details). The proportion of persons over the age of
50 years who were treated increased from 0.4 % in 2001 to
1.38% in 2008 but subsequently decreased to 1.21% in 2011.
Treatment gap
In order to assess the potential treatment gap, the numbers of
men and women eligible for treatment in Lithuania were
defined as individuals with a 10-year fracture probability
exceeding that of a woman with a prior fragility fracture
derived from FRAX®, equivalent to a ‘fracture threshold’
(See Chapter 5 of the main report for further details). Sub-
sequently, these estimates were compared to the number
individuals who received osteoporosis treatment obtained
from the analysis of IMS Health data. The treatment gaps
in men and women were estimated at 95 % and 90 %
respectively (Table 19). Note that the estimate of the treat-
ment gap is conservative given that it assumes that current
use of osteoporosis treatments are only directed to men and
women at high risk.
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Epidemiology and Economic Burden of Osteo-
porosis in Luxembourg
A report prepared in collaboration with the Internation-
al Osteoporosis Foundation (IOF) and the European
Federation of Pharmaceutical Industry Associations
(EFPIA).
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Abstract
Summary This report describes epidemiology, burden, and
treatment of osteoporosis in Luxembourg.
Introduction Osteoporosis is characterized by reduced bone
mass and disruption of bone architecture, resulting in in-
creased risks of fragility fractures which represent the main
clinical consequence of the disease. Fragility fractures are
associated with substantial pain and suffering, disability and
even death for the affected patients and substantial costs to
society. The aim of this study is to describe the epidemiol-
ogy and economic burden of fragility fractures as a conse-
quence of osteoporosis in Luxembourg, as a further detailed
addition to the report for the entire European Union (EU27):
Osteoporosis in the European Union: Medical Management,
Epidemiology and Economic Burden.
Methods The literature on fracture incidence and costs of
fractures in Luxembourg was reviewed and incorporated
into a model estimating the clinical and economic burden
of osteoporotic fractures in 2010. Furthermore, data on sales
of osteoporosis treatments and the population at high risk
were used to estimate treatment uptake and treatment gap.
Results It was estimated that approximately 2,700 new fragil-
ity fractures were sustained in Luxembourg, comprising 470
hip fractures, 410 vertebral fractures, 460 forearm fractures
and 1,400 other fractures (i.e. fractures of the pelvis, rib,
humerus, tibia, fibula, clavicle, scapula, sternum and other
femoral fractures) in 2010. The economic burden of incident
and previous fragility fractures was estimated at € 22 million
for the same year. Incident fractures represented 71 % of this
cost, long-term fracture care 20 % and pharmacological pre-
vention 9 %. Previous and incident fractures also accounted
for 900 quality-adjusted life years (QALYs) lost during 2010.
When accounting for the demographic projections for 2025,
the number of incident fractures was estimated at 4,000 in
2025, representing an increase of 1,300 fractures. Hip, clinical
vertebral (spine), forearm and other fractures were estimated
to increase by 240, 200, 180 and 700, respectively. The burden
of fractures in Luxembourg in 2025 was estimated to increase
by 41 % to € 31 million. Though the uptake of osteoporosis
treatments increased from 2001, the proportion of patients
aged 50 or above who received treatment declined in the past
few years. A substantial minority of women at high fracture
risk did not receive active treatment.
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Conclusions In spite of the high cost of osteoporosis, a
substantial treatment gap in women and projected increase
of the economic burden driven by aging populations, the use
of pharmacological prevention of osteoporosis is signifi-
cantly less than optimal, suggesting that a change in
healthcare policy concerning the disease is warranted.
Introduction
Osteoporosis is characterized by reduced bone mass and
disruption of bone architecture, resulting in increased
risks of fragility fractures which represent the main
clinical consequence of the disease. Fragility fractures
are associated with substantial pain and suffering, dis-
ability and even death for the affected patients and
substantial costs to society. The aim of this report was
to characterize the burden of osteoporosis in Luxem-
bourg in 2010 and beyond.
Methods
The literature on fracture incidence and costs of fractures in
Luxembourg was reviewed and incorporated into a model
estimating the clinical and economic burden of osteoporotic
fractures in 2010. Details of the methods used are found in
Chapters 3 and 4 of the report Osteoporosis in the
European Union: Medical Management, Epidemiology
and Economic Burden, published concurrently in Ar-
chives of Osteoporosis.
Epidemiology of osteoporosis in Luxembourg
For the purpose of this report, the population at risk of oste-
oporosiswas considered to includemen andwomen≥50years.
The number of men and women ≥50 years of age amounted to
75,000 and 83,000 respectively in Luxembourg in 2010
(Table 1). It should be noted that this includes a substantial
proportion of French, Belgian and German nationals.
In the population at risk, the number of individuals with
osteoporosis—as defined by the WHO diagnostic
criteria—was estimated at 22,000 (Table 2). There are 2
DXA scan machines per million inhabitants [2], and guide-
lines for the assessment and treatment of osteoporosis are
available [3]. A country specific FRAX model for the as-
sessment of fracture risk is not available for Luxembourg.
Incidence data was not available for Luxembourg, therefore
data for hip fractures was imputed from Belgian age-
standardized incidence rates [5]. Fracture incidence is presented
in Table 3. Standardized to the EU27 population, this hip fracture
incidence (per 100,000 person years) in men and women
≥50 years of age was estimated at 228.5 and 538.7 respectively.
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Table 1 Population at risk: men and women over the age of 50 in
Luxembourg, 2010 [1]
Age (years) Women Men All
50–59 32,000 33,000 65,000
60–69 22,000 23,000 45,000
70–79 17,000 14,000 31,000
80–89 11,000 5,000 16,000
90+ 1,000 0 1,000
50+ 83,000 75,000 158,000
Table 2 Estimated number of women and men with osteoporosis
(defined as a T-score ≤−2.5 SD) in Luxembourg by age using
female-derived reference ranges at the femoral neck, 2010 [4]
Age (years) Women Men
50–54 1,071 450
55–59 1,440 525
60–64 1,716 754
65–69 2,020 740
70–74 2,511 624
75–79 3,000 618
80+ 5,664 830
50+ 17,422 4,541
Table 3 Incidence per 100,000 person years of hip, clinical vertebral,
forearm, and “other” fractures in Luxembourg by age
Fracture at the
Age (years) hip vertebra forearm other
Women
50–54 27 70 173 179
55–59 53 148 410 469
60–64 84 149 317 324
65–69 140 203 339 477
70–74 271 382 486 768
75–79 606 589 591 1,274
80–84 1,263 794 791 2,148
85+ 2,371 1,115 1,012 3,983
Men
50–54 34 88 32 152
55–59 49 85 74 455
60–64 73 174 137 716
65–69 104 164 157 673
70–74 159 243 102 819
75–79 313 361 89 836
80–84 669 464 130 1,778
85+ 1,371 921 251 3,971
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The number of incident fractures in 2010 was estimated
at 2,700 (Table 4). Incident hip, clinical spine, forearm and
“other” fractures were estimated at 470, 400, 460 and 1,400
respectively. 66 % of fractures occurred in women.
A prior fracture was defined as a fracture in an individual
who was alive during the index year (i.e. 2010) which had
occurred after the age of 50 years and before 2010. In the
population ≥50 years of age, the proportions of individuals
who had suffered a fracture prior to 2010 were estimated at
1.55 % for hip and 1.77 % for clinical vertebral fractures.
The estimated proportions of men and women with prior hip
and vertebral fractures by age are presented in Table 5.
In the population over 50 years of age, the number of
individuals with hip and vertebral fractures that occurred
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Table 4 Estimated number of incident fractures in Luxembourg, 2010
Fracture at the All
Age (years) hip vertebra forearm other fractures
Women
50–74 68 110 223 287 688
75+ 272 144 155 521 1,092
Total 340 254 378 808 1,780
Men
50–74 54 96 64 363 577
75+ 73 55 15 200 344
Total 127 151 79 563 920
Men and Women
50–74 122 206 287 650 1,265
75+ 346 199 170 721 1,435
Total 467 405 457 1,371 2,700
Table 5 Proportion of men and women (in %) with a prior hip or
clinical vertebral fracture in Luxembourg, 2010
Age (years) Hip fracture Vertebral fracture
Women
50– 2.00.045
55– 7.02.095
60– 2.15.046
65– 7.10.196
70– 7.28.147
75– 3.44.397
80– 1.65.648
7.98.31+58
Men
50– 1.01.045
55– 4.03.095
60– 9.06.046
65– 5.19.096
70– 8.13.147
75– 4.21.297
80– 3.37.348
9.41.7+58
Table 6 Number of men and women in Luxembourg with a prior hip
or clinical vertebral fracture after the age of 50 years, 2010
Age (years) Hip fracture Vertebral fracture
Women
50– 40795347
752,1814,1+57
069,1777,1latoT
Men
50– 20522347
723743+57
928966latoT
Men and Women
50– 602,118647
385,1567,1+57
097,2644,2latoT
Table 7 Incidence (per 100,000) of causally related deaths in
Luxembourg within the first year after fracture (adjusted for
comorbidities), 2010
Age (years) Hip Clinical vertebral “Other” fracture
Women
50–54 946 1,229 24
55–59 716 881 21
60–64 316 366 10
65–69 1,527 1,674 57
70–74 1,071 1,105 49
75–79 1,826 1,764 115
80–84 2,336 2,067 260
85–89 2,942 2,287 515
90+ 2,767 1,560 962
Men
50–54 1,671 2,004 26
55–59 1,206 1,371 25
60–64 1,838 1,977 50
65–69 1,774 1,799 64
70–74 3,369 3,208 152
75–79 3,836 3,401 227
80–84 4,634 3,763 389
85–89 7,419 5,422 801
90+ 11,898 7,743 1,488
before 2010 was estimated at 2,400 and 2,800 respectively
(Table 6). Note that fractures sustained in 2010 were not
included in the estimate.
The incidence of causally related deaths (per 100,000) in
the first year after fracture by age is presented in Table 7.
The number of causally related deaths in 2010 was estimat-
ed at 28 (Table 8). Hip, vertebral and “other” fractures
accounted for 14, 10 and 4 deaths respectively. Overall,
approximately 56 % of deaths occurred in women.
Cost of osteoporosis in Luxembourg including
and excluding values of QALYs lost
For the purpose of this report, the cost of osteoporosis
in 2010 (excluding value of QALYs lost) was consid-
ered to consist of three components: (i) cost of fractures
that occurred in 2010 (“first year costs”); (ii) cost of
fractures sustained prior to year 2010 but which still
incurred costs in 2010 (“long-term disability cost”); and
(iii) cost of pharmacological fracture prevention includ-
ing administration and monitoring costs (“pharmacolog-
ical fracture prevention costs”). See Chapter 4 of the
main report for further details.
The cost of a hip fracture was not available specifically
for Luxembourg, therefore hip fracture costs has been esti-
mated at € 12,616 based on Belgian costs [6]. Given that no
cost data for the other fracture sites were found, these were
imputed as described in Chapter 4 of the main report.
Long-term disability costs were estimated by multiply-
ing the yearly cost of residing in nursing home (€ 19,787
[7,8], based on Belgian cost of public nursing home) with
the simulated number of individuals with prior fractures
that had been transferred to nursing homes due to the
fracture.
Annual drug cost for individual treatments is shown in
Table 9. In addition, it was assumed that patients on treatment
made an annual physician visit costing € 30 [9] and a DXA
scan at € 59 [9] every second year to monitor treatment.
The cost of osteoporosis in 2010 was estimated at € 22
million (Table 10). First year costs, subsequent year costs
and pharmacological fracture prevention costs amounted to
€ 15 million, € 4 million and € 2 million respectively. It is
notable that pharmacological fracture prevention costs
amounted to only 9.1 % of the total cost.
When stratifying costs of osteoporosis by fracture type, hip
fractures were most costly (€ 10 million) followed by “other”
(€ 9 million), spine (€ 1 million) and forearm fractures (€ 0.4
million) (Table 11 and Fig. 1). Please note that costs for
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Table 8 The number of deaths in men and women in Luxembourg in
the first year after fracture attributable to the fracture event (causally
related), 2010
Fracture at the
Age (years) hip vertebra “other”
Women
50–74 1 2 0
75+ 7 3 3
Total 8 5 3
Men
50–74 1 3 0
75+ 4 2 1
Total 6 5 1
Men and Women
50–74 2 4 0
75+ 11 5 4
Total 14 10 4
Table 9 One year costs
for relevant pharmaceu-
ticals in Luxembourg,
2010 [9]
Annual drug
cost (€)
Alendronate 109
Risedronate 226
Etidronate 223
Ibandronate 379
Zoledronic acid 355
Raloxifene 446
Strontium ranelate 375
Parathyroid hormone -
Teriparatide 4,666
Table 10 Cost of osteoporosis (€) in Luxembourg by age in men and
women, 2010
Age
(years)
First year
fracture
cost
Long term
disability
costs
Fracture
prevention
cost
Total cost
Women
50–74 3,109,998 443,188 1,063,439 4,616,625
75+ 6,894,237 2,624,118 665,431 10,183,785
All 10,004,235 3,067,306 1,728,869 14,800,411
Men
50–74 3,155,820 461,756 175,575 3,793,152
75+ 2,244,929 759,313 67,901 3,072,143
All 5,400,749 1,221,069 243,476 6,865,294
Women and Men
50–74 6,265,819 904,945 1,239,014 8,409,777
75+ 9,139,165 3,383,431 733,332 13,255,928
All 15,404,984 4,288,375 1,972,346 21,665,705
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pharmacological fracture prevention were not included given
that they cannot be allocated to specific fracture sites.
The number of quality adjusted life years (QALYs)
lost due to osteoporosis in 2010 was estimated at 900
(Table 12). 67 % of the total QALY loss was incurred
in women. Prior fractures accounted for 55 % of the
total QALY loss. The monetary value of a QALY was
varied between 1 to 3 times the gross domestic product
(GDP) per capita (Table 13). Assuming a QALY is
valued at 2 times GDP/capita, the total cost of the
QALYs lost was estimated at € 150 million.
When the cost of osteoporosis was combined with the
value for QALYs lost (valued at 2 × GDP), the cost of
osteoporosis amounted to € 170 million in Luxembourg in
2010. Incident fracture, prior fracture, pharmacological frac-
ture prevention, and value of QALYs lost accounted for 9 %,
3 %, 1 % and 87 % respectively.
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Table 11 Total cost (€) in 2010 by fracture site in men and women in
Luxembourg. Note that costs for fracture prevention therapy and mon-
itoring are not included
Age Hip Spine Forearm Other All
Women
50–74 1,270,805 295,197 172,044 1,815,141 3,553,186
75+ 5,704,652 367,548 119,147 3,327,007 9,518,355
All 6,975,457 662,745 291,191 5,142,148 13,071,541
Men
50–74 1,093,837 251,733 49,092 2,222,915 3,617,577
75+ 1,522,705 131,840 11,915 1,337,782 3,004,241
All 2,616,542 383,573 61,007 3,560,697 6,621,818
Women and Men
50–74 2,364,641 546,930 221,136 4,038,056 7,170,763
75+ 7,227,357 499,388 131,062 4,664,789 12,522,596
All 9,591,999 1,046,318 352,197 8,702,845 19,693,359
Hip
49%
Spine
5%
Forearm
2%
Other
44%
Fig. 1 Share (%) of fracture cost by fracture site in Luxembourg. Note
that costs for fracture prevention therapy and monitoring are not
included
Table 12 Number of QALYs lost due to fractures during 2010 in men
and women in Luxembourg according to age
Age (years)
50–74 75+ 50+
Women
Incident hip fractures 16 57 74
Incident vertebral fractures 37 42 78
Incident forearm fractures 8 5 13
Incident other fractures 35 54 89
Prior hip fractures 56 193 249
Prior vertebral fractures 40 61 101
406214191latoT
Men
Incident hip fractures 13 18 31
Incident vertebral fractures 32 18 50
Incident forearm fractures 2 1 3
Incident other fractures 43 23 66
Prior hip fractures 50 52 102
Prior vertebral fractures 28 17 45
692821961latoT
Men and Women
Incident hip fractures 30 75 105
Incident vertebral fractures 69 59 128
Incident forearm fractures 10 5 15
Incident other fractures 78 77 155
Prior hip fractures 107 245 351
Prior vertebral fractures 67 79 146
009045063latoT
Table 13 Value of lost QALYs (€) in men and women in Luxembourg
in 2010
1 × GDP/
capita
2 × GDP/
capita
3 × GDP/
capita
Incident hip fractures 8,583,304 17,166,608 25,749,911
Incident vertebral
fractures
10,492,614 20,985,228 31,477,842
Incident forearm
fractures
1,260,591 2,521,181 3,781,772
Incident other fractures 12,706,581 25,413,161 38,119,742
Prior hip fractures 28,851,341 57,702,681 86,554,022
Prior vertebral
fractures
12,004,972 24,009,944 36,014,916
Total 73,899,402 147,798,804 221,698,206
Burden of osteoporosis up to 2025
The population above 50 years of age is expected to increase
from 158,000 in 2010 to 220,000 in 2025, corresponding to
an increase of 39 % (Table 14).
The total number of fractures was estimated to rise from
approximately 2,700 in 2010 to 4,000 in 2025 (Table 15),
corresponding to an increase of 49 %. Hip, clinical spine,
forearm and other fractures increased by 200, 200, 200 and
700 respectively. The increase in the number of fractures
ranged from 40 % to 52 %, depending on fracture site. The
increase was estimated to be particularly marked in men
(66 %) compared to women (41 %).
The cost of osteoporosis (excluding values of QALYs
lost) was estimated to rise from € 22 million in 2010 to €
31 million in 2025, corresponding to an increase of 41 %
(Table 16). Costs incurred in women and men increased by
33 % and 59 % respectively.
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Table 14 Population projections in Luxembourg by age and sex [10]
Population
2010 2015 2020 2025
Women
50–59 32,000 37,000 40,000 42,000
60–69 22,000 26,000 30,000 35,000
70–79 17,000 17,000 19,000 23,000
80–89 11,000 12,000 12,000 12,000
90+ 1,000 2,000 3,000 3,000
Men
50–59 33,000 38,001 42,000 41,000
60–69 23,000 26,000 29,000 34,000
70–79 14,000 15,000 17,000 21,000
80–89 5,000 7,000 8,000 8,000
90+ 0 1,000 1,000 1,000
All
50–59 65,000 75,001 82,000 83,000
60–69 45,000 52,000 59,000 69,000
70–79 31,000 32,000 36,000 44,000
80–89 16,000 19,000 20,000 20,000
90+ 1,000 3,000 4,000 4,000
000,022000,851
Table 15 Projected annual number of incident fractures in 2010 and
2025 by fracture site and age in men and women in Luxembourg
Hip Spine Forearm Other
2010 2025 2010 2025 2010 2025 2010 2025
Women
50–74 68 101 110 160 223 321 287 416
75+ 272 384 144 194 155 198 521 731
All 340 485 254 354 378 519 808 1,146
Men
50–74 54 76 96 136 64 90 363 515
75+ 73 150 55 113 15 31 200 421
All 127 226 151 249 79 121 563 935
Women and Men
50–74 122 177 206 296 287 411 650 930
75+ 346 534 199 306 170 229 721 1,151
All 467 711 405 603 457 641 1,371 2,082
Table 16 Current and future cost (€000,000) of osteoporosis (excluding value
of QALYs lost) by age and calendar year in men and women in Luxembourg
2010 2015 2020 2025
Women
50–74 5 5 6 7
75+ 10 12 12 13
All 15 17 18 20
Men
50–74 4 4 5 5
75+ 3 5 5 6
All 7 9 10 11
Women and Men
50–74 8 9 11 12
75+ 13 16 18 19
All 22 25 28 31
Table 17 Projected QALYs lost due to incident and prior fractures for
the years 2010 and 2025 by age in men and women in Luxembourg
Incident fractures Prior fractures All fractures
2010 2025 2010 2025 2010 2025
Women
50–74 96 139 96 112 191 251
75+ 158 215 254 264 412 479
All 254 354 350 376 604 730
Men
50–74 90 128 78 97 169 225
75+ 59 121 69 93 128 214
All 149 249 147 190 296 439
Women and Men
50–74 186 267 174 209 360 476
75+ 217 336 324 357 540 693
All 402 603 498 566 900 1,169
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The total number of QALYs lost due to fracture was esti-
mated to rise from 900 in 2010 to 1,200 in 2025, corre-
sponding to an increase of 30 % (Table 17). The increase
was estimated to be particularly marked in men (48 %)
compared to women (21 %). Incident and prior fractures
accounted for 75 % and 25 % of the increase respectively.
The cost of osteoporosis including value of QALYs lost was
estimated to increase from approximately € 170 million in
2010 to € 220 million in 2025. The increase was estimated
to be particularly marked in men (+49 %) compared to
women (+23 %) (Table 18).
Treatment uptake
To estimate uptake of individual osteoporosis treatments,
sales data from IMS Health (2001–2011) were used to
derive the number of defined daily doses (DDDs) sold per
100,000 persons aged 50 years or above (Fig. 2).
Adjusting the sales data for compliance allowed for an
estimation of the proportion of population aged 50 years or
above who received any osteoporosis treatment (see Chapter 5
of the report on Osteoporosis in the European Union: Medical
Management, Epidemiology and Economic Burden for fur-
ther details). The proportion of persons over the age of
50 years who were treated increased from 4.65 % in 2001 to
8.25% in 2006 but subsequently decreased to 5.78% in 2011.
Treatment gap
In order to assess the potential treatment gap, the numbers of
men and women eligible for treatment in Luxembourg were
defined as individuals with a 10-year fracture probability
exceeding that of a woman with a prior fragility fracture
derived from FRAX®, equivalent to a ‘fracture threshold’
(See Chapter 5 of the main report for further details). Sub-
sequently, these estimates were compared to the number
individuals who received osteoporosis treatment obtained
from the analysis of IMS Health data. For men, the data
indicate that the volume of sold osteoporosis drugs would be
sufficient to cover treatment for more patients than the
number that fall above the fracture threshold. It should be
noted, however, that the results from this analysis should be
interpreted with some caution since it has been assumed that
the distribution of drug use between genders observed in
Sweden is valid for all countries. The treatment gaps in men
and women were estimated at −35 % and 43 % respectively
(Table 19). Also note that the estimate of the treatment gap
is conservative given that it assumes that current use of
osteoporosis treatments are only directed to men and women
at high risk. This has been shown not to be the case [11].
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Table 18 Present and future cost (€ 000,000) of fracture (direct cost
and cost of QALYs) by age and calendar year in men and women in
Luxembourg assuming the uptake of treatment remains unchanged
2010 2015 2020 2025
Women
50–74 36 39 43 48
75+ 78 85 89 92
All 114 123 132 140
Men
50–74 31 34 38 42
75+ 24 32 36 41
All 56 66 74 83
Women and Men
50–74 68 72 80 90
75+ 102 117 125 132
All 169 190 206 223
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Fig. 2 Treatment uptake in Luxembourg (Defined daily doses [DDDs]
per 100,000 persons aged 50 years or above)
Table 19 Number of men and women eligible for treatment, treated
and treatment gap in 2010
Number
potentially
treated
(1000 s)
Number eligible
for treatment
(1000 s)
Difference
(1000 s)
Treatment
gap (%)
Men 1 1 0 −35
Women 9 16 7 43
report. The report has been reviewed by the members of the IOF
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Epidemiology and Economic Burden of Osteo-
porosis in Malta
A report prepared in collaboration with the Internation-
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Abstract
Summary This report describes epidemiology, burden, and
treatment of osteoporosis in Malta.
Introduction Osteoporosis is characterized by reduced bone
mass and disruption of bone architecture, resulting in in-
creased risks of fragility fractures which represent the main
clinical consequence of the disease. Fragility fractures are
associated with substantial pain and suffering, disability and
even death for the affected patients and substantial costs to
society. The aim of this study is to describe the epidemiol-
ogy and economic burden of fragility fractures as a conse-
quence of osteoporosis in Malta, as a further detailed
addition to the report for the entire European Union
(EU27): Osteoporosis in the European Union: Medical
Management, Epidemiology and Economic Burden.
Methods The literature on fracture incidence and costs of
fractures in Malta was reviewed and incorporated into a
model estimating the clinical and economic burden of oste-
oporotic fractures in 2010. Furthermore, data on sales of
osteoporosis treatments and the population at high risk were
used to estimate treatment uptake and treatment gap.
Results It was estimated that approximately 2,600 new fra-
gility fractures were sustained in Malta, comprising 450 hip
fractures, 430 vertebral fractures, 470 forearm fractures and
1,300 other fractures (i.e. fractures of the pelvis, rib, humer-
us, tibia, fibula, clavicle, scapula, sternum and other femoral
fractures) in 2010. The economic burden of incident and
previous fragility fractures was estimated at € 17 million for
the same year. Incident fractures represented 65 % of this
cost, long-term fracture care 24 % and pharmacological
prevention 12 %. Previous and incident fractures also
accounted for 800 quality-adjusted life years (QALYs) lost
during 2010. When accounting for the demographic pro-
jections for 2025, the number of incident fractures was
estimated at 3,800 in 2025, representing an increase of
1,100 fractures. Hip, clinical vertebral (spine), forearm and
other fractures were estimated to increase by 230, 190, 140
and 580, respectively. The burden of fractures in Malta in
2025 was estimated to increase by 39 % to € 24 million.
Conclusions There is a high cost of osteoporosis with a
substantial projected increase of the economic burden driven
by aging populations, suggesting that a change in healthcare
policy concerning the disease is warranted.
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Introduction
Osteoporosis is characterized by reduced bone mass and
disruption of bone architecture, resulting in increased risks
of fragility fractures which represent the main clinical con-
sequence of the disease. Fragility fractures are associated
with substantial pain and suffering, disability and even death
for the affected patients and substantial costs to society. The
aim of this report was to characterize the burden of osteo-
porosis in Malta in 2010 and beyond.
Methods
The literature on fracture incidence and costs of frac-
tures in Malta was reviewed and incorporated into a
model estimating the clinical and economic burden of
osteoporotic fractures in 2010. Details of the methods
used are found in Chapters 3 and 4 of the report
Osteoporosis in the European Union: Medical Manage-
ment, Epidemiology and Economic Burden, published
concurrently in Archives of Osteoporosis.
Epidemiology of osteoporosis in Malta
For the purpose of this report, the population at risk of oste-
oporosiswas considered to includemen andwomen≥50years.
The number of men and women ≥50 years of age amounted to
71,000 and 81,000 respectively in Malta in 2010 (Table 1).
In the population at risk, the number of individuals with
osteoporosis—as defined by the WHO diagnostic
criteria—was estimated at c. 20,000 (Table 2). There
are 9.7 DXA scan machines per million inhabitants
[2], and guidelines for the assessment and treatment of
osteoporosis are available [3]. A country specific FRAX
model is also available for the assessment of fracture
risk (http://www.shef.ac.uk/FRAX/).
Data on hip fracture incidence are available for Malta for the
years 2003–2007 [5]. Given that country specific incidence of
the vertebral, forearm and, “other” fractures were not found,
these were imputed using the methods described in Chapter 3
of the main report. Fracture incidence is presented in Table 3.
Standardized to the EU27 population, hip fracture incidence
(per 100,000 person years) in men and women ≥50 years of age
was estimated at 206.1 and 502.5 respectively.
The number of incident fractures in 2010 was esti-
mated at 2,600 (Table 4). Incident hip, clinical spine,
forearm and “other” fractures were estimated at 450,
430, 470 and 1,300 respectively. 68 % of fractures
occurred in women. These figures may be conservative
since hip fracture rates appear to have increased recent-
ly. Thus, the annual number of hip fractures in men and
women appears to have risen from approximately 450
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Table 1 Population at risk: men and women over the age of 50 in
Malta, 2010 [1]
Age (years) Women Men All
50–59 31,000 31,000 62,000
60–69 24,000 23,000 47,000
70–79 17,000 13,000 30,000
80–89 8,000 4,000 12,000
90+ 1,000 0 1,000
50+ 81,000 71,000 152,000
Table 2 Estimated number of women and men with osteoporosis
(defined as a T-score ≤−2.5 SD) in Malta by age using female-
derived reference ranges at the femoral neck, 2010 [4]
Age (years) Women Men
50–54 1,008 400
55–59 1,440 525
60–64 2,145 870
65–69 1,818 592
70–74 2,790 624
75–79 2,625 515
80+ 4,248 664
50+ 16,074 4,190
Table 3 Incidence per 100,000 person years of hip, clinical vertebral,
forearm, and “other” fractures in Malta by age
Fracture at the
Age (years) hip vertebra forearm other
Women
50–54 26 67 167 172
55–59 39 109 302 346
60–64 85 150 320 327
65–69 200 291 486 684
70–74 448 631 804 1,269
75–79 856 832 835 1,801
80–84 1,426 896 893 2,425
85+ 2,062 970 880 3,465
Men
50–54 29 74 26 127
55–59 28 49 43 263
60–64 54 130 102 534
65–69 111 174 167 714
70–74 215 328 138 1,106
75–79 423 488 120 1,130
80–84 744 517 144 1,979
85+ 1,108 744 203 3,210
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using the source data for 2003–2007 to 550/year for the
years 2009–2011 [6].
A prior fracture was defined as a fracture in an individual
who was alive during the index year (i.e. 2010) which had
occurred after the age of 50 years and before 2010. In the
population ≥50 years of age, the proportion of individuals
who had suffered a fracture prior to 2010 was estimated at
1.30 % for hip and 1.52 % for clinical vertebral fractures.
The estimated proportions of men and women with prior hip
and vertebral fractures by age are presented in Table 5.
In the population over 50 years of age, the number of
individuals with hip and vertebral fractures that occurred
before 2010 was estimated at 2,000 and 2,300 respectively
(Table 6). Note that fractures sustained in 2010 were not
included in the estimate.
The incidence of causally related deaths (per 100,000) in
the first year after fracture by age is presented in Table 7.
The number of causally related deaths in 2010 was estimat-
ed at 30 (Table 8). Hip, vertebral and “other” fractures
accounted for 15, 11 and 4 deaths respectively. Overall,
approximately 56 % of deaths occurred in women.
Cost of osteoporosis in Malta including and excluding
values of QALYs lost
For the purpose of this report, the cost of osteoporosis in
2010 (excluding value of QALYs lost) was considered to
consist of three components: (i) cost of fractures that oc-
curred in 2010 (“first year costs”); (ii) cost of fractures
sustained prior to year 2010 but which still incurred costs
in 2010 (“long-term disability cost”); and (iii) cost of phar-
macological fracture prevention including administration
and monitoring costs (“pharmacological fracture prevention
costs”). See Chapter 4 of the main report for further details.
As the cost of a hip fracture was not available specifically
for Malta, the cost of a hip fracture has been estimated at €
9,084 based on Italian costs [7]. Given that no cost data for
the other fracture sites were found, these were imputed as
described in Chapter 4 of the main report.
Long-term disability costs were estimated by multiplying
the yearly cost of residing in nursing home (€ 23,265 [7,8],
Table 6 Number of men and women in Malta with a prior hip or
clinical vertebral fracture after the age of 50 years, 2010
Age (years) Hip fracture Vertebral fracture
Women
50– 91749347
879511,1+57
796,1905,1latoT
Men
50– 01463247
902922+57
916564latoT
Men and Women
50– 921,103647
781,1443,1+57
613,2479,1latoT
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Table 4 Estimated number of incident fractures in Malta, 2010
Fracture at the All
Age (years) hip vertebra forearm other fractures
Women
50–74 103 153 269 364 889
75+ 228 130 133 426 918
Total 331 283 403 790 1,807
Men
50–74 54 95 56 333 538
75+ 64 50 14 170 297
Total 117 144 70 503 835
Men and Women
50–74 156 248 326 697 1,427
75+ 292 180 147 596 1,215
Total 448 428 473 1,293 2,642
Table 5 Proportion of men and women (in %) with a prior hip or
clinical vertebral fracture in Malta, 2010
Age (years) Hip fracture Vertebral fracture
Women
50– 1.00.045
55– 6.02.095
60– 1.15.046
65– 7.10.196
70– 8.29.147
75– 4.46.397
80– 1.66.648
2.94.31+58
Men
50– 2.01.045
55– 5.02.095
60– 8.04.046
65– 0.16.096
70– 4.10.147
75– 9.16.197
80– 5.20.348
9.36.5+58
approximated using the PPP adjusted Italian cost of public
nursing home) with the simulated number of individuals
with prior fractures that had been transferred to nursing
homes due to the fracture.
Annual drug cost (€) for individual treatments is shown
in Table 9. In addition, it was assumed that patients on
treatment made an annual physician visit costing € 23 [8]
(approximated using the PPP adjusted Italian cost) and a
DXA scan costing € 184 [9] every second year to monitor
treatment.
The cost of osteoporosis in 2010 was estimated at € 17
million (Table 10). First year costs, subsequent year costs
and pharmacological fracture prevention costs amounted to
€ 11 million, € 4 million and € 2 million, respectively. It is
notable that pharmacological fracture prevention costs
amounted to only 11.8 % of the total cost.
When stratifying costs of osteoporosis by fracture type,
hip fractures were most costly (€ 8 million) followed by
“other” (€ 6 million), spine (€ 0.8 million) and forearm
fractures (€ 0.3 million) (Table 11 and Fig. 1). As noted
above, the fracture rates may be underestimated by about
20 % so that the costs may be proportionately higher.
Note also that costs for pharmacological fracture pre-
vention were not included given that they cannot be
allocated to specific fracture sites.
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Table 7 Incidence (per 100,000) of causally related deaths in Malta
within the first year after fracture (adjusted for comorbidities), 2010
Age (years) Hip Clinical vertebral “Other” fracture
Women
50–54 668 868 17
55–59 707 870 21
60–64 920 1,069 29
65–69 1,806 1,980 68
70–74 1,382 1,426 63
75–79 2,186 2,112 137
80–84 3,076 2,722 343
85–89 3,696 2,873 647
90+ 3,153 1,778 1,096
Men
50–54 981 1,177 15
55–59 1,183 1,345 24
60–64 2,207 2,374 60
65–69 3,894 3,950 140
70–74 4,345 4,137 196
75–79 5,127 4,546 304
80–84 6,390 5,189 537
85–89 10,880 7,952 1,175
90+ 15,476 10,071 1,936
Table 8 The number of deaths in men and women in Malta in the first
year after fracture attributable to the fracture event (causally related), 2010
Fracture at the
Age (years) hip vertebra “other”
Women
50–74 2 2 0
75+ 7 3 2
Total 9 6 3
Men
50–74 2 3 0
75+ 5 3 1
Total 6 5 2
Men and Women
50–74 3 5 1
75+ 12 6 4
Total 15 11 4
Table 9 One year costs
for relevant pharmaceu-
ticals in Malta, 2010 [10]
Annual drug
cost (€)
Alendronate 190
Risedronate 491
Etidronate -
Ibandronate 434
Zoledronic acid 560
Raloxifene 461
Strontium ranelate 606
Parathyroid hormone -
Teriparatide 7,170
Table 10 Cost of osteoporosis (€) inMalta by age inmen andwomen, 2010
Age
(years)
First year
fracture
cost
Long term
disability
costs
Fracture
prevention
cost
Total cost
Women
50–74 3,159,484 574,338 1,245,473 4,979,295
75+ 4,145,346 2,411,612 585,634 7,142,593
All 7,304,830 2,985,950 1,831,107 12,121,888
Men
50–74 2,236,877 387,516 195,189 2,819,581
75+ 1,374,171 607,215 63,002 2,044,388
All 3,611,048 994,731 258,191 4,863,970
Women and Men
50–74 5,396,361 961,854 1,440,662 7,798,877
75+ 5,519,518 3,018,827 648,637 9,186,981
All 10,915,878 3,980,681 2,089,298 16,985,858
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The number of quality adjusted life years (QALYs) lost
due to osteoporosis in 2010 was estimated at 800 (Table 12).
70 % of the total QALY loss was incurred in women. Prior
fractures accounted for 50 % of the total QALY loss. The
monetary value of a QALY was varied between 1 to 3 times
the gross domestic product (GDP) per capita (Table 13).
Assuming a QALY is valued at 2 times GDP/capita, the
total cost of the QALYs lost was estimated at € 24 million.
When the cost of osteoporosis was combined with the value
for QALYs lost (valued at 2 × GDP), the cost of osteoporo-
sis amounted to € 41 million in Malta in 2010. Incident
fracture, prior fracture, pharmacological fracture prevention,
and value of QALYs lost accounted for 27 %, 10 %, 5 %,
58 % respectively. Burden of osteoporosis up to 2025
The population above 50 years of age is expected to increase
from 152,000 in 2010 to 176,000 in 2025, corresponding to
an increase of 16 % (Table 14).
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Table 11 Total cost (€) in 2010 by fracture site in men and women in
Malta. Note that costs for fracture prevention therapy and monitoring
are not included.
Age Hip Spine Forearm Other All
Women
50–74 1,472,718 295,956 149,458 1,815,690 3,733,822
75+ 4,244,795 236,517 73,953 2,001,693 6,556,958
All 5,717,514 532,473 223,412 3,817,383 10,290,781
Men
50–74 839,056 177,657 31,305 1,576,374 2,624,393
75+ 1,063,713 82,724 7,641 827,308 1,981,386
All 1,902,769 260,381 38,947 2,403,683 4,605,779
Women and Men
50–74 2,311,774 473,613 180,764 3,392,064 6,358,215
75+ 5,308,508 319,241 81,595 2,829,001 8,538,344
All 7,620,282 792,853 262,358 6,221,065 14,896,559
Hip
51%
Spine
5%
Forearm
2%
Other
42%
Fig. 1 Share (%) of fracture cost by fracture site in Malta. Note that
costs for fracture prevention therapy and monitoring are not included
Table 12 Number of QALYs lost due to fractures during 2010 in men
and women in Malta according to age
Age (years)
50–74 75+ 50+
Women
Incident hip fractures 25 49 74
Incident vertebral fractures 50 38 89
Incident forearm fractures 9 4 14
Incident other fractures 43 45 88
Prior hip fractures 62 152 214
Prior vertebral fractures 40 48 88
665633032latoT
Men
Incident hip fractures 13 16 29
Incident vertebral fractures 31 16 47
Incident forearm fractures 2 0 2
Incident other fractures 39 19 59
Prior hip fractures 37 34 71
Prior vertebral fractures 23 11 34
24279541latoT
Men and Women
Incident hip fractures 38 64 102
Incident vertebral fractures 82 54 136
Incident forearm fractures 11 5 16
Incident other fractures 83 64 147
Prior hip fractures 99 186 285
Prior vertebral fractures 63 59 122
808334573latoT
Table 13 Value of lost QALYs (€) in men and women in Malta in 2010
1 × GDP/
capita
2 × GDP/
capita
3 × GDP/
capita
Incident hip fractures 1,510,316 3,020,631 4,530,947
Incident vertebral
fractures
2,013,445 4,026,889 6,040,334
Incident forearm
fractures
236,228 472,457 708,685
Incident other fractures 2,177,910 4,355,820 6,533,730
Prior hip fractures 4,213,340 8,426,680 12,640,021
Prior vertebral
fractures
1,806,697 3,613,394 5,420,091
Total 11,957,936 23,915,872 35,873,807
The total number of fractures was estimated to rise
from approximately 2,600 in 2010 to 3,800 in 2025
(Table 15), corresponding to an increase of 43 %. Hip,
clinical spine, forearm and other fractures increased by
200, 200, 100 and 600 respectively. The increase in the
number of fractures ranged from 30 % to 52 %,
depending on fracture site. The increase was estimated
to be particularly marked in men (58 %) compared to
women (36 %).
The cost of osteoporosis (excluding values of QALYs
lost) was estimated to rise from € 17 million in 2010 to €
24 million in 2025, corresponding to an increase of 40 %
(Table 16). Costs incurred in women and men increased by
33 % and 55 % respectively.
The total number of QALYs lost due to fracture was
estimated to rise from 800 in 2010 to 1,100 in 2025, corre-
sponding to an increase of 32 % (Table 17). The increase was
estimated to be particularly marked in men (47 %) compared
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Table 14 Population projections in Malta by age and sex [11]
Population
2010 2015 2020 2025
Women
50–59 31,000 30,000 27,000 25,000
60–69 24,000 30,000 30,000 29,000
70–79 17,000 16,000 21,000 26,000
80–89 8,000 8,000 10,000 10,000
90+ 1,000 1,000 1,000 2,000
Men
50–59 31,000 30,096 28,000 26,000
60–69 23,000 29,000 29,000 28,000
70–79 13,000 13,000 18,000 22,000
80–89 4,000 5,000 6,000 7,000
90+ 0 1,000 1,000 1,000
All
50–59 62,000 60,096 55,000 51,000
60–69 47,000 59,000 59,000 57,000
70–79 30,000 29,000 39,000 48,000
80–89 12,000 13,000 16,000 17,000
90+ 1,000 2,000 2,000 3,000
000,671000,251
Table 15 Projected annual number of incident fractures in 2010 and
2025 by fracture site and age in men and women in Malta
Hip Spine Forearm Other
2010 2025 2010 2025 2010 2025 2010 2025
Women
50–74 103 135 153 192 269 317 364 449
75+ 228 338 130 196 133 199 426 637
All 331 473 283 388 403 515 790 1,085
Men
50–74 54 70 95 118 56 67 333 409
75+ 64 138 50 109 14 30 170 375
All 117 208 144 227 70 97 503 784
Women and Men
50–74 156 205 248 310 326 384 697 858
75+ 292 476 180 305 147 229 596 1,011
All 448 681 428 614 473 613 1,293 1,870
Table 16 Current and future cost (€ 000,000) of osteoporosis (excluding
value ofQALYs lost) by age and calendar year inmen andwomen inMalta
2010 2015 2020 2025
Women
50–74 5 5 6 6
75+ 7 7 8 10
All 12 13 14 16
Men
50–74 3 3 4 4
75+ 2 3 2 4
All 5 6 7 8
Women and Men
50–74 8 8 10 10
75+ 9 10 11 14
All 17 19 21 24
Table 17 Projected QALYs lost due to incident and prior fractures for
the years 2010 and 2025 by age in men and women in Malta
Incident fractures Prior fractures All fractures
2010 2025 2010 2025 2010 2025
Women
50–74 128 159 102 112 230 271
75+ 136 203 200 235 336 438
All 264 362 302 347 566 709
Men
50–74 86 107 60 67 145 174
75+ 52 113 45 68 97 182
All 137 220 105 136 242 356
Women and Men
50–74 213 266 162 179 375 445
75+ 188 316 245 304 433 620
All 401 582 407 483 808 1,065
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to women (25 %). Incident and prior fractures accounted for
about 70 % and 33 % of the increase respectively.
The cost of osteoporosis including value of QALYs lost was
estimated to increase from approximately € 41 million in
2010 to € 55 million in 2025. The increase was estimated to
be particularly marked in men (+50 %) compared to women
(+29 %) (Table 18).
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Table 18 Present and future cost (€ 000,000) of fracture (direct cost
and cost of QALYs) by age and calendar year in men and women in
Malta assuming the uptake of treatment remains unchanged
2010 2015 2020 2025
Women
50–74 12 12 14 14
75+ 17 18 19 23
All 29 30 33 37
Men
50–74 7 8 9 9
75+ 5 6 7 9
All 12 14 16 18
Women and Men
50–74 19 20 23 23
75+ 22 24 26 32
All 41 44 49 55
Abstract
Summary This report describes epidemiology, burden, and
treatment of osteoporosis in the Netherlands.
Introduction Osteoporosis is characterized by reduced
bone mass and disruption of bone architecture, resulting
in increased risks of fragility fractures which represent
the main clinical consequence of the disease. Fragility
fractures are associated with substantial pain and suffer-
ing, disability and even death for the affected patients
and substantial costs to society. The aim of this study is
to describe the epidemiology and economic burden of
fragility fractures as a consequence of osteoporosis in
the Netherlands, as a further detailed addition to the
report for the entire European Union (EU27): Osteopo-
rosis in the European Union: Medical Management,
Epidemiology and Economic Burden.
Methods The literature on fracture incidence and costs of
fractures in the Netherlands was reviewed and incorporated
into a model estimating the clinical and economic burden of
osteoporotic fractures in 2010. Furthermore, data on sales of
osteoporosis treatments and the population at high risk were
used to estimate treatment uptake and treatment gap.
Results It was estimated that approximately 76,000 new
fragility fractures were sustained in the Netherlands, com-
prising 13,000 hip fractures, 12,000 vertebral fractures,
12,000 forearm fractures and 38,000 other fractures (i.e.
fractures of the pelvis, rib, humerus, tibia, fibula, clavicle,
scapula, sternum and other femoral fractures) in 2010. The
economic burden of incident and previous fragility frac-
tures was estimated at € 824 million for the same year.
Incident fractures represented 44 % of this cost, long-term
fracture care 53 % and pharmacological prevention 4 %.
Previous and incident fractures also accounted for 26,300
quality-adjusted life years (QALYs) lost during 2010. When
accounting for the demographic projections for 2025, the
number of incident fractures was estimated at 107,000 in
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2025, representing an increase of 31,000 fractures. Hip,
clinical vertebral (spine), forearm and other fractures were
estimated to increase by 6,100, 4,800, 3,900 and 15,900,
respectively. The burden of fractures in the Netherlands in
2025 was estimated to increase by 30 % to € 1,069 million.
Though the uptake of osteoporosis treatments increased from
2001, the proportion of patients aged 50 or above who
received treatment remained at very low levels in the past
few years. The majority of women at high fracture risk did
not receive active treatment.
Conclusions In spite of the high cost of osteoporosis, a
substantial treatment gap and projected increase of the eco-
nomic burden driven by aging populations, the use of phar-
macological prevention of osteoporosis is significantly less
than optimal, suggesting that a change in healthcare policy
concerning the disease is warranted.
Introduction
Osteoporosis is characterized by reduced bone mass and
disruption of bone architecture, resulting in increased
risks of fragility fractures which represent the main
clinical consequence of the disease. Fragility fractures
are associated with substantial pain and suffering, dis-
ability and even death for the affected patients and
substantial costs to society. The aim of this report was
to characterize the burden of osteoporosis in the Neth-
erlands in 2010 and beyond.
Methods
The literature on fracture incidence and costs of fractures in
the Netherlands was reviewed and incorporated into a
model estimating the clinical and economic burden of
osteoporotic fractures in 2010. Details of the methods used
are found in Chapters 3 and 4 of the report Osteoporosis in
the European Union: Medical Management, Epidemiology
and Economic Burden, published concurrently in Archives
of Osteoporosis.
Epidemiology of osteoporosis in the Netherlands
For the purpose of this report, the population at risk of
osteoporosis was considered to include men and women
≥50 years. The number of men and women ≥50 years of
age amounted to 2,798,000 and 3,095,000 respectively in
the Netherlands in 2010 (Table 1).
In the population at risk, the number of individuals with
osteoporosis—as defined by the WHO diagnostic criteria—was
estimated at 820,000 (Table 2). There are 10.7 DXA scan
machines per million inhabitants [2], and guidelines for the
assessment and treatment of osteoporosis are available [3]. A
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Table 1 Population at risk: men and women over the age of 50 in the
Netherlands, 2010 [1]
Age (years) Women Men All
50–59 1,130,000 1,145,000 2,275,000
60–69 931,000 927,000 1,858,000
70–79 607,000 508,000 1,115,000
80–89 360,000 198,000 558,000
90+ 67,000 20,000 87,000
50+ 3,095,000 2,798,000 5,893,000
Table 2 Estimated number of women and men with osteoporosis
(defined as a T-score ≤−2.5 SD) in the Netherlands by age using
female-derived reference ranges at the femoral neck, 2010 [4]
Age (years) Women Men
50–54 37,107 14,900
55–59 51,936 19,215
60–64 76,648 31,378
65–69 79,790 28,564
70–74 91,233 22,854
75–79 105,000 22,145
80+ 201,544 36,188
50+ 643,258 175,244
Table 3 Incidence per 100,000 person years of hip, clinical vertebral,
forearm, and “other” fractures in the Netherlands by age
Fracture at the
Age (years) hip vertebra forearm other
Women
50–54 21 54 133 137
55–59 39 107 296 339
60–64 60 106 227 232
65–69 108 158 263 370
70–74 220 310 395 623
75–79 480 467 469 1,011
80–84 887 558 555 1,509
85+ 1,468 691 627 2,466
Men
50–54 20 52 19 90
55–59 29 51 45 274
60–64 43 104 82 427
65–69 73 115 110 471
70–74 127 194 81 652
75–79 247 284 70 659
80–84 528 367 102 1,405
85+ 919 617 169 2,663
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country specific FRAX model is also available for the assess-
ment of fracture risk (http://www.shef.ac.uk/FRAX/).
Data on hip fracture incidence are available for the Neth-
erlands [5]. Given that country specific incidence of the ver-
tebral, forearm and, “other” fractures were not found, these
were imputed using the methods described in Chapter 3 of the
main report. Fracture incidence is presented in Table 3. Stan-
dardized to the EU27 population, hip fracture incidence (per
100,000 person years) in men and women ≥50 years of age
was estimated at 163.8 and 368.3 respectively.
The number of incident fractures in 2010 was estimated at
76,000 (Table 4). Incident hip, clinical spine, forearm and
“other” fractures were estimated at 13,000, 12,000, 12,000
and 38,000 respectively. 64% of fractures occurred in women.
A prior fracture was defined as a fracture in an individual
who was alive during the index year (i.e. 2010) which had
occurred after the age of 50 years and before 2010. In the
population ≥50 years of age, the proportion of individuals
who had suffered a fracture prior to 2010 was estimated at
1.27 % for hip and 1.39 % for clinical vertebral fractures.
The estimated proportions of men and women with prior hip
and vertebral fractures by age are presented in Table 5.
In the population over 50 years of age, the number of
individuals with hip and vertebral fractures that occurred
before 2010 was estimated at 75,000 and 82,000 respective-
ly (Table 6). Note that fractures sustained in 2010 were not
included in the estimate.
The incidence of causally related deaths (per 100,000) in
the first year after fracture by age is presented in Table 7.
The number of causally related deaths in 2010 was estimat-
ed at 870 (Table 8). Hip, vertebral and “other” fractures
accounted for 431, 285 and 154 deaths respectively. Overall,
approximately 50 % of deaths occurred in women.
Cost of osteoporosis in the Netherlands including
and excluding values of QALYs lost
For the purpose of this report, the cost of osteoporosis
in 2010 (excluding value of QALYs lost) was consid-
ered to consist of three components: (i) cost of fractures
Table 4 Estimated number of incident fractures in the Netherlands,
2010
Fracture at the All
Age (years) hip vertebra forearm other fractures
Women
50–74 2,100 3,327 6,445 8,353 20,224
75+ 7,267 3,842 3,873 13,591 28,574
Total 9,367 7,169 10,318 21,944 48,797
Men
50–74 1,404 2,467 1,602 9,215 14,688
75+ 2,624 1,988 550 7,299 12,461
Total 4,028 4,455 2,152 16,514 27,149
Men and Women
50–74 3,503 5,794 8,047 17,567 34,911
75+ 9,892 5,830 4,423 20,890 41,034
Total 13,395 11,624 12,470 38,457 75,946
Table 5 Proportion of men and women (in %) with a prior hip or
clinical vertebral fracture in the Netherlands, 2010
Age (years) Hip fracture Vertebral fracture
Women
50– 1.00.045
55– 5.02.095
60– 9.04.046
65– 3.18.096
70– 2.24.147
75– 5.37.297
80– 0.53.548
8.73.11+58
Men
50– 1.00.045
55– 3.02.095
60– 6.03.046
65– 9.06.096
70– 2.19.047
75– 8.16.197
80– 6.28.248
8.43.6+58
Table 6 Number of men and women in the Netherlands with a prior
hip or clinical vertebral fracture after the age of 50 years, 2010
Age (years) Hip fracture Vertebral fracture
Women
50– 555,02262,1147
480,73029,24+57
936,75281,45latoT
Men
50– 111,31378,747
554,11935,21+57
665,42214,02latoT
Men and Women
50– 666,33531,9147
935,84954,55+57
602,28495,47latoT
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that occurred in 2010 (“first year costs”); (ii) cost of
fractures sustained prior to year 2010 but which still
incurred costs in 2010 (“long-term disability cost”);
and (iii) cost of pharmacological fracture prevention
including administration and monitoring costs (“pharma-
cological fracture prevention costs”). See Chapter 4 of
the main report for further details.
The cost of a hip fracture has been estimated at € 10,458
in the Netherlands [6]. Given that no cost data for the other
fracture sites were found, these were imputed as described in
Chapter 4 of the main report.
Long-term disability costs were estimated by multiplying
the yearly cost of residing in nursing home (€ 63,685 [7])
with the simulated number of individuals with prior frac-
tures that had been transferred to nursing homes due to the
fracture.
Annual drug cost (€) for individual treatments is shown in
Table 9. In addition, it was assumed that patients on treatment
made an annual physician visit costing € 23 [8] and a DXA
scan at € 84 [8] every second year to monitor treatment.
The cost of osteoporosis in 2010 was estimated at € 824
million (Table 10). First year costs, subsequent year costs
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Table 8 The number of deaths in men and women in the Netherlands
in the first year after fracture attributable to the fracture event (causally
related), 2010
Fracture at the
Age (years) hip vertebra “other”
Women
50–74 32 52 5
75+ 187 75 85
Total 219 126 90
Men
50–74 38 64 8
75+ 174 95 56
Total 212 159 65
Men and Women
50–74 71 116 13
75+ 360 169 141
Total 431 285 154
Table 9 One year costs
for relevant pharmaceu-
ticals in the Netherlands
for 2010 [9]
Annual drug
cost (€)
Alendronate 4
Risedronate 23
Etidrontate 354
Ibandronate 302
Zoledronic acid 377
Raloxifene 325
Strontium ranelate 433
Parathyroid hormone 5,705
Teriparatide 5,811
Table 10 Cost of osteoporosis (€) in the Netherlands by age in men
and women, 2010
Age
(years)
First year
fracture
cost
Long term
disability
costs
Fracture
prevention
cost
Total cost
Women
50–74 77,335,965 44,567,025 16,334,056 138,237,046
75+ 149,330,380 261,832,402 9,086,295 420,249,077
All 226,666,344 306,399,427 25,420,351 558,486,123
Men
50–74 68,719,726 36,970,037 2,567,776 108,257,539
75+ 64,746,573 91,085,493 1,010,578 156,842,644
All 133,466,299 128,055,530 3,578,354 265,100,183
Women and Men
50–74 146,055,691 81,537,062 18,901,832 246,494,584
75+ 214,076,953 352,917,895 10,096,873 577,091,721
All 360,132,643 434,454,958 28,998,705 823,586,306
Table 7 Incidence (per 100,000) of causally related deaths in the
Netherlands within the first year after fracture (adjusted for
comorbidities), 2010
Age (years) Hip Clinical vertebral “Other” fracture
Women
50–54 680 884 18
55–59 848 1,043 25
60–64 1,104 1,283 35
65–69 1,436 1,574 54
70–74 1,804 1,862 82
75–79 2,172 2,098 136
80–84 2,455 2,173 274
85–89 2,856 2,220 500
90+ 2,755 1,553 958
Men
50–54 1,225 1,469 19
55–59 1,614 1,835 33
60–64 1,968 2,116 53
65–69 2,532 2,569 91
70–74 3,236 3,081 146
75–79 4,469 3,963 265
80–84 5,520 4,483 464
85–89 7,038 5,144 760
90+ 9,705 6,315 1,214
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and pharmacological fracture prevention costs amounted to
€ 360 million, € 434 million and € 29 million respectively. It
is notable that pharmacological fracture prevention costs
amounted to only 3.5 % of the total cost.
When stratifying costs of osteoporosis by fracture
type, hip fractures were most costly (€ 559 million)
followed by “other” (€ 203 million), spine (€ 25 mil-
lion) and forearm fractures (€ 8 million) (Table 11 and
Fig. 1). Please note that costs for pharmacological frac-
ture prevention were not included given that they cannot
be allocated to specific fracture sites.
The number of quality adjusted life years (QALYs)
lost due to osteoporosis in 2010 was estimated at
26,300 (Table 12). 66 % of the total QALY loss was
incurred in women. Prior fractures accounted for 57 %
of the total QALY loss. The monetary value of a QALY
Table 11 Total cost (€) in 2010 by fracture site in men and women in the Netherlands. Note that costs for fracture prevention therapy and
monitoring are not included
Table 12 Number of QALYs lost due to fractures during 2010 in men
and women in the Netherlands according to age
Age (years)
50–74 75+ 50+
Women
Incident hip fractures 506 1,519 2,025
Incident vertebral fractures 1,105 1,103 2,207
Incident forearm fractures 228 118 346
Incident other fractures 1,004 1,410 2,414
Prior hip fractures 1,771 5,770 7,540
Prior vertebral fractures 1,153 1,797 2,949
284,71517,11767,5latoT
Men
Incident hip fractures 341 629 970
Incident vertebral fractures 817 634 1,451
Incident forearm fractures 56 18 73
Incident other fractures 1,091 830 1,920
Prior hip fractures 1,230 1,854 3,084
Prior vertebral fractures 729 603 1,332
038,8765,4362,4latoT
Men and Women
Incident hip fractures 848 2,147 2,995
Incident vertebral fractures 1,921 1,736 3,658
Incident forearm fractures 284 136 419
Incident other fractures 2,095 2,240 4,334
Prior hip fractures 3,001 7,623 10,624
Prior vertebral fractures 1,881 2,400 4,281
213,62282,61030,01latoT
Hip
70%
Spine
3%
Forearm
1%
Other
26%
Fig. 1 Share (%) of fracture cost by fracture site in the Netherlands.
Note that costs for fracture prevention therapy and monitoring are not
included
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was varied between 1 to 3 times the gross domestic
product (GDP) per capita (Table 13). Assuming a
QALY is valued at 2 times GDP/capita, the total cost
of the QALYs lost was estimated at € 1.86 billion.
When the cost of osteoporosis was combined with the
value for QALYs lost (valued at 2 × GDP), the cost of
osteoporosis amounted to € 2.69 billion in Netherlands in
2010. Incident fracture, prior fracture, pharmacological
fracture prevention, and value of QALYs lost accounted
for 13 %, 16 %, 1 % and 69 %, respectively.
Burden of osteoporosis up to 2025
The population above 50 years of age is expected to increase
from 5.9 million in 2010 to 7.4 million in 2025, correspond-
ing to an increase of 26 % (Table 14).
The total number of fractures was estimated to rise from
76,000 in 2010 to 107,000 in 2025 (Table 15), correspond-
ing to an increase of 41 %. Hip, clinical spine, forearm and
other fractures increased by 6,100, 4,800, 3,900 and 15,900
respectively. The increase in the number of fractures ranged
from 31 % to 45 %, depending on fracture site. The increase
was estimated to be particularly marked in men (51 %)
compared to women (35 %).
The cost of osteoporosis (excluding values of QALYs
lost) was estimated to rise from € 824 million in 2010 to €
1069 million in 2025, corresponding to an increase of 30 %
(Table 16). Costs incurred in women and men increased by
23 % and 44 % respectively.
The total number of QALYs lost due to fracture was
estimated to rise from 26,300 in 2010 to 33,800 in 2025,
corresponding to an increase of 28 % (Table 17). The
increase was estimated to be particularly marked in men
(41 %) compared to women (22 %). Incident and prior
fractures accounted for 63 % and 37 % of the increase
respectively.
The cost of osteoporosis including value of QALYs lost
was estimated to increase from approximately € 2.7 billion
in 2010 to € 3.5 billion in 2025. The increase was estimated
to be particularly marked in men (+42 %) compared to
women (+22 %) (Table 18).
Treatment uptake
To estimate uptake of individual osteoporosis treatments,
sales data from IMS Health (2001–2011) were used to
derive the number of defined daily doses (DDDs) sold per
100,000 persons aged 50 years or above (Fig. 2).
Adjusting the sales data for compliance allowed for
an estimation of the proportion of population aged
50 years or above who received any osteoporosis treat-
ment (see Chapter 5 of the report on Osteoporosis in
the European Union: Medical Management, Epidemiol-
ogy and Economic Burden for further details). The
proportion of persons over the age of 50 years who
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Table 13 Value of lost QALYs (€) in men and women in the Nether-
lands in 2010
1 × GDP/
capita
2 × GDP/
capita
3 × GDP/
capita
Incident hip
fractures
106,032,591 212,065,182 318,097,773
Incident vertebral
fractures
129,487,389 258,974,778 388,462,167
Incident forearm
fractures
14,843,773 29,687,545 44,531,318
Incident other
fractures
153,439,417 306,878,834 460,318,251
Prior hip
fractures
376,090,222 752,180,445 1,128,270,667
Prior vertebral
fractures
151,554,259 303,108,518 454,662,777
Total 931,447,651 1,862,895,302 2,794,342,954
Table 14 Population projections in the Netherlands by age and sex [10]
Population
2010 2015 2020 2025
Women
50–59 1,130,000 1,214,000 1,258,000 1,208,000
60–69 931,000 1,045,000 1,078,000 1,160,000
70–79 607,000 665,000 824,000 927,000
80–89 360,000 375,000 399,000 448,000
90+ 67,000 85,000 99,000 109,000
Men
50–59 1,145,000 1,230,333 1,283,000 1,217,000
60–69 927,000 1,037,000 1,062,000 1,147,000
70–79 508,000 590,000 751,000 843,000
80–89 198,000 230,000 267,000 322,000
90+ 20,000 29,000 37,000 46,000
All
50–59 2,275,000 2,444,333 2,541,000 2,425,000
60–69 1,858,000 2,082,000 2,140,000 2,307,000
70–79 1,115,000 1,255,000 1,575,000 1,770,000
80–89 558,000 605,000 666,000 770,000
90+ 87,000 114,000 136,000 155,000
000,724,7000,398,5
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were treated increased from 2.2 % in 2001 to 4.69 %
in 2011.
Treatment gap
In order to assess the potential treatment gap, the num-
bers of men and women eligible for treatment in the
Netherlands were defined as individuals with a 10-year
fracture probability exceeding that of a woman with a
prior fragility fracture derived from FRAX®, equivalent
to a ‘fracture threshold’ (See Chapter 5 of the main
report for further details). Subsequently, these estimates
were compared to the number of individuals who re-
ceived osteoporosis treatment obtained from the analysis
of IMS Health data. The treatment gaps in men and
women were estimated at 52 % and 60 % respectively
(Table 19). Note that the estimate of the treatment gap
is conservative given that it assumes that current use of
osteoporosis treatments are only directed to men and
women at high risk.
Table 15 Projected annual number of incident fractures in 2010 and 2025 by fracture site and age in men and women in the Netherlands
Table 16 Current and future cost (€ 000,000) of osteoporosis (exclud-
ing value of QALYs lost) by age and calendar year in men and women
in the Netherlands
2010 2015 2020 2025
Women
50–74 138 152 167 172
75+ 420 437 466 517
All 558 589 633 689
Men
50–74 108 120 132 137
75+ 157 174 201 243
All 265 294 333 381
Women and Men
50–74 246 272 299 309
75+ 577 611 667 760
All 824 882 966 1,069
Table 17 Projected QALYs lost due to incident and prior fractures for
the years 2010 and 2025 by age in men and women in the Netherlands
Incident fractures Prior fractures All fractures
2010 2025 2010 2025 2010 2025
Women
50–74 2,843 3,624 2,924 3,258 5,767 6,882
75+ 4,149 5,816 7,566 8,624 11,715 14,440
All 6,992 9,441 10,490 11,881 17,482 21,322
Men
50–74 2,305 2,945 1,959 2,298 4,263 5,244
75+ 2,110 3,771 2,457 3,473 4,567 7,244
All 4,414 6,716 4,416 5,771 8,830 12,487
Women and Men
50–74 5,148 6,570 4,882 5,556 10,030 12,126
75+ 6,259 9,587 10,023 12,097 16,282 21,684
All 11,407 16,157 14,905 17,652 26,312 33,809
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Table 18 Present and future cost (€ 000,000) of fracture (direct cost
and cost of QALYs) by age and calendar year in men and women in the
Netherlands assuming the uptake of treatment remains unchanged
2010 2015 2020 2025
Women
50–74 547 590 637 659
75+ 1,250 1,315 1,400 1,539
All 1,796 1,905 2,036 2,198
Men
50–74 410 444 483 509
75+ 480 529 614 756
All 890 973 1,097 1,265
Women and Men
50–74 957 1,033 1,119 1,168
75+ 1,730 1,844 2,014 2,296
All 2,686 2,877 3,133 3,463
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Fig. 2 Treatment uptake in the Netherlands (Defined daily doses
[DDDs] per 100,000 persons aged 50 years or above)
Table 19 Number of men and women eligible for treatment, treated
and treatment gap in 2010
Number
potentially
treated
(1000 s)
Number eligible
for treatment
(1000 s)
Difference
(1000 s)
Treatment
gap (%)
Men 36 76 40 52
Women 242 605 363 60
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Epidemiology and Economic Burden of Osteoporosis in
Poland
A report prepared in collaboration with the Internation-
al Osteoporosis Foundation (IOF) and the European
Federation of Pharmaceutical Industry Associations
(EFPIA).
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Abstract
Summary This report describes epidemiology, burden, and
treatment of osteoporosis in Poland.
Introduction Osteoporosis is characterized by reduced bone
mass and disruption of bone architecture, resulting in in-
creased risks of fragility fractures which represent the main
clinical consequence of the disease. Fragility fractures are
associated with substantial pain and suffering, disability and
even death for the affected patients and substantial costs to
society. The aim of this study is to describe the epidemiol-
ogy and economic burden of fragility fractures as a conse-
quence of osteoporosis in Poland, as a further detailed
addition to the report for the entire European Union
(EU27): Osteoporosis in the European Union: Medical
Management, Epidemiology and Economic Burden.
Methods The literature on fracture incidence and costs of
fractures in the EU27 was reviewed and incorporated into a
model estimating the clinical and economic burden of oste-
oporotic fractures in 2010. Furthermore, data on sales of
osteoporosis treatments and the population at high risk were
used to estimate treatment uptake and treatment gap.
Results It was estimated that approximately 168,000 new
fragility fractures were sustained in Poland, comprising
28,000 hip fractures, 26,000 vertebral fractures, 28,000
forearm fractures and 85,000 other fractures (i.e. fractures
of the pelvis, rib, humerus, tibia, fibula, clavicle, scapula,
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sternum and other femoral fractures) in 2010. The economic
burden of incident and previous fragility fractures was esti-
mated at € 593 million for the same year. Incident fractures
represented 60 % of this cost, long-term fracture care 27 %
and pharmacological prevention 13 %. Previous and inci-
dent fractures also accounted for 53,300 quality-adjusted
life years (QALYs) lost during 2010. When accounting for
the demographic projections for 2025, the number of inci-
dent fractures was estimated at 209,000 in 2025,
representing an increase of 42,000 fractures. Hip, clinical
vertebral (spine), forearm and other fractures were estimated
to increase by 9,200, 6,800, 4,600 and 21,100, respectively.
The burden of fractures in Poland in 2025 was estimated to
increase by 27 % to € 753 million. Though the uptake of
osteoporosis treatments increased from 2001, the proportion
of patients aged 50 or above who received treatment de-
clined in the past few years. The majority of women at high
fracture risk did not receive active treatment.
Conclusions In spite of the high cost of osteoporosis, a
substantial treatment gap and projected increase of the eco-
nomic burden driven by an aging population, the use of
pharmacological prevention of osteoporosis is significantly
less than optimal, suggesting that a change in healthcare
policy concerning the disease is warranted.
Introduction
Osteoporosis is characterized by reduced bone mass and
disruption of bone architecture, resulting in increased risks
of fragility fractures which represent the main clinical con-
sequence of the disease. Fragility fractures are associated
with substantial pain and suffering, disability and even death
for the affected patients and substantial costs to society. The
aim of this report was to characterize the burden of osteo-
porosis in Poland in 2010 and beyond.
Methods
The literature on fracture incidence and costs of fractures in
Poland was reviewed and incorporated into a model estimat-
ing the clinical and economic burden of osteoporotic fractures
in 2010. Details of the methods used are found in Chapters 3
and 4 of the report on Osteoporosis in the European Union:
Medical Management, Epidemiology and Economic Burden,
published concurrently in Archives of Osteoporosis.
Epidemiology of osteoporosis in Poland
For the purpose of this report, the population at risk of
osteoporosis was considered to include men and women
≥50 years. The number of men and women ≥50 years of
age amounted to 5,822,000 and 7,528,000 respectively in
Poland in 2010 (Table 1).
In the population at risk, the number of individuals with
osteoporosis—as defined by the WHO diagnostic criteria by
DXA at the femoral neck [2]—was estimated at 1,850,000
(Table 2). There are 4.3 DXA scan machines per million
inhabitants [3], and guidelines for the assessment and treat-
ment of osteoporosis are available [4]. A country specific
FRAX model is also available for the assessment of fracture
risk (http://www.shef.ac.uk/FRAX/).
Data on hip fracture incidence are available for Poland
[6]. Given that country specific incidence of vertebral,
forearm and, “other” fractures were not found, these
were imputed using the methods described in Chapter
3 of the main report. Fracture incidence is presented in
Table 3. Standardized to the EU27 population, hip frac-
ture incidence (per 100,000 person years) in men and
women ≥50 years of age was estimated at 166.5 and
333.2 respectively.
The number of incident fractures in 2010 was estimated
at 168,000 (Table 4). Incident hip, clinical spine, forearm
and “other” fractures were estimated at 28,000, 26,000,
28,000 and 85,000 respectively. 61 % of fractures occurred
in women.
A prior fracture was defined as a fracture in an
individual who was alive during the index year (i.e.
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Table 1 Population at risk: men and women over the age of 50 in
Poland, 2010 [1]
Age (years) Women Men All
50–59 3,111,000 2,872,000 5,983,000
60–69 1,938,000 1,575,000 3,513,000
70–79 1,562,000 988,000 2,550,000
80–89 827,000 359,000 1,186,000
90+ 90,000 28,000 118,000
50+ 7,528,000 5,822,000 13,350,000
Table 2 Estimated number of women and men with osteoporosis
(defined as a T-score ≤−2.5 SD) in Poland by age using female-
derived reference ranges at the femoral neck, 2010 [5].
Age (years) Women Men
50–54 98,532 37,075
55–59 148,512 48,615
60–64 166,738 57,420
65–69 155,944 43,290
70–74 228,222 42,588
75–79 279,000 45,526
80+ 432,824 64,242
50+ 1,509,772 338,756
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2010) which had occurred after the age of 50 years and
before 2010. In the population ≥50 years of age, the
proportion of individuals who had suffered a fracture
prior to 2010 was estimated at 1.04 % for hip and
1.09 % for clinical vertebral fractures. The estimated
proportions of men and women with prior hip and
vertebral fractures by age are presented in Table 5.
In the population over 50 years of age, the number of
individuals with hip and vertebral fractures that occurred
before 2010 was estimated at 139,000 and 145,000 respec-
tively (Table 6). Note that fractures sustained in 2010 were
not included in the estimate.
The incidence of causally related deaths (per
100,000) in the first year after fracture by age is
presented in Table 7. The number of causally related
deaths in 2010 was estimated at 2,343 (Table 8). Hip,
Table 3 Incidence per 100,000 person years of hip, clinical vertebral,
forearm, and “other” fractures in Poland by age
Fracture at the
Age (years) hip vertebral forearm other
Women
50–54 19 49 121 124
55–59 34 93 258 296
60–64 57 101 217 221
65–69 95 139 232 326
70–74 176 248 316 499
75–79 377 366 368 793
80–84 794 499 497 1,351
85+ 1,356 638 579 2,278
Men
50–54 40 102 37 177
55–59 59 102 90 548
60–64 75 179 141 735
65–69 109 171 164 702
70–74 163 249 105 840
75–79 234 270 66 626
80–84 422 293 82 1,122
85+ 713 479 131 2,066
Table 4 Estimated number of incident fractures in Poland, 2010
Fracture at the All
Age (years) hip vertebra forearm other fractures
Women
50–74 4,519 7,390 14,078 17,989 43,976
75+ 15,145 8,445 8,133 27,134 58,857
Total 19,665 15,835 22,211 45,124 102,833
Men
50–74 4,181 7,678 5,215 29,884 46,958
75+ 3,799 2,931 803 10,337 17,871
Total 7,981 10,609 6,018 40,221 64,829
Men and Women
50–74 8,700 15,068 19,292 47,873 90,935
75+ 18,945 11,376 8,936 37,471 76,728
Total 27,645 26,444 28,229 85,345 167,663
Table 5 Proportion of men and women (in %) with a prior hip or
clinical vertebral fracture in Poland, 2010
Age (years) Hip fracture Vertebral fracture
Women
50– 1.00.045
55– 4.02.095
60– 7.04.046
65– 1.17.096
70– 7.13.147
75– 5.23.297
80– 7.33.448
9.53.9+58
Men
50– 2.01.045
55– 4.03.095
60– 7.05.046
65– 0.17.096
70– 3.11.147
75– 6.17.197
80– 9.14.248
9.34.5+58
Table 6 Number of men and women in Poland with a prior hip or
clinical vertebral fracture after the age of 50 years, 2010
Age (years) Hip fracture Vertebral fracture
Women
50– 849,83895,3247
908,06890,57+57
757,99696,89latoT
Men
50– 000,82439,9147
601,71285,02+57
601,54615,04latoT
Men and Women
50– 849,66235,3447
519,77086,59+57
368,441212,931latoT
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vertebral and “other” fractures accounted for 1,083, 941
and 319 deaths respectively. Overall, approximately
49 % of deaths occurred in women.
Cost of osteoporosis in Poland including and excluding
values of QALYs lost
For the purpose of this report, the cost of osteoporosis
in 2010 (excluding value of QALYs lost) was consid-
ered to consist of three components: (i) cost of fractures
that occurred in 2010 (“first year costs”); (ii) cost of
fractures sustained prior to year 2010 but which still
incurred costs in 2010 (“long-term disability cost”); and
(iii) cost of pharmacological fracture prevention includ-
ing administration and monitoring costs (“pharmacolog-
ical fracture prevention costs”). See Chapter 4 of the
main report for further details.
As the cost of a hip fracture was not available specifically
for Poland, hip fracture costs were estimated at € 4,881
based on data from the Czech Republic [7]. No other frac-
ture costs were available. Given that no cost data for the
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Table 7 Incidence (per 100,000) of causally related deaths in Poland
within the first year after fracture (adjusted for comorbidities), 2010
Age (years) Hip Clinical vertebral “Other” fracture
Women
50–54 833 1,083 22
55–59 1,113 1,369 33
60–64 1,634 1,897 52
65–69 2,006 2,199 75
70–74 2,406 2,482 110
75–79 3,061 2,957 192
80–84 3,224 2,852 359
85–89 3,833 2,979 671
90+ 3,074 1,733 1,069
Men
50–54 3,762 4,512 59
55–59 4,247 4,828 87
60–64 4,828 5,192 131
65–69 5,261 5,337 189
70–74 5,638 5,368 254
75–79 6,221 5,517 369
80–84 6,684 5,428 561
85–89 7,996 5,844 864
90+ 9,811 6,384 1,227
Table 8 The number of deaths in men and women in Poland in the
first year after fracture attributable to the fracture event (causally
related), 2010
Fracture at the
Age (years) hip vertebra “other”
Women
50–74 94 155 13
75+ 492 221 178
Total 586 377 191
Men
50–74 212 399 46
75+ 285 166 82
Total 497 564 128
Men and Women
50–74 305 554 59
75+ 777 387 260
Total 1,083 941 319
Table 9 One year costs for relevant pharmaceuticals in Poland, 2010
[12].
Annual drug cost (€)
Alendronate 245
Risedronate 509
Etidronate 475
Ibandronate 576
Zoledronic acid 562
Raloxifene 611
Strontium ranelate 540
Parathyroid hormone 7,853
Teriparatide 7,700
Table 10 Cost of osteoporosis (€) in Poland by age in men and
women, 2010
Age
(years)
First year
fracture
cost
Long term
disability
costs
Fracture
prevention
cost
Total cost
Women
50–74 76,051,767 19,459,338 42,540,306 138,051,410
75+ 142,746,486 93,089,492 24,371,014 260,206,993
All 218,798,253 112,548,830 66,911,320 398,258,404
Men
50–74 93,235,897 18,920,290 6,818,347 118,974,533
75+ 43,307,481 30,231,492 2,607,353 76,146,326
All 136,543,378 49,151,782 9,425,700 195,120,860
Women and Men
50–74 169,287,663 38,379,628 49,358,652 257,025,944
75+ 186,053,968 123,320,985 26,978,367 336,353,320
All 355,341,631 161,700,613 76,337,020 593,379,263
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other fracture sites were found, these were imputed as de-
scribed in Chapter 4 of the main report.
Long-term disability costs were estimated by multiplying
the yearly cost of residing in nursing home (€ 13,242 [8, 9],
an average of 4 long term care facilities in Germany, PPP
adjusted) with the simulated number of individuals with
prior fractures that had been transferred to nursing homes
due to the fracture.
Annual drug costs (€) for individual treatments are shown
in Table 9. In addition, it was assumed that patients on
treatment made an annual physician visit costing € 17 [10]
and a DXA scan costing € 10 [11] every second year to
monitor treatment.
Table 11 Total cost (€) in 2010 by fracture site in men and women in Poland. Note that costs for fracture prevention therapy and monitoring are not
included.
–
–
–
Hip
54%
Spine
5%
Forearm
2%
Other
39%
Fig. 1 Share (%) of fracture cost by fracture site in Poland. Note that
costs for fracture prevention therapy and monitoring are not included
Table 12 Number of QALYs lost due to fractures during 2010 in men
and women in Poland according to age
Age (years)
50–74 75+ 50+
Women
Incident hip fractures 1,098 3,228 4,326
Incident vertebral fractures 2,471 2,465 4,937
Incident forearm fractures 500 249 749
Incident other fractures 2,170 2,848 5,018
Prior hip fractures 3,707 10,221 13,928
Prior vertebral fractures 2,186 2,978 5,164
121,43989,12231,21latoT
Men
Incident hip fractures 1,052 923 1,975
Incident vertebral fractures 2,629 947 3,576
Incident forearm fractures 182 26 208
Incident other fractures 3,567 1,181 4,748
Prior hip fractures 3,123 3,055 6,179
Prior vertebral fractures 1,562 904 2,465
051,91630,7411,21latoT
Men and Women
Incident hip fractures 2,150 4,151 6,301
Incident vertebral fractures 5,100 3,412 8,512
Incident forearm fractures 681 275 957
Incident other fractures 5,737 4,029 9,766
Prior hip fractures 6,830 13,276 20,106
Prior vertebral fractures 3,748 3,882 7,630
272,35520,92642,42latoT
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The cost of osteoporosis in 2010 was estimated at €
593 million (Table 10). First year costs, subsequent year
costs and pharmacological fracture prevention costs
amounted to € 355 million, € 162 million and € 76
million, respectively. It is notable that pharmacological
fracture prevention costs amounted to only 12.8 % of
the total cost.
When stratifying costs of osteoporosis by fracture
type, hip fractures were most costly (€ 279 million)
followed by “other” (€ 204 million), spine (€ 26 million)
and forearm fractures (€ 8 million) (Table 11 and Fig.
1). Please note that costs for pharmacological fracture
prevention were not included given that they cannot be
allocated to specific fracture sites.
The number of quality adjusted life years (QALYs)
lost due to osteoporosis in 2010 was estimated at
53,300 (Table 12). Prior fractures accounted for 52 %
of the total loss and 64 % of the loss occurred in
women. The monetary value of a QALY was varied
between 1 to 3 times the gross domestic product
(GDP) per capita (Table 13). Assuming a QALY is
valued at 2 times GDP/capita, the total cost of the
QALYs lost was estimated at € 990 million.
When the cost of osteoporosis was combined with the
value for QALYs lost (valued at 2 × GDP), the cost of
osteoporosis amounted to € 1,580 million in Poland in
2010. Incident fracture, prior fracture, pharmacological
fracture prevention, and value of QALYs lost accounted
for 22 %, 10 %, 5 %, 63 % respectively.
Burden of osteoporosis up to 2025
The population above 50 years of age is expected to increase
from 13.4 million in 2010 to 14.7 million in 2025, corre-
sponding to an increase of 10 % (Table 14).
The total number of fractures was estimated to rise
from 168,000 in 2010 to 209,000 in 2025 (Table 15),
corresponding to an increase of 25 %. Hip, clinical
spine, forearm and other fractures increased by 9,200,
6,800, 4,600 and 21,100 respectively. The increase in
the number of fractures ranged from 16 % to 33 %,
depending on fracture site. The increase was estimated
to be particularly marked in women (27 %) compared to
men (22 %).
The cost of osteoporosis (excluding value of QALYs lost)
was estimated to rise from € 593 million in 2010 to € 753
million in 2025, corresponding to an increase of 27 % (Table
16). Costs incurred in women and men both increased by 27 %.
The total number of QALYs lost due to fracture was
estimated to rise from 53,300 in 2010 to 64,800 in 2025,
corresponding to an increase of 22 % (Table 17). The
increase was estimated to be 21 % in men and 22 % in
women. Incident and prior fractures accounted for 57 % and
43 % of the increase respectively.
The cost of osteoporosis including value of QALYs lost
was estimated to increase from approximately € 1.6 billion
in 2010 to € 2.0 billion in 2025. The increase was estimated
to be 23 % in men and 24 % in women (Table 18).
Treatment uptake
To estimate uptake of individual osteoporosis treatments,
sales data from IMS Health (2001–2011) were used to
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Table 13 Value of lost QALYs (€) in men and women in Poland in
2010
1 × GDP/
capita
2 × GDP/
capita
3 × GDP/
capita
Incident hip fractures 58,595,246 117,190,492 175,785,738
Incident vertebral
fractures
79,163,832 158,327,665 237,491,497
Incident forearm fractures 8,898,714 17,797,428 26,696,142
Incident other fractures 90,823,231 181,646,461 272,469,692
Prior hip fractures 186,989,696 373,979,391 560,969,087
Prior vertebral fractures 70,955,830 141,911,661 212,867,491
Total 495,426,549 990,853,098 1,486,279,647
Table 14 Population projections in Poland by age and sex [13].
Population
2010 2015 2020 2025
Women
50–59 3,111,000 2,762,000 2,311,000 2,352,000
60–69 1,938,000 2,610,000 2,917,000 2,598,000
70–79 1,562,000 1,426,000 1,660,000 2,252,000
80–89 827,000 918,000 925,000 862,000
90+ 90,000 143,000 199,000 232,000
Men
50–59 2,872,000 2,575,097 2,198,000 2,266,000
60–69 1,575,000 2,142,000 2,414,000 2,188,000
70–79 988,000 898,000 1,101,000 1,518,000
80–89 359,000 420,000 423,000 395,000
90+ 28,000 42,000 57,000 68,000
All
50–59 5,983,000 5,337,097 4,509,000 4,618,000
60–69 3,513,000 4,752,000 5,331,000 4,786,000
70–79 2,550,000 2,324,000 2,761,000 3,770,000
80–89 1,186,000 1,338,000 1,348,000 1,257,000
90+ 118,000 185,000 256,000 300,000
000,137,41000,053,31
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derive the number of defined daily doses (DDDs) sold per
100,000 persons aged 50 years or above (Fig. 2).
Adjusting the sales data for compliance allowed for an
estimation of the proportion of population aged 50 years or
above who received any osteoporosis treatment (see Chapter
5 of the report on Osteoporosis in the European Union:
Medical Management, Epidemiology and Economic Burden
for further details). The proportion of persons over the age
of 50 years who were treated increased from 0.59 % in 2001
to 2.46 % in 2007 but subsequently decreased to 2.10 % in
2011.
Treatment gap
In order to assess the potential treatment gap, the numbers of
men and women eligible for treatment in Poland were defined
as individuals with a 10-year fracture probability exceeding
that of a woman with a prior fragility fracture derived from
FRAX®, equivalent to a ‘fracture threshold’ (See Chapter 5 of
the main report for further details). Subsequently, these esti-
mates were compared to the number of individuals who
received osteoporosis treatment obtained from the analysis
Table 15 Projected annual number of incident fractures in 2010 and 2025 by fracture site and age in men and women in Poland
–
–
–
Table 16 Current and future cost (€ 000,000 of osteoporosis (exclud-
ing value of QALYs lost) by age and calendar year in men and women
in Poland
2010 2015 2020 2025
Women
50–74 138 146 167 179
75+ 260 283 296 327
All 398 429 463 505
Men
50–74 119 130 145 152
75+ 76 83 86 96
All 195 213 231 247
Women and Men
50–74 257 276 312 330
75+ 336 365 381 422
All 593 641 694 753
Table 17 Projected QALYs lost due to incident and prior fractures for
the years 2010 and 2025 by age in men and women in Poland
Incident fractures Prior fractures All fractures
2010 2025 2010 2025 2010 2025
Women
50–74 6,239 7,692 5,893 7,087 12,132 14,778
75+ 8,790 11,454 13,199 15,330 21,989 26,784
All 15,029 19,145 19,092 22,417 34,121 41,562
Men
50–74 7,429 8,803 4,685 5,608 12,114 14,412
75+ 3,077 4,100 3,959 4,707 7,036 8,807
All 10,507 12,903 8,644 10,316 19,150 23,219
Women and Men
50–74 13,668 16,495 10,578 12,695 24,246 29,190
75+ 11,867 15,553 17,158 20,037 29,025 35,591
All 25,536 32,048 27,736 32,732 53,272 64,781
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of IMS Health data. The treatment gaps in men and women
were estimated at 91 % and 78 % respectively (Table 19).
Note that the estimate of the treatment gap is conservative
given that it assumes that current use of osteoporosis treat-
ments are only directed to men and women at high risk.
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Table 18 Present and future cost (€ 000,000) of fracture (direct cost
and cost of QALYs) by age and calendar year in men and women in
Poland assuming the uptake of treatment remains unchanged
2010 2015 2020 2025
Women
50–74 364 380 422 453
75+ 669 722 756 825
All 1,033 1,102 1,178 1,278
Men
50–74 344 366 397 420
75+ 207 221 230 259
All 551 586 627 679
Women and Men
50–74 708 746 819 873
75+ 876 943 986 1,084
All 1,584 1,689 1,805 1,957
0
100'000
200'000
300'000
400'000
500'000
600'000
700'000
2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011
alendronate
denosumab
etidronate
ibandronate
PTH
raloxifene
risedronate
strontium ranelate
teriparatide
zoledronic acidD
D
D
s/
10
0,
00
0 
pe
rs
on
-y
e
a
rs
Fig. 2 Treatment uptake in Poland (Defined daily doses [DDDs] per
100,000 persons aged 50 years or above)
Table 19 Number of men and women eligible for treatment, treated
and treatment gap in 2010
Number
potentially
treated
(1000 s)
Number
eligible for
treatment
(1000 s)
Difference
(1000 s)
Treatment
gap (%)
Men 37 414 377 91
Women 245 1,127 882 78
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Epidemiology and Economic Burden of Osteoporosis in
Portugal
A report prepared in collaboration with the Internation-
al Osteoporosis Foundation (IOF) and the European
Federation of Pharmaceutical Industry Associations
(EFPIA).
M Ivergård, A Svedbom, E Hernlund, J Compston, C
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Monteiro and JA Kanis
Moa Ivergård, OptumInsight, Stockholm, Sweden
Abstract
Summary This report describes epidemiology, burden, and
treatment of osteoporosis in Portugal.
Introduction Osteoporosis is characterized by reduced bone
mass and disruption of bone architecture, resulting in in-
creased risks of fragility fractures which represent the main
clinical consequence of the disease. Fragility fractures are
associated with substantial pain and suffering, disability and
even death for the affected patients and substantial costs to
society. The aim of this study is to describe the epidemiol-
ogy and economic burden of fragility fractures as a conse-
quence of osteoporosis in Portugal, as a further detailed
addition to the report for the entire European Union
(EU27): Osteoporosis in the European Union: Medical
Management, Epidemiology and Economic Burden.
Methods The literature on fracture incidence and costs of
fractures in the EU27 was reviewed and incorporated
into a model estimating the clinical and economic bur-
den of osteoporotic fractures in 2010. Furthermore, data
on sales of osteoporosis treatments and the population at
high risk were used to estimate treatment uptake and
treatment gap.
Results It was estimated that approximately 52,000 new fra-
gility fractures were sustained in Portugal, comprising 10,000
hip fractures, 8,000 vertebral fractures, 8,000 forearm fractures
and 26,000 other fractures (i.e. fractures of the pelvis, rib,
humerus, tibia, fibula, clavicle, scapula, sternum and other
femoral fractures) in 2010. The economic burden of incident
and previous fragility fractures was estimated at € 577 million
for the same year. Incident fractures represented 51 % of this
cost, long-term fracture care 46 % and pharmacological pre-
vention 3 %. Previous and incident fractures also accounted
for 17,900 quality-adjusted life years (QALYs) lost during
2010. When accounting for the demographic projections for
2025, the number of incident fractures was estimated at 69,000
in 2025, representing an increase of 17,000 fractures. Hip,
clinical spine (vertebral), forearm and other fractures were
estimated to increase by 3,700, 2,400, 2,000 and 9,100, re-
spectively. The burden of fractures in Portugal in 2025 was
estimated to increase by 24 % to € 717 million. Though the
uptake of osteoporosis treatments increased from 2001, the
proportion of patients aged 50 or above who received
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treatment declined in the past few years. A substantial minority
of women at high fracture risk did not receive active treatment.
Conclusions In spite of the high cost of osteoporosis, a
substantial treatment gap and projected increase of the eco-
nomic burden driven by an aging population, the use of
pharmacological prevention of osteoporosis is significantly
less than optimal, suggesting that a change in healthcare
policy concerning the disease is warranted.
Introduction
Osteoporosis is characterized by reduced bone mass and
disruption of bone architecture, resulting in increased risks
of fragility fractures which represent the main clinical con-
sequence of the disease. Fragility fractures are associated
with substantial pain and suffering, disability and even death
for the affected patients and substantial costs to society. The
aim of this report was to characterize the burden of osteo-
porosis in Portugal in 2010 and beyond.
Methods
The literature on fracture incidence and costs of fractures in
Portugal was reviewed and incorporated into a model estimat-
ing the clinical and economic burden of osteoporotic fractures
in 2010. Details of the methods used are found in Chapters 3
and 4 of the report Osteoporosis in the European Union:
Medical Management, Epidemiology and Economic Burden,
published concurrently in Archives of Osteoporosis.
Epidemiology of osteoporosis in Portugal
For the purpose of this report, the population at risk of
osteoporosis was considered to include men and women
≥50 years. The number of men and women ≥50 years of
age amounted to 1,762,000 and 2,160,000 respectively in
Portugal in 2010 (Table 1).
In the population at risk, the number of individuals with
osteoporosis—as defined by the WHO diagnostic criteria—was
estimated at 590,000 (Table 2). There are 26.9 DXA scan
machines per million inhabitants [2], and guidelines for the
assessment and treatment of osteoporosis are available [3]. A
country specific FRAX model is also available for the assess-
ment of fracture risk (http://www.shef.ac.uk/FRAX/).
Data on hip fracture incidence are available for Portugal
[5]. Given that country specific incidence of vertebral, fore-
arm and, “other” fractures were not found, these were im-
puted using the methods described in Chapter 3 of the main
Page 163 of 218, 137
Table 1 Population at risk: men and women over the age of 50 in
Portugal, 2010 [1]
Age (years) Women Men All
50–59 720,000 674,000 1,394,000
60–69 612,000 528,000 1,140,000
70–79 516,000 387,000 903,000
80–89 271,000 158,000 429,000
90+ 41,000 15,000 56,000
50+ 2,160,000 1,762,000 3,922,000
Table 2 Estimated number of women and men with osteoporosis
(defined as a T-score ≤−2.5 SD) in Portugal by age using female-
derived reference ranges at the femoral neck, 2010 [4]
Age (years) Women Men
50–54 23,373 8,800
55–59 33,504 11,270
60–64 46,475 16,704
65–69 57,974 17,760
70–74 76,167 16,770
75–79 91,125 17,716
80+ 147,264 28,718
50+ 475,882 117,738
Table 3 Incidence per 100,000 person years of hip, clinical vertebral,
forearm, and “other” fractures in Portugal by age
Fracture at the
Age (years) hip vertebra forearm other
Women
50–54 9 24 60 61
55–59 24 68 187 214
60–64 47 83 178 182
65–69 98 143 239 336
70–74 239 338 430 679
75–79 516 501 503 1,085
80–84 983 618 615 1,671
85+ 1,700 800 726 2,856
Men
50–54 7 18 6 31
55–59 19 32 28 173
60–64 32 77 60 315
65–69 61 96 92 394
70–74 128 195 82 658
75–79 226 261 64 604
80–84 424 294 82 1,127
85+ 789 530 145 2,284
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report. Fracture incidence is presented in Table 3. Standard-
ized to the EU27 population, hip fracture incidence (per
100,000 person years) in men and women ≥50 years of
age was estimated at 139.0 and 408.2 respectively.
The number of incident fractures in 2010 was esti-
mated at 52,000 (Table 4). Incident hip, clinical spine,
forearm and “other” fractures were estimated at 10,000,
8,000, 8,000 and 26,000 respectively. 70 % of fractures
occurred in women.
In the population ≥50 years of age, the proportion of in-
dividuals who had suffered a fracture prior to 2010 was esti-
mated at 1.33 % for hip and 1.37 % for clinical vertebral
fractures. The estimated proportions of men and women with
prior hip and vertebral fractures by age are presented in Table 5.
In the population over 50 years of age, the number of
individuals with hip and vertebral fractures that occurred
before 2010 was estimated at 52,000 and 54,000 respective-
ly (Table 6). Note that fractures sustained in 2010 were not
included in the estimate.
The incidence of causally related deaths (per 100,000) in
the first year after fracture by age is presented in Table 7.
The number of causally related deaths in 2010 was estimat-
ed at 665 (Table 8). Hip, vertebral and “other” fractures
accounted for 336, 204 and 124 deaths respectively. Overall,
approximately 55 % of deaths occurred in women.
Cost of osteoporosis in Portugal including and excluding
values of QALYs lost
For the purpose of this report, the cost of osteoporosis in
2010 (excluding value of QALYs lost) was considered to
consist of three components: (i) cost of fractures that oc-
curred in 2010 (“first year costs”); (ii) cost of fractures
sustained prior to year 2010 but which still incurred costs
in 2010 (“long-term disability cost”) and; (iii) cost
of pharmacological fracture prevention including adminis-
tration and monitoring costs (“pharmacological fracture pre-
vention costs”). See Chapter 4 of the main report for further
details.
Table 4 Estimated number of incident fractures in Portugal, 2010
llAehttaerutcarF
Age (years) hip vertebra forearm other fractures
Women
50–74 1,427 2,072 3,730 5,151 12,380
75+ 5,931 3,160 3,323 11,350 23,764
Total 7,358 5,232 7,053 16,501 36,144
Men
50–74 756 1,247 751 4,608 7,363
75+ 1,746 1,326 369 4,874 8,315
Total 2,502 2,573 1,120 9,482 15,677
Men and Women
50–74 2,183 3,319 4,481 9,759 19,742
75+ 7,677 4,486 3,692 16,224 32,079
Total 9,860 7,805 8,173 25,983 51,821
Table 5 Proportion of men and women (in %) with a prior hip or
clinical vertebral fracture in Portugal, 2010
Age (years) Hip fracture Vertebral fracture
Women
50– 1.00.045
55– 3.01.095
60– 6.03.046
65– 1.16.096
70– 1.24.147
75– 5.39.297
80– 1.56.548
2.80.21+58
Men
50– 0.00.045
55– 1.01.095
60– 3.02.046
65– 6.04.096
70– 0.18.047
75– 6.14.197
80– 1.26.248
2.45.5+58
Table 6 Number of men and women in Portugal with a prior hip or
clinical vertebral fracture after the age of 50 years, 2010
Age (years) Hip fracture Vertebral fracture
Women
50– 910,21566,647
077,82641,33+57
987,04118,93latoT
Men
50– 161,5374,347
307,7228,8+57
468,21592,21latoT
Men and Women
50– 081,71831,0147
374,63869,14+57
356,35601,25latoT
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The cost of a hip fracture has been estimated at € 12,031 in
Portugal [6]. Given that no cost data for the other fracture
sites were found, these were imputed as described in Chap-
ter 4 of the main report.
Long-term disability costs were estimated by multi-
plying the yearly cost of residing in nursing home (€
54,140 [7], based on nursing home costs in Spain) with
the simulated number of individuals with prior fractures
that had been transferred to nursing home due to the
fracture.
Annual drug cost for individual treatments is shown in
Table 9. In addition, it was assumed that patients on treat-
ment made an annual physician visit costing € 3 [8] and a
DXA scan costing € 5 [9] every second year to monitor
treatment.
The cost of osteoporosis in 2010 was estimated at € 577
million (Table 10). First year costs, subsequent year costs
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Table 7 Incidence (per 100,000) of causally related deaths in Portugal
within the first year after fracture (adjusted for comorbidities), 2010
Age (years) Hip Clinical vertebral “Other” fracture
Women
50–54 598 777 15
55–59 674 829 20
60–64 961 1,116 31
65–69 1,281 1,404 48
70–74 1,610 1,661 73
75–79 2,311 2,233 145
80–84 2,804 2,481 312
85–89 3,709 2,883 650
90+ 3,025 1,705 1,052
Men
50–54 2,268 2,721 36
55–59 2,263 2,573 46
60–64 2,521 2,712 68
65–69 3,055 3,099 110
70–74 3,488 3,321 157
75–79 4,380 3,884 260
80–84 5,660 4,596 475
85–89 7,681 5,614 830
90+ 9,541 6,209 1,194
Table 8 The number of deaths in men and women in Portugal in the
first year after fracture attributable to the fracture event (causally
related), 2010
Fracture at the
Age (years) hip vertebra “other”
Women
50–74 21 31 3
75+ 169 68 76
Total 190 99 79
Men
50–74 25 39 5
75+ 121 66 40
Total 146 105 45
Men and Women
50–74 46 70 9
75+ 290 134 116
Total 336 204 124
Table 9 One year costs
for relevant pharmaceu-
ticals in Portugal, 2010
[10]
Annual drug
cost (€)
Alendronate 16
Risedronate 139
Etidronate -
Ibandronate 270
Zoledronic acid 443
Raloxifene 401
Strontium ranelate 552
Parathyroid hormone 6,106
Teriparatide 6,192
Table 10 Cost of osteoporosis (€) in Portugal by age in men and
women, 2010
Age
(years)
First year
fracture
cost
Long term
disability
costs
Fracture
prevention
cost
Total cost
Women
50–74 59,496,589 22,916,814 10,593,500 93,006,903
75+ 141,746,733 171,432,956 6,703,164 319,882,854
All 201,243,322 194,349,771 17,296,664 412,889,757
Men
50–74 42,242,758 14,723,914 1,613,631 58,580,304
75+ 49,414,534 55,086,411 817,057 105,318,002
All 91,657,293 69,810,325 2,430,688 163,898,306
Women and Men
50–74 101,739,347 37,640,729 12,207,131 151,587,207
75+ 191,161,268 226,519,367 7,520,221 425,200,856
All 292,900,615 264,160,096 19,727,352 576,788,063
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and pharmacological fracture prevention costs amounted to
€ 293 million, € 264 million and € 20 million respectively. It
is notable that pharmacological fracture prevention costs
amounted to only 3.5 % of the total cost.
When stratifying costs of osteoporosis by fracture
type, hip fractures were most costly (€ 368 million)
followed by “other” (€ 164 million), spine (€ 19 million)
and forearm fractures (€ 6 million) (Table 11 and Fig.
1). Please note that costs for pharmacological fracture
prevention were not included given that they cannot be
allocated to specific fracture sites.
The number of quality adjusted life years (QALYs)
lost due to osteoporosis in 2010 was estimated at
17,900 (Table 12). Prior fractures accounted for 57 %
of the total loss and 71 % of the loss occurred in
women. The monetary value of a QALY was varied
Table 11 Total cost (€) in 2010 by fracture site inmen andwomen in Portugal. Note that costs for fracture prevention therapy andmonitoring are not included.
–
–
–
Hip
66%
Spine
3%
Forearm
1%
Other
30%
Fig. 1 Share (%) of fracture cost by fracture site in Portugal. Note that
costs for fracture prevention therapy and monitoring are not included
Table 12 Number of QALYs lost due to fractures during 2010 in men
and women in Portugal according to age
Age (years)
50–74 75+ 50+
Women
Incident hip fractures 341 1,248 1,588
Incident vertebral fractures 680 912 1,592
Incident forearm fractures 131 101 232
Incident other fractures 612 1,184 1,796
Prior hip fractures 1,038 4,486 5,524
Prior vertebral fractures 668 1,402 2,070
208,21233,9074,3latoT
Men
Incident hip fractures 184 420 604
Incident vertebral fractures 413 424 837
Incident forearm fractures 26 12 38
Incident other fractures 544 555 1,098
Prior hip fractures 541 1,305 1,845
Prior vertebral fractures 286 406 691
411,5021,3399,1latoT
Men and Women
Incident hip fractures 525 1,667 2,192
Incident vertebral fractures 1,093 1,335 2,428
Incident forearm fractures 156 113 270
Incident other fractures 1,156 1,738 2,894
Prior hip fractures 1,579 5,791 7,370
Prior vertebral fractures 954 1,807 2,761
519,71354,21364,5latoT
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between 1 to 3 times the gross domestic product (GDP)
per capita (Table 13). Assuming a QALY is valued at 2
times GDP/capita, the total cost of the QALYs lost was
estimated at € 580 million.
When the cost of osteoporosis was combined with the
value for QALYs lost (valued at 2 × GDP), the cost of
osteoporosis amounted to € 1.16 billion in Portugal in
2010. Incident fracture, prior fracture, pharmacological frac-
ture prevention, and value of QALYs lost accounted for
25 %, 23 %, 2 %, 50 % respectively.
Burden of osteoporosis up to 2025
The population above 50 years of age is expected to increase
from 3.9 million in 2010 to 4.8 million in 2025, correspond-
ing to an increase of 21 % (Table 14).
The total number of fractures was estimated to rise from
52,000 in 2010 to 69,000 in 2025 (Table 15), corresponding
to an increase of 33 %. Hip, clinical spine, forearm and other
fractures increased by 3,700, 2,400, 2,000 and 9,100 respec-
tively. The increase in the number of fractures ranged from
25 % to 38 %, depending on fracture site. The increase was
estimated to be particularly marked in men (38 %) compared
to women (31 %).
The cost of osteoporosis (excluding value of QALYs lost)
was estimated to rise from € 577 million in 2010 to € 717
million in 2025, corresponding to an increase of 24 % (Table
16). Costs incurred in women and men increased by 22 %
and 30 % respectively.
The total number of QALYs lost due to fracture was
estimated to rise from 17,900 in 2010 to 21,700 in
2025, corresponding to an increase of 21 % (Table
17). The increase was estimated to be particularly
marked in men (30 %) compared to women (18 %).
Incident and prior fractures accounted for 67 % and
33 % of the increase respectively.
The cost of osteoporosis including value of QALYs lost
was estimated to increase from approximately € 1.2 billion
in 2010 to € 1.4 billion in 2025. The increase was estimated
to be particularly marked in men (+30 %) compared to
women (+20 %) (Table 18).
Treatment uptake
To estimate uptake of individual osteoporosis treatments,
sales data from IMS Health (2001–2011) were used to
derive the number of defined daily doses (DDDs) sold per
100,000 persons aged 50 years or above (Fig. 2).
Adjusting the sales data for compliance allowed for an
estimation of the proportion of population aged 50 years or
above who received any osteoporosis treatment (see Chapter
5 of the report on Osteoporosis in the European Union:
Medical Management, Epidemiology and Economic Burden
for further details). The proportion of persons over the age
of 50 years who were treated increased from 2.22 % in 2001
to 8.65 % in 2008 but subsequently decreased to 7.12 % in
2011.
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Table 14 Population projections in Portugal by age and sex [11]
Population
2010 2015 2020 2025
Women
50–
60–
70–
80–
Men
50–
60–
70–
80–
All
50–
60–
70–
80–
59 720,000 767,000 793,000 815,000
69 612,000 660,000 698,000 745,000
79 516,000 517,000 547,000 592,000
89 271,000 310,000 329,000 337,000
90+ 41,000 54,000 71,000 85,000
59 674,000 726,228 758,000 791,000
69 528,000 582,000 627,000 676,000
79 387,000 394,000 425,000 472,000
89 158,000 185,000 202,000 210,000
90+ 15,000 23,000 29,000 37,000
59 1,394,000 1,493,228 1,551,000 1,606,000
69 1,140,000 1,242,000 1,325,000 1,421,000
79 903,000 911,000 972,000 1,064,000
89 429,000 495,000 531,000 547,000
90+ 56,000 77,000 100,000 122,000
000,067,4000,229,3
Table 13 Value of lost QALYs (€) in men and women in Portugal in
2010
1 × GDP/
capita
2 × GDP/
capita
3 × GDP/
capita
Incident hip fractures 35,514,395 71,028,791 106,543,186
Incident vertebral
fractures
39,339,425 78,678,849 118,018,274
Incident forearm
fractures
4,371,340 8,742,680 13,114,020
Incident other fractures 46,884,286 93,768,572 140,652,857
Prior hip fractures 119,387,307 238,774,613 358,161,920
Prior vertebral
fractures
44,730,600 89,461,201 134,191,801
Total 290,227,353 580,454,706 870,682,059
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Treatment gap
In order to assess the potential treatment gap, the num-
bers of men and women eligible for treatment in Portu-
gal were defined as individuals with a 10-year fracture
probability exceeding that of a woman with a prior
fragility fracture derived from FRAX®, equivalent to a
‘fracture threshold’ (See Chapter 5 of the main report
for further details). Subsequently, these estimates were
compared to the number of individuals who received
osteoporosis treatment obtained from the analysis of
IMS Health data. The treatment gaps in men and wom-
en were estimated at 24 % and 37 % respectively (Table
19). Note that the estimate of the treatment gap is
conservative given that it assumes that current use of
osteoporosis treatments are only directed to men and
women at high risk.
Table 15 Projected annual number of incident fractures in 2010 and 2025 by fracture site and age in men and women in Portugal
–
–
–
Table 16 Current and future cost (€ 000, 000) of osteoporosis (excluding
value of QALYs lost) by age and calendar year inmen and women in Portugal
2010 2015 2020 2025
Women
50–74 93 96 102 106
75+ 320 342 368 397
All 413 438 469 503
Men
50–74 59 62 67 71
75+ 105 116 127 142
All 164 178 194 213
Women and Men
50–74 152 157 168 177
75+ 425 458 495 539
All 577 616 663 717
Table 17 Projected QALYs lost due to incident and prior fractures for
the years 2010 and 2025 by age in men and women in Portugal
Incident fractures Prior fractures All fractures
2010 2025 2010 2025 2010 2025
Women
50–74 1,763 2,083 1,706 1,738 3,470 3,821
75+ 3,444 4,707 5,888 6,565 9,332 11,272
All 5,207 6,790 7,594 8,303 12,802 15,093
Men
50–74 1,167 1,453 826 930 1,993 2,383
75+ 1,410 2,110 1,710 2,134 3,120 4,244
All 2,577 3,563 2,537 3,065 5,114 6,628
Women and Men
50–74 2,930 3,536 2,533 2,669 5,463 6,204
75+ 4,854 6,817 7,598 8,699 12,453 15,516
All 7,785 10,353 10,131 11,368 17,915 21,720
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Table 19 Number of men and women eligible for treatment, treated
and treatment gap in 2010
Number
potentially
treated
(1000 s)
Number
eligible for
treatment
(1000 s)
Difference
(1000 s)
Treatment
gap (%)
Men 40 53 13 24
Women 269 425 156 37
Table 18 Present and future cost (€ 000,000) of fracture (direct cost
and cost of QALYs) by age and calendar year in men and women in
Portugal assuming the uptake of treatment remains unchanged
2010 2015 2020 2025
Women
50–
Men
50–
Women and Men
50–
74 205 211 221 230
75+ 622 666 712 763
All 828 878 933 992
74 123 128 138 149
75+ 206 225 247 279
All 330 354 385 428
74 329 340 360 378
75+ 829 892 959 1,042
All 1,157 1,231 1,318 1,420
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Fig. 2 Treatment uptake in Portugal (Defined daily doses [DDDs] per
100,000 persons aged 50 years or above)
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Epidemiology and Economic Burden of Osteo-
porosis in Romania
A report prepared in collaboration with the Internation-
al Osteoporosis Foundation (IOF) and the European
Federation of Pharmaceutical Industry Associations
(EFPIA).
M Ivergård, A Svedbom, E Hernlund, J Compston, C
Cooper, J Stenmark, EV McCloskey, B Jönsson, D
Grigorie and JA Kanis
Moa Ivergård, OptumInsight, Stockholm, Sweden
Abstract
Summary This report describes epidemiology, burden, and
treatment of osteoporosis in Romania.
Introduction Osteoporosis is characterized by reduced bone
mass and disruption of bone architecture, resulting in in-
creased risks of fragility fractures which represent the main
clinical consequence of the disease. Fragility fractures are
associated with substantial pain and suffering, disability and
even death for the affected patients and substantial costs to
society. The aim of this study is to describe the epidemiol-
ogy and economic burden of fragility fractures as a conse-
quence of osteoporosis in Romania, as a further detailed
addition to the report for the entire European Union
(EU27): Osteoporosis in the European Union: Medical
Management, Epidemiology and Economic Burden.
Methods The literature on fracture incidence and costs of
fractures in the EU27 was reviewed and incorporated
into a model estimating the clinical and economic bur-
den of osteoporotic fractures in 2010. Furthermore, data
on sales of osteoporosis treatments and the population at
high risk were used to estimate treatment uptake and
treatment gap.
Results It was estimated that approximately 94,000 new
fragility fractures were sustained in Romania, comprising
14,000 hip fractures, 16,000 vertebral fractures, 16,000
forearm fractures and 48,000 other fractures (i.e. fractures
of the pelvis, rib, humerus, tibia, fibula, clavicle, scapula,
sternum and other femoral fractures) in 2010. The economic
burden of incident and previous fragility fractures was esti-
mated at € 129 million for the same year. Incident fractures
represented 68 % of this cost, long-term fracture care 27 %
and pharmacological prevention 5 %. Previous and incident
fractures also accounted for 29,700 quality-adjusted life
years (QALYs) lost during 2010. When accounting for the
demographic projections for 2025, the number of incident
fractures was estimated at 110,000 in 2025, representing an
increase of 16,000 fractures. Hip, clinical vertebral (spine),
forearm and other fractures were estimated to increase by
3,000, 2,400, 2,300 and 8,200, respectively. The burden of
fractures in Romania in 2025 was estimated to increase by
17 % to € 151 million. Though the uptake of osteoporosis
treatments increased from 2001, the proportion of patients
aged 50 or above that received treatment remained at very
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low levels in the past few years. The majority of women at
high fracture risk did not receive active treatment.
Conclusions In spite of the high cost of osteoporosis, a
substantial treatment gap and projected increase of the eco-
nomic burden driven by an aging population, the use of
pharmacological prevention of osteoporosis is significantly
less than optimal, suggesting that a change in healthcare
policy concerning the disease is warranted.
Introduction
Osteoporosis is characterized by reduced bone mass and
disruption of bone architecture, resulting in increased risks
of fragility fractures which represent the main clinical con-
sequence of the disease. Fragility fractures are associated
with substantial pain and suffering, disability and even death
for the affected patients and substantial costs to society. The
aim of this report was to characterize the burden of osteo-
porosis in Romania in 2010 and beyond.
Methods
The literature on fracture incidence and costs of frac-
tures in Romania was reviewed and incorporated into a
model estimating the clinical and economic burden of
osteoporotic fractures in 2010. Details of the methods
used are found in Chapters 3 and 4 of the report
Osteoporosis in the European Union: Medical Manage-
ment, Epidemiology and Economic Burden, published
concurrently in Archives of Osteoporosis.
Epidemiology of osteoporosis in Romania
For the purpose of this report, the population at risk of
osteoporosis was considered to include men and women
≥50 years. The number of men and women ≥50 years
of age amounted to 3,212,000 and 4,077,000 respective-
ly in Romania in 2010 (Table 1).
In the population at risk, the number of individuals with
osteoporosis—as defined by the WHO diagnostic
criteria—was estimated at 1,030,000 (Table 2). There are
2.4 DXA scan machines per million inhabitants, and guide-
lines for osteoporosis treatment are available [2]. A country
specific FRAX model is also available for the assessment of
fracture risk (http://www.shef.ac.uk/FRAX/).
Data on hip fracture incidence are available for Romania
[4]. Given that country specific incidence of vertebral, fore-
arm and, “other” fractures were not found, these were im-
puted using the methods described in Chapter 3 of the main
report. Fracture incidence is presented in Table 3.
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Table 1 Population at risk: men and women over the age of 50 in
Romania, 2010 [1]
Age (years) Women Men All
50–59 1,525,000 1,401,000 2,926,000
60–69 1,124,000 916,000 2,040,000
70–79 991,000 666,000 1,657,000
80–89 408,000 218,000 626,000
90+ 29,000 11,000 40,000
50+ 4,077,000 3,212,000 7,289,000
Table 2 Estimated number of women and men with osteoporosis
(defined as a T-score ≤−2.5 SD) in Romania by age using female-
derived reference ranges at the femoral neck, 2010 [3]
Age (years) Women Men
50–54 48,069 17,925
55–59 73,152 23,940
60–64 89,661 30,798
65–69 100,394 28,490
70–74 154,845 30,264
75–79 163,500 28,634
80+ 206,264 38,014
50+ 835,885 198,065
Table 3 Incidence per 100,000 person years of hip, clinical vertebral,
forearm, and “other” fractures in Romania by age
Fracture at the
Age (years) hip vertebra forearm other
Women
50–54 17 44 108 112
55–59 34 94 260 298
60–64 60 105 225 230
65–69 115 168 280 394
70–74 228 321 409 646
75–79 407 396 397 856
80–84 667 419 417 1,133
85+ 1,048 493 447 1,761
Men
50–54 50 129 46 223
55–59 70 121 106 648
60–64 94 225 177 924
65–69 124 194 186 797
70–74 186 283 119 954
75–79 274 316 78 732
80–84 410 285 80 1,091
85+ 587 394 108 1,701
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Standardized to the EU27 population, hip fracture incidence
(per 100,000 person years) in men and women ≥50 years of
age was estimated at 170.3 and 282.3 respectively.
The number of incident fractures in 2010 was estimated at
94,000 (Table 4). Incident hip, clinical spine, forearm and
“other” fractures were estimated at 14,000, 16,000, 16,000
and 48,000 respectively. 56% of fractures occurred in women.
A prior fracture was defined as a fracture in an
individual who was alive during the index year (i.e.
2010) which had occurred after the age of 50 years
and before 2010. In the population ≥50 years of age,
the proportion of individuals who had suffered a frac-
ture prior to 2010 was estimated at 0.99 % for hip and
1.14 % for clinical vertebral fractures. The estimated
proportions of men and women with prior hip and
vertebral fractures by age are presented in Table 5.
In the population over 50 years of age, the number of
individuals with hip and vertebral fractures that occurred
before 2010 was estimated at 72,000 and 83,000 respective-
ly (Table 6). Note that fractures sustained in 2010 were not
included in the estimate.
The incidence of causally related deaths (per
100,000) in the first year after fracture by age is
presented in Table 7. The number of causally related
deaths in 2010 was estimated at 1,609 (Table 8). Hip,
vertebral and “other” fractures accounted for 723, 712
and 174 deaths respectively. Overall, approximately
47 % of deaths occurred in women.
Cost of osteoporosis in Romania including and excluding
values of QALYs lost
For the purpose of this report, the cost of osteoporosis in
2010 (excluding value of QALYs lost) was considered to
consist of three components: (i) cost of fractures that
occurred in 2010 (“first year costs”); (ii) cost of fractures
sustained prior to year 2010 but which still incurred costs
in 2010 (“long-term disability cost”); and (iii) cost of
pharmacological fracture prevention including administra-
tion and monitoring costs (“pharmacological fracture
prevention costs”). See Chapter 4 of the main report
for further details.
Table 4 Estimated number of incident fractures in Romania, 2010
Fracture at the All
Age (years) hip vertebra forearm other fractures
Women
50–74 3,269 5,061 8,787 11,764 28,881
75+ 6,063 3,708 3,588 10,873 24,232
Total 9,332 8,768 12,375 22,638 53,113
Men
50–74 2,893 5,249 3,429 19,896 31,467
75+ 2,082 1,653 451 5,517 9,704
Total 4,975 6,901 3,880 25,413 41,170
Men and Women
50–74 6,163 10,309 12,216 31,661 60,348
75+ 8,145 5,360 4,039 16,390 33,935
Total 14,308 15,670 16,255 48,051 94,283
Table 5 Proportion of men and women (in %) with a prior hip or
clinical vertebral fracture in Romania, 2010
Age (years) Hip fracture Vertebral fracture
Women
50– 1.00.045
55– 4.02.095
60– 7.04.046
65– 2.17.096
70– 9.13.147
75– 7.23.297
80– 2.38.348
6.48.6+58
Men
50– 2.01.045
55– 5.03.095
60– 9.06.046
65– 2.19.096
70– 4.13.147
75– 7.17.197
80– 9.13.248
8.22.4+58
Table 6 Number of men and women in Romania with a prior hip or
clinical vertebral fracture after the age of 50 years, 2010
Age (years) Hip fracture Vertebral fracture
Women
50–
Men
50–
Men and Women
50–
74 14,391 24,862
75+ 31,610 27,920
Total 46,001 52,782
74 14,637 20,325
75+ 11,386 9,721
Total 26,023 30,046
74 29,028 45,187
75+ 42,997 37,642
Total 72,024 82,829
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As the cost of a hip fracture was not specifically available
for Romania, hip fracture costs were estimated at € 2,168
based on costs in Slovenia [5]. Given that no cost data for
the other fracture sites were found, these were imputed as
described in Chapter 4 of the main report.
Long-term disability costs were estimated by multiplying
the yearly cost of residing in nursing home (€ 5,756 [6]) with
the simulated number of individuals with prior fractures that
had been transferred to nursing home due to the fracture.
Annual drug cost (€) for individual treatments is shown
in Table 9. In addition, it was assumed that patients on
treatment made an annual physician visit costing € 26 [7]
and a DXA scan reimbursed at € 5 [7] every second year to
monitor treatment. In practice, the price of DXA is much
higher and borne by the patient.
The cost of osteoporosis in 2010 was estimated at €
129 million (Table 10). First year costs, subsequent year
costs and pharmacological fracture prevention costs
amounted to € 88 million, € 35 million and € 7 million,
respectively. It is notable that pharmacological fracture
prevention costs amounted to only 5.2 % of the total
cost.
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Table 7 Incidence (per 100,000) of causally related deaths in Romania
within the first year after fracture (adjusted for comorbidities), 2010
Age (years) Hip Clinical vertebral “Other” fracture
Women
50–54 973 1,265 25
55–59 1,366 1,681 40
60–64 1,991 2,312 63
65–69 2,553 2,799 96
70–74 3,261 3,365 149
75–79 4,455 4,304 279
80–84 4,293 3,798 478
85–89 5,321 4,136 932
90+ 6,487 3,657 2,255
Men
50–54 4,437 5,322 70
55–59 5,223 5,938 107
60–64 6,097 6,558 165
65–69 6,245 6,335 224
70–74 6,493 6,182 293
75–79 7,411 6,572 439
80–84 7,729 6,277 649
85–89 10,173 7,436 1,099
90+ 19,560 12,728 2,447
Table 8 The number of deaths in men and women in Romania in the
first year after fracture attributable to the fracture event (causally
related), 2010
Fracture at the
Age (years) hip vertebra “other”
Women
50–74 93 143 13
75+ 279 143 78
Total 372 286 91
Men
50–74 171 315 37
75+ 181 111 46
Total 351 426 83
Men and Women
50–74 264 458 50
75+ 459 254 124
Total 723 712 174
Table 9 One year costs for relevant pharmaceuticals in Romania,
2010 [8]
Annual drug cost (€)
Alendronate 53
Risedronate 106
Etidrontate -
Ibandronate 195
Zoledronic acid 747
Raloxifene 362
Strontium ranelate 414
Parathyroid hormone -
Teriparatide 4,266
Table 10 Cost of osteoporosis (€) in Romania by age in men and
women, 2010
Age
(years)
First year
fracture
cost
Long term
disability
costs
Fracture
prevention
cost
Total cost
Women
50–74 23,616,069 5,219,913 3,890,507 32,726,489
75+ 25,453,787 16,271,196 2,051,296 43,776,280
All 49,069,856 21,491,109 5,941,804 76,502,769
Men
50–74 28,376,886 6,135,464 594,664 35,107,014
75+ 10,418,603 7,172,582 242,144 17,833,329
All 38,795,488 13,308,047 836,808 52,940,343
Women and Men
50–74 51,992,955 11,355,377 4,485,171 67,833,503
75+ 35,872,390 23,443,779 2,293,441 61,609,609
All 87,865,345 34,799,156 6,778,612 129,443,112
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When stratifying costs of osteoporosis by fracture type, hip
fractures were most costly (€ 61 million) followed by “other”
(€ 53 million), spine (€ 7 million) and forearm fractures (€ 2
million) (Table 11 and Fig. 1). Please note that costs for
pharmacological fracture prevention were not included given
that they cannot be allocated to specific fracture sites.
The number of quality adjusted life years (QALYs) lost
due to osteoporosis in 2010 was estimated at 29,700 (Table
12). Prior fractures accounted for 51 % of the total loss and
58 % of the loss occurred in women. The monetary value of
a QALY was varied between 1 to 3 times the gross domestic
product (GDP) per capita (Table 13). Assuming a QALY is
valued at 2 times GDP/capita, the total cost of the QALYs
lost was estimated at € 340 million. When the cost of osteoporosis was combined with the value
for QALYs lost (valued at 2 × GDP), the cost of osteoporosis
amounted to € 470million inRomania in 2010. Incident fracture,
prior fracture, pharmacological fracture prevention, and value of
QALYs lost accounted for 19 %, 7 %, 1 %, 72 % respectively.
Table 11 Total cost (€) in 2010 by fracture site in men and women in
Romania. Note that costs for fracture prevention therapy and monitor-
ing are not included.
Age Hip Spine Forearm Other All
Women
50–74 11,804,197 2,259,003 1,163,900 13,608,883 28,835,982
75+ 27,269,158 1,531,657 475,296 12,448,873 41,724,984
All 39,073,354 3,790,660 1,639,195 26,057,756 70,560,965
Men
50–74 11,523,671 2,160,474 454,210 20,373,995 34,512,350
75+ 10,542,194 626,605 59,773 6,362,613 17,591,185
All 22,065,864 2,787,079 513,983 26,736,609 52,103,535
Women and Men
50–74 23,327,867 4,419,477 1,618,110 33,982,878 63,348,332
75+ 37,811,351 2,158,262 535,069 18,811,486 59,316,169
All 61,139,219 6,577,739 2,153,179 52,794,364 122,664,501
Hip
50%
Spine
5%
Forearm
2%
Other
43%
Fig. 1 Share of fracture cost (%) by fracture site in Romania. Note that
costs for fracture prevention therapy and monitoring are not included
Table 12 Number of QALYs lost due to fractures during 2010 in men
and women in Romania according to age
Age (years)
50–74 75+ 50+
Women
Incident hip fractures 797 1,337 2,134
Incident vertebral fractures 1,691 1,115 2,806
Incident forearm fractures 310 112 421
Incident other fractures 1,410 1,166 2,576
Prior hip fractures 2,252 4,377 6,629
Prior vertebral fractures 1,389 1,389 2,777
343,71594,9848,7latoT
Men
Incident hip fractures 733 515 1,248
Incident vertebral fractures 1,807 543 2,350
Incident forearm fractures 119 15 134
Incident other fractures 2,373 635 3,008
Prior hip fractures 2,291 1,698 3,989
Prior vertebral fractures 1,133 516 1,649
873,21229,3654,8latoT
Men and Women
Incident hip fractures 1,530 1,852 3,382
Incident vertebral fractures 3,499 1,658 5,157
Incident forearm fractures 429 126 555
Incident other fractures 3,783 1,801 5,584
Prior hip fractures 4,543 6,075 10,618
Prior vertebral fractures 2,522 1,905 4,427
127,92714,31503,61latoT
Table 13 Value of lost QALYs (€) in men and women in Romania in
2010
1 × GDP/
capita
2 × GDP/
capita
3 × GDP/
capita
Incident hip fractures 19,276,074 38,552,148 57,828,222
Incident vertebral
fractures
29,392,408 58,784,817 88,177,225
Incident forearm
fractures
3,164,827 6,329,654 9,494,482
Incident other fractures 31,825,963 63,651,925 95,477,888
Prior hip fractures 60,520,194 121,040,388 181,560,582
Prior vertebral
fractures
25,232,311 50,464,622 75,696,933
Total 169,411,777 338,823,554 508,235,331
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Burden of osteoporosis up to 2025
The population above 50 years of age is expected to increase
from 7.3 million in 2010 to 8.2 million in 2025, correspond-
ing to an increase of 12 % (Table 14).
The total number of fractures was estimated to rise from
94,000 in 2010 to 110,000 in 2025 (Table 15), correspond-
ing to an increase of 17 %. Hip, clinical spine, forearm and
other fractures increased by 3,000, 2,400, 2,300 and 8,200
respectively. The increase in the number of fractures ranged
from 14 % to 21 %, depending on fracture site. The increase
was estimated to be 13 % in men and 20 % in women.
The cost of osteoporosis (excluding value of QALYs lost)
was estimated to rise from € 129 million in 2010 to € 151
million in 2025, corresponding to an increase of 17 % (Table
16). Costs incurred in women and men increased by 20 %
and 13 % respectively.
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Table 14 Population projections in Romania by age and sex [9]
Population
2010 2015 2020 2025
Women
50–59 1,525,000 1,338,000 1,423,000 1,638,000
60–69 1,124,000 1,328,000 1,420,000 1,252,000
70–79 991,000 911,000 919,000 1,102,000
80–89 408,000 467,000 517,000 483,000
90+ 29,000 52,000 74,000 91,000
Men
50–59 1,401,000 1,239,000 1,354,000 1,573,000
60–69 916,000 1,087,000 1,167,000 1,044,000
70–79 666,000 596,000 614,000 743,000
80–89 218,000 239,000 249,000 225,000
90+ 11,000 18,000 23,000 25,000
All
50–59 2,926,000 2,577,000 2,777,000 3,211,000
60–69 2,040,000 2,415,000 2,587,000 2,296,000
70–79 1,657,000 1,507,000 1,533,000 1,845,000
80–89 626,000 706,000 766,000 708,000
90+ 40,000 70,000 97,000 116,000
000,671,8000,982,7
Table 15 Projected annual number of incident fractures in 2010 and 2025 by fracture site and age in men and women in Romania
Table 16 Current and future cost (€ 000,000) of osteoporosis (ex-
cluding value of QALYs lost) by age and calendar year in men and
women in Romania
2010 2015 2020 2025
Women
50–74 33 32 35 37
75+ 44 48 50 54
All 77 80 85 91
Men
50–74 35 35 38 40
75+ 18 19 19 19
All 53 54 57 60
Women and Men
50–74 68 67 73 78
75+ 62 67 69 73
All 129 134 142 151
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The total number of QALYs lost due to fracture was esti-
mated to rise from 29,700 in 2010 to 33,800 in 2025,
corresponding to an increase of 14 % (Table 17). The
increase was estimated to be 11 % in men and 16 % in
women. Incident and prior fractures accounted for 59 % and
41 % of the increase respectively.
The cost of osteoporosis including value of QALYs
lost was estimated to increase from approximately € 468
million in 2010 to € 537 million in 2025. The increase
was estimated to be 12 % in men and 17 % in women
(Table 18).
Treatment uptake
To estimate uptake of individual osteoporosis treatments,
sales data from IMS Health (2001–2011) were used to
derive the number of defined daily doses (DDDs) sold per
100,000 persons aged 50 years or above (Fig. 2).
Adjusting the sales data for compliance allowed for an
estimation of the proportion of population aged 50 years or
above who received any osteoporosis treatment (see Chapter 5
of the report on Osteoporosis in the European Union: Medical
Management, Epidemiology and Economic Burden for further
details). The proportion of persons over the age of 50 years who
were treated increased from 0.05 % in 2001 to 1.65 % in 2011.
Treatment gap
In order to assess the potential treatment gap, the numbers of
men and women eligible for treatment in Romania were de-
fined as individuals with a 10-year fracture probability exceed-
ing that of a woman with a prior fragility fracture derived from
FRAX®, equivalent to a ‘fracture threshold’ (See Chapter 5 of
the main report for further details). Subsequently, these esti-
mates were compared to the number of individuals who re-
ceived osteoporosis treatment obtained from the analysis of
IMS Health data. The treatment gaps in men and women were
estimated at 94 % and 83 % respectively (Table 19). Note that
the estimate of the treatment gap is conservative given that it
assumes that current use of osteoporosis treatments are only
directed to men and women at high risk.
Table 17 Projected QALYs lost due to incident and prior fractures for
the years 2010 and 2025 by age in men and women in Romania
Incident fractures Prior fractures All fractures
2010 2025 2010 2025 2010 2025
Women
50–74 4,207 4,823 3,641 3,963 7,848 8,786
75+ 3,729 4,660 5,766 6,622 9,495 11,281
All 7,937 9,482 9,406 10,585 17,343 20,067
Men
50–74 5,032 5,726 3,424 3,761 8,456 9,487
75+ 1,708 1,884 2,214 2,377 3,922 4,262
All 6,740 7,610 5,638 6,138 12,378 13,748
Women and Men
50–74 9,240 10,549 7,065 7,724 16,305 18,273
75+ 5,437 6,544 7,980 8,999 13,417 15,543
All 14,677 17,092 15,044 16,723 29,721 33,815
Table 18 Present and future cost (€ 000,000) of fracture (direct cost
and cost of QALYs) by age and calendar year in men and women in
Romania assuming the uptake of treatment remains unchanged
2010 2015 2020 2025
Women
50–74 122 120 129 138
75+ 152 165 171 183
All 274 285 300 320
Men
50–74 132 130 139 149
75+ 63 65 64 68
All 194 195 203 216
Women and Men
50–74 254 250 268 286
75+ 215 229 235 250
All 468 479 503 537
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Fig. 2 Treatment uptake in Romania (defined daily doses [DDDs] per
100,000 persons aged 50 years or above)
Table 19 Number of men and women eligible for treatment, treated
and treatment gap in 2010
Number
potentially
treated
(1000 s)
Number eligible
for treatment
(1000 s)
Difference
(1000 s)
Treatment
gap (%)
Men 15 235 220 94
Women 100 599 499 83
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Epidemiology and Economic Burden of Osteo-
porosis in Slovakia
A report prepared in collaboration with the Internation-
al Osteoporosis Foundation (IOF) and the European
Federation of Pharmaceutical Industry Associations
(EFPIA).
M Ivergård, A Svedbom, E Hernlund, J Compston, C
Cooper, J Stenmark, EV McCloskey, B Jönsson, P Ma-
saryk, J Payer, P Jackuliak and JA Kanis
Moa Ivergård, OptumInsight, Stockholm, Sweden
Abstract
Summary This report describes epidemiology, burden, and
treatment of osteoporosis in Slovakia.
Introduction Osteoporosis is characterized by reduced
bone mass and disruption of bone architecture, resulting
in increased risks of fragility fractures which represent
the main clinical consequence of the disease. Fragility
fractures are associated with substantial pain and suffer-
ing, disability and even death for the affected patients
and substantial costs to society. The aim of this study is
to describe the epidemiology and economic burden of
fragility fractures as a consequence of osteoporosis in
Slovakia, as a further detailed addition to the report for
the entire European Union (EU27): Osteoporosis in the
European Union: Medical Management, Epidemiology
and Economic Burden.
Methods The literature on fracture incidence and costs of
fractures in Slovakia was reviewed and incorporated into a
model estimating the clinical and economic burden of oste-
oporotic fractures in 2010. Furthermore, data on sales of
osteoporosis treatments and the population at high risk were
used to estimate treatment uptake and treatment gap.
Results It was estimated that approximately 39,000 new
fragility fractures were sustained in Slovakia, comprising
6,000 hip fractures, 6,000 vertebral fractures, 7,000 forearm
fractures and 20,000 other fractures (i.e. fractures of the
pelvis, rib, humerus, tibia, fibula, clavicle, scapula, sternum
and other femoral fractures) in 2010. The economic burden
of incident and previous fragility fractures was estimated at
€ 107 million for the same year. Incident fractures repre-
sented 71 % of this cost, long-term fracture care 18 % and
pharmacological prevention 10 %. Previous and incident
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fractures also accounted for 11,700 quality-adjusted life
years (QALYs) lost during 2010. When accounting for the
demographic projections for 2025, the number of incident
fractures was estimated at 50,000 in 2025, representing an
increase of 11,000 fractures. Hip, clinical vertebral (spine),
forearm and other fractures were estimated to increase by
2,100, 1,900, 1,600 and 5,700, respectively. The burden of
fractures in Slovakia in 2025 was estimated to increase by
31 % to € 140 million. Though the uptake of osteoporosis
treatments increased from 2001, the proportion of patients
aged 50 or above who received treatment remained at very
low levels in the past few years. A substantial minority of
women at high fracture risk did not receive active treatment.
Conclusions In spite of the high cost of osteoporosis, a
substantial treatment gap and projected increase of the eco-
nomic burden driven by aging populations, the use of phar-
macological prevention of osteoporosis is significantly less
than optimal, suggesting that a change in healthcare policy
concerning the disease is warranted.
Introduction
Osteoporosis is characterized by reduced bone mass and
disruption of bone architecture, resulting in increased
risks of fragility fractures which represent the main
clinical consequence of the disease. Fragility fractures
are associated with substantial pain and suffering, dis-
ability and even death for the affected patients and
substantial costs to society. The aim of this report was
to characterize the burden of osteoporosis in Slovakia in
2010 and beyond.
Methods
The literature on fracture incidence and costs of fractures in
Slovakia was reviewed and incorporated into a model esti-
mating the clinical and economic burden of osteoporotic
fractures in 2010. Details of the methods used are found in
Chapters 3 and 4 of the report Osteoporosis in the
European Union: Medical Management, Epidemiology
and Economic Burden, published concurrently in Ar-
chives of Osteoporosis.
Epidemiology of osteoporosis in Slovakia
For the purpose of this report, the population at risk of
osteoporosis was considered to include men and women
≥50 years. The number of men and women ≥50 years of
age amounted to 755,000 and 975,000 respectively in Slo-
vakia in 2010 (Table 1).
In the population at risk, the number of individuals with
osteoporosis—as defined by the WHO diagnostic
criteria—was estimated at 230,000 (Table 2). There are
10.7 DXA scan machines per million inhabitants [2], and
guidelines for the assessment and treatment of osteoporosis
are available [3]. A country specific FRAX model is also
available for the assessment of fracture risk (http://
www.shef.ac.uk/FRAX/).
Data on hip fracture incidence are available for Slovakia
[5]. Given that country specific incidence of the vertebral,
forearm and, “other” fractures were not found, these were
imputed using the methods described in Chapter 3 of the main
report. Fracture incidence is presented in Table 3. Standard-
ized to the EU27 population, hip fracture incidence (per
100,000 person years) in men and women ≥50 years of age
was estimated at 326 and 572 respectively.
The number of incident fractures in 2010 was estimated
at 39,000 (Table 4). Incident hip, clinical spine, forearm and
“other” fractures were estimated at 6,000, 6,000, 7,000 and
20,000 respectively. 57 % of fractures occurred in women.
A prior fracture was defined as a fracture in an individual
who was alive during the index year (i.e. 2010) which had
occurred after the age of 50 years and before 2010. In the
population ≥50 years of age, the proportion of individuals
who had suffered a fracture prior to 2010 was estimated at
1.62 % for hip and 1.88 % for clinical vertebral fractures.
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Table 1 Population at risk: men and women over the age of 50 in
Slovakia, 2010 [1]
Age (years) Women Men All
50–59 405,000 379,000 784,000
60–69 279,000 221,000 500,000
70–79 187,000 111,000 298,000
80–89 95,000 41,000 136,000
90+ 9,000 3,000 12,000
50+ 975,000 755,000 1,730,000
Table 2 Number of women and men with osteoporosis (defined as a
T-score ≤−2.5 SD) in Slovakia by age using female-derived reference
ranges at the femoral neck, 2010 [4]
Age (years) Women Men
50–54 12,789 4,875
55–59 19,392 6,440
60–64 22,165 7,540
65–69 25,048 6,734
70–74 28,179 4,992
75–79 32,250 4,841
80+ 49,088 7,304
50+ 188,911 42,726
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The estimated proportions of men and women with prior hip
and vertebral fractures by age are presented in Table 5.
In the population over 50 years of age, the number of
individuals with hip and vertebral fractures that occurred
before 2010 was estimated at 28,000 and 32,000 respective-
ly (Table 6). Note that fractures sustained in 2010 were not
included in the estimate.
The incidence of causally related deaths (per
100,000) in the first year after fracture by age is
presented in Table 7. The number of causally related
deaths in 2010 was estimated at 574 (Table 8). Hip,
vertebral and “other” fractures accounted for 261, 241
and 71 deaths respectively. Overall, approximately 47 %
of deaths occurred in women.
Table 3 Incidence per 100,000 person years of hip, clinical vertebral,
forearm, and “other” fractures in Slovakia by age
Fracture at the
Age (years) hip vertebral forearm other
Women
50–54 36 92 227 234
55–59 67 187 516 591
60–64 113 200 428 437
65–69 142 206 344 483
70–74 342 483 615 971
75–79 760 739 742 1,600
80–84 1,465 921 917 2,491
85+ 2,383 1,121 1,017 4,003
Men
50–54 89 229 82 395
55–59 124 216 189 1,156
60–64 157 376 296 1,545
65–69 204 321 306 1,314
70–74 312 475 199 1,601
75–79 463 533 131 1,236
80–84 823 571 159 2,187
85+ 1,459 980 267 4,225
Table 4 Estimated number of incident fractures in Slovakia, 2010
Fracture at the All
Age (years) hip vertebra forearm other fractures
Women
50–74 1,092 1,792 3,521 4,480 10,885
75+ 2,807 1,602 1,626 5,175 11,210
Total 3,899 3,395 5,147 9,655 22,095
Men
50–74 1,111 2,057 1,433 8,085 12,685
75+ 816 627 173 2,238 3,854
Total 1,927 2,683 1,606 10,322 16,539
Men and Women
50–74 2,203 3,849 4,954 12,564 23,570
75+ 3,623 2,229 1,799 7,413 15,064
Total 5,826 6,078 6,753 19,977 38,634
Table 5 Proportion of men and women (in %) with prior hip or
clinical vertebral fracture in Slovakia, 2010
Age (years) Hip fracture Vertebral fracture
Women
50– 2.01.045
55– 8.03.095
60– 5.17.046
65– 0.21.196
70– 0.30.247
75– 6.49.397
80– 9.51.748
0.91.41+58
Men
50– 4.02.045
55– 0.16.095
60– 6.10.146
65– 0.24.196
70– 3.29.147
75– 7.27.297
80– 3.34.448
4.61.9+58
Table 6 Number of men and women in Slovakia with a prior hip or
clinical vertebral fracture after the age of 50 years, 2010
Age (years) Hip fracture Vertebral fracture
Women
50– 729,9231,547
633,11796,31+57
362,12038,81latoT
Men
50– 979,7952,547
542,3779,3+57
422,11632,9latoT
Men and Women
50– 609,71293,0147
285,41476,71+57
884,23560,82latoT
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Cost of osteoporosis in Slovakia including and excluding
values of QALYs lost
For the purpose of this report, the cost of osteoporosis in
2010 (excluding value of QALYs lost) was considered to
consist of three components: (i) cost of fractures that oc-
curred in 2010 (“first year costs”); (ii) cost of fractures
sustained prior to year 2010 but which still incurred costs
in 2010 (“long-term disability cost”); and (iii) cost of
pharmacological fracture prevention including adminis-
tration and monitoring costs (“pharmacological fracture
prevention costs”). See Chapter 4 of the main report for
further details.
As the cost of a hip fracture was not available specifically
for Slovakia, hip fracture costs were estimated at € 4,690
based on costs in the Czech Republic [6]. Given that no cost
data for the other fracture sites were found, these were
imputed as described in Chapter 4 of the main report.
Long-term disability costs were estimated by multiplying
the yearly cost of residing in nursing home (€ 8,030 [7])
with the simulated number of individuals with prior frac-
tures that had been transferred to nursing homes due to the
fracture.
Annual drug cost (€) for individual treatments is shown
in Table 9. In addition, it was assumed that patients on
treatment made an annual physician visit costing € 16 [8]
(approximated by adjusting Polish cost for health adjusted
price levels) and a DXA scan costing € 32 [9] every
second year to monitor treatment.
The cost of osteoporosis in 2010 was estimated at €
107 million (Table 10). First year costs, subsequent year
costs and pharmacological fracture prevention costs
amounted to € 76 million, € 19 million and € 11
million, respectively. It is notable that pharmacological
fracture prevention costs amounted to only 10.6 % of
the total cost.
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Table 7 Incidence (per 100,000) of causally related deaths in Slovakia
within the first year after fracture (adjusted for comorbidities), 2010
Age (years) Hip Clinical vertebral “Other” fracture
Women
50–54 930 1,209 24
55–59 1,031 1,268 30
60–64 1,557 1,808 50
65–69 2,171 2,380 81
70–74 2,716 2,803 124
75–79 3,656 3,532 229
80–84 3,913 3,462 436
85–89 4,667 3,628 818
90+ 3,304 1,863 1,149
Men
50–54 3,126 3,750 49
55–59 4,208 4,784 86
60–64 4,555 4,899 123
65–69 5,276 5,352 189
70–74 5,950 5,665 268
75–79 6,401 5,677 380
80–84 7,233 5,874 608
85–89 8,943 6,537 966
90+ 9,833 6,399 1,230
Table 8 The number of deaths in men and women in Slovakia in the
first year after fracture attributable to the fracture event (causally
related), 2010
Fracture at the
Age (years) hip spine other
Women
50–74 25 41 4
75+ 110 52 35
Total 136 93 39
Men
50–74 58 109 12
75+ 68 39 20
Total 126 149 32
Men and Women
50–74 83 150 16
75+ 178 91 55
Total 261 241 71
Table 9 One year costs for relevant pharmaceuticals in Slovakia, 2010
[10]
Annual drug cost (€)
Alendronate 116
Risedronate 320
Etidrontate -
Ibandronate 404
Zoledronic acid 480
Raloxifene 509
Strontium ranelate 610
Parathyroid hormone 5,651
Teriparatide 6,414
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When stratifying costs of osteoporosis by fracture
type, other fractures were most costly (€ 45 million)
followed by hip (€ 43 million), spine (€ 6 million) and
forearm fractures (€ 2 million) (Table 11 and Fig. 1).
Please note that costs for pharmacological fracture pre-
vention were not included given that they cannot be
allocated to specific fracture sites.
The number of quality adjusted life years (QALYs)
lost due to osteoporosis in 2010 was estimated at
11,700 (Table 12). Prior fractures accounted for 50 %
of the total loss and 60 % of the loss occurred in
women. The monetary value of a QALY was varied
between 1 to 3 times the gross domestic product
(GDP) per capita (Table 13). Assuming a QALY is
valued at 2 times GDP/capita, the total cost of the
QALYs lost was estimated at € 280 million.
When the cost of osteoporosis was combined with the value
for QALYs lost (valued at 2 × GDP), the cost of osteoporo-
sis amounted to € 390 million in Slovakia in 2010. Incident
fracture, prior fracture, pharmacological fracture prevention,
and value of QALYs lost accounted for 20 %, 5 %, 3 %,
73 % respectively.
Burden of osteoporosis up to 2025
The population above 50 years of age is expected to increase
from 1.7 million in 2010 to 2.1 million in 2025, correspond-
ing to an increase of 21 % (Table 14).
The total number of fractures was estimated to rise
from 39,000 in 2010 to 50,000 in 2025 (Table 15), cor-
responding to an increase of 29 %. Hip, clinical spine,
forearm and other fractures increased by 2,100, 1,900,
1,600 and 5,700 respectively. The increase in the number
of fractures ranged from 23 % to 35 %, depending on
fracture site. The increase was estimated to be the same in
both men and women (29 %).
The cost of osteoporosis (excluding values of QALYs
lost) was estimated to rise from € 107 million in 2010 to €
140 million in 2025, corresponding to an increase of 31 %
(Table 16). Costs incurred in women and men increased by
30 % and 33 % respectively.
Table 11 Total cost (€) in 2010 by fracture site in men and women in
Slovakia. Note that costs for fracture prevention therapy and monitor-
ing are not included
Age Hip Spine Forearm Other All
Women
50–74 7,407,091 1,756,990 1,009,062 10,311,193 20,484,336
75+ 21,449,488 1,456,571 465,887 12,574,308 35,946,255
All 28,856,580 3,213,561 1,474,949 22,885,501 56,430,590
Men
50–74 7,497,448 1,867,933 410,587 17,045,134 26,821,101
75+ 6,458,636 516,602 49,580 5,414,921 12,439,740
All 13,956,084 2,384,535 460,167 22,460,055 39,260,841
Women and Men
50–74 14,904,539 3,624,923 1,419,648 27,356,326 47,305,437
75+ 27,908,125 1,973,173 515,468 17,989,229 48,385,995
All 42,812,663 5,598,096 1,935,116 45,345,556 95,691,431
Hip
45%
Spine
6%
Forearm
2%
Other
47%
Fig. 1 Share (%) of fracture cost by fracture site in Slovakia. Note that
costs for fracture prevention therapy and monitoring are not included
Table 10 Cost of osteoporosis (€) in Slovakia by age in men and
women, 2010
Age
(years)
First year
fracture
cost
Long term
disability
costs
Fracture
prevention
cost
Total cost
Women
50–74 17,906,196 2,578,139 6,638,817 27,123,153
75+ 25,739,097 10,207,158 3,285,115 39,231,370
All 43,645,293 12,785,297 9,923,932 66,354,523
Men
50–74 23,893,275 2,927,826 1,059,711 27,880,812
75+ 8,850,935 3,588,805 339,274 12,779,014
All 32,744,209 6,516,632 1,398,985 40,659,826
Women and Men
50–74 41,799,471 5,505,966 7,698,528 55,003,965
75+ 34,590,032 13,795,963 3,624,389 52,010,384
All 76,389,503 19,301,929 11,322,918 107,014,349
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The total number of QALYs lost due to fracture was estimated
to rise from 11,700 in 2010 to 14,500 in 2025, corresponding
to an increase of 24 % (Table 17). The increase was estimated
to be particularly marked in men (26 %) compared to women
(22 %). Incident and prior fractures accounted for 64 % and
36 % of the increase respectively.
The cost of osteoporosis including value of QALYs lost was
estimated to increase from approximately € 390 million in
2010 to € 490 million in 2025. The increase was estimated
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Table 13 Value of lost QALYs (€) in men and women in Slovakia in
2010
1 × GDP/
capita
2 × GDP/
capita
3 × GDP/
capita
Incident hip fractures 16,389,056 32,778,111 49,167,167
Incident vertebral
fractures
24,011,984 48,023,967 72,035,951
Incident forearm
fractures
2,792,210 5,584,419 8,376,629
Incident other fractures 27,969,960 55,939,921 83,909,881
Prior hip fractures 49,575,092 99,150,184 148,725,276
Prior vertebral
fractures
20,974,906 41,949,812 62,924,718
Total 141,713,207 283,426,414 425,139,621
Table 12 Number of QALYs lost due to fractures during 2010 in men
and women in Slovakia according to age
Age (years)
50–74 75+ 50+
Women
Incident hip fractures 266 608 874
Incident vertebral fractures 601 474 1,075
Incident forearm fractures 125 50 175
Incident other fractures 541 549 1,089
Prior hip fractures 808 1,874 2,682
Prior vertebral fractures 559 558 1,116
210,7311,4998,2latoT
Men
Incident hip fractures 280 200 480
Incident vertebral fractures 706 204 909
Incident forearm fractures 50 6 56
Incident other fractures 966 256 1,222
Prior hip fractures 825 590 1,415
Prior vertebral fractures 446 171 617
007,4724,1372,3latoT
Men and Women
Incident hip fractures 547 808 1,354
Incident vertebral fractures 1,307 678 1,984
Incident forearm fractures 175 56 231
Incident other fractures 1,507 805 2,312
Prior hip fractures 1,633 2,464 4,097
Prior vertebral fractures 1,004 729 1,733
217,11935,5271,6latoT
Table 14 Population projections in Slovakia by age and sex [11]
Population
2010 2015 2020 2025
Women
50–59 405,000 388,000 362,000 377,000
60–69 279,000 342,000 379,000 364,000
70–79 187,000 198,000 232,000 289,000
80–89 95,000 98,000 101,000 112,000
90+ 9,000 15,000 19,000 22,000
Men
50–59 379,000 367,369 349,000 371,000
60–69 221,000 282,000 319,000 314,000
70–79 111,000 121,000 149,000 196,000
80–89 41,000 41,000 43,000 49,000
90+ 3,000 5,000 5,000 6,000
All
50–59 784,000 755,369 711,000 748,000
60–69 500,000 624,000 698,000 678,000
70–79 298,000 319,000 381,000 485,000
80–89 136,000 139,000 144,000 161,000
90+ 12,000 20,000 24,000 28,000
000,001,2000,037,1
Table 15 Projected annual number of incident fractures in 2010 and
2025 by fracture site and age in men and women in Slovakia
Hip Spine Forearm Other
2010 2025 2010 2025 2010 2025 2010 2025
Women
50–74 1,092 1,509 1,792 2,310 3,521 4,173 4,480 5,561
75+ 2,807 3,772 1,602 2,130 1,626 2,130 5,175 6,970
All 3,899 5,281 3,395 4,440 5,147 6,303 9,655 12,530
Men
50–74 1,111 1,511 2,057 2,697 1,433 1,768 8,085 10,164
75+ 816 1,097 627 857 173 236 2,238 2,989
All 1,927 2,609 2,683 3,553 1,606 2,004 10,322 13,153
Women and Men
50–74 2,203 3,020 3,849 5,007 4,954 5,940 12,564 15,724
75+ 3,623 4,869 2,229 2,987 1,799 2,367 7,413 9,959
All 5,826 7,889 6,078 7,994 6,753 8,307 19,977 25,683
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to be particularly marked in men (+28 %) compared to
women (+24 %) (Table 18).
Treatment uptake
To estimate uptake of individual osteoporosis treatments,
sales data from IMS health (2001–2011) were used to derive
the number of defined daily doses (DDDs) sold per 100,000
persons aged 50 years or above (Fig. 2).
Adjusting the sales data for compliance allowed for an
estimation of the proportion of population aged 50 years or
above who received any osteoporosis treatment (see Chapter
5 of the report on Osteoporosis in the European Union:
Medical Management, Epidemiology and Economic Burden
for further details). The proportion of persons over the age
of 50 years who were treated increased from 1.07 % in 2001
to 5.08 % in 2011.
Treatment gap
In order to assess the potential treatment gap, the numbers of
men and women eligible for treatment in Slovakia were de-
fined as individuals with a 10-year fracture probability ex-
ceeding that of a woman with a prior fragility fracture derived
from FRAX®, equivalent to a ‘fracture threshold’ (See Chap-
ter 5 of the main report for further details). Subsequently, these
estimates were compared to the number individuals who
received osteoporosis treatment obtained from the analysis
of IMS Health data. The treatment gaps in men and women
were estimated at 78 % and 49 % respectively (Table 19).
Note that the estimate of the treatment gap is conservative
Table 16 Current and future cost (€ 000,000) of osteoporosis (excluding
values ofQALYs lost) by age and calendar year inmen andwomen inSlovakia
2010 2015 2020 2025
Women
50–74 27 30 33 36
75+ 39 41 45 50
All 66 71 78 86
Men
50–74 28 31 35 38
75+ 13 13 14 17
All 41 45 49 54
Women and Men
50–74 55 61 68 73
75+ 52 55 59 67
All 107 116 127 140
Table 17 Projected QALYs lost due to incident and prior fractures for
the years 2010 and 2025 by age in men and women in Slovakia
Incident fractures Prior fractures All fractures
2010 2025 2010 2025 2010 2025
Women
50–74 1,533 1,948 1,366 1,591 2,899 3,538
75+ 1,681 2,239 2,432 2,768 4,113 5,007
All 3,214 4,186 3,799 4,359 7,012 8,546
Men
50–74 2,002 2,575 1,271 1,547 3,273 4,122
75+ 666 898 761 913 1,427 1,810
All 2,668 3,472 2,032 2,460 4,700 5,932
Women and Men
50–74 3,535 4,522 2,638 3,138 6,172 7,661
75+ 2,346 3,136 3,193 3,681 5,539 6,817
All 5,881 7,659 5,831 6,819 11,712 14,478
Table 18 Present and future cost (€ 000,000) of fracture (direct cost
and cost of QALYs) by age and calendar year in men and women in
Slovakia assuming the uptake of treatment remains unchanged
2010 2015 2020 2025
Women
50–74 97 104 112 121
75+ 139 145 155 172
All 236 249 267 293
Men
50–74 107 116 125 137
75+ 47 48 52 60
All 154 164 177 198
Women and Men
50–74 204 220 237 259
75+ 186 194 207 232
All 390 414 444 491
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Fig. 2 Treatment uptake in Slovakia (Defined daily doses [DDDs] per
100,000 persons aged 50 years or above)
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given that it assumes that current use of osteoporosis treat-
ments are only directed to men and women at high risk.
Sensitivity Analysis
Following the analysis presented in this report, a non-indexed
local language publication on the costs of osteoporotic frac-
ture came to our attention. This suggested that we had mark-
edly underestimated the cost of fracture [12].We estimated the
first year direct costs cost of hip, clinical spine and forearm
fracture at €4,690, €1,037 and €287, respectively whereas the
empirical cost was given as €15,889, €13,774 and €2,249,
respectively i.e. 4 to 10 times higher than the assumptions
used in the present report. Along with the inclusion of these
costs, we also updated costs for pharmaceuticals [13], physi-
cian visits and DXA scans [14], and present the results as a
sensitivity analysis. Except for the assumptions and costs
described above, all other assumptions and costs were the
same as in the base case analysis.
Fracture cost for 2010 The cost of osteoporosis in 2010 was
estimated at € 352 million (Table 20). First year costs,
subsequent year costs and pharmacological fracture preven-
tion costs amounted to € 323 million, € 19 million and € 10
million, respectively. The total cost of €352 million exceeds
the base case estimate by approximately 3-fold (see Table
10). It is notable that pharmacological fracture prevention
costs amounted to only 2.9 % of the total cost.
When stratifying costs of osteoporosis by fracture
type, “other fractures” were most costly (€154 million)
followed by hip (€99 million), spine (€ 74 million) and
forearm fractures (€ 15 million) accounting for 45 %,
29 %, 22 % and 4 % of the total cost, respectively.
Note that costs for pharmacological fracture prevention
are not included.
As would be expected, when the cost of osteoporosis was
combined with the value for QALYs lost (valued at 2 ×
GDP) the costs were substantially higher than given in the
base case. The cost of osteoporosis amounted to € 636
million in Slovakia for 2010 compared with the estimate
of € 390 million in the base case (see Table 13). Incident
fracture, prior fracture, pharmacological intervention, and
value of QALYs lost accounted for 51 %, 3 %, 2 %, and
45 % of the cost, respectively.
Fracture cost up to 2025 The cost of osteoporosis (ex-
cluding values of QALYs lost) was estimated to rise
from € 352 million in 2010 to € 467 million in 2025,
corresponding to an increase of 33 % (Table 21). This
compared to an increase from € 107 million in 2010 to
€ 140 million in the base case over the same interval
(see Table 16). Costs incurred in women and men
increased by 32 % and 34 % respectively.
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Table 19 Number of men and women eligible for treatment, treated
and treatment gap in 2010
Number
potentially
treated
(1000 s)
Number eligible
for treatment
(1000 s)
Difference
(1000 s)
Treatment
gap (%)
Men 11 50 39 78
Women 75 148 73 49
Table 20 Cost of osteoporosis (€) in Slovakia by age in men and
women, 2010
Age First year
fracture
cost
Long term
disability
costs
Fracture
prevention
cost
Total cost
Women
50–74 82,540,244 2,578,139 6,031,930 91,150,313
75+ 103,683,374 10,207,158 2,984,806 116,875,338
All 186,223,619 12,785,297 9,016,736 208,025,652
Men
50–74 101,251,373 2,927,826 962,838 105,142,037
75+ 35,315,838 3,588,805 308,259 39,212,903
All 136,567,211 6,516,632 1,271,097 144,354,940
Women and Men
50–74 183,791,617 5,505,966 6,994,768 196,292,351
75+ 138,999,213 13,795,963 3,293,066 156,088,241
All 322,790,830 19,301,929 10,287,833 352,380,592
Table 21 Current and future cost (€ 000,000) of osteoporosis (exclud-
ing values of QALYs lost) by age and calendar year in men and women
in Slovakia
2010 2015 2020 2025
Women
50–74 91 100 120 120
75+ 117 124 153 154
All 208 224 273 274
Men
50–74 105 119 105 141
75+ 39 41 39 52
All 144 160 145 194
Women and Men
50–74 196 219 225 261
75+ 156 165 193 206
All 352 384 418 467
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The cost of osteoporosis including the value of QALYs
lost was estimated to increase from approximately € 636
million in 2010 to € 818 million in 2025. This compared to
an increase from € 390 million in 2010 to € 491 million in
the base case over the same interval (see Table 18). The
increase was estimated to be more marked in men (+31 %)
compared to women (+27 %).
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Epidemiology and Economic Burden of Osteo-
porosis in Slovenia
A report prepared in collaboration with the Internation-
al Osteoporosis Foundation (IOF) and the European
Federation of Pharmaceutical Industry Associations
(EFPIA).
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Cooper, J Stenmark, EV McCloskey, B Jönsson, T
Kocjan and JA Kanis
Moa Ivergård, OptumInsight, Stockholm, Sweden
Abstract
Summary This report describes epidemiology, burden, and
treatment of osteoporosis in Slovenia.
Introduction Osteoporosis is characterized by reduced bone
mass and disruption of bone architecture, resulting in in-
creased risks of fragility fractures which represent the main
clinical consequence of the disease. Fragility fractures are
associated with substantial pain and suffering, disability and
even death for the affected patients and substantial costs to
society. The aim of this study is to describe the epidemiology
and economic burden of fragility fractures as a consequence of
osteoporosis in Slovenia, as a further detailed addition to the
report for the entire European Union (EU27): Osteoporosis in
the European Union: Medical Management, Epidemiology
and Economic Burden.
Methods The literature on fracture incidence and costs of
fractures in the EU27 was reviewed and incorporated
into a model estimating the clinical and economic bur-
den of osteoporotic fractures in 2010. Furthermore, data
on sales of osteoporosis treatments and the population at
high risk were used to estimate treatment uptake and
treatment gap.
Results It was estimated that approximately 16,000 new
fragility fractures were sustained in Slovenia, comprising
3,000 hip fractures, 2,000 vertebral fractures, 2,000 forearm
fractures and 8,000 other fractures (i.e. fractures of the
pelvis, rib, humerus, tibia, fibula, clavicle, scapula, sternum
and other femoral fractures) in 2010. The economic burden
of incident and previous fragility fractures was estimated at
€ 56 million for the same year. Incident fractures represented
65 % of this cost, long-term fracture care 23 % and phar-
macological prevention 13 %. Previous and incident frac-
tures also accounted for 4,900 quality-adjusted life years
(QALYs) lost during 2010. When accounting for the demo-
graphic projections for 2025, the number of incident frac-
tures was estimated at 22,000 in 2025, representing an
increase of 6,000 fractures. Hip, clinical spine, forearm
and other fractures were estimated to increase by 1,400,
900, 700 and 3,400, respectively. The burden of fractures
in Slovenia in 2025 was estimated to increase by 37 % to €
77 million. Though the uptake of osteoporosis treatments
increased from 2001, the proportion of patients aged 50 or
above who received treatment remained at very low levels in
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the past few years. A substantial minority of women at high
fracture risk did not receive active treatment.
Conclusions In spite of the high cost of osteoporosis, a
substantial treatment gap and projected increase of the eco-
nomic burden driven by an aging population, the use of
pharmacological prevention of osteoporosis is significantly
less than optimal, suggesting that a change in healthcare
policy concerning the disease is warranted.
Introduction
Osteoporosis is characterized by reduced bone mass and
disruption of bone architecture, resulting in increased risks
of fragility fractures which represent the main clinical con-
sequence of the disease. Fragility fractures are associated
with substantial pain and suffering, disability and even death
for the affected patients and substantial costs to society. The
aim of this report was to characterize the burden of osteo-
porosis in Slovenia in 2010 and beyond.
Methods
The literature on fracture incidence and costs of fractures in
Slovenia was reviewed and incorporated into a model esti-
mating the clinical and economic burden of osteoporotic
fractures in 2010. Details of the methods used are found in
Chapters 3 and 4 of the report Osteoporosis in the
European Union: Medical Management, Epidemiology
and Economic Burden, published concurrently in Ar-
chives of Osteoporosis.
Epidemiology of osteoporosis in Slovenia
For the purpose of this report, the population at risk of
osteoporosis was considered to include men and women
≥50 years. The number of men and women ≥50 years of
age amounted to 343,000 and 416,000 respectively in Slo-
venia in 2010 (Table 1).
In the population at risk, the number of individuals with
osteoporosis—as defined by the WHO diagnostic
criteria—was estimated at 110,000 (Table 2). There are 27.1
DXA scan machines per million inhabitants [2], and guidelines
for the assessment and treatment of osteoporosis are available
[3]. A country specific FRAX model for the assessment
of fracture risk is not available for Slovenia.
Detailed incidence data were not available for Slovenia,
therefore data for hip fractures were imputed from Hungar-
ian age-standardized incidence rates [5]. The incidences of
vertebral, forearm and “other” fractures were imputed using
the methods described in Chapter 3 of the main report.
Fracture incidence is presented in Table 3. Standardized to
Table 1 Population at risk: men and women over the age of 50 in
Slovenia, 2010 [1]
Age (years) Women Men All
50–59 151,000 155,000 306,000
60–69 111,000 102,000 213,000
70–79 94,000 64,000 158,000
80–89 54,000 21,000 75,000
90+ 6,000 1,000 7,000
50+ 416,000 343,000 759,000
Table 2 Estimated number of women and men with osteoporosis
(defined as a T-score ≤−2.5 SD) in Slovenia by age using female-
derived reference ranges at the femoral neck, 2010 [4]
Age (years) Women Men
50–54 4,851 1,950
55–59 7,104 2,695
60–64 8,866 3,422
65–69 9,898 3,182
70–74 13,950 2,964
75–79 16,500 2,678
80+ 28,320 3,652
50+ 89,489 20,543
Table 3 Incidence per 100,000 person years of hip, clinical vertebral,
forearm, and “other” fractures in Slovenia by age
Fracture at the
Age (years) hip vertebra forearm other
Women
50–
55–
60–
65–
70–
75–
80–84 1,385 870 867 2,355
Men
50–
55–
60–
65–
70–
75–
80–
54 10 25 61 63
59 46 126 350 400
64 91 161 345 352
69 156 228 380 534
74 285 402 512 808
79 557 542 544 1,173
85+ 2,684 1,263 1,146 4,509
54 13 33 12 57
59 66 115 100 614
64 107 255 201 1,050
69 142 224 214 918
74 190 290 122 976
79 377 435 107 1,007
84 872 606 169 2,319
85+ 1,660 1,115 304 4,807
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the EU27 population, this hip fracture incidence (per
100,000 person years) in men and women ≥50 years of
age was estimated at 273.8 and 558.6 respectively.
The number of incident fractures in 2010 was estimated
at approximately 15,500 (Table 4). Incident hip, clinical
spine, forearm and “other” fractures were estimated at
2,800, 2,300, 2,500 and 7,900 respectively. 64 % of frac-
tures occurred in women.
In the population ≥50 years of age, the proportion of in-
dividuals who had suffered a fracture prior to 2010 was
estimated at 1.64 % for hip and 1.88 % for vertebral fractures.
The estimated proportions of men and women with prior hip
and clinical vertebral fractures by age are presented in Table 5.
In the population over 50 years of age, the number of
individuals with hip and vertebral fractures that occurred
before 2010 was estimated at 12,000 and 14,000 respective-
ly (Table 6). Note that fractures sustained in 2010 were not
included in the estimate.
The incidence of causally related deaths (per 100,000) in
the first year after fracture by age is presented in Table 7.
The number of causally related deaths in 2010 was estimat-
ed at 192 (Table 8). Hip, vertebral and “other” fractures
accounted for 95, 66 and 31 deaths respectively. Overall,
approximately 54 % of deaths occurred in women.
Cost of osteoporosis in Slovenia including and excluding
values of QALYs lost
For the purpose of this report, the cost of osteoporosis
in 2010 (excluding value of QALYs lost) was consid-
ered to consist of three components: (i) cost of fractures
that occurred in 2010 (“first year costs”); (ii) cost of
fractures sustained prior to year 2010 but which still
incurred costs in 2010 (“long-term disability cost”); and
(iii) cost of pharmacological fracture prevention inclu-
ding administration and monitoring costs (“phar-
macological fracture prevention costs”). See Chapter 4
of the main report for further details.
In Slovenia, the costs of hip, vertebral, and forearm
fractures have been estimated at € 5,306, € 810, and
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Table 4 Estimated number of incident fractures in Slovenia, 2010
Fracture at the All
Age (years) hip vertebra forearm other fractures
Women
50–
Men
50–
Men and Women
50–
74 373 578 1,090 1,433 3,474
75+ 1,659 873 887 3,069 6,487
Total 2,032 1,451 1,977 4,502 9,962
74 314 563 392 2,235 3,504
75+ 434 327 91 1,192 2,044
Total 748 890 483 3,427 5,548
74 687 1,141 1,482 3,668 6,979
75+ 2,092 1,200 978 4,261 8,531
Total 2,780 2,341 2,460 7,929 15,510
Table 5 Proportion of men and women (in %) with a prior hip or
clinical fracture in Slovenia, 2010
Age (years) Hip fracture Vertebral fracture
Women
50– 1.00.045
55– 5.02.095
60– 1.15.046
65– 8.10.196
70– 9.27.147
75– 2.41.397
80– 1.63.648
4.015.41+58
Men
50– 1.00.045
55– 5.03.095
60– 1.16.046
65– 7.10.196
70– 0.25.147
75– 6.22.297
80– 6.32.448
6.61.9+58
Table 6 Number of men and women in Slovenia with a prior hip or
clinical fracture after the age of 50 years, 2010
Age (years) Hip fracture Vertebral fracture
Women
50– 184,3238,147
795,6902,7+57
770,01140,9latoT
Men
50– 945,2745,147
976,1148,1+57
922,4883,3latoT
Men and Women
50– 030,6973,347
672,8050,9+57
603,41924,21latoT
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€ 161, respectively [6]. Costs for “other fractures” were
imputed as described in Chapter 4 of the main report.
Long-term disability costs were estimated by multiplying
the yearly cost of residing in nursing home (€ 11,308 [7])
with the simulated number of individuals with prior
fractures that had been transferred to nursing home due to
the fracture.
Annual drug cost (€) for individual treatments is shown in
Table 9. In addition, it was assumed that patients on treatment
made an annual physician visit costing € 15 [8] and a DXA
scan costing € 29 [8] every second year to monitor treatment.
The cost of osteoporosis in 2010 was estimated at € 56
million (Table 10). First year costs, subsequent year costs and
pharmacological fracture prevention costs amounted to € 36
million, € 13 million and € 7 million respectively. It is notable
that pharmacological fracture prevention costs amounted to
only 12.5 % of the total cost.
When stratifying costs of osteoporosis by fracture type, hip
fractures were most costly (€ 26 million) followed by “other”
(€ 21 million), spine (€ 2 million) and forearm fractures (€
0.4 million) (Table 11 and Fig. 1). Please note that costs for
pharmacological fracture prevention were not included given
that they cannot be allocated to specific fracture sites.
Table 7 Incidence (per 100,000) of causally related deaths in Slovenia
within the first year after fracture (adjusted for comorbidities), 2010
Age (years) Hip Clinical vertebral “Other” fracture
Women
50–54 657 854 17
55–59 897 1,103 27
60–64 1,131 1,314 36
65–69 1,455 1,595 55
70–74 1,653 1,706 75
75–79 2,496 2,412 157
80–84 2,833 2,507 316
85–89 3,645 2,834 639
90+ 2,953 1,665 1,027
Men
50–54 2,251 2,700 35
55–59 2,832 3,220 58
60–64 2,758 2,966 75
65–69 3,633 3,685 130
70–74 4,228 4,026 191
75–79 5,463 4,845 324
80–84 6,108 4,960 513
85–89 7,690 5,620 831
90+ 10,085 6,563 1,262
Table 8 The number of deaths in men and women in Slovenia in the
first year after fracture attributable to the fracture event (causally
related), 2010
Fracture at the
Age (years) hip vertebra “other”
Women
50–
Men
50–
Men and Women
50–
74 6 9 1
75+ 49 20 19
Total 55 29 20
74 11 20 3
75+ 29 17 8
Total 41 37 11
74 17 29 3
75+ 78 36 28
Total 95 66 31
Table 9 One year costs for relevant pharmaceuticals in Slovenia, 2010 [9]
Annual drug cost (€)
Alendronate 161
Risedronate 332
Etidronte -
Ibandronate 104
Zoledronic acid 360
Raloxifene 323
Strontium ranelate 474
Parathyroid hormone -
Teriparatide 5,193
Table 10 Cost of osteoporosis (€) in Slovenia by age in men and
women, 2010
Age
(years)
First year
fracture
cost
Long term
disability
costs
Fracture
prevention
cost
Total cost
Women
50–74 6,511,255 1,295,316 3,760,056 11,566,627
75+ 16,720,093 7,799,570 2,386,366 26,906,029
All 23,231,349 9,094,886 6,146,422 38,472,657
Men
50–74 7,649,012 1,301,927 636,428 9,587,367
75+ 5,348,734 2,391,354 229,696 7,969,783
All 12,997,746 3,693,281 866,124 17,557,150
Women and Men
50–74 14,160,267 2,597,243 4,396,484 21,153,994
75+ 22,068,827 10,190,923 2,616,062 34,875,813
All 36,229,094 12,788,167 7,012,546 56,029,807
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The number of quality adjusted life years (QALYs) lost
due to osteoporosis in 2010 was estimated at 4,900 (Table
12). Prior fractures accounted for 52 % of the total loss and
66 % of the loss occurred in women. The monetary value of
a QALY was varied between 1 to 3 times the gross domestic
product (GDP) per capita (Table 13). Assuming a QALY is
valued at 2 times GDP/capita, the total cost of the QALYs
lost was estimated at € 170 million.
When the cost of osteoporosis was combined with the
value for QALYs lost (valued at 2 × GDP), the cost of
osteoporosis amounted to € 220 million in Slovenia in
2010. Incident fracture, prior fracture, pharmacological frac-
ture prevention, and value of QALYs lost accounted for
16 %, 6 %, 3 %, 75 % respectively.
Burden of osteoporosis up to 2025
The population above 50 years of age is expected to increase
from 760,000 in 2010 to 910,000 in 2025, corresponding to
an increase of 20 % (Table 14).
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Table 11 Total cost (€) in 2010 by fracture site in men and women in
Slovenia. Note that costs for fracture prevention therapy and monitor-
ing are not included
Age Hip Spine Forearm Other All
Women
50–74 3,195,677 450,107 175,397 3,985,391 7,806,572
75+ 15,540,455 636,964 142,667 8,199,577 24,519,663
All 18,736,132 1,087,071 318,065 12,184,967 32,326,234
Men
50–74 2,825,804 417,419 63,034 5,644,682 8,950,939
75+ 4,227,361 221,388 14,648 3,276,691 7,740,088
All 7,053,164 638,807 77,682 8,921,373 16,691,027
Women and Men
50–74 6,021,480 867,526 238,431 9,630,073 16,757,511
75+ 19,767,816 858,352 157,315 11,476,268 32,259,751
All 25,789,296 1,725,878 395,747 21,106,340 49,017,261
Hip
53%
Spine
3%
Forearm
1%
Other
43%
Fig. 1 Share (%) of fracture cost by fracture site in Slovenia. Note that
costs for fracture prevention therapy and monitoring are not included
Table 12 Number of QALYs lost due to fractures during 2010 in men
and women in Slovenia according to age
Age (years)
50–74 75+ 50+
Women
Incident hip fractures 90 350 440
Incident vertebral fractures 191 252 443
Incident forearm fractures 38 27 65
Incident other fractures 172 320 491
Prior hip fractures 287 977 1,264
Prior vertebral fractures 194 322 516
022,3742,2279latoT
Men
Incident hip fractures 77 105 182
Incident vertebral fractures 188 105 294
Incident forearm fractures 14 3 17
Incident other fractures 265 136 401
Prior hip fractures 242 273 515
Prior vertebral fractures 141 89 230
836,1117729latoT
Men and Women
Incident hip fractures 167 454 621
Incident vertebral fractures 380 357 737
Incident forearm fractures 52 30 82
Incident other fractures 437 456 892
Prior hip fractures 528 1,251 1,779
Prior vertebral fractures 336 411 746
858,4859,2009,1latoT
Table 13 Value of lost QALYs (€) in men andwomen in Slovenia in 2010
1 × GDP/
capita
2 × GDP/
capita
3 × GDP/
capita
Incident hip fractures 10,751,278 21,502,555 32,253,833
Incident vertebral
fractures
12,743,758 25,487,517 38,231,275
Incident forearm
fractures
1,418,350 2,836,700 4,255,049
Incident other fractures 15,437,686 30,875,372 46,313,059
Prior hip fractures 30,782,194 61,564,389 92,346,583
Prior vertebral
fractures
12,910,724 25,821,448 38,732,172
Total 84,043,990 168,087,981 252,131,971
Arch Osteoporos (2013) 8:137
The total number of fractures was estimated to rise from
16,000 in 2010 to 22,000 in 2025 (Table 15), corresponding
to an increase of 41 %. Hip, clinical spine, forearm and other
fractures increased by 1,400, 900, 700 and 3,400 respective-
ly. The increase in the number of fractures ranged from 27 %
to 50 %, depending on fracture site. The increase was
estimated to be particularly marked in men (47 %) compared
to women (37 %).
The cost of osteoporosis (excluding value of QALYs lost)
was estimated to rise from € 56 million in 2010 to € 77
million in 2025, corresponding to an increase of 37 % (Table
16). Costs incurred in women and men increased by 32 %
and 47 % respectively.
The total number of QALYs lost due to fracture was
estimated to rise from 4,900 in 2010 to 6,300 in 2025,
corresponding to an increase of 30 % (Table 17). The
increase was estimated to be particularly marked in men
Table 14 Population projections in Slovenia by age and sex [10]
Population
2010 2015 2020 2025
Women
50–59 151,000 153,000 149,000 145,000
60–69 111,000 132,000 144,000 147,000
70–79 94,000 92,000 98,000 117,000
80–89 54,000 59,000 62,000 61,000
90+ 6,000 12,000 15,000 18,000
Men
50–59 155,000 152,654 150,000 150,000
60–69 102,000 127,000 138,000 138,000
70–79 64,000 67,000 78,000 98,000
80–89 21,000 26,000 31,000 33,000
90+ 1,000 2,000 3,000 5,000
All
50–59 306,000 305,654 299,000 295,000
60–69 213,000 259,000 282,000 285,000
70–79 158,000 159,000 176,000 215,000
80–89 75,000 85,000 93,000 94,000
90+ 7,000 14,000 18,000 23,000
000,219000,957
Table 15 Projected annual number of incident fractures in 2010 and
2025 by fracture site and age in men and women in Slovenia
Hip Spine Forearm Other
2010 2025 2010 2025 2010 2025 2010 2025
Women
50–74 373 477 578 715 1,090 1,295 1,433 1,745
75+ 1,659 2,483 873 1,225 887 1,177 3,069 4,578
All 2,032 2,960 1,451 1,940 1,977 2,473 4,502 6,323
Men
50–74 314 410 563 716 392 478 2,235 2,750
75+ 434 796 327 603 91 167 1,192 2,228
All 748 1,206 890 1,319 483 645 3,427 4,978
Women and Men
50–74 687 887 1,141 1,431 1,482 1,773 3,668 4,495
75+ 2,092 3,279 1,200 1,829 978 1,344 4,261 6,806
All 2,780 4,166 2,341 3,260 2,460 3,117 7,929 11,301
Table 16 Current and future cost (€ 000,000) of osteoporosis (exclud-
ing value of QALYs lost) by age and calendar year in men and women
in Slovenia
2010 2015 2020 2025
Women
50–74 12 12 13 14
75+ 27 31 33 37
All 38 43 47 51
Men
50–74 10 10 12 12
75+ 8 10 11 13
All 18 20 23 26
Women and Men
50–74 21 23 25 27
75+ 35 41 44 50
All 56 63 69 77
Table 17 Projected QALYs lost due to incident and prior fractures for
the years 2010 and 2025 by age in men and women in Slovenia
Incident fractures Prior fractures All fractures
2010 2025 2010 2025 2010 2025
Women
50–74 491 604 481 529 972 1,133
75+ 948 1,360 1,299 1,542 2,247 2,902
All 1,439 1,964 1,780 2,071 3,220 4,035
Men
50–74 544 682 383 458 927 1,139
75+ 349 643 362 509 711 1,151
All 893 1,324 745 966 1,638 2,291
Women and Men
50–74 1,036 1,286 864 987 1,900 2,273
75+ 1,297 2,003 1,662 2,050 2,958 4,053
All 2,332 3,289 2,526 3,037 4,858 6,325
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(40 %) compared to women (25 %). Incident and prior
fractures accounted for 65 % and 35 % of the increase
respectively.
The cost of osteoporosis including value of QALYs lost
was estimated to increase from approximately € 224 million
in 2010 to € 296 million in 2025. The increase was estimat-
ed to be particularly marked in men (+41 %) compared to
women (+27 %) (Table 18).
Treatment uptake
To estimate uptake of individual osteoporosis treatments,
sales data from IMS Health (2001–2011) were used to
derive the number of defined daily doses (DDDs) sold per
100,000 persons aged 50 years or above (Fig. 2).
Adjusting the sales data for compliance allowed for an
estimation of the proportion of population aged 50 years or
above who received any osteoporosis treatment (see Chapter 5
of the report on Osteoporosis in the European Union: Medical
Management, Epidemiology and Economic Burden for fur-
ther details). The proportion of persons over the age of
50 years who were treated increased from 2.35 % in 2001 to
5.88% in 2008 but subsequently decreased to 5.11 % in 2011.
Treatment gap
In order to assess the potential treatment gap, the numbers of
men and women eligible for treatment in Slovenia were de-
fined as individuals with a 10-year fracture probability ex-
ceeding that of a woman with a prior fragility fracture derived
from FRAX, equivalent to a ‘fracture threshold’ (See Chapter
5 of the main report for further details). Given that a FRAX
model for Slovenia was not available, the FRAX model for
Hungary was used as a surrogate. Subsequently, these esti-
mates were compared to the number of individuals who
received osteoporosis treatment obtained from the analysis
of IMS Health data. The treatment gaps in men and women
were estimated at 63 % and 44 % respectively (Table 19).
Note that the estimate of the treatment gap is conservative
given that it assumes that current use of osteoporosis treat-
ments are only directed to men and women at high risk.
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Abstract
Summary This report describes epidemiology, burden, and
treatment of osteoporosis in Spain.
Introduction Osteoporosis is characterized by reduced
bone mass and disruption of bone architecture, resulting
in increased risks of fragility fractures which represent
the main clinical consequence of the disease. Fragility
fractures are associated with substantial pain and suffer-
ing, disability and even death for the affected patients
and substantial costs to society. The aim of this study is
to describe the epidemiology and economic burden of
fragility fractures as a consequence of osteoporosis in
Spain, as a further detailed addition to the report for the
entire European Union (EU27): Osteoporosis in the Eu-
ropean Union: Medical Management, Epidemiology and
Economic Burden.
Methods The literature on fracture incidence and costs of
fractures in the EU27 was reviewed and incorporated
into a model estimating the clinical and economic bur-
den of osteoporotic fractures in 2010. Furthermore, data
on sales of osteoporosis treatments and the population at
high risk were used to estimate treatment uptake and
treatment gap.
Results It was estimated that approximately 204,000 new
fragility fractures were sustained in Spain, comprising
40,000 hip fractures, 30,000 vertebral fractures, 30,000 fore-
arm fractures and 104,000 other fractures (i.e. fractures of the
pelvis, rib, humerus, tibia, fibula, clavicle, scapula, sternum
and other femoral fractures) in 2010. The economic burden of
incident and previous fragility fractures was estimated at €
2,842 million for the same year. Incident fractures represented
48 % of this cost, long-term fracture care 37 % and pharma-
cological prevention 15 %. Previous and incident fractures
also accounted for 70,800 quality-adjusted life years (QALYs)
lost during 2010. When accounting for the demographic pro-
jections for 2025, the number of incident fractures was esti-
mated at 286,000 in 2025, representing an increase of 82,000
fractures. Hip, clinical vertebral (spine), forearm and other
fractures were estimated to increase by 16,700, 11,500,
10,000 and 43,500, respectively. The burden of fractures in
Spain in 2025 was estimated to increase by 30 % to € 3,680
million. Though the uptake of osteoporosis treatments in-
creased from 2001, the proportion of patients aged 50 or
above who received treatment declined in the past few years.
Arch Osteoporos (2013) 8:137 Page 195 of 218, 137
Epidemiology and Economic Burden of Osteoporosis
in Spain
A report prepared in collaboration with the International Osteoporosis Foundation (IOF)
and the European Federation of Pharmaceutical Industry Associations (EFPIA)
Moa Ivergård & Axel Svedbom & Emma Hernlund &
Juliet Compston & Cyrus Cooper & Judy Stenmark &
Eugene V. McCloskey & Bengt Jönsson &
Adolfo Diez-Perez & John A. Kanis
M. Ivergård :A. Svedbom : E. Hernlund
OptumInsight, Stockholm, Sweden
J. Compston
Department of Medicine, Addenbrooke’s Hospital,
Cambridge University, Cambridge, UK
C. Cooper
MRC Lifecourse Epidemiology Unit, University of Southampton,
Southampton and NIHR Musculoskeletal Biomedical Research Unit,
Institute ofMusculoskeletal Sciences, University of Oxford, Oxford, UK
J. Stenmark
International Osteoporosis Foundation, Nyon, Switzerland
E. V. McCloskey
Academic Unit of Bone Metabolism, Northern General Hospital,
Sheffield, UK and WHO Collaborating Centre for Metabolic Bone
Diseases, University of Sheffield, Sheffield, UK
B. Jönsson
Stockholm School of Economics, Stockholm, Sweden
A. Diez-Perez
Department of Internal Medicine, Hospital del Mar-IMIM,
University of Barcelona, Barcelona, Spain
J. A. Kanis
WHO Collaborating Centre for Metabolic Bone Diseases,
University of Sheffield, Sheffield, UK
J. A. Kanis (*)
WHO Collaborating Centre for Metabolic Bone Diseases,
University of Sheffield Medical School, Beech Hill Road,
Sheffield S10 2RX, UK
e-mail: w.j.pontefract@shef.ac.uk
A substantial minority of women at high fracture risk did not
receive active treatment.
Conclusions In spite of the high cost of osteoporosis, a
substantial treatment gap and projected increase of the eco-
nomic burden driven by an aging population, the use of
pharmacological prevention of osteoporosis is significantly
less than optimal, suggesting that a change in healthcare
policy concerning the disease is warranted.
Introduction
Osteoporosis is characterized by reduced bone mass and
disruption of bone architecture, resulting in increased risks
of fragility fractures which represent the main clinical con-
sequence of the disease. Fragility fractures are associated
with substantial pain and suffering, disability and even death
for the affected patients and substantial costs to society. The
aim of this report was to characterize the burden of osteo-
porosis in Spain in 2010 and beyond.
Methods
The literature on fracture incidence and costs of frac-
tures in Spain was reviewed and incorporated into a
model estimating the clinical and economic burden of
osteoporotic fractures in 2010. Details of the methods
used are found in Chapters 3 and 4 of the report
Osteoporosis in the European Union: Medical Manage-
ment, Epidemiology and Economic Burden, published
concurrently in Archives of Osteoporosis.
Epidemiology of osteoporosis in Spain
For the purpose of this report, the population at risk of
osteoporosis was considered to include men and women
≥50 years. The number of men and women ≥50 years of
age amounted to 7,277,000 and 8,628,000 respectively in
Spain in 2010 (Table 1).
In the population at risk, the number of individuals with
osteoporosis—as defined by the WHO diagnostic criteria—was
estimated at 2,450,000 (Table 2). There are 8.4 DXA scan
machines per million inhabitants [2], and guidelines for the
assessment and treatment of osteoporosis are available [3]. A
country specific FRAX model is also available for the assess-
ment of fracture risk (http://www.shef.ac.uk/FRAX/).
Incidence data for hip fractures were retrieved from mean
values of four regional estimates [5–8]. Given that country
specific incidence of vertebral, forearm and, “other” frac-
tures were not found, these were imputed using the methods
described in Chapter 3 of the main report. Fracture inci-
dence is presented in Table 3. Standardized to the EU27
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Table 1 Population at risk: men and women over the age of 50 in
Spain, 2010 [1]
Age (years) Women Men All
50–59 2,859,000 2,774,000 5,633,000
60–69 2,351,000 2,141,000 4,492,000
70–79 1,961,000 1,543,000 3,504,000
80–89 1,234,000 735,000 1,969,000
90+ 223,000 84,000 307,000
50+ 8,628,000 7,277,000 15,905,000
Table 2 Estimated number of women and men with osteoporosis
(defined as a T-score ≤−2.5 SD) in Spain by age using female-
derived reference ranges at the femoral neck, 2010 [4]
Age (years) Women Men
50–54 96,705 37,625
55–59 127,104 44,415
60–64 182,039 68,382
65–69 217,756 71,188
70–74 272,304 62,790
75–79 369,375 76,014
80+ 687,704 135,954
50+ 1,952,987 496,368
Table 3 Incidence per 100,000 person years of hip, clinical vertebral,
forearm, and “other” fractures in Spain by age
Fracture at the
Age (years) hip vertebra forearm other
Women
50–54 8 21 51 53
55–59 24 65 181 207
60–64 44 78 166 170
65–69 75 110 183 258
70–74 179 253 322 508
75–79 386 375 376 811
80–84 858 540 537 1,460
85+ 1,709 804 729 2,870
Men
50–54 5 14 5 23
55–59 17 30 26 159
60–64 42 102 80 417
65–69 54 85 81 347
70–74 103 157 66 527
75–79 190 219 54 507
80–84 387 269 75 1,029
85+ 811 545 149 2,349
137, Page 196 of 218
population, hip fracture incidence (per 100,000 person
years) in men and women ≥50 years of age was estimated
at 125.9 and 353.0 respectively.
The number of incident fractures in 2010 was estimated at
204,000 (Table 4). Incident hip, clinical spine, forearm and
“other” fractures were estimated at 40,000, 30,000, 30,000
and 104,000 respectively. 68% of fractures occurred inwomen.
A prior fracture was defined as a fracture in an individual
who was alive during the index year (i.e. 2010) which had
occurred after the age of 50 years and before 2010. In the
population ≥50 years of age, the proportion of individuals
who had suffered a fracture prior to 2010 was estimated at
1.32 % for hip and 1.34 % for clinical vertebral fractures.
The estimated proportions of men and women with prior hip
and vertebral fractures by age are presented in Table 5.
In the population over 50 years of age, the number of
individuals with hip and vertebral fractures that occurred
before 2010 was estimated at 211,000 and 212,000 respec-
tively (Table 6). Note that fractures sustained in 2010 were
not included in the estimate.
The incidence of causally related deaths (per 100,000) in
the first year after fracture by age is presented in Table 7.
The number of causally related deaths in 2010 was estimat-
ed at 2,550 (Table 8). Hip, vertebral and “other” fractures
accounted for 1,289, 719 and 542 deaths respectively. Over-
all, approximately 53 % of deaths occurred in women.
Cost of osteoporosis in Spain including and excluding
values of QALYs lost
For the purpose of this report, the cost of osteoporosis in
2010 (excluding value of QALYs lost) was considered to
consist of three components: (i) cost of fractures that
occurred in 2010 (“first year costs”); (ii) cost of frac-
tures sustained prior to year 2010 but which still in-
curred costs in 2010 (“long-term disability cost”); and
(iii) cost of pharmacological fracture prevention includ-
ing administration and monitoring costs (“pharmacolog-
ical fracture prevention costs”). See Chapter 4 of the
main report for further details.
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Table 4 Estimated number of incident fractures in Spain, 2010
Fracture at the All
Age (years) hip vertebra forearm other fractures
Women
50–74 4,102 6,127 11,626 15,596 37,450
75+ 25,929 13,028 13,529 49,483 101,969
Total 30,030 19,155 25,155 65,079 139,419
Men
50–74 2,694 4,723 2,946 17,304 27,667
75+ 7,748 5,811 1,617 21,889 37,066
Total 10,442 10,534 4,563 39,193 64,733
Men and Women
50–74 6,796 10,850 14,572 32,900 65,117
75+ 33,677 18,839 15,147 71,372 139,035
Total 40,473 29,689 29,719 104,272 204,152
Table 5 Proportion of men and women (in %) with a prior hip or
clinical vertebral fracture in Spain, 2010
Age (years) Hip fracture Vertebral fracture
Women
50– 0.00.045
55– 3.01.095
60– 6.03.046
65– 0.16.096
70– 8.11.147
75– 9.22.297
80– 3.45.448
6.75.11+58
Men
50– 0.00.045
55– 1.01.095
60– 4.02.046
65– 8.04.096
70– 1.17.047
75– 5.12.197
80– 0.23.248
1.40.6+58
Table 6 Number of men and women in Spain with a prior hip or
clinical vertebral fracture after the age of 50 years, 2010
Age (years) Hip fracture Vertebral fracture
Women
50– 422,04581,2247
407,311258,431+57
729,351730,751latoT
Men
50– 279,32792,3147
925,43622,04+57
105,85325,35latoT
Men and Women
50– 691,46284,5347
332,841870,571+57
824,212065,012latoT
The cost of a hip fracture has been estimated at €
9,421 in Spain, imputed from the UK data [9,10] by
adjusting for differences in health care price levels.
Given that no cost data for the other fracture sites were
found, these were imputed as described in Chapter 4 of
the main report.
Long-term disability costs were estimated by multiplying
the yearly cost of residing in nursing home (€ 51,786 [11])
with the simulated number of individuals with prior frac-
tures that had been transferred to nursing homes due to the
fracture.
Annual drug cost (€) for individual treatments is shown
in Table 9 for 2010. For the purposes of this report drug
costs were used for 2010 [12]. In addition, it was assumed
that patients on treatment made an annual physician visit
costing € 109 [13] and a DXA scan costing € 79 [14] every
second year to monitor treatment.
The cost of osteoporosis in 2010 was estimated at €
2,842 million (Table 10). First year costs, subsequent
year costs and pharmacological fracture prevention costs
amounted to € 1,372 million, € 1,055 million and € 414
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Table 7 Incidence (per 100,000) of causally related deaths in Spain
within the first year after fracture (adjusted for comorbidities), 2010
Age (years) Hip Clinical vertebral “Other” fracture
Women
50–54 464 604 12
55–59 509 626 15
60–64 774 898 25
65–69 1,049 1,150 39
70–74 1,410 1,455 64
75–79 1,979 1,912 124
80–84 2,260 1,999 252
85–89 2,962 2,303 519
90+ 2,837 1,599 986
Men
50–54 1,796 2,154 28
55–59 2,038 2,317 42
60–64 2,525 2,715 68
65–69 2,891 2,932 104
70–74 3,429 3,265 155
75–79 4,199 3,724 249
80–84 5,079 4,125 427
85–89 6,810 4,977 736
90+ 9,709 6,318 1,215
Table 8 The number of deaths in men and women in Spain in the first
year after fracture attributable to the fracture event (causally related), 2010
Fracture at the
Age (years) hip vertebra “other”
Women
50–
Men
50–
Men and Women
50–
74 51 74 8
75+ 648 233 341
Total 699 308 348
74 83 141 18
75+ 507 271 175
Total 590 411 194
74 134 215 26
75+ 1,155 504 516
Total 1,289 719 542
Table 9 One year costs
for relevant pharmaceu-
ticals in Spain, 2010 [12]
Annual drug
cost (€)
Alendronate 150
Risedronate 238
Etidronate 14
Ibandronate 156
Zoledronic acid 422
Denosumab* 480
Raloxifene 248
Bazedoxifene* 413
Strontium ranelate 593
Parathyroid hormone 4,754
Teriparatide 4,865
Table 10 Cost of osteoporosis (€) in Spain by age in men and women,
2010
Age
(years)
First year
fracture
cost
Long term
disability
costs
Fracture
prevention
cost
Total cost
Women
50–74 152,012,122 72,019,926 210,802,334 434,834,382
75+ 807,370,308 687,245,489 152,314,690 1,646,930,486
All 959,382,430 759,265,414 363,117,024 2,081,764,868
Men
50–74 127,703,007 53,816,151 32,436,227 213,955,385
75+ 285,123,435 242,199,475 18,525,842 545,848,752
All 412,826,442 296,015,626 50,962,069 759,804,137
Women and Men
50–74 279,715,129 125,836,077 243,238,561 648,789,767
75+ 1,092,493,743 929,444,963 170,840,532 2,192,779,238
All 1,372,208,872 1,055,281,040 414,079,092 2,841,569,005
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million respectively. It is notable that pharmacological
fracture prevention costs amounted to only 14.6 % of
the total cost.
When stratifying costs of osteoporosis by fracture
type, hip fractures were most costly (€ 1,591 million)
followed by “other” (€ 742 million), spine (€ 63 million)
and forearm fractures (€ 32 milllion) (Table 11 and Fig.
1). Please note that costs for pharmacological fracture
prevention were not included given that they cannot be
allocated to specific fracture sites.
The number of quality adjusted life years (QALYs)
lost due to osteoporosis in 2010 was estimated at
70,800 (Table 12). Prior fractures accounted for 57 %
of the total loss and 69 % of the loss occurred in
women. The monetary value of a QALY was varied
between 1 to 3 times the gross domestic product
Arch Osteoporos (2013) 8:137 Page 199 of 218, 137
Table 11 Total cost (€) in 2010 by fracture site in men and women in Spain. Note that costs for fracture prevention therapy and monitoring are not
included.
Hip
65%
Spine
3%
Forearm
1%
Other
31%
Fig. 1 Share (%) of fracture cost by fracture site in Spain. Note that
costs for fracture prevention therapy and monitoring are not included
Table 12 Number of QALYs lost due to fractures during 2010 in men
and women in Spain according to age
Age (years)
50–74 75+ 50+
Women
Incident hip fractures 980 5,368 6,348
Incident vertebral fractures 2,014 3,697 5,710
Incident forearm fractures 409 408 817
Incident other fractures 1,861 5,100 6,961
Prior hip fractures 3,466 18,038 21,504
Prior vertebral fractures 2,242 5,491 7,733
370,94201,83079,01latoT
Men
Incident hip fractures 655 1,850 2,505
Incident vertebral fractures 1,563 1,845 3,408
Incident forearm fractures 102 53 154
Incident other fractures 2,042 2,484 4,526
Prior hip fractures 2,071 5,926 7,998
Prior vertebral fractures 1,327 1,815 3,141
337,12379,31067,7latoT
Men and Women
Incident hip fractures 1,635 7,218 8,853
Incident vertebral fractures 3,577 5,542 9,119
Incident forearm fractures 510 461 971
Incident other fractures 3,903 7,585 11,487
Prior hip fractures 5,537 23,965 29,502
Prior vertebral fractures 3,568 7,306 10,874
608,07570,25137,81latoT
(GDP) per capita (Table 13). Assuming a QALY is
valued at 2 times GDP/capita, the total cost of the
QALYs lost was estimated at € 3.27 billion.
When the cost of osteoporosis was combined with the
value for QALYs lost (valued at 2 × GDP), the cost of
osteoporosis amounted to € 6.11 billion in Spain in 2010.
Incident fracture, prior fracture, pharmacological fracture
prevention, and value of QALYs lost accounted for 22 %,
17 %, 7 %, 54 % respectively.
Burden of osteoporosis up to 2025
The population above 50 years of age is expected to increase
from 15.9 million in 2010 to 21.5 million in 2025, corre-
sponding to an increase of 35 % (Table 14).
The total number of fractures was estimated to rise
from 204,000 in 2010 to 286,000 in 2025 (Table 15),
corresponding to an increase of 40 %. Hip, clinical
spine, forearm and other fractures increased by 16,700,
11,500, 10,000 and 43,500 respectively. The increase in
the number of fractures ranged from 34 % to 42 %,
depending on fracture site. The increase was estimated
to be particularly marked in men (49 %) compared to
women (36 %).
The cost of osteoporosis (excluding value of QALYs lost)
was estimated to rise from € 2.8 billion in 2010 to € 3.7
billion in 2025, corresponding to an increase of 30 % (Table
16). Costs incurred in women and men increased by 26 %
and 39 % respectively.
The total number of QALYs lost due to fracture was
estimated to rise from 70,800 in 2010 to 89,000 in 2025,
corresponding to an increase of 26 % (Table 17). The
increase was estimated to be particularly marked in men
(37 %) compared to women (21 %). Incident and prior
fractures accounted for 66 % and 34 % of the increase
respectively.
The cost of osteoporosis including value of QALYs
lost was estimated to increase from approximately € 6.1
billion in 2010 to € 7.8 billion in 2025. The increase
was estimated to be particularly marked in men (+38 %)
compared to women (+23 %) (Table 18).
Treatment uptake
To estimate uptake of individual osteoporosis treat-
ments, sales data from IMS Health (2001–2011) were
used to derive the number of defined daily doses
(DDDs) sold per 100,000 persons aged 50 years or
above (Fig. 2).
Adjusting the sales data for compliance allowed for
an estimation of the proportion of population aged
50 years or above who received any osteoporosis treat-
ment (see Chapter 5 of the report on Osteoporosis in
the European Union: Medical Management, Epidemiol-
ogy and Economic Burden for further details). The
proportion of persons over the age of 50 years who
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Table 13 Value of lost QALYs (€) in men and women in Spain in 2010
1 × GDP/
capita
2 × GDP/
capita
3 × GDP/
capita
Incident hip fractures 204,496,899 408,993,798 613,490,697
Incident vertebral
fractures
210,643,500 421,286,999 631,930,499
Incident forearm
fractures
22,430,809 44,861,618 67,292,428
Incident other
fractures
265,357,330 530,714,660 796,071,990
Prior hip fractures 681,493,449 1,362,986,897 2,044,480,346
Prior vertebral
fractures
251,189,028 502,378,055 753,567,083
Total 1,635,611,014 3,271,222,028 4,906,833,042
Table 14 Population projections in Spain by age and sex [15]
Population
2010 2015 2020 2025
Women
50–59 2,859,000 3,276,000 3,619,000 3,859,000
60–69 2,351,000 2,569,000 2,824,000 3,234,000
70–79 1,961,000 1,945,000 2,178,000 2,387,000
80–89 1,234,000 1,387,000 1,384,000 1,412,000
90+ 223,000 288,000 375,000 444,000
Men
50–59 2,774,000 3,212,585 3,632,000 3,987,000
60–69 2,141,000 2,352,000 2,622,000 3,054,000
70–79 1,543,000 1,568,000 1,790,000 1,989,000
80–89 735,000 865,000 889,000 946,000
90+ 84,000 125,000 174,000 219,000
All
50–59 5,633,000 6,488,585 7,251,000 7,846,000
60–69 4,492,000 4,921,000 5,446,000 6,288,000
70–79 3,504,000 3,513,000 3,968,000 4,376,000
80–89 1,969,000 2,252,000 2,273,000 2,358,000
90+ 307,000 413,000 549,000 663,000
000,135,12000,509,51
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were treated increased from 2.74 % in 2001 to 9.56 %
in 2009 but subsequently decreased to 8.51 % in 2011.
Treatment gap
In order to assess the potential treatment gap, the numbers of
men and women eligible for treatment in Spain were defined
as individuals with a 10-year fracture probability exceeding
that of a woman with a prior fragility fracture derived from
FRAX®, equivalent to a ‘fracture threshold’ (See Chapter 5
of the main report for further details). Subsequently, these
estimates were compared to the number of individuals who
received osteoporosis treatment obtained from the analysis
of IMS Health data. The treatment gaps in men and
women were estimated at 20 % and 25 % respectively
(Table 19). Note that the estimate of the treatment gap
is conservative given that it assumes that current use of
osteoporosis treatments are only directed to men and
women at high risk.
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Table 15 Projected annual number of incident fractures in 2010 and 2025 by fracture site and age in men and women in Spain
Table 16 Current and future cost (€ 000, 000) of osteoporosis (ex-
cluding value of QALYs lost) by age and calendar year in men and
women in Spain
2010 2015 2020 2025
Women
50–74 435 471 521 562
75+ 1,647 1,778 1,909 2,063
All 2,082 2,249 2,430 2,625
Men
50–74 214 233 261 289
75+ 546 612 681 766
All 760 845 942 1,055
Women and Men
50–74 649 704 781 852
75+ 2,193 2,390 2,590 2,829
All 2,842 3,094 3,371 3,680
Table 17 Projected QALYs lost due to incident and prior fractures for
the years 2010 and 2025 by age in men and women in Spain
Incident fractures Prior fractures All fractures
2010 2025 2010 2025 2010 2025
Women
50–74 5,263 7,077 5,708 6,183 10,970 13,259
75+ 14,573 19,726 23,529 26,281 38,102 46,007
All 19,836 26,803 29,237 32,464 49,073 59,267
Men
50–74 4,362 6,159 3,398 4,090 7,760 10,249
75+ 6,232 9,546 7,741 9,908 13,973 19,454
All 10,594 15,705 11,139 13,998 21,733 29,703
Women and Men
50–74 9,625 13,236 9,106 10,273 18,731 23,509
75+ 20,805 29,272 31,270 36,189 52,075 65,461
All 30,430 42,508 40,376 46,462 70,806 88,970
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Table 18 Present and future cost (€ 000,000) of fracture (direct cost
and cost of QALYs) by age and calendar year in men and women in
Spain assuming the uptake of treatment remains unchanged
2010 2015 2020 2025
Women
50–74 942 1,007 1,095 1,175
75+ 3,407 3,667 3,905 4,188
All 4,349 4,674 5,000 5,363
Men
50–74 572 614 683 763
75+ 1,191 1,313 1,460 1,665
All 1,764 1,927 2,142 2,428
Women and Men
50–74 1,514 1,621 1,778 1,938
75+ 4,599 4,980 5,365 5,853
All 6,113 6,601 7,143 7,791
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Fig. 2 Treatment uptake in Spain (Defined daily doses [DDDs] per
100,000 persons aged 50 years or above)
Table 19 Number of men and women eligible for treatment, treated
and treatment gap in 2010
Number
potentially
treated
(1000 s)
Number eligible
for treatment
(1000 s)
Difference
(1000 s)
Treatment
gap (%)
Men 191 239 48 20
Women 1,277 1,709 432 25
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Abstract
Summary This report describes epidemiology, burden, and
treatment of osteoporosis in Sweden.
Introduction Osteoporosis is characterized by reduced bone
mass and disruption of bone architecture, resulting in in-
creased risks of fragility fractures which represent the main
clinical consequence of the disease. Fragility fractures are
associated with substantial pain and suffering, disability and
even death for the affected patients and substantial costs to
society. The aim of this study is to describe the epidemiol-
ogy and economic burden of fragility fractures as a conse-
quence of osteoporosis in Sweden, as a further detailed
addition to the report for the entire European Union
(EU27): Osteoporosis in the European Union: Medical
Management, Epidemiology and Economic Burden.
Methods The literature on fracture incidence and costs of
fractures in the EU27 was reviewed and incorporated into a
model estimating the clinical and economic burden of oste-
oporotic fractures in 2010. Furthermore, data on sales of
osteoporosis treatments and the population at high risk were
used to estimate treatment uptake and treatment gap.
Results It was estimated that approximately 107,000 new
fragility fractures were sustained in Sweden, comprising
20,000 hip fractures, 16,000 vertebral fractures, 16,000 fore-
arm fractures and 54,000 other fractures (i.e. fractures of the
pelvis, rib, humerus, tibia, fibula, clavicle, scapula, sternum
and other femoral fractures) in 2010. The economic burden
of incident and previous fragility fractures was estimated at €
1,486 million for the same year. Incident fractures represent-
ed 62 % of this cost, long-term fracture care 36 % and
pharmacological prevention 2 %. Previous and incident frac-
tures also accounted for 36,000 quality-adjusted life years
(QALYs) lost during 2010. When accounting for the demo-
graphic projections for 2025, the number of incident frac-
tures was estimated at 135,000 in 2025, representing an
increase of 28,000 fractures. Hip, clinical vertebral (spine),
forearm and other fractures were estimated to increase by
6,100, 4,500, 3,300 and 14,400, respectively. The burden of
fractures in Sweden in 2025 was estimated to increase by
23 % to € 1,828 million. Though the uptake of osteoporosis
treatments increased from 2001, the proportion of patients
aged 50 or above who received treatment remained at very
low levels in the past few years. The majority of women at
high fracture risk did not receive active treatment.
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Conclusions In spite of the high cost of osteoporosis, a
substantial treatment gap and projected increase of the
economic burden driven by an aging population, the
use of pharmacological prevention of osteoporosis is
significantly less than optimal, suggesting that a
change in healthcare policy concerning the disease is
warranted.
Introduction
Osteoporosis is characterized by reduced bone mass and
disruption of bone architecture, resulting in increased risks
of fragility fractures which represent the main clinical con-
sequence of the disease. Fragility fractures are associated
with substantial pain and suffering, disability and even death
for the affected patients and substantial costs to society. The
aim of this report was to characterize the burden of osteo-
porosis in Sweden in 2010 and beyond.
Methods
The literature on fracture incidence and costs of fractures in
Sweden was reviewed and incorporated into a model esti-
mating the clinical and economic burden of osteoporotic
fractures in 2010. Details of the methods used are found
in Chapters 3 and 4 of the report Osteoporosis in the
European Union: Medical Management, Epidemiology
and Economic Burden, published concurrently in Archives
of Osteoporosis.
Epidemiology of osteoporosis in Sweden
For the purpose of this report, the population at risk of
osteoporosis was considered to include men and women
≥50 years. The number of men and women ≥50 years of
age amounted to 1,659,000 and 1,830,000 respectively in
Sweden in 2010 (Table 1).
In the population at risk, the number of individuals with
osteoporosis—as defined by the WHO diagnostic
criteria—was estimated at 520,000 (Table 2). There are 10
DXA scan machines per million inhabitants [2], and guidelines
for the assessment and treatment of osteoporosis are available
[3]. A country specific FRAX model is also available for the
assessment of fracture risk (http://www.shef.ac.uk/FRAX/).
Data on incidence for all fracture types under consider-
ation are available for Sweden [5,6]. Standardized to the
EU27 population, hip fracture incidence (per 100,000 per-
son years) in men and women ≥50 years of age was esti-
mated at 318.6 and 802.8 respectively.
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Table 1 Population at risk: men and women over the age of 50 in
Sweden, 2010 [1]
Age (years) Women Men All
50–59 571,000 580,000 1,151,000
60–69 583,000 579,000 1,162,000
70–79 365,000 317,000 682,000
80–89 253,000 161,000 414,000
90+ 58,000 22,000 80,000
50+ 1,830,000 1,659,000 3,489,000
Table 2 Estimated number of women and men with osteoporosis
(defined as a T-score ≤−2.5 SD) in Sweden by age using female-
derived reference ranges at the femoral neck, 2010 [4]
Age (years) Women Men
50–54 18,018 7,300
55–59 27,360 10,080
60–64 44,902 18,154
65–69 54,338 19,684
70–74 54,963 14,118
75–79 63,000 14,008
80+ 146,792 30,378
50+ 409,373 113,722
Table 3 Incidence per 100,000 person years of hip, clinical vertebral,
forearm, and “other” fractures in Sweden by age
Fracture at the
Age (years) hip vertebra forearm other
Women
50–54 63 162 401 414
55–59 57 159 440 504
60–64 138 245 523 534
65–69 264 385 642 903
70–74 456 642 819 1,292
75–79 1,006 978 981 2,116
80–84 1,817 1,142 1,138 3,090
85+ 3,082 1,450 1,315 5,178
Men
50–54 88 225 81 390
55–59 86 149 131 800
60–64 77 183 144 753
65–69 150 236 225 966
70–74 260 396 166 1,334
75–79 495 571 141 1,323
80–84 1,163 807 225 3,091
85+ 1,623 1,090 297 4,699
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The number of incident fractures in 2010 was estimated at
107,000 (Table 4). Incident hip, clinical spine, forearm and
“other” fractures were estimated at 20,000, 16,000, 16,000
and 54,000 respectively. 66% of fractures occurred in women.
A prior fracture was defined as a fracture in an individual
who was alive during the index year (i.e. 2010) which had
occurred after the age of 50 years and before 2010. In the
population ≥50 years of age, the proportion of individuals
who had suffered a fracture prior to 2010 was estimated at
2.84 % for hip and 3.19 % for clinical vertebral fractures.
The estimated proportions of men and women with prior hip
and vertebral fractures by age are presented in Table 5.
In the population over 50 years of age, the number of in-
dividuals with hip and vertebral fractures that occurred before
2010was estimated at 99,000 and 111,000 respectively (Table 6).
Note that fractures sustained in 2010 were not included in the
estimate.
The incidence of causally related deaths (per
100,000) in the first year after fracture by age is
presented in Table 7. The number of causally related
deaths in 2010 was estimated at 1,171 (Table 8). Hip,
vertebral and “other” fractures accounted for 589, 362
and 220 deaths respectively. Overall, approximately
54 % of deaths occurred in women.
Cost of osteoporosis in Sweden including and excluding
values of QALYs lost
For the purpose of this report, the cost of osteoporosis
in 2010 (excluding value of QALYs lost) were consid-
ered to consist of three components: (i) cost of fractures
that occurred in 2010 (“first year costs”); (ii) cost of
fractures sustained prior to year 2010 but which still
incurred costs in 2010 (“long-term disability cost”); and
(iii) cost of pharmacological fracture prevention includ-
ing administration and monitoring costs (“pharmacolog-
ical fracture prevention costs”). See Chapter 4 of the
main report for further details.
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Table 4 Estimated number of incident fractures in Sweden, 2010
Fracture at the All
Age (years) hip vertebra forearm other fractures
Women
50–74 2,870 4,388 7,799 10,329 25,386
75+ 11,819 6,121 5,757 21,321 45,018
Total 14,688 10,509 13,556 31,650 70,403
Men
50–74 1,852 3,195 2,070 11,889 19,006
75+ 3,740 2,788 767 10,342 17,636
Total 5,592 5,983 2,837 22,231 36,643
Men and Women
50–74 4,722 7,582 9,869 22,218 44,392
75+ 15,558 8,909 6,524 31,663 62,654
Total 20,280 16,492 16,393 53,881 107,046
Table 5 Proportion of men and women (in %) with a prior hip or
clinical vertebral fracture in Sweden, 2010
Age (years) Hip fracture Vertebral fracture
Women
50– 3.01.045
55– 0.13.095
60– 6.18.046
65– 6.25.196
70– 4.46.247
75– 9.61.597
80– 6.93.948
8.411.91+58
Men
50– 4.02.045
55– 0.15.095
60– 5.19.046
65– 0.23.196
70– 8.20.247
75– 9.34.397
80– 4.53.648
0.99.11+58
Table 6 Number of men and women in Sweden with a prior hip or
clinical vertebral fracture after the age of 50 years, 2010
Age (years) Hip fracture Vertebral fracture
Women
50– 334,42487,2147
699,94347,35+57
824,47725,66latoT
Men
50– 147,81147,1147
871,81486,02+57
919,63524,23latoT
Men and Women
50– 471,34525,4247
471,86724,47+57
843,111259,89latoT
In Sweden, the costs of hip and vertebral fractures have
been estimated to range from € 12,870 to € 19,667, and from
€2,048 to €14,219 respectively. The cost of forearm fracture
has been estimated at € 2,401 [7]. Costs for “other
fractures” were imputed as described in Chapter 4 of
the main report.
Long-term disability costs were estimated by multiplying
the yearly cost of residing in nursing home (€ 57,247 [7])
with the simulated number of individuals with prior frac-
tures that had been transferred to nursing home due to the
fracture.
Annual drug cost (€) for individual treatments is shown
in Table 9. In addition, it was assumed that patients on
treatment made an annual physician visit costing € 130 [8]
and a DXA scan costing € 152 [8] every second year to
monitor treatment.
The cost of osteoporosis in 2010 was estimated at €
1,486 million (Table 10). First year costs, subsequent
year costs and pharmacological fracture prevention costs
amounted to € 927 million, € 529 million and € 29
million respectively. It is notable that pharmacological
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Table 7 Incidence (per 100,000) of causally related deaths in Sweden
within the first year after fracture (adjusted for comorbidities), 2010
Age (years) Hip Clinical vertebral “Other” fracture
Women
50–54 408 530 11
55–59 648 797 19
60–64 938 1,089 30
65–69 1,288 1,412 48
70–74 1,710 1,765 78
75–79 1,899 1,834 119
80–84 2,084 1,844 232
85–89 2,629 2,044 461
90+ 2,633 1,484 915
Men
50–54 1,019 1,222 16
55–59 1,463 1,663 30
60–64 1,652 1,776 45
65–69 2,140 2,171 77
70–74 2,706 2,576 122
75–79 3,471 3,078 206
80–84 4,305 3,496 362
85–89 6,395 4,674 691
90+ 9,749 6,344 1,220
Table 8 The number of deaths in men and women in Sweden in the
first year after fracture attributable to the fracture event (causally
related), 2010
Fracture at the
Age (years) hip vertebra “other”
Women
50–
Men
50–
Total 268 192 79
Men and Women
50–
74 41 64 6
75+ 280 106 135
Total 321 170 140
74 44 72 9
75+ 224 121 70
74 85 135 15
75+ 504 227 205
Total 589 362 220
Table 9 One year costs for relevant pharmaceuticals in Sweden, 2010 [9]
Annual drug cost (€)
Alendronate 27
Risedronate 366
Etidronate 241
Ibandronate -
Zoledronic acid 443
Raloxifene 358
Strontium ranelate 468
Parathyroid hormone 4,585
Teriparatide 5,174
Table 10 Cost of osteoporosis (€) in Sweden by age in men and
women, 2010
Age
(years)
First year
fracture
cost
Long term
disability
costs
Fracture
prevention
cost
Total cost
Women
50–74 164,775,011 45,041,829 15,865,811 225,682,651
75+ 459,502,549 299,410,779 9,840,865 768,754,194
All 624,277,561 344,452,608 25,706,677 994,436,845
Men
50–74 129,916,509 47,296,421 2,429,058 179,641,988
75+ 172,932,982 137,583,421 1,179,974 311,696,377
All 302,849,491 184,879,842 3,609,032 491,338,365
Women and Men
50–74 294,691,520 92,338,250 18,294,870 405,324,640
75+ 632,435,531 436,994,201 11,020,839 1,080,450,571
All 927,127,051 529,332,450 29,315,709 1,485,775,210
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fracture prevention costs amounted to only 2.0 % of the
total cost.
When stratifying costs of osteoporosis by fracture type, hip
fractures were most costly (€ 823million) followed by “other”
(€ 421 million), spine (€ 173 million) and forearm fractures (€
39 million) (Table 11 and Fig. 1). Please note that costs for
pharmacological fracture prevention were not included given
that they cannot be allocated to specific fracture sites.
The number of quality adjusted life years (QALYs) lost
due to osteoporosis in 2010 was estimated at 36,000 (Table
12). Prior fractures accounted for 55 % of the total loss and
64 % of the loss occurred in women. The monetary value of
a QALY was varied between 1 to 3 times the gross domestic
product (GDP) per capita (Table 13). Assuming a QALY is
valued at 2 times GDP/capita, the total cost of the QALYs
lost was estimated at € 2.67 billion.
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Table 11 Total cost (€) in 2010 by fracture site in men andwomen in Sweden. Note that costs for fracture prevention therapy andmonitoring are not included
Hip
56%
Spine
12%
Forearm
3%
Other
29%
Fig. 1 Share (%) of fracture cost by fracture site in Sweden. Note that
costs for fracture prevention therapy and monitoring are not included
Table 12 Number of QALYs lost due to fractures during 2010 in men
and women in Sweden according to age
Age (years)
50–74 75+ 50+
Women
Incident hip fractures 690 2,446 3,136
Incident vertebral fractures 1,449 1,740 3,189
Incident forearm fractures 275 174 449
Incident other fractures 1,236 2,193 3,430
Prior hip fractures 2,007 7,189 9,196
Prior vertebral fractures 1,368 2,406 3,775
471,32841,61720,7latoT
Men
Incident hip fractures 450 891 1,340
Incident vertebral fractures 1,058 886 1,944
Incident forearm fractures 72 25 97
Incident other fractures 1,411 1,174 2,584
Prior hip fractures 1,836 3,051 4,888
Prior vertebral fractures 1,043 955 1,998
158,21289,6968,5latoT
Men and Women
Incident hip fractures 1,140 3,336 4,476
Incident vertebral fractures 2,508 2,626 5,133
Incident forearm fractures 347 199 545
Incident other fractures 2,647 3,367 6,014
Prior hip fractures 3,844 10,241 14,084
Prior vertebral fractures 2,411 3,361 5,772
520,63031,32698,21latoT
When the cost of osteoporosis was combined with
the value for QALYs lost (valued at 2 × GDP), the
cost of osteoporosis amounted to € 4.15 billion in
Sweden in 2010. Incident fracture, prior fracture, phar-
macological fracture prevention, and value of QALYs
los t accounted for 22 %, 13 %, 1 %, 64 %
respectively.
Burden of osteoporosis up to 2025
The population above 50 years of age is expected to increase
from 3.5 million in 2010 to 4.1 million in 2025, correspond-
ing to an increase of 18 % (Table 14).
The total number of fractures was estimated to rise
from 107,000 in 2010 to 135,000 in 2025 (Table 15),
corresponding to an increase of 26 %. Hip, clinical
spine, forearm and other fractures increased by 6,100,
4,500, 3,300 and 14,400 respectively. The increase in
the number of fractures ranged from 20 % to 30 %,
depending on fracture site. The increase was estimated
to be particularly marked in men (33 %) compared to
women (23 %).
The cost of osteoporosis (excluding value of QALYs lost)
was estimated to rise from € 1.5 billion in 2010 to € 1.8
billion in 2025, corresponding to an increase of 23 % (Table
16). Costs incurred in women and men increased by 19 %
and 32 % respectively.
The total number of QALYs lost due to fracture was
estimated to rise from 36,000 in 2010 to 43,300 in 2025,
corresponding to an increase of 20 % (Table 17). The
increase was estimated to be particularly marked in men
(27 %) compared to women (16 %). Incident and prior
fractures accounted for 61 % and 39 % of the increase
respectively.
The cost of osteoporosis including value of QALYs lost
was estimated to increase from approximately € 4.2 billion
in 2010 to € 5 billion in 2025. The increase was estimated to
be particularly marked in men (+29 %) compared to women
(+17 %) (Table 18).
Treatment uptake
To estimate uptake of individual osteoporosis treat-
ments, sales data from IMS Health (2001–2011) were
used to derive the number of defined daily doses
(DDDs) sold per 100,000 persons aged 50 years or
above (Fig. 2).
Adjusting the sales data for compliance allowed for
an estimation of the proportion of population aged
50 years or above who received any osteoporosis treat-
ment (see Chapter 5 of the report on Osteoporosis in
the European Union: Medical Management, Epidemiol-
ogy and Economic Burden for further details). The
proportion of persons over the age of 50 years who
were treated increased from 1.53 % in 2001 to 3.28 %
in 2011.
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Table 13 Value of lost QALYs (€) in men and women in Sweden in 2010
1 × GDP/
capita
2 × GDP/
capita
3 × GDP/
capita
Incident hip fractures 165,618,254 331,236,508 496,854,762
Incident vertebral
fractures
189,937,256 379,874,511 569,811,767
Incident forearm
fractures
20,182,331 40,364,663 60,546,994
Incident other
fractures
222,513,731 445,027,462 667,541,192
Prior hip fractures 521,113,364 1,042,226,728 1,563,340,092
Prior vertebral
fractures
213,567,199 427,134,398 640,701,598
Total 1,332,932,135 2,665,864,269 3,998,796,404
Table 14 Population projections in Sweden by age and sex [10]
Population
2010 2015 2020 2025
Women
50–59 571,000 594,000 634,000 639,000
60–69 583,000 584,000 551,000 574,000
70–79 365,000 433,000 520,000 524,000
80–89 253,000 242,000 249,000 306,000
90+ 58,000 67,000 72,000 75,000
Men
50–59 580,000 605,636 649,000 650,000
60–69 579,000 575,000 543,000 573,000
70–79 317,000 398,000 482,000 483,000
80–89 161,000 162,000 183,000 240,000
90+ 22,000 28,000 33,000 37,000
All
50–59 1,151,000 1,199,636 1,283,000 1,289,000
60–69 1,162,000 1,159,000 1,094,000 1,147,000
70–79 682,000 831,000 1,002,000 1,007,000
80–89 414,000 404,000 432,000 546,000
90+ 80,000 95,000 105,000 112,000
000,101,4000,984,3
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Treatment gap
In order to assess the potential treatment gap, the numbers of
men and women eligible for treatment in Sweden were de-
fined as individuals with a 10-year fracture probability ex-
ceeding that of a woman with a prior fragility fracture derived
from FRAX®, equivalent to a ‘fracture threshold’ (See Chap-
ter 5 of the main report for further details). Subsequently, these
estimates were compared to the number of individuals who
received osteoporosis treatment obtained from the analysis of
IMS Health data. The treatment gaps in men and women were
estimated at 63 % and 72 % respectively (Table 19). Note that
the estimate of the treatment gap is conservative given that it
assumes that current use of osteoporosis treatments are only
directed to men and women at high risk.
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Table 15 Projected annual number of incident fractures in 2010 and 2025 by fracture site and age in men and women in Sweden
Table 16 Current and future cost of (€ 000, 000) osteoporosis (ex-
cluding value of QALYs lost) by age and calendar year in men and
women in Sweden
2010 2015 2020 2025
Women
50–
All 994 1,039 1,096 1,181
Men
50–
All 491 527 580 648
Women and Men
50–
74 226 251 258 251
75+ 769 788 838 929
74 180 198 203 201
75+ 312 328 377 447
74 405 449 461 452
75+ 1,080 1,116 1,215 1,376
All 1,486 1,565 1,676 1,828
Table 17 Projected QALYs lost due to incident and prior fractures for
the years 2010 and 2025 by age in men and women in Sweden
Incident fractures Prior fractures All fractures
2010 2025 2010 2025 2010 2025
Women
50–74 3,651 4,074 3,376 3,542 7,027 7,616
75+ 6,552 8,501 9,595 10,831 16,148 19,331
All 10,203 12,574 12,971 14,373 23,174 26,947
Men
50–74 2,990 3,355 2,879 3,081 5,869 6,436
75+ 2,976 4,662 4,006 5,228 6,982 9,890
All 5,966 8,017 6,885 8,310 12,851 16,326
Women and Men
50–74 6,641 7,429 6,255 6,623 12,896 14,052
75+ 9,528 13,162 13,602 16,059 23,130 29,222
All 16,169 20,591 19,856 22,682 36,025 43,273
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Table 18 Present and future cost (€ 000,000) of fracture (direct cost
and cost of QALYs) by age and calendar year in men and women in
Sweden assuming the uptake of treatment remains unchanged
2010 2015 2020 2025
Women
50–74 746 802 821 815
75+ 1,964 2,027 2,149 2,360
All 2,709 2,829 2,970 3,175
Men
50–74 614 655 672 677
75+ 828 866 987 1,178
All 1,442 1,521 1,659 1,856
Women and Men
50–74 1,360 1,457 1,493 1,492
75+ 2,792 2,892 3,136 3,538
All 4,152 4,349 4,629 5,031
0
100'000
200'000
300'000
400'000
500'000
600'000
700'000
2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011
alendronate
denosumab
etidronate
ibandronate
PTH
raloxifene
risedronate
strontium ranelate
teriparatide
zoledronic acidD
D
D
s/
10
0,
00
0 
pe
rs
on
-y
e
a
rs
Fig. 2 Treatment uptake in Sweden (Defined daily doses [DDDs] per
100,000 persons aged 50 years or above)
Table 19 Number of men and women eligible for treatment, treated
and treatment gap in 2010
Number
potentially
treated
(1000 s)
Number eligible
for treatment
(1000 s)
Difference
(1000 s)
Treatment
gap (%)
Men 15 41 26 63
Women 100 358 258 72
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Epidemiology and Economic Burden of Osteo-
porosis in the UK
A report prepared in collaboration with the Internation-
al Osteoporosis Foundation (IOF) and the European
Federation of Pharmaceutical Industry Associations
(EFPIA).
M Ivergård, A Svedbom, >
Abstract
Summary This report describes epidemiology, burden, and
treatment of osteoporosis in the UK.
Introduction Osteoporosis is characterized by reduced bone
mass and disruption of bone architecture, resulting in in-
creased risks of fragility fractures which represent the main
clinical consequence of the disease. Fragility fractures are
associated with substantial pain and suffering, disability and
even death for the affected patients and substantial costs to
society. The aim of this study is to describe the epidemiol-
ogy and economic burden of fragility fractures as a conse-
quence of osteoporosis in the UK, as a further detailed
addition to the report for the entire European Union
(EU27): Osteoporosis in the European Union: Medical
Management, Epidemiology and Economic Burden.
Methods The literature on fracture incidence and costs of
fractures in the UK was reviewed and incorporated into a
model estimating the clinical and economic burden of oste-
oporotic fractures in 2010. Furthermore, data on sales of
osteoporosis treatments and the population at high risk were
used to estimate treatment uptake and treatment gap. Costs,
calculated in Euros, were converted to £ for the purpose of
this report (1.00 GBP=€ 1.23; 21st Dec 2012).
Results It was estimated that approximately 536,000 new
fragility fractures were sustained in the UK, comprising
79,000 hip fractures, 66,000 vertebral fractures, 69,000
forearm fractures and 322,000 other fractures (i.e. fractures
of the pelvis, rib, humerus, tibia, fibula, clavicle, scapula,
sternum and other femoral fractures) in 2010. The economic
burden of incident and previous fragility fractures was esti-
mated at £ 3,496 (€ 5,408) million for the same year.
Incident fractures represented 74 % of this cost, long-term
fracture care 25 % and pharmacological prevention 2 %.
Previous and incident fractures also accounted for 158,700
quality-adjusted life years (QALYs) lost during 2010. When
accounting for the demographic projections for 2025, the
number of incident fractures was estimated at 682,000 in
2025, representing an increase of 146,000 fractures. Hip,
clinical vertebral (spine), forearm and other fractures were
estimated to increase by 23,000, 18,000, 15,900 and 89,300,
respectively. The burden of fractures in the UK in 2025 was
estimated to increase by 24 % to £ 5,465 (€ 6,723) million.
Though the uptake of osteoporosis treatments increased
from 2001, the proportion of patients aged 50 years or above
that received treatment remained at very low levels in the
past few years. The majority of women at high fracture risk
did not receive active treatment.
Conclusions In spite of the high cost of osteoporosis, a
substantial treatment gap in women and projected increase
of the economic burden driven by an aging population, the
use of pharmacological prevention of osteoporosis is signif-
icantly less than optimal, suggesting that a change in
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healthcare policy concerning the disease is warranted.
Introduction
Osteoporosis is characterized by reduced bone mass and
disruption of bone architecture, resulting in increased risks
of fragility fractures which represent the main clinical con-
sequence of the disease. Fragility fractures are associated
with substantial pain and suffering, disability and even death
for the affected patients and substantial costs to society. The
aim of this report was to characterize the burden of osteo-
porosis in the UK in 2010 and beyond.
Methods
The literature on fracture incidence and costs of fractures in
the UK was reviewed and incorporated into a model estimat-
ing the clinical and economic burden of osteoporotic fractures
in 2010. Details of the methods used are found in Chapters 3
and 4 of the report on Osteoporosis in the European Union:
Medical Management, Epidemiology and Economic Burden,
published concurrently in Archives of Osteoporosis.
Epidemiology of osteoporosis in the UK
For the purpose of this report, the population at risk of
osteoporosis was considered to include men and women
≥50 years. The number of men and women ≥50 years of
age amounted to 10,102,000 and 11,534,000 respectively in
the UK in 2010 (Table 1).
In the population at risk, the number of individuals with
osteoporosis—as defined by theWHOdiagnostic criteria—was
estimated at 3.21 million (Table 2). There are 8.2 DXA scan
machines per million inhabitants [2], and guidelines for the
assessment and treatment of osteoporosis are available [3]. A
country specific FRAX model is also available for the assess-
ment of fracture risk (http://www.shef.ac.uk/FRAX/).
Incidence data for hip and forearm fractures were retrieved
from Singer et al. [5]. Given that country specific incidences
of vertebral and “other” fractures were not found, these were
imputed using the methods described in Chapter 3 of the main
report. Fracture incidence is presented in Table 3. Standard-
ized to the EU27 population, hip fracture incidence (per
100,000 person years) in men and women ≥50 years of age
was estimated at 186.0 and 523.5 respectively.
The number of incident fractures in 2010 was estimated at
536,000 (Table 4). Incident hip, clinical vertebral, forearm and
“other” fractures were estimated at 79,000, 66,000, 69,000 and
322,000 respectively. 64 % of fractures occurred in women.
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Table 1 Population at risk: men and women over the age of 50 in the
UK, 2010 [1]
Age (years) Women Men All
50–59 3,844,000 3,740,000 7,584,000
60–69 3,449,000 3,262,000 6,711,000
70–79 2,418,000 2,053,000 4,471,000
80–89 1,486,000 925,000 2,411,000
90+ 337,000 122,000 459,000
50+ 11,534,000 10,102,000 21,636,000
Table 2 Estimated number of women and men with osteoporosis
(defined as a T-score ≤−2.5 SD) in the UK by age using female-
derived reference ranges at the femoral neck, 2010 [4]
Age (years) Women Men Men and women
50–54 127,134 49,275 176,409
55–59 175,296 61,915 237,211
60–64 274,703 106,720 381,423
65–69 308,656 105,228 413,884
70–74 365,211 90,402 455,613
75–79 415,875 92,082 507,957
80+ 860,456 173,802 1,034,258
50+ 2,527,331 679,424 3,206,755
Table 3 Incidence per 100,000 person years of hip, clinical vertebral,
forearm, and “other” fractures in the UK by age
Fracture at the
Age (years) hip vertebra forearm other
Women
50–54 33 84 219 414
55–59 51 142 309 504
60–64 81 143 445 534
65–69 132 192 522 903
70–74 282 397 636 1,292
75–79 619 602 775 2,116
80–84 1,236 777 696 3,090
85+ 2,255 1,061 780 5,178
Men
50–54 45 115 100 390
55–59 59 102 110 800
60–64 81 193 34 753
65–69 107 169 62 966
70–74 176 269 65 1,334
75–79 313 361 220 1,323
80–84 623 433 53 3,091
85+ 1,220 819 223 4,699
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A prior fracture was defined as a fracture in an individual
who was alive during the index year (i.e. 2010) which had
occurred after the age of 50 years and before 2010. In the
population ≥50 years of age, the proportion of individuals
who had suffered a fracture prior to 2010 was estimated at
1.94 % for hip and 2.02 % for clinical vertebral fractures.
The estimated proportions of men and women with prior hip
and vertebral fractures by age are presented in Table 5.
In the population over 50 years of age, the number of
individuals with hip and vertebral fractures that occurred
before 2010 was estimated at 419,000 and 437,000 respec-
tively (Table 6). Note that fractures sustained in 2010 were
not included in the estimate.
The incidence of causally related deaths (per 100,000)
in the first year after fracture by age is presented in
Table 7. The number of causally related deaths in 2010
was estimated at 6,059 (Table 8). Hip, vertebral and
“other” fractures accounted for 2,764, 1,795 and 1,500
deaths respectively. Overall, approximately 54 % of
deaths occurred in women.
Cost of osteoporosis in the UK including and excluding
values of QALYs lost
For the purpose of this report, the cost of osteoporosis in
2010 (excluding value of QALYs lost) was considered to
consist of three components: (i) cost of fractures that
occurred in 2010 (“first year costs”); (ii) cost of fractures
sustained prior to year 2010 but which still incurred costs
in 2010 (“long-term disability cost”); and (iii) cost of
pharmacological fracture prevention including administra-
tion and monitoring costs (“pharmacological fracture
prevention costs”). See Chapter 4 of the main report for
further details.
The cost of hip, vertebral and forearm fractures has been
estimated at £ 9,390 (€ 11,055), £ 2,341 (€ 2,756), and £ 1,073
(€ 1,263) respectively [6,7]. Costs for “other fractures” were
imputed as described in Chapter 4 of the main report.
Long-term disability costs were estimated by multiplying the
yearly cost of residing in nursing home £24,444 (€ 33,756) [6])
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Table 4 Estimated number of incident fractures in the UK, 2010
Fracture at the All
Age (years) hip vertebra forearm other fractures
Women
50–74 10,504 16,482 37,567 64,277 128,830
75+ 45,632 23,640 21,440 125,656 216,367
Total 56,136 40,121 59,007 189,933 345,197
Men
50–74 8,070 14,485 6,672 71,410 100,637
75+ 15,037 11,317 3,242 60,443 90,039
Total 23,107 25,803 9,913 131,853 190,676
Men and Women
50–74 18,574 30,967 44,238 135,688 229,467
75+ 60,669 34,957 24,681 186,099 306,406
Total 79,243 65,924 68,920 321,786 535,873
Table 5 Proportion of men and women (in %) with a prior hip or
clinical vertebral fracture in the UK, 2010
Age (years) Hip fracture Vertebral fracture
Women
50– 2.01.045
55– 7.03.095
60– 2.16.046
65– 7.10.196
70– 6.28.147
75– 0.44.397
80– 8.56.648
4.011.51+58
Men
50– 2.01.045
55– 6.03.095
60– 1.16.046
65– 5.19.096
70– 9.14.147
75– 4.22.297
80– 1.37.348
2.65.8+58
Table 6 Number of men and women in the UK with a prior hip or
clinical vertebral fracture after the age of 50 years, 2010
Age (years) Hip fracture Vertebral fracture
Women
50– 810,89620,5547
670,491860,832+57
390,292590,392latoT
Men
50– 168,77952,6447
545,76725,97+57
604,541687,521latoT
Men and Women
50–74 101,286 175,879
126,162595,713+57
994,734188,814latoT
with the simulated number of individuals with prior fractures
that had been transferred to nursing homes due to the fracture.
Annual drug cost for individual treatments is shown in
Table 9. In addition, it was assumed that patients on
treatment made an annual physician visit costing £ 41 (€
50) [8] and a DXA scan costing £ 41 (€ 51) [6] every
second year to monitor treatment.
The cost of osteoporosis in 2010 was estimated at £
4,397 (€ 5,408) million (Table 10). First year costs,
subsequent year costs and pharmacological fracture pre-
vention costs amounted to £3,233 (€ 3,977) million, £
1,080 (€ 1,328) million and £84 (€ 103) million, re-
spectively. It is notable that pharmacological fracture
prevention costs amounted to only 1.9 % of the total
cost.
When stratifying costs of osteoporosis by fracture
type, “other fractures” were most costly at £2,069 mil-
lion (€ 2,545 million) followed by hip fractures at
£2,039 million (€ 2,508 million), vertebral fractures at
£ 134 million (€ 165 million) and forearm fractures at
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Table 8 The number of deaths in men and women in the UK in the
first year after fracture attributable to the fracture event (causally
related), 2010
Fracture at the
Age (years) hip vertebra “other”
Women
50–
Men
50–
Men and Women
50–
74 197 304 46
75+ 1,291 513 938
Total 1,487 817 984
74 241 419 72
75+ 1,035 559 444
Total 1,277 978 516
74 438 723 118
75+ 2,326 1,073 1,382
Total 2,764 1,795 1,500
Table 9 One year costs for relevant pharmaceuticals in the UK, 2010 [9]
Annual drug cost
£ €
Alendronate 11 13
Risedronate 176 217
Etidronate 64 79
Ibandronate 153 188
Zoledronic acid 197 242
Raloxifene 180 221
Strontium ranelate 232 285
Parathyroid hormone 2355 2,897
Teriparatide 2459 3,024
Table 10 Cost of osteoporosis (£) in the UK by age in men and
women, 2010
Age
(years)
First year
fracture
cost
Long term
disability
costs
Fracture
prevention
cost
Total cost
Women
50–74 495,992,508 93,791,815 45,809,624 635,593,947
75+ 1,624,852,298 642,093,815 27,826,902 2,294,773,015
All 2,120,844,806 735,885,630 73,636,526 2,930,366,962
Men
50–74 446,135,385 93,353,413 6,946,167 546,434,965
75+ 666,005,143 250,509,467 3,398,496 919,913,106
All 1,112,140,528 343,862,880 10,344,663 1,466,348,071
Women and Men
50–74 942,127,892 187,145,228 52,755,790 1,182,028,910
75+ 2,290,857,441 892,603,281 31,225,398 3,214,686,120
All 3,232,985,333 1,079,748,509 83,981,188 4,396,715,030
Table 7 Incidence (per 100,000) of causally related deaths in the UK
within the first year after fracture (adjusted for comorbidities), 2010
Age (years) Hip Clinical vertebral “Other” fracture
Women
50–54 667 867 17
55–59 824 1,014 24
60–64 1,131 1,313 36
65–69 1,606 1,760 60
70–74 2,194 2,264 100
75–79 2,869 2,772 180
80–84 2,867 2,536 319
85–89 3,323 2,583 582
90+ 2,898 1,634 1,008
Men
50–54 1,599 1,918 25
55–59 1,910 2,172 39
60–64 2,192 2,357 59
65–69 2,761 2,801 99
70–74 3,551 3,381 160
75–79 4,577 4,059 271
80–84 5,629 4,571 473
85–89 7,369 5,386 796
90+ 10,039 6,533 1,256
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£71 million (€ 87 million) (Table 11 and Fig. 1). Please
note that costs for pharmacological fracture prevention
were not included given that they cannot be allocated to
specific fracture sites.
The number of quality adjusted life years (QALYs)
lost due to osteoporosis in 2010 was estimated at
158,700 (Table 12). Prior fractures accounted for 52 %
of the total loss and 64 % of the loss occurred in
women. The monetary value of a QALY was varied
between 1 to 3 times the gross domestic product (GDP)
per capita (Table 13). Assuming a QALY is valued at 2
times GDP/capita, the total cost of the QALYs lost was
estimated at £7.0 billion (€ 8.7 billion).
Arch Osteoporos (2013) 8:137 Page 215 of 218, 137
Hip
47%
Spine
3%
Forearm
2%
Other
48%
Fig. 1 Share (%) of fracture cost by fracture site in the UK. Note that
costs for fracture prevention therapy and monitoring are not included
Table 12 Number of QALYs lost due to fractures during 2010 in men
and women in the UK according to age
Age (years)
50–74 75+ 50+
Women
Incident hip fractures 2,539 9,516 12,055
Incident vertebral fractures 5,478 6,763 12,241
Incident forearm fractures 1,322 652 1,975
Incident other fractures 7,702 12,989 20,691
Prior hip fractures 8,644 31,772 40,416
Prior vertebral fractures 5,496 9,312 14,808
581,201300,17381,13latoT
Men
Incident hip fractures 1,972 3,607 5,579
Incident vertebral fractures 4,822 3,608 8,430
Incident forearm fractures 234 106 340
Incident other fractures 8,488 6,880 15,368
Prior hip fractures 7,225 11,725 18,951
Prior vertebral fractures 4,325 3,548 7,873
145,65474,92760,72latoT
Men and Women
Incident hip fractures 4,511 13,123 17,634
Incident vertebral fractures 10,300 10,371 20,671
Incident forearm fractures 1,556 758 2,315
Incident other fractures 16,190 19,869 36,059
Prior hip fractures 15,870 43,497 59,367
Prior vertebral fractures 9,822 12,859 22,681
627,851774,001942,85latoT
Table 11 Total cost (£) in 2010 by fracture site in men and women in the UK. Note that costs for fracture prevention therapy and monitoring are not
included
When the cost of osteoporosis was combined with
the value for QALYs lost (valued at 2 × GDP), the cost
of osteoporosis amounted to £11.47 billion (€ 14.11
billion) in the UK in 2010. Incident fracture, prior
fracture, pharmacological fracture prevention, and value
of QALYs lost accounted for 28 %, 9 %, 1 % and
62 %, respectively.
Burden of osteoporosis up to 2025
The population above 50 years of age is expected to increase
from 21.6 million in 2010 to 26.2 million in 2025, corre-
sponding to an increase of 21 % (Table 14).
The total number of fractures was estimated to rise
from 536,000 in 2010 to 682,000 in 2025 (Table 15),
corresponding to an increase of 27 %. Hip, clinical
vertebral, forearm and other fractures increased by
23,000, 18,000, 15,900 and 89,300 respectively. The
increase in the number of fractures ranged from 23 %
to 29 %, depending on fracture site. The increase was
estimated to be particularly marked in men (32 %)
compared to women (24 %).
The cost of osteoporosis (excluding value of QALYs lost)
was estimated to rise from £ 4.4 billion (€ 5.4 billion) in
2010 to £ 5.5 billion (€ 6.7 billion) in 2025, corresponding
to an increase of 24 % (Table 16). Costs incurred in women
and men increased by 20 % and 32 % respectively.
The total number of QALYs lost due to fracture was
estimated to rise from 158,700 in 2010 to 190,500 in 2025,
corresponding to an increase of 20 % (Table 17). The increase
was estimated to be particularly marked in men (27 %) com-
pared to women (16 %). Incident and prior fractures
accounted for 67 % and 33 % of the increase respectively.
The cost of osteoporosis including value of QALYs
lost was estimated to increase from approximately £11.5
billion (€ 14.1 billion) in 2010 to £14.0 billion (€ 17.2
billion) in 2025. The increase was estimated to be
particularly marked in men (+29 %) compared to wom-
en (+18 %) (Table 18).
Treatment uptake
To estimate uptake of individual osteoporosis treatments,
sales data from IMS Health (2001–2011) were used to
derive the number of defined daily doses (DDDs) sold per
100,000 persons aged 50 years or above (Fig. 2).
Adjusting the sales data for compliance allowed for an
estimation of the proportion of population aged 50 years or
above who received any osteoporosis treatment (see Chapter
5 of the report on Osteoporosis in the European Union:
Medical Management, Epidemiology and Economic Burden
for further details). The proportion of persons over the age
of 50 years who were treated increased from 1.11 % in 2001
to 5.5 % in 2011.
Treatment gap
In order to assess the potential treatment gap, the
numbers of men and women eligible for treatment in
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Table 13 Value of lost QALYs (£) in men and women in the UK in 2010
1 × GDP/
capita
2 × GDP/
capita
3 × GDP/
capita
Incident hip
fractures
392,829,516 785,659,033 1,178,488,549
Incident vertebral
fractures
460,472,157 920,944,314 1,381,416,471
Incident forearm
fractures
51,561,273 103,122,546 154,683,820
Incident other
fractures
803,258,637 1,606,517,275 2,409,775,912
Prior hip fractures 1,322,480,924 2,644,961,849 3,967,442,773
Prior vertebral
fractures
505,249,355 1,010,498,711 1,515,748,066
Total 3,535,851,862 7,071,703,728 10,607,555,591
Table 14 Population projections in the UK by age and sex [10]
Population
2010 2015 2020 2025
Women
50–59 3,844,000 4,271,000 4,559,000 4,373,000
60–69 3,449,000 3,624,000 3,654,000 4,076,000
70–79 2,418,000 2,595,000 3,016,000 3,184,000
80–89 1,486,000 1,496,000 1,574,000 1,733,000
90+ 337,000 391,000 439,000 474,000
Men
50–59 3,740,000 4,140,197 4,423,000 4,268,000
60–69 3,262,000 3,423,000 3,450,000 3,842,000
70–79 2,053,000 2,253,000 2,649,000 2,791,000
80–89 925,000 1,014,000 1,125,000 1,271,000
90+ 122,000 162,000 198,000 231,000
All
50–59 7,584,000 8,411,197 8,982,000 8,641,000
60–69 6,711,000 7,047,000 7,104,000 7,918,000
70–79 4,471,000 4,848,000 5,665,000 5,975,000
80–89 2,411,000 2,510,000 2,699,000 3,004,000
90+ 459,000 553,000 637,000 705,000
000,342,62000,636,12
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the UK were defined as individuals with a 10-year
fracture probability exceeding that of a woman with a
prior fragility fracture derived from FRAX®, equivalent
to a ‘fracture threshold’ (See Chapter 5 of the main
report for further details). Subsequently, these estimates
were compared to the number of individuals who re-
ceived osteoporosis treatment obtained from the analy-
sis of IMS Health data. For men, the data indicate that
the volume of sold osteoporosis drugs would be suffi-
cient to cover treatment for more patients than the
number that fall above the fracture threshold. It should
be noted, however, that the results from this analysis
should be interpreted with some caution since it has
been assumed that the distribution of drug use between
genders observed in Sweden is valid for all countries.
The treatment gaps in men and women were estimated
at −34 % and 54 % respectively (Table 19). Note that
the estimate of the treatment gap is conservative given
that it assumes that current use of osteoporosis treat-
ments are only directed to men and women at high
risk.
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Table 15 Projected annual number of incident fractures in 2010 and 2025 by fracture site and age in men and women in the UK
rehtOmraeroFlarbetreVpiH
2010 2025 2010 2025 2010 2025 2010 2025
Women
50–74 10,504 12,668 16,482 19,732 37,567 44,634 64,277 76,638
75+ 45,632 57,609 23,640 30,118 21,440 27,580 125,656 160,668
All 56,136 70,277 40,121 49,850 59,007 72,213 189,933 237,305
Men
50–74 8,070 9,684 14,485 17,171 6,672 7,811 71,410 85,326
75+ 15,037 22,315 11,317 16,927 3,242 4,837 60,443 88,424
All 23,107 31,999 25,803 34,098 9,913 12,649 131,853 173,749
Women and Men
50–74 18,574 22,352 30,967 36,903 44,238 52,445 135,688 161,964
75+ 60,669 79,924 34,957 47,045 24,681 32,417 186,099 249,091
All 79,243 102,276 65,924 83,948 68,920 84,862 321,786 411,055
Table 16 Current and future cost (£ 000, 000) of osteoporosis (ex-
cluding value of QALYs lost) by age and calendar year in men and
women in the UK
2010 2015 2020 2025
Women
50–74 636 690 916 751
75+ 2,295 2,388 3,111 2,775
All 2,931 3,078 4,028 3,526
Men
50–74 546 594 786 650
75+ 920 1,011 1,384 1,289
All 1,466 1,605 2,170 1,939
Women and Men
50–74 1,182 1,285 1,703 1,402
75+ 3,215 3,398 4,495 4,064
All 4,397 4,683 6,198 5,466
Table 17 Projected QALYs lost due to incident and prior fractures for
the years 2010 and 2025 by age in men and women in the UK
−
−
−
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Table 18 Present and future cost (£ 000,000) of fracture (direct cost
and cost of QALYs) by age and calendar year in men and women in the
UK assuming the uptake of treatment remains unchanged
2010 2015 2020 2025
Women
50–74 2,025 2,157 2,818 2,333
75+ 5,459 5,680 7,345 6,484
All 7,484 7,837 10,163 8,817
Men
50–74 1,752 1,860 2,438 2,046
75+ 2,233 2,402 3,275 3,087
All 3,985 4,262 5,713 5,133
Women and Men
50–74 3,777 4,017 5,255 4,380
75+ 7,691 8,082 10,620 9,571
All 11,468 12,099 15,876 13,951
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Fig. 2 Treatment uptake in the UK (Defined daily doses [DDDs] per
100,000 persons aged 50 years or above)
Table 19 Number of men and women eligible for treatment, treated
and treatment gap in 2010
Number
potentially
treated
(1000 s)
Number eligible
for treatment
(1000 s)
Difference
(1000 s)
Treatment
gap (%)
Men 159 119 −40 −34
Women 1,064 2,298 1,234 54
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